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ABSTRACT 
 
Biotechnology entrepreneurship is a relatively new and distinct field of 
entrepreneurship. Most current empirical research is conducted in the developed 
economies and cannot be directly extrapolated to the developing economies. The 
paucity of empirical research and the lack of a conceptual framework for 
biotechnology entrepreneurship constitute gaps that this research addressed through 
the development of a proposed theoretical framework of biotechnology 
entrepreneurship based on empirical research conducted within the context of the 
developing economies of South Africa and Brazil. 
 
The current methodological approaches to research in biotechnology 
entrepreneurship predominantly make use of a nomothetic philosophical approach 
and employs quantitative methods. Current research is also often based on surveys 
conducted within one developing economy context. Consequently, few studies in 
biotechnology entrepreneurship use the qualitative multiple case study approach. 
This methodological gap is addressed in this research through the use of qualitative 
multiple case studies, in the idiographic philosophical tradition, in two developing 
economies; South Africa and Brazil. The data collection process included in-depth 
interviews, documents review and observations, which improved the quality of the 
research through data triangulation.  
 
Ten themes were identified, which formed the basis for developing the proposed 
theoretical framework. In addition, seven factors that influence the process of 
biotechnology entrepreneurship in South Africa and Brazil were identified as 
regulation; funding; infrastructure; skills; entrepreneurial and commercialisation 
capabilities; market for biotechnology products; and social development. 
 
This research shows that the individual-opportunity nexus of entrepreneurship does 
not entirely hold for biotechnology entrepreneurship in South Africa and Brazil. 
Instead, there is a nexus of research and development; and a government-
incentivised environment that is conducive for biotechnology entrepreneurship.  
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The policy implications of these dynamics in South Africa and Brazil; as well as 
implications for the other stakeholders in the biotechnology industry are articulated 
as being linked to the control of the factors that influence biotechnology 
entrepreneurship by the various stakeholders. Hence, the implications for 
government are predominantly linked to regulation and infrastructure; and the 
implications for the other stakeholders are predominantly linked to funding and skills. 
 
 
Keywords: Biotechnology entrepreneurship, entrepreneurship, biotechnology, triple 
helix, university, industry, government, South Africa, Brazil, qualitative analysis 
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PART I: FOUNDATION FOR THE RESEARCH 
Chapter 1:  Introduction 
 
The introduction of the first biotechnology drug, recombinant insulin, in 1982 marked 
the turning point in the commercial viability of biotechnology innovation, and its 
potential to address some of the major global problems of healthcare, food security, 
energy sufficiency, renewable resources and environmental sustainability (Ahn and 
Meeks, 2007; Ahn, Meeks, Bednarek, Ross and Dalziel, 2010a; Ahn, Meeks, 
Davenport and Bednarek, 2010b; Battelle/Biotechnology Industry Organisation, 
2010; Ahn and York, 2011; Ahn, Hajela and Akbar, 2012; Dunham, Ahn and York, 
2012). Within the context of entrepreneurship, biotechnology entrepreneurship is 
relatively new (Meyers, 2012), research-driven and requires the collaboration of 
human talent, capital and institutions to achieve economic and social development, 
job creation, poverty alleviation, skills development and technology transfer. These 
benefits have captured the interest of the developed and developing economies in 
programmes and activities aimed at promoting biotechnology entrepreneurship, in 
order to capitalise on what has been termed the “biocentury” (Battelle/Biotechnology 
Industry Organisation, 2010). 
 
However, the biotechnology industry is currently dominated by the developed 
economies, which are innovation-driven (Kelley, Singer and Herrington, 2012). 
Consequently, most of the benefits outlined above also accrue to the developed 
economies. The efforts of the developing economies, which are either factor or 
efficiency-driven (Kelley et al., 2012), to develop the biotechnology industry are 
impeded by the lack of entrepreneurial conditions (Herrington, Kew and Kew, 2008; 
Bosma and Levie, 2010; Herrington, Kew and Kew, 2010; Kelley et al., 2012) and 
the paucity of critical mass of empirical research aimed at understanding the industry 
in the context of developing economies. Ironically, the global problems of healthcare, 
food security, renewable resources and environmental sustainability are more 
pertinent in the developing than the developed economies. In addition, the 
developing economies still grapple with high levels of unemployment, social 
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inequalities, low levels of entrepreneurship and entrepreneurial culture, acute 
poverty and skills shortages (Kelley et al., 2012). 
 
There is an abundance of empirical research on biotechnology entrepreneurship by 
several scholars (Dibner, 1986; Bud, 1991; Gittelman, 1999; Kettler and Casper, 
2001; Nilsson, 2001; Kivinen and Varelius, 2003; Müller, Fujiwara and Herstatt, 
2004; Ahn and Meeks, 2007; Ahn et al., 2010a; Ahn et al., 2010b; Ahn and York, 
2011; Ahn et al., 2012; Dunham et al., 2012) and organisations (Biotechnology 
Industry Organisation, 2008; Battelle/Biotechnology Industry Organisation, 2010; 
Ernst & Young, 2010b; Organisation for Economic Cooperation and Development, 
2013d, 2013b, 2013c, 2013a) related to the developed economies, where relevant 
information exists to differentiate between small and entrepreneurial businesses, and 
the economic contribution of entrepreneurship can be quantified systematically.  
 
Previous studies on biotechnology in South Africa (Department of Science and 
Technology, 2001; Department of Science and Technology and eGoli Bio, 2003; 
Cloete, Nel and Theron, 2006; Ernst & Young, 2006; Department of Science and 
Technology, 2007; Gastrow, 2008) outline the structures put in place by the 
government to create an environment that is conducive for biotechnology and 
provide quantitative information on the state of the industry in South Africa. There 
have been other studies carried out on biotechnology entrepreneurship in developing 
economies such as China, Brazil and India (Herrington et al., 2008; Phan, 
Venkataraman and Velamuri, 2008; Herrington et al., 2010; Ernst & Young, 2010b). 
The outcome of these studies consistently indicates that there is little understanding 
of biotechnology entrepreneurship in developing economies even though the 
industry holds great promise for developing economies.   
 
Apart from the annual Global Entrepreneurship Monitor (GEM) report, which South 
Africa joined in 2001, very few frameworks exist to provide a comparative basis for 
evaluating entrepreneurship in the developing economies relative to the developed 
economies. Fewer frameworks exist that are specific to biotechnology 
entrepreneurship in developing economies. 
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Given the importance of entrepreneurship in general, and specifically biotechnology 
entrepreneurship, to the economic and social imperatives of the developing 
economies, it would have been expected that this industry would command a great 
deal of empirical research interest and support from government, universities and the 
private sector. The scarcity of research impedes policy directions, institutional 
development, regulatory decisions, technology transfer strategy, national 
competitiveness, investments in innovation and skills development. 
 
This study explores the dynamics of biotechnology entrepreneurship in the 
developing economies of South Africa and Brazil with the aim of understanding the 
practical realities of biotechnology entrepreneurship in these economies.  
 
1.1 Significance of the study 
 
The importance of entrepreneurship to the economic development of any economy 
has been established through several empirical research studies (Schumpeter, 1934; 
Wennekers and Thurik, 1999; Thurik and Wennekers, 2004; Stel, Carree and Thurik, 
2005; Wennekers, Van Wennekers, Thurik and Reynolds, 2005; Herrington et al., 
2008; Bosma and Levie, 2010; Carree and Thurik, 2010; Kelley et al., 2012).  
 
Biotechnology is an industry that is based on scientific innovation and 
entrepreneurship, and it has been frequently described as the economic growth 
engine of the 21st century (Thurik and Wennekers, 2004; Biotechnology Industry 
Organisation, 2008; Battelle/Biotechnology Industry Organisation, 2010; Ernst & 
Young, 2010a). While much interest has been generated globally by the potential of 
biotechnology, very little is known about the industry in the developing economies 
despite the fact that biotechnology is seen as the driver of economic growth, 
competitiveness and job creation (Thurik and Wennekers, 2004) in the current 
globalised knowledge-based economy. There is also an expectation for the 
emergence of the bio-economy, which is driven by biotechnology entrepreneurship 
(Organisation for Economic Cooperation and Development, 2013a), and to which 
South Africa has aligned its national policy on biotechnology entrepreneurship. 
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It has been shown that there are differences in the entrepreneurial process between 
the developed and developing economies (Lingelbach, De La Vina and Asel, 2005). 
The current discourse on the process of biotechnology entrepreneurship in 
developing economies is based on empirical research carried out in developed 
economies. This lack of empirical research on biotechnology entrepreneurship in 
developing economies represents a gap, which this study seeks to address.  
 
In addition to bridging the gap in literature, this study is significant to government 
policy-making related to biotechnology, skills development, economic development, 
technology transfer, job creation and legislation, which improve the environment for 
entrepreneurial activities. The outcome of this research is expected to inform the 
improvement of government policies such as the National Bio-economy Strategy in 
South Africa, the Biotechnology Development Policy in Brazil, and specific policies 
related to the development of bioentrepreneurship in other developing economies. 
 
Other stakeholders that will benefit from this study include research institutions, 
universities, large companies and venture capitalists. The understanding of the 
dynamics of biotechnology entrepreneurship in developing economies aids decision 
making related to strategic alliances, and the commercialisation of intellectual 
property by the various stakeholders. 
 
1.2 Problem statement 
 
The biotechnology industry is currently dominated by the United States of America 
(USA) and to a lesser extent by the other developed economies, and most of the 
empirical research on biotechnology entrepreneurship relates to the developed 
economies.  
 
Specifically in South Africa and Brazil there is a paucity of empirical research on 
biotechnology entrepreneurship (Cloete et al., 2006; Gastrow, 2008; Natesh and 
Bhan, 2009; Ernst & Young, 2010b; Ahn and York, 2011; Meyers and Pruthi, 2011; 
Ahn et al., 2012; Battelle/Biotechnology Industry Organisation, 2012; Organisation 
for Economic Cooperation and Development, 2013a). Most studies in these two 
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developing economies are conducted as either market research by consultants in the 
biotechnology industry (Cloete et al., 2006; Gastrow, 2008; Natesh and Bhan, 2009; 
Ernst & Young, 2010b; Ahn and York, 2011; Meyers and Pruthi, 2011; Ahn et al., 
2012; Battelle/Biotechnology Industry Organisation, 2012; Organisation for Economic 
Cooperation and Development, 2013a), or empirical research on general 
entrepreneurship not specific to biotechnology entrepreneurship (Baumol, 1993; Ács 
and Audretsch, 2003; Shane, 2003; Lingelbach et al., 2005; Audretsch and 
Lehmann, 2005a; Alvarez and Barney, 2007; Lingelbach, Murray and Gilbert, 2008; 
Acs, 2010; Lingelbach, Murray and Gilbert, 2013).  
 
Methodologically, the few research studies on biotechnology entrepreneurship, in 
developing economies, employ mostly the survey or single case study 
methodologies within one developing economy. These studies cannot be directly 
extrapolated to developing economies generally due to differences at individual, 
institutional and environmental levels among developing economies (Lingelbach et 
al., 2005). 
 
Theoretically, at the time of this research there is no known conceptual framework of 
biotechnology entrepreneurship, especially in a developing economies context. 
  
This research is aimed at making contributions that address the empirical, 
methodological and theoretical gaps identified above.  
 
South Africa and Brazil have well-developed first and second-generation 
biotechnology (Department of Science and Technology, 2001) and have made good 
progress in developing third-generation biotechnology (Cloete et al., 2006). 
However, third-generation biotechnology and biotechnology entrepreneurship in 
South Africa and Brazil still lag far behind the level attained in developed economies 
across many dimensions (Organisation for Economic Cooperation and Development, 
2013d, 2013b, 2013c). 
The understanding of the dynamics of biotechnology entrepreneurship in these two 
developing economies, within its original context, contributes significantly to the 
knowledge of this field in the developing economies and addresses the identified 
empirical, methodological and theoretical gaps.   
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1.3 Purpose statement 
 
The purpose of this study is to explore the dynamics of biotechnology 
entrepreneurship in South Africa and Brazil. 
 
1.4 Assumptions underpinning the research 
 
There is one assumption that underpins the proposed research. In spite of the 
difficulties of measuring entrepreneurship in a cross-national context (Carree and 
Thurik, 1998), it is assumed that the developing economies of South Africa and 
Brazil are good candidates for the study of biotechnology entrepreneurship in 
developing economies. 
 
1.5 Structure of the thesis 
 
This study is written up in a thesis that is divided into five parts. 
 
Part I  
Part I contains the foundation for the research and include chapters 1 to 4. 
Chapter 1 provides the introduction to the study. It also describes the significance of 
the study, and delineates the problem and purpose statements and assumptions of 
this study. 
 
Chapter 2 presents a detailed review of the literature on entrepreneurship and 
biotechnology. Literature on general, academic and technical entrepreneurship, as 
well as intrapreneurship and entrepreneurial orientation from developed and 
emerging economies was reviewed in order to gain a broad context in which to 
position biotechnology entrepreneurship as a specific form of entrepreneurship. 
From this theoretical basis, specific literature on biotechnology entrepreneurship was 
reviewed further as the focus of this study was on understanding the extent of 
empirical research already carried out on this form of entrepreneurship, and the 
extent to which this is applicable to developing economies. 
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Chapter 3 contains the research questions that emanated from the literature 
reviewed, as well as the organising frameworks of entrepreneurship and the triple 
helix of university, industry, government relations. 
 
Chapter 4 provides a detailed description of the research design and methodology 
for the study.  
 
Part II  
Part II contains the case narratives and includes chapters 5 to 6. Chapter 5 contains 
the case narrative for South Africa. Chapter 6 contains the case narrative for Brazil. 
 
Part III  
Part III contains the case analyses and includes Chapters 7 and 8. Chapter 7 
contains the case analysis for South Africa. Chapter 8 contains the case analysis for 
Brazil. 
 
Part IV  
Part IV contains the cross-case analysis, discussion and theory development; and 
includes Chapter 9. 
 
Part V  
Part V contains the conclusions and includes Chapter 10. Chapter 10 contains the 
conclusions to the research, and articulates the methodological, empirical and 
theoretical contributions of the research. In addition, this chapter contains policy 
implications and suggestions for future research. 
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Chapter 2:  Literature Review 
 
The purpose of Chapter 2 is to present a review of literature relevant to the 
understanding of biotechnology entrepreneurship in developing economies. The 
scope of the review includes literature from developed economies as this establishes 
the context for comparison with developing economies and aids the formulation of a 
relevant theoretical framework and research questions for this study. 
 
 
2.1 Introduction 
 
The review of literature for this research was based, on literature on general, 
academic, and technology entrepreneurship, and on Intrapreneurship and 
Entrepreneurial Orientation (EO) in order to establish the relevant conceptual and 
theoretical frameworks for entrepreneurship, within which to locate biotechnology 
entrepreneurship as a specific form of entrepreneurship.  
 
From this theoretical basis, research focused on biotechnology entrepreneurship 
was reviewed further to gain a deeper understanding of the focus of this study. 
Furthermore, the review sought to establish the extent of empirical research already 
carried out on this form of entrepreneurship; the extent to which this empirical 
research is applicable to developing economies; the gaps in empirical, 
methodological and theoretical knowledge; and the relevant research questions to be 
developed. 
 
In fulfilling the above aims, the literature review was structured in terms of the sub-
sections shown in the literature review mind map presented in Figure 2.1 below. 
  
Figure 2.1: A mind map of the literature review headings and sub-headings 
Entrepreneurship 
Entrepreneurship as a field of 
study 
Conceptual framework of 
entrepreneurship 
Individual-
Opportunity Nexus 
Other organising frameworks 
Triple Helix of 
University, Industry, 
Government 
relations 
Entrepreneurship in developed 
and developing economies 
Academic entrepreneurship 
Intrapreneurship and 
Entrepreneurial orientation 
Technology entrepreneurship 
Biotechnology 
entrepreneurship 
The context of 
developed 
economies 
The context of 
developing 
economies 
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2.2 Entrepreneurship 
 
Entrepreneurship is an interdisciplinary field with links to psychology, economics, 
organisational theory, finance, strategy, technology management and public policy 
(Shane and Venkataraman, 2000). Much prior research on entrepreneurship has 
been driven by a researcher’s field of affiliation. This constraint has contributed to the 
lack of a coherent or over-arching conceptual framework for the field of 
entrepreneurship (Shane, 2003), in spite of wide interest in the field from business, 
government and academics. 
 
The many definitions of entrepreneurship emanating from these fields and schools of 
thought incorporate common elements such as the individual, environment, 
opportunity, innovation, risk, action and new business creation, to varying degrees 
(Schumpeter, 1934; Gartner, 1988; Venkataraman, 1997; Shane and Venkataraman, 
2000). While these definitions cover relevant aspects of entrepreneurship that range 
from firm creation to self-employment, the definition which is most closely aligned to 
the objectives of this study is that of Venkataraman (1997) and Shane and 
Venkataraman (2000), which is based on the conceptual framework of “the 
individual-opportunity nexus”.   
 
Entrepreneurship is an activity that involves the discovery, evaluation and 
exploitation of opportunities to introduce new goods and services, ways of 
organising, markets, processes, and raw materials through organising 
efforts that previously had not existed. (Shane, 2003:4) 
 
The integration of the individual, environmental and entrepreneurial opportunities 
(Cunningham and Lischeron, 1991; Shane and Venkataraman, 2000) in exploring 
the dynamics of biotechnology entrepreneurship has the potential to provide an in-
depth understanding of the key aspects of this field in the chosen developing 
economies. Entrepreneurship is critical to the economic development (Baumol, 
1989) of these developing economies, especially in the areas of employment 
creation and poverty alleviation (Thurik and Wennekers, 2004; Stel et al., 2005; 
Wennekers et al., 2005; Herrington et al., 2010).  
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The review of the literature for this study encompassed the two dominant 
entrepreneurial schools of thought: “focus on the individual” (McClelland, 1961; 
Kihlstrom and Laffont, 1979; Schere, 1982; Gartner, 1990) and “focus on external 
forces” (Tushman and Anderson, 1986; Hannan and Freeman, 1987; Ács and 
Audretsch, 2003). Other schools of thought such as “great person”, “psychological 
characteristics”, “classical”, “management”, “leadership”, and “Intrapreneurship” 
(Cunningham and Lischeron, 1991) can be explained in the context of either the 
individual or the external environment in which opportunities exist (Shane and 
Venkataraman, 2000). However, “Intrapreneurship”, or corporate entrepreneurship, 
relates specifically to entrepreneurial activities carried out in an organisational setting 
(Miller, 1983; Covin and Slevin, 1989) which involves entrepreneurial actions and 
decision making on the part of senior management and the leadership of the 
organisation (Covin and Slevin, 1989; Lumpkin and Dess, 1996; Covin and Wales, 
2011).  
 
Intrapreneurship, or corporate entrepreneurship, while it is discussed in Section 2.2.5 
to provide a context for the study, is outside the scope of this study. Furthermore, 
this research does not focus on any particular theoretical construct underlying 
entrepreneurship, but approaches the study from an interdisciplinary perspective, 
which underlies the individual-opportunity nexus framework of entrpreneurship 
(Venkataraman, 1997; Shane and Venkataraman, 2000; Eckhardt and Shane, 2003). 
 
An interdisciplinary approach to entrepreneurial research is advocated by 
researchers such as Shane (2003) and Murphy, Liao and Welsch (2006). The 
multidisciplinary approach is aligned with the researcher’s interest in gaining a 
holistic understanding of the field of biotechnology entrepreneurship in the chosen 
developing economies by drawing on literature from multiple fields and of how 
bioentrepreneurship contributes to the economic and social development of these 
economies, job creation, poverty alleviation and innovation (Kelley et al., 2012). 
 
In addition, recent efforts have been made by entrepreneurship scholars to define 
theoretical foundations for creating a field of entrepreneurial research drawing on 
disciplines such as economics, management, geography, finance, strategy, 
12 
 
organisation theory, technology management, public policy, psychology and 
sociology (Shane and Venkataraman, 2000; Ács and Audretsch, 2003:3-4). 
  
2.2.1 Entrepreneurship as a field of study  
 
Recent developments in entrepreneurial research are focused on integrating the 
different approaches to research in the field into a coherent conceptual and 
theoretical framework (Shane and Venkataraman, 2000; Ács and Audretsch, 2003; 
Phan, 2004), which bridges the gap between theoretical and practical research 
(Casson, 2005).  
 
Some of the key areas most discussed in recent literature are: the multidisciplinary 
approach to research (Ács and Audretsch, 2003; Shane, 2003; Murphy et al., 2006); 
a common purpose to forge unity among researchers (Low and MacMillan, 1988; 
Shane and Venkataraman, 2000); alternative theories of entrepreneurial action 
(Alvarez and Barney, 2007); opportunity-based theories (Eckhardt and Shane, 2003; 
Murphy and Welsch, 2010); a multidimensional view of entrepreneurial discovery 
(Murphy and Welsch, 2010); and employment of multiple levels of analysis in 
entrepreneurship research (Davidsson and Wiklund, 2007). This is by no means an 
exhaustive list of most recent areas of emphasis in entrepreneurship research, but 
serves the purpose of highlighting some of the key discourses shaping the future of 
entrepreneurship research. 
 
This recent trend in entrepreneurship research has several positive implications for 
biotechnology entrepreneurship. 
  
First, the contemporary nature of recombinant DNA-based biotechnology 
(Biotechnology Industry Organisation, 2008; Battelle/Biotechnology Industry 
Organisation, 2012) lends itself to the application of contemporary approaches in 
entrepreneurship research. The multidisciplinary approach (Ács and Audretsch, 
2003; Shane, 2003; Murphy et al., 2006) is suited to the multifaceted nature of 
biotechnology (Dibner, 1986; Muller and Fujiwara, 2002; Müller et al., 2004; Ahn and 
Meeks, 2007; Biotechnology Industry Organisation, 2008; Battelle/Biotechnology 
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Industry Organisation, 2012). Biotechnology is plagued by the same crisis of 
definitional identity (Bud, 1991) as entrepreneurship (Cunningham and Lischeron, 
1991) and will benefit from a unified research approach, as proposed by Low and 
MacMillan (1988).  
 
Secondly, the distinct nature of bioentrepreneurial opportunities, which requires the 
application of research and development (R&D) in order to be exploited, defies the 
one-dimensional model of opportunity discovery (Shane and Venkataraman, 2000; 
Eckhardt and Shane, 2003; Shane, 2003) and discovery or creation as proposed by 
Alvarez and Barney (2007). Bioentrepreneurial opportunities straddle the continuum 
between discovery and creation (Audretsch, Taylor Aldridge and Perry, 2008), hence 
falling on a continuum between the Kirznerian (Kirzner, 1978) and Schumpeterian 
(Schumpeter, 1934) views of sources of entrepreneurial opportunities. 
Bioentrepreneurial opportunities are better explained by the multidimensional model 
proposed by Murphy and Welsch (2010), in which there is high serendipity and high 
deliberation, which Murphy and Welsch termed “Eureka”. This terminology is apt for 
biotechnology entrepreneurship as some of the exploited opportunities in 
biotechnology have resulted in significant advancement in healthcare (Ahn and 
Meeks, 2007). In addition future opportunity exploitation in biotechnology is expected 
to contribute significantly to solutions to the global problems of poverty, healthcare, 
energy and environment (Biotechnology Industry Organisation, 2008).  
 
Thirdly, the pervasive nature of biotechnology entrepreneurship (Dibner, 1986; 
Muller and Fujiwara, 2002; Müller et al., 2004; Ahn and Meeks, 2007; Biotechnology 
Industry Organisation, 2008) and the involvement of multiple stakeholders at micro 
and aggregate levels require the employment of multiple levels of analysis in 
bioentrepreneurship research (Davidsson and Wiklund, 2007; Prodan, 2007) in order 
to articulate the role of bioentrepreneurship in economic development fully (Low and 
MacMillan, 1988). However, due to the centrality of the bioscientist in the 
biotechnology entrepreneurship process (Audretsch et al., 2008), many researchers 
have focused their studies on the individual unit of analysis (Zucker, Darby and 
Brewer, 1999; Thursby, Jensen and Thursby, 2001; Bercovitz and Feldman, 2004). 
In the study carried out by Zucker, Darby and Armstrong (2002) on the role of 
scientific talent in the creation of university start-ups, the authors found that firms 
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founded by star scientists perform better than others even when the effects of 
external factors such as location and amount of venture capital financing are 
accounted for. The implications of this study for levels of analysis in biotechnology 
entrepreneurship are that interconnectedness occurs between levels of analysis in 
biotechnology entrepreneurship (Davidsson and Wiklund, 2007) and  the individual 
unit of analysis can explain firm performance (Zucker et al., 2002).  
 
Studies at the organisational unit of analysis (Nerkar and Shane, 2003; Audretsch 
and Lehmann, 2005b) provide the organisational context such as strategic alliances, 
funding sources and organisational performance (Audretsch et al., 2008). Other 
aggregate levels of analysis, such as the country level of analysis (Di Gregorio and 
Shane, 2003; Lockett and Wright, 2005), provide the institutional context.    
 
As the field of entrepreneurship research develops and matures, the trend is moving 
towards unification of concepts and approaches towards common goals, explanation 
of causal relationships and exploration of implications for practice (Low and 
MacMillan, 1988). These contemporary approaches by entrepreneurship scholars 
(Low and MacMillan, 1988; Venkataraman, 1997; Shane and Venkataraman, 2000; 
Shane, 2003; Murphy et al., 2006; Alvarez and Barney, 2007; Davidsson and 
Wiklund, 2007; Murphy and Welsch, 2010; Wiklund, Davidsson, Audretsch and 
Karlsson, 2011) provide a better alignment with bioentrepreneurship research than 
previous approaches based either on the characteristics of the individual 
entrepreneur (McClelland, 1961; Kihlstrom and Laffont, 1979; Schere, 1982; Gartner, 
1990) or on the environment (Tushman and Anderson, 1986; Hannan and Freeman, 
1987; Ács and Audretsch, 2003). 
 
Multidisciplinary approach 
 
In order to develop a meaningful approach to entrepreneurial studies, the divergent 
views of scholars in the different fields underlying entrepreneurship need to be 
integrated into a coherent framework that provides a basis for the development of 
the field of entrepreneurship. Murphy, Liao and Welsch (2006) provide an illustrated 
conceptual history of entrepreneurial thought, which tracks the historical 
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development of entrepreneurial thought from “prehistoric bases” to “multidisciplinary 
bases”.  
 
The illustration by Murphy et al. (2006) shows that during the “prehistoric bases” 
entrepreneurship was synonymous with activities such as farming, engineering, 
architecture and military warfare. Followers of the “economic bases” school thought 
of entrepreneurship as a new combination of existing resources, explained by 
psychological factors and dependent on knowledge. The “multidisciplinary bases” 
are underpinned by the opportunity view of entrepreneurship, in which innovation is 
considered to be constructive (Murphy et al., 2006). 
 
“The prehistoric bases” are mainly characterised by social controls, regulations and 
institutions, which place more emphasis on environmental variables as determinants 
of entrepreneurial activity. In contrast, the economics-based approaches to 
describing entrepreneurship in the “economic bases” are mainly characterised by 
innovation, coordination, risk-bearing, and national-level comparative advantages, 
which emphasise the cognitive and non-psychological aspects of the individual, as 
well as economic aspects of entrepreneurial activity. Hence, the “economic bases” 
marked the beginning of the shift towards the realisation that human and 
environmental factors are relevant in describing entrepreneurial activities, in addition 
to economic factors (Murphy et al., 2006). The shift of emphasis to the convergence 
of individual (McClelland, 1961) and environmental factors (Gnyawali and Fogel, 
1994) gave rise to the “multidisciplinary bases”, which have opportunity discovery 
and exploitation (Shane and Venkataraman, 2000; Shane, 2003; Murphy et al., 
2006) as the central tenet. 
 
The opportunity view of entrepreneurship is the core of Shane’s (2003) individual-
opportunity nexus conceptual framework, which is discussed in the next section. 
 
2.2.2 Conceptual frameworks of entrepreneurship 
 
Although there is no generally accepted conceptual framework for entrepreneurship, 
recent effort towards the formulation of a conceptual framework for the field of 
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entrepreneurship is gathering momentum. At the forefront of this endeavour is 
Shane’s (2003) proposed individual-opportunity nexus framework, which is based on 
an interdisciplinary approach to entrepreneurship.  
 
Another important framework that informs the approach to this study is the Triple 
Helix of University, Industry, Government relations (Etzkowitz and Leydesdorff, 1997; 
Etzkowitz, 1998; Leydesdorff and Etzkowitz, 1998; Etzkowitz and Leydesdorff, 2000; 
Etzkowitz, 2001; Leydesdorff and Etzkowitz, 2001). 
 
Individual-opportunity nexus framework  
 
Shane’s (2003) individual-opportunity nexus framework (see Figure 2.2) seeks to 
integrate entrepreneurial research with opportunities, their discovery and 
exploitation; the enterprising individuals that discover and exploit these opportunities; 
and the environment in which the entrepreneurial activities occur. 
 
There has been growing support for this approach (Ács and Audretsch, 2003; 
Murphy et al., 2006; Murphy and Welsch, 2010) owing to its promise to provide the 
basis for the emergence of entrepreneurship as a distinct field of research. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: The individual-opportunity nexus framework (Shane, 2003:11) 
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Shane’s (2003) framework considers the existence of entrepreneurial opportunities 
as independent of the actors and as needing to be discovered by enterprising 
individuals. The individual attributes needed to exploit these opportunities effectively 
include psychological factors, such as cognition and motivation and non-
psychological factors such as education and career experience.   
 
In the environment of entrepreneurship, the three categories of factors believed to 
influence productive entrepreneurial activity are the economic, political and cultural 
environments (Shane, 2003). There are marked differences between the developed 
and developing countries in all three categories of environmental factors. While the 
four aspects of the economic environment: wealth, economic stability, capital 
availability and taxation, are all at advanced levels and favourable for productive 
entrepreneurship in the developed economies, the developing economies face 
issues of poverty, economic instability, lack of capital and restrictive tax laws 
(Herrington et al., 2008; Bosma and Levie, 2010). Similarly, political instability in 
developing economies and low levels of a national culture of innovation and 
entrepreneurship hamper productive entrepreneurial activity (Herrington et al., 2010).   
 
Shane’s (2003) individual-opportunity nexus framework for entrepreneurship is able 
to explain the process of biotechnology entrepreneurship. This makes this framework 
useful for understanding the process of biotechnology entrepreneurship in South 
Africa and Brazil. 
 
Triple Helix Approach (University-Industry-Government relations)  
 
The relevance of the interactions among the university, industry and government, in 
transforming academic research into societal and economic capital, is demonstrated 
in the field of biotechnology (Liebeskind, Oliver, Zucker and Brewer, 1996; Agrawal, 
2001; Müller et al., 2004; Rothaermel and Deeds, 2004; Powell, White, Koput and 
Owen-Smith, 2005; Ahn and Meeks, 2007; Sytch and Bubenzer, 2008). Here 
collaboration between participants has evolved into what is termed: “inter-
organisational relationships” (Powell, Koput and Smith-Doerr, 1996), “collaborative 
networks” (Etzkowitz and Leydesdorff, 1997; Powell et al., 2005), “innovation 
systems” (Etzkowitz and Leydesdorff, 1997), and more recently “triple helix of 
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university, industry, government relations” (Etzkowitz and Leydesdorff, 1997; 
Leydesdorff and Etzkowitz, 1998, 2001).  
 
The concept of “capitalised knowledge” in a knowledge-based economy represents a 
transformation of the traditional role of universities from the provider of basic 
knowledge, in the form of teaching and research (Etzkowitz, 1998; Leydesdorff and 
Etzkowitz, 2001), to a key player in the economic development of regions and 
nations through the commercialisation of academic research (Etzkowitz, 2001). 
Biotechnology entrepreneurship is at the forefront of this collaboration across 
universities, government, and industry through the dense network of collaboration 
and alliances (Oliver, 2008) that characterise the process of exploitation of 
bioentrepreneurial opportunities (Müller et al., 2004; Rothaermel and Deeds, 2004; 
Ahn and Meeks, 2007; Sytch and Bubenzer, 2008). 
 
The study on the “dynamics of innovation” (Etzkowitz and Leydesdorff, 2000) traces 
the emergence of Triple Helix III from Triple Helices I and II. Triple Helix I represents 
a configuration in which the government encompasses both industry and university 
and directs the interaction and relations between them (Etzkowitz and Leydesdorff, 
2000). There is a strong possibility that the development of biotechnology 
entrepreneurship can be differentiated between the developed and developing 
economies on the basis of the innovation system that predominates (Etzkowitz and 
Leydesdorff, 2000).  
 
Triple Helix II represents a configuration in which the three institutional spheres are 
separate with strong borders dividing them and restricted relations (Etzkowitz and 
Leydesdorff, 2000). Triple Helices I and II are expected to be the predominant form 
of university-industry-government relations in the developing economies for historical 
reasons that influence the rate of institutional change and economic growth (Sokoloff 
and Engerman, 2000; Oyelaran Oyeyinka and Barclay, 2004; Engerman and 
Sokoloff, 2005; Oyelaran-Oyeyinka, 2006; Engerman and Sokoloff, 2008). Here the 
transition from Triple Helix I to Triple Helix II is aimed at reducing the influence of 
government in the university, industry, government relationships (Etzkowitz and 
Leydesdorff, 2000). 
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In Triple Helix III, as shown in Figure 2.3, overlapping institutional spheres generate 
a knowledge infrastructure, with overlapping roles and hybrid organisations emerging 
at the interfaces (Etzkowitz and Leydesdorff, 2000).  
 
 
Figure 2.3: The Triple Helix Model of University-Industry-Government Relations 
(Etzkowitz and Leydesdorff, 2000) 
  
 
The Triple Helix III configuration aims to create an innovation environment that 
supports knowledge-based economic development in which collaborations and 
alliances are aimed at creating, reinforcing and sustaining the knowledge 
infrastructure (Etzkowitz and Leydesdorff, 2000) without direct control by any of the 
institutions. The type of triple helix and the extent to which it operates in most 
developing countries can only be determined anecdotally, as current discussions and 
studies on the triple helix are focused on developed economies (Leydesdorff and 
Etzkowitz, 1998; Etzkowitz and Leydesdorff, 2000; Etzkowitz, 2001; Leydesdorff and 
Etzkowitz, 2001). 
 
Some scholars have criticised the Triple Helix approach as being too abstract and 
emphasising the consensus aspects of relationships among distinctive epistemic 
communities (Cooke, 2005); ignoring the entrepreneur (Brannback, Carsrud, 
Krueger Jr and Elfving, 2008); failing to recognise the role of social movements 
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(Chataway, Tait and Wield, 2004) and failing to traverse boundaries among 
epistemic communities successfully (Haas, 1992). In addition, studies by Jensen and 
Tragardh (2004) and Gunasekara (2006) on the validity of Triple Helix Approach in 
Sweden and Australia respectively did not yield similar results to that of the 
Massachusetts Institute of Technology (Cooke, 2005). However, despite these 
criticisms there is acknowledgment that the abstract principles of the Triple Helix 
Approach may hold in general (Haas, 1992).  
 
It is also expected that different regions and locations would have different outcomes 
in applying the Triple Helix Approach due to the different dynamics inherent in the 
epistemic communities (Haas, 1992; Cooke, 2005). While this may not support 
generalisation, it may be important to understanding the critical differences between 
regions in successfully implementing a deliberate strategy for enhancing university, 
industry, and government relations.   
 
The dynamics of the university, industry, and government relations highlight the need 
for a multilevel approach to biotechnology entrepreneurship research (Davidsson 
and Wiklund, 2007; Prodan, 2007). However, this is appropriate in the context of the 
developed economies where extant literature on single-level analysis (individual, 
organisation, and regional) readily exists (Davidsson and Wiklund, 2007). For the 
developing economies, there is a dearth of empirical research on biotechnology 
entrepreneurship at any level of analysis. This requires a concerted effort from 
researchers for further research at a multilevel analysis that explains the dynamics of 
biotechnology entrepreneurship across the innovation network (Etzkowitz, 2001). 
 
2.2.3 Entrepreneurship in developed and developing economies 
 
Entrepreneurship in developed economies has been shown to be different from 
developing economies because of differences in individual, institutional and 
environmental factors (Lingelbach et al., 2005; Kelley et al., 2012). These 
differences, as shown in Table 2.1, make it imperative for more empirical research 
on entrepreneurship to be conducted in developing economies, rather than draw 
conclusions based on research conducted in developed economies. 
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Table 2.1: Distinctive features of entrepreneurship in developed and 
developing economies (adapted from (Lingelbach et al., 2005) 
 
Measure Developed economies Developing economies 
Opportunities Less pervasive and specialised Broader in scope and pervasive 
Locus of operation 
Operates at the fringes of the 
economy 
Operates closer to the core of 
the economy 
Markets 
Stable, matured markets with 
proven consistency 
Lacks matured markets 
Competition 
Heightened competition from 
established incumbents 
Reduced direct competitive 
threats 
Risk Mostly business and market risks 
Mostly economic, political and 
regulatory risks; in addition to 
higher levels of business and 
market risks 
Strategy Specialised and concentrated 
Portfolio approach to mitigate 
higher levels of business and 
market risks 
Information flow 
Advanced information flow 
allowing access to upstream and 
downstream businesses 
Limited information flow 
Capital availability 
Developed venture capital 
industry and other sources of 
financing 
Lack of alternative sources of 
financing; prevalence of 
bootstrap financing 
Skills 
Access to broader pool of skills 
and resources 
Inadequate availability of skills 
and resources 
Distribution 
Advanced distribution network 
and access to end customers 
Lack of access to end customers 
forces entrepreneurs to start 
downstream businesses 
 
 
Table 2.1 shows that the entrepreneurial process in developing economies tends to 
be different from that of the developed economies across many dimensions 
(Lingelbach et al., 2005). A key individual factor such as skills availability differs 
markedly between the developed and developing economies. Biotechnology 
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entrepreneurship specifically requires the availability of a pool of human talent skilled 
in bioscience. The extent to which this is available determines to a large extent the 
success of developing biotechnology entrepreneurship. 
 
Institutional factors such as government, infrastructure, markets, regulation, 
competition, risk, information flow, capital availability and distribution have also been 
shown to be different across the developed and developing economies (Kelley et al., 
2012). 
 
Furthermore, environmental factors such as opportunities, which are central to the 
entrepreneurial process, and strategies employed to exploit such opportunities have 
been shown to be different across the developed and developing economies 
(Lingelbach et al., 2005). Hence, entrepreneurship as a field of study is significantly 
enhanced when studied in the contexts of both the developed and developing 
economies, especially the latter given the paucity of empirical research currently 
available. 
 
The Global Entrepreneurship Monitor (GEM) model discussed in the next section 
shows the link among individual entrepreneurial attitudes, activities and aspirations, 
and national economic growth; and how entrepreneurial activities can be compared 
across the developed and developing economies and different levels of national 
conditions. 
 
Global Entrepreneurship Monitor  
 
The GEM conceptual model provides a credible basis for the comparison of 
entrepreneurial activities across the developed and developing economies, based on 
their level of economic development (Herrington et al., 2008; Bosma and Levie, 
2010; Herrington et al., 2010). Three categories of countries’ economies, factor-
driven, efficiency-driven and innovation-driven economies, are measured across 12 
national conditions aligned to the 12 pillars of global competitiveness (Schwab, Sala-
i-Martin, Blanke, Hanouz, Mia and Geiger, 2009; Kelley et al., 2012).   
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One of the key measures of the GEM model is Total Early-stage Entrepreneurial 
Activity (TEA), which measures the level of dynamic entrepreneurial activity in a 
country (Herrington et al., 2008; Bosma and Levie, 2010; Herrington et al., 2010; 
Kelley et al., 2012). The national conditions are key determinants of the TEA rates 
across nations. The developed economies have a lower average TEA rate than 
developing economies, which points to the pervasiveness of opportunities in 
developing economies and more matured and competitive markets in developed 
economies (Lingelbach et al., 2005). The differences in national conditions influence 
the nature and extent of entrepreneurship across different countries.  
 
The GEM model starts off with national conditions within the social, cultural and 
political context. Most developing economies are still driven by the primary economy 
owing to their national conditions falling under basic requirements and efficiency 
enhancers. On the other hand, the national conditions for the developed economies 
fall under innovation and entrepreneurship, and entrepreneurship makes a greater 
contribution towards the output of the model, which is national economic growth. 
 
The nature of opportunities also tends to differ between the developing and the 
developed economies. While there is a predominance of necessity-driven 
opportunities in the developing economies, the developed economies have a 
predominance of improvement-driven opportunities (Kelley et al., 2012). 
  
The efficiency-driven countries display marked differences from the innovation-driven 
countries across factors such as R&D transfer, commercial and services 
infrastructure, internal market dynamics, internal market openness, physical 
infrastructure, and cultural and social norms (Kelley et al., 2012). In addition to these 
differences, there are also differences in factors like finance, general policy, 
regulatory policy, government programmes, and education (Kelley et al., 2012). 
 
2.2.4 Academic entrepreneurship  
 
Academic entrepreneurship encompasses all research activities that scientists 
engage in, which lead to the exploitation of opportunities through the start-up of a 
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new firm or licensing of the intellectual property (Audretsch and Stephan, 1998; 
Mowery and Shane, 2002; Shane, 2004a; Audretsch and Lehmann, 2005a; 
Audretsch et al., 2008). In the late 20th century and the 21st century most of the 
emphasis on academic entrepreneurship has been on biotechnology 
entrepreneurship (Louis, Blumenthal, Gluck and Stoto, 1989; Mowery and Shane, 
2002; Audretsch et al., 2008). In addition to commercialisation and licensing, Louis et 
al., (1989) identified three other forms of academic entrepreneurship that 
bioscientists engage in: engaging in large-scale science (externally funded 
research); earning supplemental income; and gaining industry support for university 
research. 
 
In explaining the role of entrepreneurship in biotechnology, and how scientists 
engaged in biotechnology research at universities become entrepreneurs, 
Audretsch, Aldridge and Perry (2008) comment that the “exact role of 
entrepreneurship in industries such as biotechnology has generally eluded the 
analytical lens of scholars” (Audretsch et al., 2008). In the same article, Audretsch et 
al. (2008) offer a quote from Jurassic Park as follows: “the late twentieth century has 
witnessed a scientific gold rush of astonishing proportions: the headlong and furious 
haste to commercialise genetic engineering. This enterprise has proceeded so 
rapidly – with so little outside commentary – that its dimensions and implications are 
hardly understood at all” (Audretsch et al., 2008:179). 
 
Studies that focus on the technology transfer offices (TTOs) of universities 
(Markman, Espina and Phan, 2004a; Markman, Gianiodis, Phan and Balkin, 2004b; 
Lockett and Wright, 2005; Markman, Gianiodis, Phan and Balkin, 2005; Wolson, 
2007; Oliver, 2008) have explored the link between the activities of the TTOs and the 
scientist’s entrepreneurial activities in the form of university spin-offs.  
 
The importance of the bioscientist to the process of academic entrepreneurship 
makes it imperative that analysis at the level of the bioscientist is well understood in 
developing economies where empirical research has been limited (Lingelbach et al., 
2005) across all levels of analysis. A similar view has been put forward by Audretsch 
et al. (2008) who advocated direct interaction with the bioscientist to create 
comprehensive and systematic new sources of measurement to assess the extent, 
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nature, determinants and impact of scientific commercialisation of research 
(Audretsch et al., 2008). Part of this call by Audretsch et al., (2008) has been heeded 
in the study conducted by Nilsson, Rickne and Bengtsson (2010b) in which four 
determinants of commercialisation of research were identified: perceived role of the 
university, supportive infrastructure, industrial actor set-up and networks. 
 
Some of the studies at an individual level of analysis considered the differences 
across individual cognitive processes (McClelland, 1961; Stevenson and Jarillo, 
2007) and their link to opportunity identification and the exploitation of such 
opportunities (Krueger, 2005). Other studies identified individual attributes such as 
self-efficacy, collective efficacy, social norms, willingness to incur risk, preference for 
autonomy and self-direction, and differential access to scarce and expensive 
resources (Shane and Venkataraman, 2000; Eckhardt and Shane, 2003; Shane, 
2003). While these studies of individual cognitive processes and characteristics are 
perfectly applicable to general entrepreneurship, they do not fully explain the role of 
the bioscientist, which transcends organisational, regional and national levels of 
analysis.  
 
The study conducted by Zucker et al. (2002) focused on this pivotal role of the 
bioscientist in influencing firm performance. This is an area that requires further 
research as the role of the bioscientist is expected to influence not only firm 
performance but also the process of strategic alliances and government policies on 
biotechnology. This transcending of levels of analysis is similar to the call by 
Audretsch et al. (2008) for comprehensive and systematic new sources of 
measurement, through direct interaction with scientists, to gauge the extent, nature, 
determinants, and impact of scientist commercialisation of research (Audretsch et 
al., 2008). 
 
2.2.5 Intrapreneurship and entrepreneurial orientation 
 
The review of the literature on Intrapreneurship and EO is aimed at providing a 
context in which the design of this empirical study and the appropriateness of the 
utilisation of different theories can be assessed (Davidsson and Wiklund, 2007).  
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Intrapreneurship and EO are concepts that represent corporate entrepreneurship 
(Miller, 1983; Covin and Slevin, 1989; Covin and Wales, 2011) and the degree to 
which organisations are predisposed to entrepreneurial activities (Miller, 1983; 
Lumpkin and Dess, 1996). Lumpkin and Dess (1996) differentiate Intrapreneurship 
from EO. They see Intrapreneurship as the “new entry”, which represents the launch 
of a new venture, while EO is the processes, practices, and decision-making 
activities that lead to the “new entry” (Lumpkin and Dess, 1996).   
 
From the earlier formulation of the EO construct as comprising of “innovativeness”, 
“risk taking” and “proactiveness” (Miller, 1983), which must positively covary, to the 
later expansion of the construct by Lumpkin and Dess (1996) as multidimensional 
and including the dimensions of “autonomy”, “competitive aggressiveness”, 
“innovativeness”, “risk taking” and “proactiveness”, which independently and 
collectively define the domain of EO, it has been applicable to firm-level analysis and 
is seen as an organisational-level strategy-making process (Dess and Lumpkin, 
2001).  
 
The application of EO at the individual level of analysis is deemed inappropriate as 
this is a firm-level construct (Khandwalla, 1977; Miller and Friesen, 1982; Lumpkin 
and Dess, 1996; Dess and Lumpkin, 2001; Basso, Fayolle and Bouchard, 2009). As 
noted by Urban (2008) in the study of  the “prevalence of EO in a developing 
country”, the representation of the firm by surveys of individuals contributes to the 
confusion about the level of operationalisation of EO.  
 
Measurement of the link between EO and firm success and performance in the 
context of developed economies (Zahra, 1991; Zahra and Covin, 1995; Lumpkin and 
Dess, 1996; Zahra, 1999; Lee and Peterson, 2000; Lyon, Lumpkin and Dess, 2000; 
Kuratko, Ireland and Hornsby, 2001) and developing economies (Urban, 2008, 2010) 
has established positive associations within the context of the environment being 
studied. This may provide a basis of comparability for the entrepreneurial disposition 
of organisations across the developed and developing economies divide, taking the 
environmental and organisational factors into consideration (Lumpkin and Dess, 
1996).  
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Having reviewed the literature on the concept of EO (Khandwalla, 1977; Miller and 
Friesen, 1982; Miller, 1983; Covin and Slevin, 1989; Lumpkin and Dess, 1996; Dess 
and Lumpkin, 2001; Urban, 2008; Basso et al., 2009; Urban, 2010; Covin and Wales, 
2011) and the link between EO and firm success and performance (Zahra, 1991; 
Zahra and Covin, 1995; Lumpkin and Dess, 1996; Zahra, 1999; Lee and Peterson, 
2000; Lyon et al., 2000; Kuratko et al., 2001), it is evident that it is a firm-level 
construct that is widely researched, contextualised and accepted as a stable 
construct that explains the process of corporate strategy (Basso et al., 2009). 
However, its applicability to the study of biotechnology entrepreneurship at 
organisational level may not yield similar results for the reasons set out below. 
 
First, the very nature of biotechnology entrepreneurship means that EO is a given for 
situations where a bioscientist follows through on the process of commercialisation 
of biotechnological research (Audretsch et al., 2008). Hence, research that evaluates 
the degree of EO in a biotechnology firm set up by an entrepreneurial bioscientist 
may not yield appropriate results. Even in situations where biotechnology firms are 
set up by larger organisations as a sub-unit, the very basis of setting up the firm has 
to be entrepreneurial and innovation-inclined in order to fit into the definition of 
bioentrepreneurship. Hence, EO is also a given in this situation. 
 
Secondly, the entrepreneurial activities of individuals in biotechnology 
entrepreneurship do not explicitly require organisational structures, activities and 
decision making (Lumpkin and Dess, 1996). While EO is more aligned to strategic 
management and decision making, biotechnology entrepreneurship is dependent on 
research as a necessary condition and the activities of the individual bioscientists 
(Zucker et al., 2002). 
 
Thirdly, the activities of the individual in entrepreneurship can often be explained 
through the individual level of analysis (McClelland, 1961; Shane and 
Venkataraman, 2000; Eckhardt and Shane, 2003; Shane, 2003; Stevenson and 
Jarillo, 2007) and can be bounded from the organisational level of analysis. 
However, in bioentrepreneurship the activities of the individual may span multiple 
levels of analysis (Zucker et al., 2002) and consequently the use of EO will only 
partially capture the dynamics of the process.  
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In addition, while opportunity discovery (Alvarez and Barney, 2007) is prevalent in 
entrepreneurship (including Intrapreneurship), a combination of opportunity 
discovery and opportunity creation (Alvarez and Barney, 2007) is applicable to 
bioentrepreneurship (Murphy and Welsch, 2010). Opportunity creation is prevalent 
as research is a prerequisite (Shane, 2004b; Audretsch et al., 2008).  
 
Thus, while EO is less applicable to individual-level analysis, it may equally not be 
applicable to firm level analysis in biotechnology entrepreneurship because of 
possible partial representation, or misrepresentation, of the dynamics of 
biotechnology entrepreneurship. The dynamics of biotechnology entrepreneurship 
are expected to be better represented, at a firm-level, through the use of the Triple 
Helix approach (Etzkowitz and Leydesdorff, 2000; Etzkowitz, 2001), which captures 
the university, industry, government relations. The sub-dynamics of the Triple Helix 
approach can be studied as a build-up to the university, industry, government 
relations dynamics. Hence, the university component of the Triple Helix can be 
studied in the context of TTOs (Markman et al., 2004a; Markman et al., 2004b; 
Lockett and Wright, 2005; Markman et al., 2005; Wolson, 2007; Oliver, 2008); the 
institutional and cultural contexts of the university (Di Gregorio and Shane, 2003; 
Lockett and Wright, 2005); the new firm started by the scientist (Nerkar and Shane, 
2003; Audretsch and Lehmann, 2005b); and the individual bioscientist (Shane, 
2004b; Lockett, Siegel, Wright and Ensley, 2005).    
 
2.2.6 Technology entrepreneurship 
 
Technology entrepreneurship comprises mostly Information and Computer 
Technology (ICT), Engineering Technology and Biotechnology (Eisenhardt and 
Forbes, 1984). While ICT was the predominant technology of interest in the 20th 
century (Cooke, 2008), the 21st century area of interest is on biotechnology 
(Battelle/Biotechnology Industry Organisation, 2010). In the next section, the review 
of the literature on technology entrepreneurship is focused on biotechnology 
entrepreneurship. 
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2.3 Biotechnology entrepreneurship  
 
Biotechnology is situated at the boundary of the fields of biology and engineering. It 
is a combination of science (medical science, biochemistry, molecular biology, cell 
biology) and industrial production (medical, food, forest industries) (Kivinen and 
Varelius, 2003). Hence, similar to entrepreneurship, biotechnology has been defined 
differently by scholars affiliated to either of the underlying fields (Bud, 1991). This 
contributes to the confusion about what a single unifying definition for the field in the 
early stages of development should be. However, 21st century biotechnology has 
been defined as “the use of cellular and biomolecular processes to solve problems or 
make useful products” (Biotechnology Industry Organisation, 2008:1). 
 
20th century biotechnology evolved from an emphasis on population problems and 
agriculture to a focus on areas such as pharmaceuticals, agricultural chemicals, food 
production, waste disposal and chemical manufacture (Bud, 1991). 
 
In the 21st century, biotechnology has assumed global importance in the areas of 
healthcare, environmental protection, agriculture, chemistry, and material science 
(Biotechnology Industry Organisation, 2008), with significant commercial potential 
(Dibner, 1986; Muller and Fujiwara, 2002; Müller et al., 2004; Ahn and Meeks, 2007; 
Ahn et al., 2010a; Ahn et al., 2012), as shown in Figure 2.4.  
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Figure 2.4: Biotechnology solutions to global issues (Battelle/Biotechnology 
Industry Organisation, 2010) 
 
 
The large-scale global issues as depicted in Figure 2.4 include human health, food 
security, renewable resources and environmental sustainability. Biotechnology 
currently holds the best prospect of providing solutions to these global issues, which 
are more prevalent in the developing economies. Much progress has been made in 
terms of solutions across these four global issues, as highlighted in Figure 2.4 
(Biotechnology Industry Organisation, 2008), and these solutions are expected to be 
accelerated in the 21st century; hence, the 21st century has been termed the 
“biocentury” (Battelle/Biotechnology Industry Organisation, 2010). 
 
In order for the expected benefits of the “biocentury” to be applicable to the 
developing economies, biotechnology entrepreneurship needs to be well understood 
in the context of the developing economies, and sustainably developed to boost the 
competitiveness of these economies. 
 
Within the context of this research, “biotechnology entrepreneurship” and 
“bioentrepreneurship” refer to activities that involve the discovery, evaluation and 
exploitation of biotechnological opportunities, through the use of cellular and 
biomolecular processes, to introduce new goods and services, ways of organising, 
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markets, processes, and raw materials through organising efforts that previously had 
not existed (Shane and Venkataraman, 2000). 
 
Biotechnology entrepreneurship is synonymous with innovation, as the whole 
concept is dependent on innovative new solutions driven through entrepreneurial 
efforts, the commercialisation of which often leads to collaboration between the 
public and private sectors (Etzkowitz and Leydesdorff, 1997; Leydesdorff and 
Etzkowitz, 1998; Gittelman, 1999; Kettler and Casper, 2001; Gittelman, 2006). 
 
The importance of biotechnology entrepreneurship extends to technology transfer 
and technological innovation (Shan, Walker and Kogut, 1994; Leydesdorff and 
Etzkowitz, 1998), in addition to economic development and job creation (Jones-
Evans, 1996; Stringer, 2000). These are areas that are vital to the sustainable 
economic and social development of both South Africa and Brazil. 
 
2.3.1 The context of developed economies 
 
In developed economies, the United States (US) leads the chart in biotechnology.  
The US has more companies, employs more people, invests more in research and 
development, and earns more than all of Europe combined (Kettler and Casper, 
2001). This may be as a result of the early-mover advantage which the US gained by 
embracing biotechnology and actively encouraging the development of the industry 
decades before Europe took the same route.  
 
In 2010, the bioscience industry was estimated to have directly created 1.6 million 
jobs in the US and to be indirectly responsible for about 3.4 million jobs in total 
(Battelle/Biotechnology Industry Organisation, 2012), with a net income of $3.7 
billion for publicly traded biotech companies in 2009 (Ernst & Young, 2010b). 
 
Owing to globalisation and through international collaboration, there is extensive 
interaction between the American and European biotechnology industry through the 
big multinational biotechnology corporations (Dibner, 1986) and research scientist 
networks. At a governmental level, many European countries implement similar 
32 
 
policy initiatives to America in order to fast-track their biotechnology industries. The 
existence of similar policy initiatives to those of America has been confirmed in the 
biotechnology industries of Finland (Kivinen and Varelius, 2003); the United 
Kingdom, Germany and Japan (Dibner, 1986; Müller, 2002; Muller and Fujiwara, 
2002; Müller et al., 2004); and Sweden (Nilsson, 2001).  
 
The combination of American and European biotechnology industries, under the 
banner of developed economies, constitutes a near total domination of the entirety of 
the global biotechnology industry, with the developing economies having very little or 
no impact currently.  
 
It is difficult to make a direct comparison between the biotechnology industry in the 
developed and developing economies, except in cases such as the biofuel industry 
in Brazil, owing to the general lack of empirical research and data, and the 
undeveloped nature of the industry in most developing economies. However, the 
GEM report provides a basis of comparison for general entrepreneurial activities 
across these two types of economies (Herrington et al., 2008; Bosma and Levie, 
2010), which is assumed to provide a similar comparative basis for biotechnology 
entrepreneurship. 
 
The GEM report has categorised the national conditions of the developed economies 
under “innovation-driven” as shown in Table 2.2. 
 
Table 2.2: Importance of different types of national conditions for economic 
development (Bosma and Levie, 2010) 
 
Basic requirements 
Efficiency 
enhancers 
Entrepreneurial 
conditions 
Factor-driven 
economies 
Key focus Develop Start enabling 
Efficiency-driven 
economies 
Maintain Key focus Develop 
Innovation-driven 
economies 
Maintain  Maintain Key focus 
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For developed economies, the basic requirements (institutions, infrastructure, 
macroeconomic stability, health and primary education) and efficiency enhancers 
(higher education and training, goods market efficiency, labour market efficiency, 
financial market sophistication, technological readiness and market size) are in place 
and are maintained. Nevertheless, the key focus is on the entrepreneurial conditions 
(Bosma and Levie, 2010) listed below: 
 
i. Entrepreneurial finance 
ii. Government policies 
iii. Government entrepreneurship programmes 
iv. Entrepreneurship education 
v. R&D transfer 
vi. Commercial and legal infrastructure for entrepreneurship 
vii. Internal market openness 
viii. Physical infrastructure for entrepreneurship 
ix. Cultural and social norms 
 
The prevalence of entrepreneurial activities in the US attests to the availability of 
basic requirements and efficiency enhancers. About 4% to 6% of America’s working 
population take action to start a new business annually, and about 40% experience 
bouts of self-employment in their lifetime (Ács and Audretsch, 2003:5). The result of 
this is that an estimated 761,000 new corporations, the number of which number 
increases to 4.5 million with the inclusion of all forms of business, are started per 
year in America as at 1998 (Ács and Audretsch, 2003:28). The trend for the rest of 
the developed economies is expected to be similar to America, although not to the 
same magnitude. 
 
Some of the differences linked to the national conditions for the developed and 
developing economies (Phan et al., 2008) are shown in Table 2.3. 
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Table 2.3: Differences in national conditions for developed and emerging 
economies (Adapted from (Phan et al., 2008) 
 
Measure Developed economies Emerging economies 
Competitiveness High competitive intensity Vagaries of policy making 
and not much competition 
Socio-economic linkages These issues are usually 
hidden or taken for granted 
in extant literature 
Link between economic 
development, social welfare 
and entrepreneurial action 
Inputs Availability of critical mass of 
inputs required to ignite 
entrepreneurial action 
Lacks the critical mass of 
inputs (capital, human talent, 
technology) required to ignite 
entrepreneurial action 
Nature of entrepreneurial 
action 
May be accidental and 
spontaneous as the 
necessary conditions already 
exist 
Non-accidental and 
purposefully orchestrated by 
government, providing 
resource endowments, 
institutions and markets. 
Government provide both 
macro- and microeconomic 
factors aimed at providing 
incentives for entrepreneurial 
action 
 
 
Biotechnology entrepreneurship activities are currently entrenched in the developed 
economies, and are continually being improved as biotechnology is expected to be 
the economic growth engine of the 21st century (Battelle/Biotechnology Industry 
Organisation, 2010). Expectedly, most of the published literature on biotechnology 
entrepreneurship is based in the developed economies, where industry statistics 
have been tracked for decades.  
 
The empirical studies on biotechnology entrepreneurship for the developing 
economies are still at the exploratory stage and the industry has not developed to a 
stage where statistics are readily available and tracked. 
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2.3.2 The context of developing economies 
 
In developing economies, biotechnology entrepreneurship holds the tantalising 
prospect of significantly contributing to food security, improved agricultural output, 
sustainable environmental development practices, improved healthcare, job creation, 
poverty alleviation and economic development (Clarke, 2002). The achievement of 
all, or any, of these benefits depends on the national conditions that exist in the 
developing economies. The “bigger” economies of the developing world, such as 
BRIC (Brazil, Russia, India and China), South Africa and possibly Nigeria 
(Department of Science and Technology, 2001), may be in a better position to exploit 
the benefits of biotechnology in a globalised world, whether through technology 
transfer, innovative development of the industry, development of particular niches 
within the biotechnology industry or a combination of these and other options. These 
bigger economies represent a vital link between the developing and the developed 
economies as the basic requirements already exist in these economies. 
 
The GEM report classifies the developing economies used in this study as efficiency-
driven (refer to Table 2.2) and as such the key focus is on the efficiency enhancers 
shown below: 
 
i. Higher education and training 
ii. Goods market efficiency 
iii. Labour market efficiency  
iv. Financial market sophistication  
v. Technological readiness  
vi. Market size 
 
While these efficiency enhancers are critical to the development of entrepreneurial 
culture in general, the developing economies still need to develop the 
entrepreneurial conditions (entrepreneurial finance, government policies, 
government entrepreneurship programmes, entrepreneurship education, R&D 
transfer, commercial and legal infrastructure for entrepreneurship, internal market 
openness, physical infrastructure for entrepreneurship, and cultural and social 
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norms) necessary for an innovation-driven industry such as biotechnology 
(Herrington et al., 2008; Bosma and Levie, 2010). 
 
The global issues (human health, food security, renewable resources and 
environmental sustainability) (Battelle/Biotechnology Industry Organisation, 2010) 
that are addressed by biotechnological solutions are more prevalent in developing 
economies as are the issues of economic and social development, unemployment 
and global competitiveness. These issues highlight the importance of understanding 
and developing entrepreneurship in general, and specifically bioentrepreneurship, in 
the developing economies. 
 
2.4 Conclusion  
 
In recent times, there has been growing support for a multidisciplinary approach to 
entrepreneurship research (Thornton, 1999; Ács and Audretsch, 2003; Shane, 2003; 
Murphy et al., 2006; Murphy and Welsch, 2010). The interdisciplinary approach used 
in this study supports Shane’s (2003) individual-opportunity nexus conceptual 
framework, which has opportunity discovery and exploitation as its central premise 
and the Triple Helix of university, industry, government relations (Leydesdorff and 
Etzkowitz, 1998, 2001), which points to the collaboration-intensive nature of 
biotechnology entrepreneurship. 
 
The literature on biotechnology entrepreneurship aligns to the components of the 
individual-opportunity nexus framework (Pisano, 1990, 1991; Gittelman, 1999; 
Feldman and Ronzio, 2001; Kettler and Casper, 2001; Müller et al., 2004; 
Rothaermel and Deeds, 2004; Ahn and Meeks, 2007; Bagchi-Sen, 2007). At the 
same time it highlights the uniqueness of biotechnology entrepreneurship in terms of 
R&D; alliances between multiple stakeholders, which are aligned to the Triple Helix 
of university, industry, government relations approach (Leydesdorff and Etzkowitz, 
1998, 2001); and the commercialisation of intellectual property.  
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These unique features of biotechnology entrepreneurship are the basis for the 
development of the proposed theoretical framework for biotechnology 
entrepreneurship.  
 
Biotechnology is poised to provide answers to most of the global issues and national 
imperatives in the 21st century. Hence, the development of the industry ranks high on 
the list of priorities for many countries, both developed and developing. However, the 
unique set of requirements for making a success of biotechnology entrepreneurship, 
such as bioscience skills, capital, technology and an accommodating political, social 
and economic environment, tilts the odds in favour of developed economies 
(Lingelbach et al., 2005).  
 
The developed economies dominate the biotechnology industry, with the US leading 
the charge. This is confirmed in the literature, which shows that across many 
dimensions such as the following, the developed economies are far ahead of the 
developing economies: 
 
i. Research publication (Gastrow, 2008) 
ii. Patent application (Gastrow, 2008)  
iii. Number of biotechnology companies (Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry Organisation, 2010; Ernst & Young, 
2010b; Battelle/Biotechnology Industry Organisation, 2012) 
iv. R&D spend (Organisation for Economic Cooperation and Development, 
2013b)  
v. R&D intensity (Organisation for Economic Cooperation and Development, 
2013c)  
vi. Revenue generated (Biotechnology Industry Organisation, 2008; 
Battelle/Biotechnology Industry Organisation, 2010; Ernst & Young, 2010b) 
vii. Employment generated (Biotechnology Industry Organisation, 2008; 
Battelle/Biotechnology Industry Organisation, 2010, 2012)  
viii. Biotechnology products in the pipeline and  
ix. Approved biotechnology products in the market (Biotechnology Industry 
Organisation, 2008; Battelle/Biotechnology Industry Organisation, 2010, 2012) 
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The developing economies ranked as efficiency-driven in the GEM report (Herrington 
et al., 2008; Bosma and Levie, 2010; Kelley et al., 2012) may be proficient in first-
generation biotechnology as in the case of South Africa, but not in the recombinant 
DNA-driven third-generation biotechnology. In developing countries where third-
generation biotechnology seems to be relatively developed, such as Brazil, it is 
concentrated in the agricultural biotechnology sector.  
 
These differences (Lingelbach et al., 2005), gaps and preferences for a particular 
type of biotechnology entrepreneurship were taken into account in developing the 
research questions for this study, which are presented in the next chapter. 
 
Research questions were chosen instead of propositions firstly because of the 
exploratory nature of this study; secondly, because very little empirical research 
exists for developing economies; and, thirdly, because of the need for an in-depth 
understanding of biotechnological entrepreneurship in developing economies within 
its real-life context. 
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Chapter 3:  Research Questions and Organising Frameworks 
 
3.1 Research questions 
 
This section outlines the research questions explored in this study to achieve the 
purpose of the study, which is to explore the dynamics of biotechnology 
entrepreneurship in the developing economies of South Africa and Brazil. 
 
Question 1 
How do bioscientists carry out biotechnology entrepreneurship in the developing 
economies of South Africa and Brazil? 
 
Question 2 
How is biotechnology entrepreneurship conducted by bioscientists in developing 
economies similar to the process defined in the literature for developed economies? 
 
Question 3 
How is biotechnology entrepreneurship conducted by bioscientists in developing 
economies different from the process defined in the literature for developed 
economies? 
 
Question 4 
What are the factors that influence biotechnology entrepreneurship in developing 
economies, and how do they exert their influence?  
 
Question 5 
What Triple Helix of university, industry, government relations are experienced by 
the stakeholders in the biotechnology industry of South Africa and Brazil? 
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3.2 Organising frameworks  
 
This section outlines the organising frameworks for this research, which guided the 
exploration of the dynamics of biotechnology entrepreneurship in the developing 
economies of South Africa and Brazil. These are the individual-opportunity nexus 
framework of entrepreneurship as shown in Figure 2.2 on page 16 (Shane, 2003:11), 
and the triple helix model of university, industry, government relations as shown in 
Figure 2.3 on page 19 (Etzkowitz and Leydesdorff, 2000). 
 
The individual-opportunity nexus framework was used to explore how biotechnology 
entrepreneurship is carried out in South Africa and Brazil. The process of 
biotechnology entrepreneurship in South Africa and Brazil is then compared to the 
literature on the process of biotechnology entrepreneurship in developed economies, 
in order to identify similarities and differences.  
 
The triple helix approach was used to explore what relationships are experienced by 
the stakeholders in the biotechnology industries of South Africa and Brazil across the 
university, industry, and government spheres. 
 
Given the paucity of empirical research on biotechnology entrepreneurship in the 
context of the developing economies, these organising frameworks linked the 
literature on entrepreneurship to the data from this research. In this way, the 
researcher was able to develop an understanding of biotechnology entrepreneurship 
in the developing economies of South Africa and Brazil.  
 
 
 
 
 
 
 
 
41 
 
Chapter 4:  Research Methodology 
 
 
The purpose of Chapter 4 is to describe the philosophical foundations of this 
research and the strategies of inquiry underpinning it, and to articulate the rationale 
for choosing the methodological approach described in this chapter. The chapter 
also describes the research design, the case-selection criteria, data-collection and 
analysis processes, the steps taken to ensure the validity and reliability of this 
research, and finally the limitations and delimitations of the research. 
 
 
4.1 The philosophical foundations of this research 
 
The philosophical foundation of entrepreneurship is not easily defined because 
entrepreneurship as a field of study has been characterised by multiple underlying 
disciplines, which influence the approaches used in empirical research. Scholars 
have tended to support either the individual view (McClelland, 1961; Kihlstrom and 
Laffont, 1979; Schere, 1982; Gartner, 1990; Bouchikhi, 1993) or the environmental 
view of entrepreneurship (Tushman and Anderson, 1986; Hannan and Freeman, 
1987; Bouchikhi, 1993; Ács and Audretsch, 2003), with each camp defending its 
philosophical position. Consequently, no consensus has been achieved on the 
appropriate unit of analysis or design processes, or appropriate data-collection and 
analysis techniques (Brazeal and Herbert, 1999). 
 
Current empirical studies are dominated by a nomothetic, as opposed to an 
idiographic, philosophical approach. Biotechnology entrepreneurship is a relatively 
new field within entrepreneurship (Meyers, 2012) and consequently suffers the same 
methodological bias. The nomothetic approach is based on objective inquiry and 
requires the verification of facts through mostly quantitative methods (Guba and 
Lincoln, 1994). Hence, the predominant school of thought in the field of 
entrepreneurship, which determines the predominant methodology employed in 
entrepreneurship research, is positivism (Guba and Lincoln, 1994; Onwuegbuzie, 
2002; Onwuegbuzie and Leech, 2005; Neuman, 2006). This fact is supported by the 
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prevalence of quantitative over qualitative methods in the decade ending 2001 
(Chandler and Lyon, 2001), in which only 18% of studies used qualitative methods. 
 
In the idiographic philosophical tradition, which is based on the subjective 
relationship between the researcher and the participants and the co-creation of 
meaning, the verification of facts is through mostly qualitative methods (Guba and 
Lincoln, 1994). Hence, the predominant school of thought is interpretive social 
science (Neuman, 2006; Creswell, 2009). 
 
Despite the low levels of application of the idiographic philosophical tradition, and 
hence qualitative approaches, in entrepreneurship studies, there has been 
increasing recognition of the usefulness of a convergence of quantitative and 
qualitative approaches, or mixed methods, in empirical research. This is aligned to 
efforts to encourage multidisciplinary approaches to the field of entrepreneurship 
(Shane and Venkataraman, 2000; Shane, 2003; Murphy et al., 2006; Murphy and 
Welsch, 2010), which extends to the broadening of the strategies of inquiry 
(Creswell, 2009). 
 
Some of the reasons for the support of the convergence of quantitative and 
qualitative approaches in empirical research include:  
 
i. Criticism of the supposed superiority of quantitative methods (Guba and 
Lincoln, 1994; Long, White, Friedman and Brazeal, 2000; Mir and Watson, 
2000; Onwuegbuzie, 2002; Onwuegbuzie and Leech, 2005) 
ii. Use of qualitative and quantitative methods for theory generation and theory 
testing respectively (Long et al., 2000)  
iii. The need for practical research and results dissemination in lay language 
iv. Generation of possible outcomes of corroboration, elaboration, 
complementarity and contradiction  
v. Provision of a holistic framework for understanding meanings and actions 
(Brannen, 2005) 
vi. Lack of one-to-one correspondence between paradigm and method  
vii. The re-conceptualisation of qualitative and quantitative paradigms to lie on an 
epistemological continuum (Onwuegbuzie, 2002) 
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The approach taken for this research is guided by Creswell’s (2009) framework for 
design, the interconnection of worldviews, strategies of inquiry and research 
methods, as shown in Figure 4.1. The philosophical worldviews determine the 
selected strategies of inquiry, which in turn determine the research methods. The 
social construction world view or philosophical approach was employed for this 
research. 
 
 
Figure 4.1: Creswell’s (2009:5) framework for design – the interconnection of 
worldviews, strategies of inquiry and research methods 
 
For the social construction worldview, the strategies of inquiry include 
phenomenology, grounded theory, ethnography, case study and narrative (Creswell, 
2009).  
 
The suggested methods to be employed for these strategies of inquiry include 
emerging methods; open-ended questions; interview data, observation data, 
document data, and audio-visual data; text and image analysis; and interpretation of 
Philosophical 
Worldviews
Postpositive
Social construction
Advocacy/participatory
Pragmatic
Selected Strategies of 
Inquiry
Qualitative strategies 
(e.g., ethnography)
Quantitative strategies 
(e.g., experiments)
Mixed methods strategies 
(e.g., sequential)
Research Methods
Questions
Data collection
Data analysis
Interpretation
Write-up
Validation
Research Designs
Qualitative
Quantitative
Mixed methods
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themes and patterns (Creswell, 2009). The researcher’s practices of research 
include: positioning themselves, collecting participants’ meanings, focusing on a 
single concept or phenomenon, bringing personal values into the study, studying the 
context or setting of participants, validating the accuracy of findings, making 
interpretations of the data, creating an agenda for change or reform, and 
collaborating with the participants (Creswell, 2009). 
 
Creswell (2009) also advocates a pragmatic approach to research, which removes 
emphasis from the defence of individual philosophical positions and rather 
concentrates on the context of the problem and the need for a solution. 
 
The rationale for using an idiographic philosophical tradition for this study is the 
complex nature of the social interactions involved at the individual, organisational, 
institutional and national levels which underlie the dynamics of bioentrepreneurship. 
These interactions are non-linear and have multiple overlapping meanings, and are 
suitably studied through the case study method. 
 
4.2 Strategies of inquiry underpinning this research 
 
The strategy of inquiry used for this research is the case study.  
 
Yin (2009) defines a case study as an empirical enquiry that: 
 
investigates a contemporary phenomenon in depth and within its real-life 
context, especially when the boundaries between phenomenon and 
context are not clearly evident (Yin, 2009:18). 
 
The study of the dynamics of biotechnology entrepreneurship in South Africa and 
Brazil is exploratory. Most of the current empirical research is carried out in 
developed economies and cannot be directly extrapolated to developing economies 
owing to differences at individual, institutional and environmental levels between the 
developed and developing economies (Lingelbach et al., 2005). In addition, 
biotechnology entrepreneurship is a contemporary phenomenon (Yin, 2009) that 
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needs to be investigated in depth and within its real-life context (Creswell, 2009). 
The “how” and “why” questions needed to explore and understand how 
biotechnology entrepreneurship is practised in developing economies also lend 
themselves to the use of the case study strategy of inquiry (Yin, 2009). 
 
4.3 Research design 
 
The design of this research is informed by the context of biotechnology 
entrepreneurship in developing economies. This context includes: 
 
i. The nature of the research problem and the research questions to be 
answered, as detailed in Chapter 3 
ii. The fact that current empirical research on this topic is based on developed 
economies, and very little empirical research exists for developing economies 
(Lingelbach et al., 2005)  
iii. The possibility that entrepreneurship, and hence biotechnology 
entrepreneurship, is different across the developed and developing 
economies  
iv. The move towards multidisciplinary approaches to entrepreneurship research 
(Shane, 2003; Murphy et al., 2006; Murphy and Welsch, 2010)  
v. The need for methodological expansion in entrepreneurial research (Hindle, 
2004)  
vi. The need to achieve an in-depth understanding of the phenomenon of 
biotechnology entrepreneurship in developing economies through qualitative 
methods of inquiry in the idiographic philosophical tradition 
 
Primary data from a case study design was used for this study. Multiple cases, 
comprising South Africa and Brazil, were investigated in order to achieve literal and 
theoretical replication (Eisenhardt, 1989, 1991; Yin, 2009). The individual cases were 
holistic within the multiple-case study. The case study was carried out at country 
level of analysis with interviews conducted with individuals associated with the 
biotechnology industry in various capacities. Environmental and institutional factors 
have key influences on the dynamics of biotechnology entrepreneurship at a country 
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level. The use of a country level of analysis was expected to embody these 
environmental factors and be broad enough to provide a true understanding of the 
dynamics of biotechnology entrepreneurship in the developing economy context. In 
addition, conducting interviews with individuals within the biotechnology industry 
ensured that the lived dynamics of biotechnology entrepreneurship within its original 
context were adequately captured (Creswell, 2009; Yin, 2009). 
 
The research design process followed was Yin’s (2009) case study method as 
shown in Figure 4.2. There are three broad phases: define and design; prepare, 
collect and analyse; and analyse and conclude, which in total contain five steps. 
 
Steps one and two fall under the “define and design” phase; steps three and four fall 
under the “prepare, collect and analyse” phase; and step five falls under the “analyse 
and conclude” phase.   
 
 
 
Figure 4.2: Case study method (adapted from (Yin, 2009) 
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The process started with an organising framework, based on the individual-
opportunity nexus framework of entrepreneurship, which guided the definition of 
appropriate research design and data collection, and the analytical generalisation of 
the results of the case study (Yin, 2009).  
 
Step two involved the design of a data-collection protocol and the selection of cases. 
The case selection criteria are outlined in Section 4.4. 
 
Step three involved the conducting of interviews for the case studies in South Africa, 
and Brazil. The conducting of these interviews was expected to be sequential; 
hence, the completion of interviews in South Africa was to be followed immediately 
by interviews in Brazil. However, the initial interviews for South Africa were 
conducted; then followed by interviews in Brazil; before completing the rest of the 
South African interviews. The challenges of conducting research in multiple countries 
were highlighted in this study through the difficulty of securing appointments with key 
respondents within the same timeframe.   
 
Step three led to the refinement of the organising framework; a review of the 
selected cases; and a review of the design of the data-collection protocol. The 
details of the data-collection technique are given in Section 4.5.  
 
Step four involved the writing up of the individual case reports. This included the 
case narratives, case analysis, the discussion of the outcome of the analysis, and 
theory development. 
 
Step five is the last step in this design model and in this study comprised the 
concluding activities of the study such as: drawing cross-case conclusions; modifying 
theory; developing policy implications; and articulating the methodological, empirical 
and theoretical contributions of the research. 
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4.4 The case selection  
 
The focus of this study on a specific type of entrepreneurship, biotechnology 
entrepreneurship, limited the respondents to bioscientists who had started 
biotechnology companies or had utilised licensing to commercialise their intellectual 
property; and subject matter experts involved in biotechnology entrepreneurship 
through the university, industry or government. Hence, cases were selected 
purposively. In addition, industry documents were selected purposively to enable 
data triangulation and enhance the reliability of the research. 
 
The use of homogeneous purposive sampling is aligned to the nature of the 
respondents for this study, who were expected to be hard to reach (Guest, Bunce 
and Johnson, 2006), especially considering that the study was conducted across two 
countries. The sampling methodology also supports the fact that the focus of this 
study was not on statistical generalisability (Miles and Huberman, 1999; Bowen, 
2008) but on the understanding of the dynamics of biotechnology entrepreneurship 
in South Africa and Brazil within its original context (Yin, 2009). 
 
4.4.1 Rationale for selecting cases 
 
In the context of developing economies, there are other countries that could easily 
be considered for inclusion into this research, such as Malaysia and Indonesia. 
However, within the context of biotechnology entrepreneurship there are clear 
similarities that make Brazil and South Africa good candidates for this research. 
 
Both countries are classified as efficiency-driven economies in the GEM study 
(Bosma and Levie, 2010; Kelley et al., 2012) and are seen as ideal emerging market 
partners for biotechnology alliances with developed economies (Veilleux, Haskell 
and Béliveau, 2010). In addition, they have fairly developed economy, government 
institutions, educational institutions, regulatory environment and markets according 
to the standard of developing countries (Veilleux et al., 2010). 
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On the basis of patent publication, both have fairly good representation of patent 
publications according to the standard of developing economies (Bound, 2008; 
United States Patent and Trademark Office, 2009) and are often included in the 
Organisation for Cooperation and Development (OECD) analysis and reports on 
biotechnology (Organisation for Economic Cooperation and Development, 2013d). 
 
On the basis of the stage of their biotechnology industry, both have abundant 
biodiversity and advanced agricultural biotechnology (Cloete et al., 2006; Bound, 
2008) and are considered as viable partners for direct foreign investment in 
biotechnology (Ernst & Young, 2010b). 
 
In terms of government policy on biotechnology entrepreneurship, both have high 
level of government involvement and clearly defined policies on biotechnology 
development (Department of Science and Technology, 2001; da Silveira and de 
Carvalho Borges, 2005; Marques and Gonçalves Neto, 2007; Bound, 2008; 
Technology Innovation Agency, 2010; Ernst & Young, 2010b). 
 
4.4.2 Rationale for selecting respondents 
 
The purposive samples were made up of individuals with a high degree of 
knowledge and competence in the research topic (Romney, Weller and Batchelder, 
1986; Bowen, 2008) and had either commercialised a biotechnological innovation 
through firm formation or licensing or were subject matter experts in the area of 
biotechnology entrepreneurship. The purposive selection of 12 respondents in South 
Africa and 5 respondents in Brazil, supported by 16 industry documents, rendered an 
accurate reflection of the dynamics of biotechnology entrepreneurship in South 
Africa and Brazil respectively (Romney et al., 1986; Guest et al., 2006).  
 
Emphasis was placed on selecting respondents that were relevant to the 
phenomenon being studied, provided diversity across contexts, provided 
opportunities to learn about complexities and contexts (Stake, 2006), and explicitly 
supported literal and theoretical replication, in this way enhancing analytic 
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generalisation of the outcome of the case study (Eisenhardt, 1989, 1991; Yin, 2009). 
With this in mind, the selection criteria included the following conditions: 
 
i. All respondents were either bioscientists who started biotechnology 
companies, or utilised licensing, to commercialise their intellectual property or 
subject matter experts involved with biotechnology entrepreneurship at a 
university, or in industry or government 
ii. The respondents worked in one of the areas of biotechnology 
entrepreneurship that are prioritised by the governments of South Africa and 
Brazil, which are industrial, health and agricultural biotechnology 
iii. All bioscientists in the sample should have gone through the stages of the 
organising framework from bioentrepreneurial (entrepreneurial) opportunities 
to commercialisation of intellectual property (execution). Thus, they should 
have products that were already in the market or ready to be marketed 
iv. All respondents should have engaged or should currently engage in varying 
degrees of collaboration with other biotechnology stakeholders 
 
Access to the respondents was facilitated through the networks of the researcher’s 
academic supervisors. In addition, the researcher established links to academic 
networks in Brazil through the biotechnology unit of Ernst & Young, respondents in 
South Africa after the first interviews, and online internet searches. Links were also 
established with the Biotechnology Unit of the Department of Science and 
Technology in South Africa, and similar links were established with other bodies 
directly or indirectly responsible for biotechnology policy development in South Africa 
and Brazil.  
The profile of the respondents is attached in Tables 7.1 on page 152 and 8.1 on 
page 206. 
 
4.4.3 Rationale for selecting documents 
 
The documents reviewed and coded for this research were intended to augment the 
in-depth interviews in providing a complete and triangulated view of the dynamics of 
biotechnology entrepreneurship in South Africa and Brazil from multiple sources. The 
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documents included in this research fall under the broad categories of policy 
documents and industry research documents from credible organisations such as 
the OECD, Ernst & Young, Biotechnology Industry Organisation (BIO), and Battelle. 
 
The policy documents included legislated national policy documents on 
biotechnology, regional funding policy documents on biotechnology 
entrepreneurship, university intellectual property policy documents, and the policy 
document for the government innovation agency. The industry research documents 
included innovation policy reviews, science and technology industry outlook, 
agricultural innovation systems, industrial biotechnology, bio-economy, and the 
general biotechnology industry documents. 
 
These documents were deemed to be credible, reliable, and provided information 
that enriched the understanding of biotechnology entrepreneurship in general and 
the context in developing economies in particular. 
 
The documents included for the research in South Africa are: 
 
i. National Bio-economy Strategy 2013 
ii. Technology Innovation Agency (TIA) Act 2008 
iii. OECD Reviews of Innovation Policy 
iv. OECD Science, Technology and Industry Outlook 2010 
v. WITS University Intellectual Property Policy 2012 
 
The documents included for the research in Brazil are: 
 
i. National Biotechnology Development Policy 
ii. OECD Boosting Innovation Performance in Brazil 
iii. FAPESP Creation and Structure Document 
iv. FAPESP Co-ordination Document 
v. OECD Science, Technology and Industry Outlook 2008 
vi. OECD Managing Relations with Industry: The Case of Brazilian Universities 
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The industry documents that are applicable to South Africa, Brazil, and the 
developed economies are: 
 
i. Ernst & Young Beyond Borders 2013 
ii. OECD Agricultural Innovation Systems - A framework for analysing the role of 
the Government 
iii. OECD Future prospects for industrial biotechnology 
iv. OECD Bioeconomy 2030 
v. Battelle/BIO 2012 State Bioscience Industry Development 
 
The graphical depiction of the cases, respondents and documents selection aligned 
to the case study protocol is shown in Figure 4.3. 
 
Under each of the cases, South Africa and Brazil, there are 3 groups of respondents, 
namely: bioentrepreneurs, subject matter experts and respondents that are both 
bioentrepreneur and subject matter expert. The subject matter expert group is further 
sub-divided into those respondents affiliated to university, industry or government. 
There is a certain degree of overlap within the subject matter experts group, in which 
a respondent can be affiliated to more than one entity, such as university and 
government. 
 
The fourth grouping under each case is documents. This comprises of industry and 
policy documents related to biotechnology entrepreneurship in this specific case.  
 
The fifth grouping under the hermeneutic unit contains documents related to 
biotechnology entrepreneurship in general, which includes both cases as well as 
other developing and developed economies. 
  
Note: The numbering of the respondents in South Africa is aligned to the sequence 
in which the transcripts were coded. Hence the first 5 interviews are numbered 1 – 5; 
then the next 7 interviews were numbered 11 – 17; and between these are the 
interviews conducted in Brazil, which are numbered 6 – 10. 
Hence, there are a total of 12 respondents in South Africa and 5 respondents in 
Brazil. 
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Format for numbering respondents and documents 
 
The numbering of respondents, and referencing of verbatim quotes, in the document 
was dictated by the Atlas.ti CAQDAS used for the data analysis, which analysed the 
transcripts sequentially and assigned primary document number. Hence, 
(Respondent 11 6:46) refers to interview number 11; primary document 6; transcript 
line 46. 
 
Table 4.1 illustrates the format for numbering of respondents and referencing the 
transcript verbatim quotes from Atlas.ti.. 
 
Table 4.1: Format for naming respondents and referencing transcript verbatim 
quotes 
Atlas.ti Primary document number Interview number Respondent Case 
PD 1 1 1 South Africa 
PD 2 2 2 South Africa 
PD 3 3 3 South Africa 
PD 4 4 4 South Africa 
PD 5 5 5 South Africa 
PD 6 11 6 South Africa 
PD 7 12 7 South Africa 
PD 8 13 8 South Africa 
PD 9 14 9 South Africa 
PD 10 15 10 South Africa 
PD 11 16 11 South Africa 
PD 12 17 12 South Africa 
PD 18 6 1 Brazil 
PD 19 7 2 Brazil 
PD 20 8 3 Brazil 
PD 21 9 4 Brazil 
PD 22 10 5 Brazil 
 
The PD ranges P13 – P17 refer to the industry documents for South Africa; P23 - 
P25, and P32 – P34 refer to the industry documents for Brazil; and the range P27 – 
P31 refer to the industry document for the overall biotechnology industry (cross-
case).
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Figure 4.3: A graphical depiction of the case, respondents and documents selection for the research 
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55 
 
4.5 Data collection 
 
The process of data collection illustrated in Figure 4.4 was guided by the case study 
protocol (see Appendix C).  
 
4.5.1 Development of data-collection instrument 
 
The case study protocol was developed after the literature on biotechnology 
entrepreneurship was reviewed and subsequently the researcher chose two 
organising frameworks for the research. The data-collection process included 
multiple sources of evidence: in-depth interviews, documents and observations. This 
triangulation of data sources improves the quality of the research, as well as 
addressing validity and reliability issues (Creswell, 2000; Onwuegbuzie, Johnson 
and Collins, 2011).  
 
 
 
Figure 4.4: A graphical depiction of the data collection process 
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The case study protocol was developed concurrently with the interview guide and at 
this stage the two cases, South Africa and Brazil, were also identified. 
 
The next step was the identification of appropriate respondents who fit into the 
category of respondents required for the research: bioentrepreneurs and subject 
matter experts in the biotechnology industry affiliated to university, industry or 
government. Some of the respondents were expected to be both bioentrepreneurs 
and subject matter experts. 
 
Having identified appropriate respondents, the consent of the respondents to 
participate in the interviews was sought via email. Of the 12 respondents identified in 
South Africa, five responded positively. These five were included in the first phase of 
the case study in South Africa. Subsequently, another eight respondents were 
identified in South Africa and seven of whom agreed to participate in the research. 
This brought the total number of respondents in South Africa to 12. 
 
Of the eight respondents identified in Brazil, five responded positively while the 
remaining three could not participate in the study because of their unavailability at 
the time the researcher conducted fieldwork in Brazil. 
 
The next step involved sending the respondents the research summary and the 
consent letters for participation in the study and for the interview to be recorded. This 
was followed by the researcher’s confirmation of the appointment and scheduling of 
the interview. This stage was performed concurrently with gathering the relevant 
documents for the research. With all the respondents confirmed and the relevant 
documents gathered, the case file was opened. Documents included formal prior 
studies of the same cases, university and government policy documents, and 
industry documents. This source of evidence yielded background information in the 
form of written evidence and descriptive statistics that were used to corroborate the 
other sources of evidence. 
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4.5.2 Observing the respondents 
 
Observations require the researcher to be present in the real-life environment of the 
cases to record observed conditions (Creswell, 2009; Yin, 2009; Qu and Dumay, 
2011; Klonoski, 2013). Observation as a source of evidence provided real-time 
information as it occurred and information that was not shared in the interview by the 
respondent. (A sample observational form is provided in Appendix G).  
 
Observation includes the environment in which the bioentrepreneur or subject matter 
expert operates; the disposition of the respondent; the respondent’s reactions to 
interview questions; and the attitude of the respondent. These were captured in the 
field notes by the researcher. 
 
4.5.3 Conducting the interviews 
 
Semi-structured interviews were conducted with the bioscientists and subject matter 
experts using the earlier-developed interview guide (see Appendices E and F) and 
the case study protocol (see Appendix D). The development of the interview guide 
was guided by a review of the literature, the research questions, and the organising 
frameworks. 
 
The interview guide gave a general outline of the type of interview questions needed 
to cover all the relevant aspects of the study (Yin, 2009). Given that this was a semi-
structured interview, the exact questions posed during the interview differed slightly 
on occasions but conveyed the same meaning and understanding. There was also 
scope to probe deeper, where necessary, in order to clarify the respondents’ points 
of view. 
 
The purpose of the protocol is to guide the operational conduct of the data-collection 
procedure by the investigator in a single case, which forms part of the multiple 
cases. The protocol is a standardised agenda for the investigator’s line of inquiry 
(Yin, 2009). The effective use of the protocol for each case in a multiple case study 
guarantees uniformity of data collection aligned to the research questions, theoretical 
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framework and propositions. This is expected to enhance the reliability of the 
research (Creswell, 2000; Onwuegbuzie et al., 2011). 
 
Fifteen of the interviews were conducted at the respondents’ offices. The location of 
the offices varied from universities, to a business park, a mall, government offices 
and business premises. Two of the interviews in Brazil were conducted at the 
respondents’ homes because one respondent was on leave at the time and the other 
undergoing medical treatment. 
 
Conducting the interviews at a time and place convenient to the respondents 
ensured that the respondents were relaxed and comfortable with accommodating the 
time needed for the interview, which was one to two hours in most cases. The 
interviews started with a detailed explanation of the research topic, with the 
researcher clarifying any question the respondent had from the research summary 
sent earlier. The respondents were then requested to sign the letters of consent to 
participate in the research and to have the interview tape-recorded. 
 
The first interview in South Africa was used as a pilot interview to ensure that 
questions covered during the interview would provide answers to the research 
questions. This interview was transcribed and reviewed by the researcher’s 
academic supervisor, and her recommendations were used to refine the interview 
guide for the interviews that followed. Subsequently each interview was reviewed to 
ensure alignment to the case study protocol, and to identify improvements that were 
needed for the remaining interviews.  
 
All interviews were tape-recorded and transcribed and the transcripts confirmed as 
accurate by the respondents before being analysed by the researcher. In addition to 
the transcripts, the researcher maintained field notes to capture thoughts, 
observations and reflections on the research. 
 
The transcripts (see Appendix H), documents and the researcher’s field notes were 
the source of the data for the data analysis.  
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4.6 Data analysis 
 
The qualitative data analysis for this research was conducted in the tradition of 
building theory from case studies in order to understand the “how” and “why” of 
contemporary events (Eisenhardt and Graebner, 2007b; Yin, 2009:8; Klonoski, 
2013). The dynamics of biotechnology entrepreneurship in South Africa and Brazil 
were examined in detail to generate theoretical insights (Welch, Piekkari, 
Plakoyiannaki and Paavilainen-mäntymäki, 2011), understand their peculiarities 
(Stake, 2006), and the structures and contexts (Klonoski, 2013) in which observed 
behaviours were analysed. 
 
A Computer Aided Qualitative Data Analysis Software (CAQDAS) package called 
Atlas.ti version 7.1.6 was used for the data analysis. The use of Atlas.ti was meant to 
aid rapid, consistent and rigorous qualitative data analysis (Weitzman, 1999; 
Rambaree, 2007; Hwang, 2008), and extended the researcher’s ability to organise, 
remember and be systematic (Zdenek, 2008). 
 
There were eight steps in the data analysis stage (see in Figure 4.5): 
 
i. Deductive development of the codebook  
ii. Preparation of transcripts and documents for coding 
iii. Selection of data to code 
iv. Coding of the primary documents and the generation of inductive codes and 
memos 
v. Case narratives based on the outcome of the coding exercise 
vi. Within-case analysis of cases 1 and 2 
vii. Cross-case analysis 
viii. Theory development 
 
4.6.1 Deductive development of the codebook  
 
The first step of the data analysis was the deductive development of the codebook 
(see Appendix I). Guided by the available literature, the proposed conceptual 
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frameworks and the case study protocol, the codebook comprised 176 codes and 21 
categories. The deductive codes developed in this step were appropriately described 
and formed the basis of the coding that occurred in step 3. 
    
 
Figure 4.5: A graphical depiction of the data analysis process 
 
4.6.2 Preparation of transcripts and documents for coding 
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being loaded into the personal library created within the hermeneutic unit for the 
project. The hermeneutic unit is the container for the project and holds all the 
documents and resources necessary for the project. A total of 33 primary documents 
were loaded into the personal library comprising 17 interview transcripts and 16 
policy and industry documents.  
 
Prior to commencing with coding, the primary documents were grouped into primary 
document families, representing the units of analysis for the research at country and 
individual levels. This was an aggregation of the code families and categories into 
super families (Hwang, 2008; Zdenek, 2008). The super families were: “All 
respondents” (which represented a country level of analysis); “bioentrepreneurs”, 
“both bioentrepreneur and subject matter expert”, and “subject matter experts” 
(which represented an individual level of analysis); and documents (which 
represented an industry level of analysis). These were created at the level of 
individual cases and at a cross-case level to enable the within-case and cross-case 
analysis (Stake, 2006; Yin, 2009) later on. 
 
In addition to preparing the primary documents and creating the primary document 
families, the deductive codes were manually transferred into Atlas.ti and 
appropriately described. The codes were also grouped into code families, which 
represented the categories. The completion of this step was the prerequisite for 
carrying out the actual coding in the next step. 
 
4.6.3 Selection of data to code 
 
The selection of data for coding was driven by the need to embed the outcome of the 
coding process in the data, to understand the exact meaning of what the 
respondents were saying within the context of the research, and to reflect the reality 
being portrayed in the data segment or quotation accurately (Corbin and Strauss, 
2008). Hence, data segments were carefully chosen either to validate the deductive 
codes or to lead to the generation of inductive codes as a starting point to the 
development of theory (Charmaz, 2003). 
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4.6.4 Coding of the primary documents 
 
The primary documents consisted of 402 pages of interview transcripts, 423 pages 
of documents related to the two cases at country level, and 817 pages of industry 
documents. This made up a total of 1,642 pages. Most of the industry documents 
were from credible organisations such as the OECD and Ernst & Young. In addition 
to the primary documents, 73 memos were created during the course of the coding 
exercise.  
 
The sequence of the coding was a complete coding of all primary documents related 
to case 1 in the order in which the interviews were conducted, followed by the coding 
of all primary documents related to case 2 in the order in which the interviews were 
conducted.  
 
The primary documents were coded line-by-line to ensure intimacy with the data and 
accurate understanding of the meaning (Corbin and Strauss, 2008). The deductive 
codes were assigned to quotations where appropriate and inductive codes (see 
Appendix J) were created whenever new insights emerged. A total of 170 inductive 
codes were created in the coding process. This, combined with the 176 deductive 
codes, resulted in a total of 346 code, which was further rationalised to 335 codes. 
One new category was also created through the inductive process thereby 
increasing the number of categories to 22. 
 
This study does not qualify as pure grounded theory (Corbin and Strauss, 2008) as it 
used both deductive and inductive coding, and involved theory testing and theory 
development (Lillis, 1999; Miles and Huberman, 1999). However, it can be noted that 
the number of inductive codes was higher than deductive codes post rationalisation. 
Furthermore, 29 of the 165 deductive codes were redundant and did not appear in 
any of the quotations.  
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Demonstrating data saturation 
 
Data saturation was demonstrated for both cases (Figures 4.6 and 4.7) using Atlas.ti 
CAQDAS. The definition of saturation in this context is the point where little or no 
new codes (insights) are generated from additional respondents or documents 
(Morse, Barrett, Mayan, Olson and Spiers, 2002; Guest et al., 2006). 
 
Figure 4.6 shows that 43% of all the unique codes were generated from the first 
respondent; 84% by the 12th respondent; and 100% of all the unique codes for case 
1 generated by the 16th respondent (document). Hence, no new additional insights 
were generated from the last respondent (document). 
 
The spikes at “P5: Interview 5” and “P13: Bioeconomy Strategy_Dev2” mark the first 
transcript of a bioentrepreneur after four subject matter experts (SMEs) and the first 
coded document after transcripts of SMEs and bioentrepreneurs respectively. 
 
 
Figure 4.6: Demonstration of data saturation for South Africa 
 
Figure 4.7 shows that 44% of all the unique codes were generated from the first 
respondent; 77% by the fifth respondent; and 93% of all the unique codes for case 2 
generated by the sixth respondent (document). Hence, very little new additional 
insights were generated from the seventh respondent (document). 
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The spike at “P34: National Biotechnology Development Policy” marks the first 
coded document after transcripts of SMEs and bioentrepreneurs. 
 
 
Figure 4.7: Demonstration of data saturation for Brazil 
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influences”; “business level influences”; “macro-environment influences”; “triple helix 
relationships”; and “similarities and differences between South Africa or Brazil and 
the developed economies”. 
 
The personal views of the researcher were captured under the “observations” sub-
heading and were intended to enrich the discourse within objective parameters 
(Eisenhardt and Graebner, 2007b). However, since these observations are not part 
of the case study data, they have been limited to the case narratives section of the 
research. The personal views of the researcher contributed to the “thick” description 
of what was observed during the interview process.  
 
The verbatim quotes enabled the grounding in data of the patterns that eventually 
emerged in the within-case analysis stage. The aggregated responses of the 
respondents captured the predominant insights as well as divergences from the 
predominant view where such divergences were material to a deeper understanding 
of the real-life experiences of the respondents.  
 
The case narratives provided a rich, “thick” description of the experiences of the 
respondents within a real-life context (Eisenhardt and Graebner, 2007b; Yin, 2009) 
of biotechnology entrepreneurship, which guided the identification of patterns; as 
well as theory development (Carroll and Swatman, 2000; Eisenhardt and Graebner, 
2007b; Welch et al., 2011; Klonoski, 2013). 
 
4.6.6 Within-case analysis 
 
The detailed within-case analyses integrated the deep interrogation of the current 
empirical and market research studies on biotechnology entrepreneurship in South 
Africa and Brazil; interview transcripts; the output of Atlas.ti CAQDAS; and 
documents. This was done to get to a consistent and rigorous analytical view 
(Weitzman, 1999; Rambaree, 2007; Hwang, 2008) of the dynamics of biotechnology 
entrepreneurship in South Africa and Brazil within its original context (Eisenhardt and 
Graebner, 2007b; Klonoski, 2013). The patterns identified represented a further 
aggregation of data to a higher level of abstraction towards theory building (Lillis, 
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1999; Miles and Huberman, 1999; Eisenhardt and Graebner, 2007b; Klonoski, 
2013). 
 
The organising frameworks of the individual-opportunity nexus (Shane, 2003), and 
the triple helix of university, industry, government relations (Etzkowitz and 
Leydesdorff, 2000) were utilised to analyse how biotechnology entrepreneurship is 
carried out in South Africa and Brazil; establish the similarities and differences 
between this process and the process in the developed economies based on the 
literature reviewed; and examine the experience of the triple helix relations among 
the university, industry and government in South Africa and Brazil. 
 
The outcome of the within-case analyses showed the process of biotechnology 
entrepreneurship as experienced by the respondents in this research. The analysis 
revealed similarities and differences between South Africa and Brazil; as well as 
between these two developing economies and the developed economies based on 
the literature reviewed. Most of these differences were in the environment of 
biotechnology entrepreneurship, especially related to policy and regulation, funding, 
aggregate skills, the role of government, the size of the market, and university 
culture. Differences also related to the nature of bioentrepreneurial opportunities; the 
scale of R&D; infrastructure and support availability; and the strategic alliances 
necessary to exploit bioentrepreneurial opportunities. 
 
The similarities were mostly in the psychological and non-psychological attributes of 
the individual bioscientists and the abundant biodiversity that was considered a 
competitive advantage for South Africa and Brazil, but not the developed economies. 
 
The triple helix of university, industry, government relations as experienced by the 
respondents is different from what is achivable in the developed economies as 
revealed by the empirical research reviewed (Etzkowitz and Leydesdorff, 2000). Both 
South Africa and Brazil have a hybrid type of triple helix relations that bypasses the 
sequential progression from triple helix I, to triple helix II, to triple helix III and is 
characterised by the strong influence of the government. 
 
67 
 
4.6.7 Cross-case analysis 
 
The cross-case analysis of the combined cases yielded themes, which acted as the 
building blocks to the proposed theoretical framework of biotechnology 
entrepreneurship and were compared to the literature in order to deepen 
interpretation and understanding, as well as enhance generalisability (Eisenhardt 
and Graebner, 2007b; Welch et al., 2011; Klonoski, 2013). The themes identified in 
the cross-case analysis stage were used to explore the “how” and “why” (Yin, 2009) 
of the dynamics of biotechnology entrepreneurship in South Africa and Brazil in the 
theory development phase.  
 
4.6.8 Theory development 
 
The final step in the data analysis section is the development of theory based on the 
identified themes in the cross-case analysis stage. This step involved the 
interrogation of the themes to provide explanations and develop the theory of the 
dynamics of biotechnology entrepreneurship in South Africa and Brazil. This process 
enhances the internal validity, generalisability and the theoretical contribution of the 
research to the extant literature (Eisenhardt and Graebner, 2007b; Yin, 2009; Welch 
et al., 2011; Klonoski, 2013). 
 
The process of building theory from case study research described by Eisenhardt 
(1989) goes through eight stages: 
 
i. Getting started, in which the research questions are defined 
ii. Selecting cases appropriate to the context being studied 
iii. Crafting instruments and protocols for multiple data collection 
iv. Entering the field 
v. Analysing the data using within-case analysis and cross-case pattern search 
vi. Shaping hypothesis using iteration, replication and search for the evidence of 
“how” and “why” behind relationships 
vii. Unfolding literature compared with existing conflicting and similar literature 
viii. Reaching closure through theoretical saturation 
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These steps are similar to the case study method suggested by Yin (2009) (see 
Figure 4.2), which was followed by the researcher. Yin’s (2009) method has three 
stages: 
 
i. Define and design (develop theory, select cases, design case study protocol) 
ii. Prepare, collect, and analyse (conduct case studies, transcribe, code, conduct 
within-case analysis) 
iii. Analyse and conclude (conduct cross-case analysis, draw cross-case 
conclusions, modify theory) 
 
The difference between the method followed for this study and that proposed by 
Eisenhardt (1989) is that this research started with an organising framework of 
entrepreneurship. The other steps are the same as that proposed by Eisenhardt 
(1989). This means that there is a combination of a deductive and inductive 
approach to theory building (Lillis, 1999; Miles and Huberman, 1999; Carlile, 2004). 
 
This approach was chosen because of the relative abundance of empirical literature 
on entrepreneurship but very few studies, which are specifically related to 
biotechnology entrepreneurship in the developing economies context. Hence, the 
proposed conceptual framework was based on Shane’s (2003) individual-opportunity 
nexus framework of entrepreneurship from which the conceptual framework of 
biotechnology entrepreneurship was adapted. 
 
The proposed theoretical framework that emerged from this research showed the 
dynamics of biotechnology entrepreneurship in South Africa and Brazil. The 
comparison of this proposed theoretical framework to the organising frameworks that 
guided the research clearly demonstrated the theoretical contribution of this research 
to the body of knowledge on the process of biotechnology entrepreneurship in South 
Africa and Brazil.  
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4.7 Validity 
 
This section outlines the steps taken to ensure that construct and external validity is 
enhanced. Although this research is exploratory, inferences made in the conducting 
of the study were based on the convergence of evidence from multiple sources, 
which led to triangulation, with rival explanations and possibilities considered (Miles 
and Huberman, 1999; Yin, 2009). This enhances internal validity.   
 
Construct validity was enhanced by following clearly specified operational 
procedures which are aligned to the steps in the proposed organising framework of 
entrepreneurship (see Figure 2.2 on page 16). Multiple sources of evidence, and the 
review of draft transcripts by respondents were also used to enhance the construct 
validity of this study (Stake, 2006; Yin, 2009). 
 
External validity was enhanced by the use of literal and theoretical replication logic 
(Yin, 2009) in the multiple case design. The case-selection criteria (Section 4.4) were 
designed to ensure that the external validity of the study was enhanced. 
 
Although purposive sampling was employed, this may not have reduced the 
theoretical generalisation of this study because this generalisation is confined to the 
dynamics of biotechnology entrepreneurship in the developing economies of South 
Africa and Brazil. Generalisation to all developing economies may be hampered by 
differences in individual, institutional and environmental contexts. However, the fact 
that this is an exploratory study lends itself to improvements of external validity 
through further research. 
 
4.8 Reliability 
 
Reliability for this study was enhanced through the development of a research 
design that integrates different aspects of the study, such as the research problem, 
literature review, research questions, theoretical framework, and data-collection and 
analysis methods, in a logical manner (Miles and Huberman, 1999). Reliability was 
further enhanced by the use of an interview guide (Bell, 2005; Leedy and Ormrod, 
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2005); the use of a case study protocol; and the development of a case study 
database (Yin, 2009).  
 
In addition, at the level of data collection, the triangulation of data sources at multiple 
levels was aimed at enhancing the trustworthiness of the outcome of this research 
(Bowen, 2008).  
 
At the level of interview transcription, each transcript was reviewed by the researcher 
and validated by the respondent as an accurate reflection of the interview before 
being included in the data analysis. 
 
At the level of data analysis, data saturation was demonstrated across all super 
families. Furthermore, the coding process was iterative to capture the underlying 
meaning expressed by the respondents accurately. Where this could not be captured 
by the deductive codes, inductive codes were developed. 
 
At the level of reporting, thick descriptions were provided in the case narratives in 
order to answer the “how” and “why” questions related to the dynamics of 
biotechnology entrepreneurship in South Africa and Brazil (Yin, 2009). This was 
supported by verbatim quotations from the interview transcripts. 
 
Finally the conclusions drawn from the research and the theory developed were 
informed by the literature on biotechnology entrepreneurship, the data and the 
rigorous application of the principles for qualitative inquiry and multiple case study 
methodology (Lincoln and Guba, 1986; Eisenhardt, 1989, 1991; Guba and Lincoln, 
1994; Miles and Huberman, 1999; Creswell, 2000; Denzin and Lincoln, 2000b, 
2000a; Lincoln and Guba, 2000; Stake, 2006; Eisenhardt and Graebner, 2007b; 
Corbin and Strauss, 2008; Creswell, 2009; Yin, 2009; Klonoski, 2013). 
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4.9 Limitations of the study 
 
i. This study may have been limited by the chosen sampling procedure, which 
was purposive and not random. An attempt was made to achieve analytic 
generalisation, rather than statistical generalisation (Yin, 2009) 
ii. The inability of the researcher to speak or understand Portuguese may have 
limited the range of literature that could have been reviewed for this research 
in Brazil.  
 
4.10 Delimitations of the study 
 
I. This study includes only entrepreneurial bioscientists who started  
biotechnology companies, or utilise licensing, to commercialise their 
intellectual property and biotechnology entrepreneurship subject matter 
experts 
II. The proposed theoretical framework from this study is based on Shane’s 
(2003) individual-opportunity nexus conceptual framework of entrepreneurial 
process. 
 
4.11 Ethical considerations 
 
The design of this study takes into account important ethical issues related to the 
respondents, such as fair and professional treatment of respondents; satisfactory 
steps taken to guarantee anonymity; full and complete disclosure of the purpose of 
the study (see Appendix A); obtaining respondents’ consent to participate in the 
study willingly (see Appendix B); and verification of the accuracy of transcripts by the 
respondents before being taken as the final version. 
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PART II: CASE NARRATIVES 
 
Part II consists of chapters 5 and 6. 
 
Chapter 5 is a narrative summary of the transcripts of the interviews conducted in 
South Africa. 
 
Chapter 6 is a narrative summary of the transcripts of the interviews conducted in 
Brazil. 
 
Each summary narrative describes the experience of the process of biotechnology 
entrepreneurship by the respondents, using the verbatim quotes expressed during 
the interviews. 
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Chapter 5: Case Narrative – South Africa 
 
The narrative summary of the transcripts of the interviews conducted in South Africa 
is provided in this chapter. The interview guide was used to organise the narratives 
according to categories identified from the literature reviewed, as shown below: 
 
i. Individual level influences  
ii. Business level influences  
iii. Macro-environment influences 
iv. Triple helix relationships 
v. Similarities and differences between South Africa and the developed 
economies 
 
The case narrative describes the experience of the process of biotechnology 
entrepreneurship by the respondents in South Africa, using the verbatim quotes 
expressed by these respondents during their interviews.  
 
5.1 Individual level influences 
 
The category individual level influences considered the dynamics that exist at 
individual level across the respondents in South Africa. There is a relatively low level 
of inter-connectedness across the university, industry, and government spheres by 
both the bioentrepreneurs and the subject matter experts in this study. Most of the 
respondents operate in academia, industry or government but not across these 
entities. 
 
I am not a biotechnologist by training, but I am a biologist. I have a 
research management background, and when the strategy was introduced 
they were looking for someone who could actually implement it and I 
seemed to have the right credentials for that. (Respondent 1 1:143) 
 
I have to provide basically a scientific innovation environment, focussed on 
applying their skills to some of our unique resources, particularly our 
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biological resources and genetic resources in South Africa. (Respondent 4 
4:1-2) 
 
The lack of experience of working across multiple entities by the respondents in 
South Africa results in individualism, self-preservation and the tendency to employ 
the “individual” approach to biotechnology entrepreneurship. This also encourages 
unhealthy competition instead of collaboration. 
 
I would like to say that I am truly committed to creating techno 
entrepreneurs, which I am, as long as it is not competing with me. 
There is an element of caution. I do not want to create competition to my 
entity, so it is a little bit ironical because I am a bioentrepreneur but at the 
same time, my immediate staff I do not want to create a potential threat to 
my organisation through a discovery that can commercially turn over my 
company. Because to be an entrepreneur in the first place you have to be 
tenacious, aggressive, protective, competitive and anti-competitive – you 
do not want competition. So I do not support competition to me. 
(Respondent 5 5:70-72) 
 
The language of the bioentrepreneurs in South Africa was devoid of terms that 
related to collaboration and instead portrayed an inclination to demonstrate personal 
achievement rather than develop an industry. 
 
I imported some products, so I acquired some market share and 
generated some cash and used that cash to set up my own manufacturing 
facility. (Respondent 11 6:10) 
 
On the few occasions where the respondents worked for more than one of the 
university, industry, or government entities they worked in an advisory capacity for 
the development of the bioeconomy strategy; and not in a collaborative project or in 
a permanent position in these entities.  
 
Although I have never been employed by government I have worked a lot 
for government on various things in the Department of Health and Science 
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and Technology. So I have been involved in drafting legislation and policy 
in both departments for many years. And I have seen the bioeconomy 
strategy because I have been working on it now with the people at DST 
(Department of Science and Technology) for several years in one way or 
another. (Respondent 12 7:4,38) 
 
The lack of inter-connectedness among the respondents in South Africa meant that 
the individual influences were very personal and shaped by the individual 
bioscientist’s personal circumstances. This may explain why there were no known 
successful collaborative projects carried out in the biotechnology industry in South 
Africa; a lack of effective collaboration among the key stakeholders; internal 
competition among the stakeholders; and a lack of trust.  
 
These individual influences were also observed during the field work and articulated 
in the Section 5.1.1 below. 
 
5.1.1 Observations during fieldwork 
 
Some of the interesting observations during fieldwork that are worthy of inclusion in 
this report relate to the magnitude of gaps highlighted by the respondents in South 
Africa; the role of apartheid in creating mistrust among the stakeholders in the 
biotechnology industry; and the differences between individual and official views of 
the stakeholders affiliated to the government.  
 
It was observed that the predominant experience of the respondents was more 
negative than positive from the numerous challenges raised by the respondents. 
While some expressed their frustration in a more subtle way, others had an 
extremely negative view of a lack of prospects for biotechnology entrepreneurship in 
South Africa. 
 
But you know it is an industry that sort of showed promise, there was a 
little spark but it is, in my view it is died. That spark has died. (Respondent 
13 8:20) 
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The second noteworthy observation relates to the racial dynamics in South Africa, 
which were caused by apartheid. The role of apartheid in the level of trust between 
the stakeholders in the industry was highlighted as a constraint. 
  
But I think we still carry the burden of apartheid with us. Where there is still 
a lot of mistrust, there is still a lot of people not wanting to relinquish 
power, and I say that in inverted commas, or responsibility to people who 
would actually be more competent in them because they do not want to 
end up in the same situation that they were in many years ago. 
(Respondent 12 7:44) 
 
This race-based social dynamic is further highlighted in the South African 
government’s affirmative action policies aimed at redressing the consequences of 
apartheid.  
 
Then I am not black enough but I still have to pay tax, I am white enough 
to pay tax and I am white enough to employ people, that I am white 
enough to do. (Respondent 17 12:40) 
 
The third interesting observation relates to the conflict between the personal and 
official views of the subject matter experts affiliated to the government on 
biotechnology entrepreneurship in South Africa. 
 
But then you must take it as my opinion as opposed to what is in the 
government policy. (Respondent 1 1:150) 
 
Although I work for the government, the view may not be representative of 
what the agency feels on biotechnology, so as I say it is my personal view 
based on my experience in the area. (Respondent 3 3:1) 
 
These respondents were tasked with implementing the policies related to 
biotechnology entrepreneurship in South Africa, even though they did not agree with 
the approach taken by government in implementing these policies. 
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5.2 Business level influences  
 
The environment in which biotechnology entrepreneurship takes place in South 
Africa includes economic, regulatory, policy, social, cultural and political 
environments. The extent to which this environment is conducive to the development 
of biotechnology entrepreneurship determines the success or failure of strategies 
and initiatives aimed at improving the biotechnology industry in South Africa. 
 
According to the respondents, the dynamics of biotechnology entrepreneurship in 
South Africa face many challenges among which are lack of direction and leadership 
from the government; lack of appropriate funding; lack of aggregate skills; lack of a 
developed market for biotechnology products and solutions; lack of infrastructure 
and support structures; low level of research and development spend; an inclination 
by the universities to prioritise research publication over commercialisation; the loss 
of skills through the brain drain; and the low level of commercialisation of research. 
 
But I think one of the biggest caveats is that that environment, that 
nurturing environment is not there, either virtually or physically. 
(Respondent 14 9:65)   
 
There is a tremendous amount of entrepreneurial spirit. There is a strong 
desire for people to get involved; there are a lot of creative ideas but there 
are significant obstacles to people realising those goals. (Respondent 12 
7:18)  
 
And I do not think we have a biotech industry so to say in South Africa. 
(Respondent 3 3:53) 
 
Lack of direction and leadership from the government 
 
The role of the government as a facilitator in the development of biotechnology 
entrepreneurship in South Africa entails setting the direction, and providing the 
leadership needed for the effective development of the biotechnology industry. Some 
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of these functions are fulfilled through the government agencies tasked with these 
responsibilities, such as the Department of Science and Technology (DST) and the 
Technology Innovation Agency (TIA). While the role of the government is known and 
acknowledged, the experience of the respondents did not show that the government 
had effectively carried out this role. 
 
Government has to take the lead and drive the development of the sector, 
which means that government leadership in South Africa, in our context is 
more important than perhaps in developed economies where their systems 
are operating. (Respondent 1 1:21) 
 
Government needs to carefully consider the regulations in this area, and 
the policies. They also need to provide a bit more guidance on what the 
needs really are. Where are the priority areas in government? 
 So I think from government’s side they need to provide more guidance in 
these areas. And more emphasis to the scientists, to the researchers 
involved in these areas. We need to move away from bureaucracy. 
(Respondent 4 4:51-55) 
 
So that is why we need a development strategy that says, here and here is 
going to be the focus around development, and for that we need strong 
universities, we need lots of ideas that are coming out of that space. We 
need ways to ensure that those ideas are commercialised, so that we kick-
start this ball rolling. (Respondent 2 2:139) 
 
The establishment of TIA was meant to improve the ability of the government to fulfil 
its role of providing direction and leadership effectively. However, the challenges 
experienced by the respondents in this research meant that TIA had not achieved 
this objective yet. 
 
TIA is not functioning optimally yet. What TIA should be doing, but it's not 
yet doing properly, is stimulating the bio-economy. It should be creating 
critical mass in certain areas. (Respondent 1 1:118-120) 
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I think the biggest disappointment that many of us in the field have had 
over the last 2 or 3 years is that the instrument that TIA was meant to 
represent has not, has not come to the party, has not come to the fore and 
the delays that people are experiencing with TIA at the moment have 
actually meant that in several cases, businesses have had to close down 
and that is an absolute tragedy in a country where there is such a strong 
will to grow biotechnology but there was this major obstacle. (Respondent 
12 7:20)   
 
Well I do not know what TIA is doing you know. By the time I pulled out of 
this sector I was so the hell-in with the BRICS and TIA and what I had 
seen with the inability to move forward. You know I had problems with the 
way the BRICS were doing things but then when TIA was on the cards, 
basically the whole sector froze and nobody was willing to make decisions 
or move forward because no one knew what was happening and what TIA 
was doing and how much money there would be. So for 2 or 3 years there 
was just no money. And I just saw biotech companies fall by the wayside. 
Just literally dropping like flies because there was nobody to fund them. 
And I saw a bunch of technology move offshore. The government has no 
idea it is gone. So if you want to develop your local sector government has 
to come to the party. (Respondent 13 8:30-32) 
 
TIA in particular but also some of the other institutions that I am aware of. 
As institutions they fail, they fail to establish what they have been 
mandated to do. With TIA there is a history of failure, failure to deliver, 
failure to be on time with payments, failure to be responsible with tax 
payers’ money, failure to be responsible in the projects that they run with, 
it is just complete failure. In general people talk about them as a 
technology incompetent agency and not an innovation agency. 
(Respondent 17 12:13-15) 
 
In contrast to the experience of the respondents regarding TIA, at least two 
respondents experienced effective fulfilment of the government’s role by agencies 
such as the DST and the Department of Trade and Industry (DTI). 
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I have been quietly impressed, particularly with our two departments which 
are involved in this, the Department of Science and Technology and the 
Department and Trade and Industry. I think they have got a number of 
very good programmes in place of which my company has been a 
beneficiary and so was the University. (Respondent 15 10:35) 
 
The Department of Science and Technology have been phenomenal in 
their support of this sector but none of the other ministries have bought 
into it. DTI has not bought into it, Treasury has not bought into it, and more 
importantly Department of Health and Agriculture had not bought into it. 
(Respondent 13 8:52)   
 
The contradictory experience mentioned above may point to the veracity of the 
expressed lack of government direction and of leadership being localised to a 
particular agency and not generalised. 
 
Another area of government’s failure to provide leadership was deemed to be its 
inability to curb bureaucracy and provide efficient services and processes. 
 
You will just be astounded at some of the bureaucratic obstacles to 
commercialisation. It is not that it can't be done but it certainly seems as 
though South Africa is not making it easy to commercialise a product. 
(Respondent 1 1:83-84) 
 
Given the role of the government as facilitator in the development of 
biotechnology entrepreneurship in South Africa its inability to provide effective 
leadership and direction to the biotechnology industry hampers the 
development of the industry. 
 
 
 
 
81 
 
Lack of appropriate funding 
 
The lack of appropriate funding for the development of biotechnology 
entrepreneurship in South Africa is another gap identified by most of the respondents 
in the environment of biotechnology entrepreneurship in South Africa. 
 
It is financial, a very big component. But it is the right kind of financial. So it 
is not just a case of like earmark more money. (Respondent 13 8:49-50)  
 
The next challenge is the funding gap, but that money is not prepared to 
take the risks. So the issue is, how do you de-risk the opportunities and 
then the money will flow. (Respondent 2 2:85-86) 
 
In South Africa we have a low risk appetite for entrepreneurs in general 
and the funding of entrepreneurs. (Respondent 3 3:5) 
 
The lack of appropriate funding in South Africa resulted in some of the respondents 
meeting their funding needs overseas. 
 
If you got a really big idea then you should probably look for your funding 
overseas that is what I like to do now, I am raising ten million dollars and 
no South African bank or investor can even come close to the funding.  
I think they are more advanced in accepting the opportunities for new 
ideas, and I think the funds are more readily available. (Respondent 15 
10:24-25) 
 
So I think that one of the things to get right is the finance. (Respondent 15 
10:32) 
 
We have got a foreign balance sheet, we have establish everything from 
foreign balance sheet, we have funding from BioVentures and industrial 
development corporation (IDC) they are also a shareholder, but largely we 
put in a foreign balance sheet. (Respondent 16 11:34) 
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A key component of the funding mechanism for the biotechnology industry in South 
Africa that was deemed by the respondents to be lacking is the venture capital 
industry. 
 
The other thing obviously that is not working properly here is the venture 
capital sector. (Respondent 14 9:45)      
 
We have got non-existent venture capital when it comes to biotechnology. 
(Respondent 16 11:26) 
 
In countries with a smaller and less mature bio-economy, such as South 
Africa, state intervention is imperative to bolster business activities in the 
absence of large private sector players and readily available venture 
capital. To date, the government has played a key role in promoting 
market success in strategic biosectors through its policy instruments and 
by enlisting public research institutions. However, there remains much 
work to be done. (Documents Case 1 13:72) 
 
The experience of the respondents who received adequate funding from the 
government was positive compared to those who deemed the funding from the 
government to be inadequate or inappropriate.  
 
I found my experience in South Africa with the government funding 
agencies absolutely fantastic. 
They understand the dynamic, there is a dynamic there of 
competitiveness. (Respondent 5 5:43-44) 
 
I think from a governmental perspective, from a funding perspective, it is 
good enough. (Respondent 11 6:31) 
 
The fact that the government was able to provide appropriate funding on certain 
occasions was explored further to understand the possible factors responsible for 
this contradiction. The data showed that on the two occasions where the 
respondents deemed the government funding to be appropriate, both spent their own 
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money to get their products to the stage of proof of concept: hence, government 
funding was deployed at a late stage. It can be inferred from the data that the 
government may prefer funding late-stage projects because of the higher chances of 
success.   
 
I started my own laboratory, private laboratory with private funding, and 
this laboratory is called Altis Biologics. Subsequently, I registered the IP in 
my personal name and gave Bone SA the rights to commercialise the IP in 
the territory of South Africa.  
And once I put my application in a second time to the Innovation Fund 
after 3 years, a number of things had changed. Number 1, there was new 
IP, number 2, it had been filed for PCT giving access to big markets, 
number 3, I had proof of concept in small animals like rats, number 4, I 
had proof of concept in a completed human study in humans, from a tissue 
coming from humans. Therefore I was able to reduce the risk having used 
private money to do it, reduce the risk of sample technology, new 
technology risk. New technology is risky at early stage, you do not know if 
it is going to work, it is just an idea; you need proof of concept, principles. 
(Respondent 5 5:22-24) 
 
I imported some products, so I acquired some market share and 
generated some cash and used that cash to set up my own manufacturing 
facility. (Respondent 11 6:10) 
Being a bioentrepreneur you have to spend a lot of money upfront. 
(Respondent 11 6:17) 
 
The challenge regarding appropriate funding for biotechnology entrepreneurship in 
South Africa is a gap that has resulted in high failure rates of biotechnology 
companies in the past and may severely hamper the future development of the 
biotechnology industry in South Africa. 
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Lack of skills 
 
Another key resource requirement is the availability of research, entrepreneurial and 
commercialisation skills and capacity to develop the biotechnology industry in South 
Africa effectively. In the experience of the respondents, although the individual 
bioscientists have the appropriate research and scientific skills, the entrepreneurial 
and commercialisation skills are lacking. In addition, there is a shortage of the 
aggregate skills required to ensure the effective development of the biotechnology 
industry. 
 
So one of the things that we really need to continue and expand is the 
development of bio-entrepreneurship skills. (Respondent 1 1:139) 
 
I think that the universities in general lack capacity to translate their basic 
research findings into products and services and that may be in part 
because there is a lack of adequate technology transfer knowledge. 
(Respondent 12 7:65) 
 
On top of that you get inventors who think they can be entrepreneurs and 
CEOs and then you also have a problem because they do not know what 
they are doing. (Respondent 2 2:39) 
 
It is just that most academics are not very entrepreneurial. (Respondent 2 
2:42) 
 
But then somebody in there needs to understand how a business works 
and those fundamentals of a business and often they do not. (Respondent 
13 8:58)  
 
There are not enough people that you can gather together, companies to 
put up this science park. You need a critical mass for this science park to 
work and we do not have that. (Respondent 16 11:40) 
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Some of the respondents believed that the problem of lack of skills goes further back 
in the educational system, which has not produced enough science and mathematics 
skills to ensure the development of science and technology-based industries in 
South Africa. 
 
Global Competitive Index which is put out by the World Economic Forum, 
as you know, we sit second from the bottom in terms of competency in 
science and mathematics. (Respondent 12 7:27) 
 
But again it does not help spending 50 million rand setting up a facility if 
you do not have the people who can use the facility. So we are evolving 
the two in parallel. We are training the people. (Respondent 12 7:53) 
 
The challenge of the lack of entrepreneurial skills highlights the differences between 
a bioscientist and a bioentrepreneur. According to the literature on biotechnology 
entrepreneurship in the developed economies, the availability of a critical mass of 
inputs and support structures may mask the fact that the bioscientist, or star scientist 
according to some literature, does not have entrepreneurial skills. However, the lack 
of a critical mass of input in South Africa often means that the bioscientist also needs 
to acquire entrepreneurial skills to make the transition to a bioentrepreneur. 
 
Very often we find that if the researcher is the one that runs the company 
as well, and they do not have the entrepreneurial capability and the 
business passion to take that project forward and that is a challenge that 
we often come across. (Respondent 3 3:40) 
 
Doing my MBA at Wits university was a key step to empower myself with 
sufficient knowledge capital to better understand the business of science. 
How to do financial models, how to calculate net present values, how to 
understand strategies and scenario planning. (Respondent 5 5:12-13) 
 
The lack of entrepreneurial and commercialisation skills in South Africa and the lack 
of a system to provide these skills together form a notable gap in the biotechnology 
industry in South Africa. This gap was often closed by the bioentrepreneurs, 
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effectively or otherwise, in an effort to give their firm a chance to succeed. 
 
Lack of a developed market for biotechnology products and solutions 
 
Another key consideration for the development of biotechnology entrepreneurship in 
South Africa is the size and efficiency of the market for biotechnology products and 
solutions. The “size of the market” is often used interchangeably with the “size of the 
biotechnology industry”, and both the market and industry were deemed small and 
under-developed by the respondents. 
 
Our industry is so small; it does not yet have clear vision, direction and 
knowledge of markets and so on. (Respondent 1 1:27) 
 
However, the biggest challenge that is faced in South Africa is that the 
South African market itself with its biotechnological innovations are too 
small, the market is too small. (Respondent 4 4:6) 
 
But so I would say that biotechnology in South Africa is nascent. 
(Respondent 12 7:30) 
 
I mean the market is not here and that is one of the problems, you know 
the local pharmaceutical industry is focussed on generic manufacturing, 
they are not focussed on new drug development so any of the 
pharmaceutical stuff, even the medical device stuff, are all offshore sales. 
(Respondent 13 8:10) 
 
Bioentrepreneurship in South Africa is still fairly new. Probably being 
around 20 to 30 years and it is getting momentum all the time, but in terms 
of the big picture it is a very small part of the business activity in this 
country, for sure. (Respondent 15 10:3)          
 
We could not survive in South African market because we were not selling 
enough systems. (Respondent 15 10:7)          
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The views on the size of the market in South Africa were not consistent across all the 
respondents. From a medical diagnostics point of view, there seems to be a 
developed market in South Africa. This may be due to the nature of the products and 
the target market. 
 
First the market, do we have a direct market for products in South Africa? I 
believe we do. I think we are far along enough to be able to procure 
products for biotechnology companies in South Africa; we have the 
infrastructure to do that. (Respondent 11 6:95-96) 
 
The government was seen as the biggest buyer of biotechnology products in South 
Africa, and hence as influencing the size of the market. However, the government as 
a buyer is often caught between balancing the need to provide service to as many of 
the populace as possible at an affordable price and the need to protect and promote 
the local industry. Hence, there were instances where local companies lost out on 
tenders to foreign companies due to price. If the local biotechnology companies 
cannot win the competition in their local market, the odds are heavily against them 
making inroads in the international market with competitors with a far better 
operational environment than in South Africa. 
 
I would say from the government in assisting, in procuring products, it is 
not good enough. (Respondent 11 6:33) 
 
The tender process here is totally, totally, totally not in our favour, there is 
a ninety point system in my industry where sixty points they award toward 
price, thirty points they award toward local content, BEE and others. 
We are competing against first world countries like China where they have 
tech parks, science parks where they don’t have to import components. 
So when they come to our country and tender obviously it is cheaper for 
them, so now governments are awarding tenders to the Chinese and to 
other Asian countries based on price. 
They should actually award more points to local content to promote 
companies growing here and government buying from us. (Respondent 11 
6:36-39)  
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If you cannot win your own tender in your own country you are just never 
going to be able to commercialise and right now you cannot because 
government is buying the cheapest stuff they can find in China or you 
know whatever the story is. It is the policies and stuff that make business 
work in the country. (Respondent 13 8:61-63)   
 
Given the pervasiveness and global nature of biotechnology, South Africa can 
always compete globally. However, this is dependent on how developed and efficient 
the biotechnology industry in South Africa is and its global competitiveness across 
the dimensions that best define the industry best in biotechnology. 
 
The challenge with the international markets is it is highly competitive. 
And I am not sure whether South Africa has that competitive edge to 
compete in that market. There is a lot of biotechnology that happens within 
the pharmaceuticals industry. They have huge amounts of resources and 
funding to fund the biotechnology research within the pharmaceutical 
industry and we cannot compete. (Respondent 4 4:7-10) 
 
It can be concluded from the above verbatim quotes that although one respondent 
believed that the market for biotechnology products is adequate in South Africa, the 
majority of the respondents were of the opinion that the market for biotechnology 
products is under-developed in South Africa. 
 
Lack of infrastructure and support structures 
 
The resource and infrastructural support to biotechnology entrepreneurship in South 
Africa is deemed inadequate to the development of the industry, especially in the 
area of dedicated research institutes and the availability of biotechnology parks and 
auxiliary services to the industry. 
 
Africa is lacking capacity and infrastructure. But there is not enough depth 
of capacity to do anything properly. (Respondent 1 1:126-127)  
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You get a great biotechnologist there and there just is not the support, 
even in the academic side, there is not the support available to him or her, 
but there are real opportunities. (Respondent 1 1:128) 
 
But what we are lacking are a set of institutes that have a specific focus. 
(Respondent 1 1:103)  
 
In my view and it is a resource issue, putting the resources together to 
create a dedicated institute that focuses on certain areas. It is just a better 
environment for commercialisation than an academic setting. (Respondent 
1 1:114-115) 
 
I think the BRICS also did not have enough resources to nurture some of 
those businesses, because entrepreneurs sometimes they are not just 
looking for money, sometimes they are also just looking for business 
support and I think that was lacking as well. (Respondent 3 3:94) 
 
I need to compete against China but there is no support companies in 
South Africa where I can buy from, so that is why I export a lot, my biggest 
sales are export. (Respondent 11 6:41) 
 
Like I said we need, we seriously need a science park in this country 
where we look at the high impacting biotech businesses, and we look at 
their needs. (Respondent 11 6:55) 
 
Like a CFO, a really good Chartered Accountant that can do people’s 
finances and report the way investors want reported. No small biotech 
company needs a full time CFO. One CFO can work across four 
companies easily so put that person in and there they have got four 
companies they are working with that is great. (Respondent 13 8:66) 
 
The infrastructural deficiencies in South Africa may have contributed to the tendency 
of the bioentrepreneurs to approach the process of biotechnology entrepreneurship 
as individuals rather than being a part of a system of support that provides the 
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necessary requirements for effective bioentrepreneurial activities. 
 
An inclination by the universities to prioritise research publication over 
commercialisation 
 
The universities are seen to be misaligned to the requirements of biotechnology 
entrepreneurship in their approach to the management of the need for publication 
and the economic importance of their innovation. 
 
Researchers are under pressure to publish, but at the same time if they 
publish they lose their intellectual property unless they publish after they 
have registered their IP or their patent for example. So that is another 
challenge that I think we definitely face. (Respondent 3 3:77) 
 
So the primary focus of universities is to train students, publish scientific 
awareness, that is the primary objective. (Respondent 4 4:17) 
 
And I believe a vast majority of researchers are academic researchers that 
enjoy basic research for their core competency, for their core passion, 
which is to uncover knowledge. It does not matter if it is linked to dollars, 
they do not care, they want to know how life works, and they wanted to 
know how water is transported into a cell. Because it is curiosity and it is 
research, and it is very, very good and it has to be done. (Respondent 5 
5:57) 
 
Secondly, we have got still an academic culture and their incentives at this 
stage are to publish and to train students. So we have just introduced our 
IP Act [Intellectual property Act] which says before you publish first check 
to see if you’ve got some IP there and if so register this with our national 
IP management office. (Respondent 1 1:138) 
 
The need for publication at the universities may be driven by several other factors 
that are not covered in this research. However, it is apparent that the prioritisation of 
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publication over the commercialisation of research, for whatever reason, does not 
help the development of biotechnology entrepreneurship in South Africa. 
 
The loss of skills through the brain drain 
 
The consequence of the war for talent and the unfavourable environment for the 
development of biotechnology entrepreneurship in South Africa is the migration of 
skills to other locations with a more favourable environment.  
 
That is very important and it all starts with the scarce skills. Our scarce 
skills are leaving South Africa; they are going overseas because the 
environment is not right here. (Respondent 11 6:72) 
 
I mean by poaching that core, by going to countries like South Africa 
where there are good researchers and stealing our researchers effectively. 
(Respondent 13 8:42) 
 
Look we have skills in terms of knowledge but it is diminishing. Many of 
the top people have left the country. (Respondent 17 12:22-23)   
 
Relevant skills are being lost through the brain drain not only internationally to 
biotechnology industry in other countries but also locally to other industries owing to 
the lack of opportunities in academia and the industry not being developed enough 
to absorb new entrants. 
 
But because there was a lack of opportunities in the academic sphere 
many of them have been absorbed by insurance companies or that kind of 
thing, so they are all gone. (Respondent 14 9:66)     
 
In additional to the challenges mentioned in the sections above, other challenges 
were mentioned by some of the respondents such as a national culture that does not 
support the development of biotechnology entrepreneurship; the evidence of 
corruption in the industry; and the stigmatisation of, and inability to accommodate, 
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failure as a part of the process of biotechnology entrepreneurship. These challenges 
were not elaborated on as they did not constitute the experiences of the majority of 
the respondents. 
 
Low level of commercialisation of research 
 
The eventual outcome of biotechnological entrepreneurship is the commercialisation 
of the intellectual property either through the formation of a new company or through 
licensing of the innovation to more established companies. 
 
It is because we realised if we want to improve the impact of biotechnology 
in South Africa, we cannot focus on technology and the science, and we 
must focus on the end point, the economy and the market. (Respondent 1 
1:16) 
 
A key criterion for evaluating a proposal was the team, and what the 
BRICS often did was they required a company to be formed in order to 
commercialise the product. That immediately put into perspective that this 
is not an academic exercise, this is a commercial exercise. There are 
failings with this approach as well but the one positive is it made it very 
clear, this is not an academic with a pet idea that is just tinkering along, 
this is a commercial enterprise. (Respondent 1 1:57) 
 
If we say biodiversity, we have to say, right the point here is we want to 
create an industry out of biodiversity; and we are going to create that 
industry off the back of our own IP so that it is competitive. 
So that means you have to have a whole value chain from universities to 
companies, including regulations and have all those things working 
seamlessly. (Respondent 2 2:145-147) 
 
The experience of the respondents on the commercialisation of research in South 
Africa was deemed to be below the levels obtainable in the developed economies 
and some other developing economies such as China. 
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To commercialise ideas coming out of universities, in the past that has not 
really happened. (Respondent 2 2:132) 
 
We’re used to doing basic research and that is it, and not have that 
commercial mind-set. (Respondent 3 3:46) 
And in terms of projects which can actually be taken to market, there are 
very few out there. (Respondent 3 3:15) 
 
The problem is we have people that are good at science but they are very 
bad at pushing these things through into the real world. (Respondent 2 
2:103) 
 
The other reason is lack of funding for commercialisation.  You can fund 
20 R&D projects and probably three serious commercialisation attempts. 
Secondly, to commercialise globally is a big challenge, both in terms of 
people, partners and money. (Respondent 2 2:28-30) 
 
I think personally in South Africa, the universities lack certain things in 
terms of commercialisation. They do the research and they do the training 
of the students but to complete that innovation chasm, they do not do that. 
No, they do not have the skills and the capacity to do that, they are not 
setup to do that. (Respondent 4 4:21-22) 
 
Yes, we lack in commercialisation, we are doing brilliant research, we are 
publishing the research and I promise you the Chinese and the European, 
they are probably downloading our own papers here and making a product 
out of it, where we lack. (Respondent 11 6:47) 
 
The commercialisation of research in South Africa is deemed to be sub-optimal by 
the respondents for the reasons given above. It is expected that being at the end of 
the value chain of biotechnology entrepreneurship, inefficiencies in the stages of 
opportunity identification, R&D, and opportunity exploitation will negatively affect the 
efficiency of commercialisation of research. 
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Owing to these challenges, licensing was seen as an easier means of 
commercialising research than company formation in addition to improving 
efficiencies. 
 
Licensing could be the easiest way to go, it is an easy way to 
commercialise. (Respondent 3 3:91) 
 
We are looking at that now, we are looking at licensing companies in 
Nigeria because it makes sense from a distribution perspective and to also 
take a load off of us, to licence to a company in Nigeria and they can 
distribute to the surrounding areas of West Africa, and obviously for the 
malaria product. (Respondent 11 6:86-87) 
 
Social linkages 
 
The social linkages to biotechnology entrepreneurship in South Africa was 
highlighted by more than half of the respondents, which makes it prudent to include 
the details of the quotes from the respondents in this narrative. This enriches the 
understanding of the context of biotechnology entrepreneurship in South Africa. 
 
Biotechnology entrepreneurship in South Africa cannot be absolved from the social 
dynamics of the country. Hence, most of the respondents highlighted the social 
linkages, which pointed to the unique circumstances of South Africa and the 
expectations from biotechnology entrepreneurship.  
 
We have got huge social issues that need to be resolved in South Africa 
because of our apartheid past, so that is a high priority and education is a 
top priority in South Africa. (Respondent 1 1:37)   
 
Obviously if you are developing biotechnology there is a social 
responsibility. (Respondent 1 1:39)   
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The other thing is, there is a community called South Africa, it is everybody 
and there can be ways to say right, in this region, the benefits from what is 
exploited out of this region have to go into this region’s schools, hospitals, 
roads, police stations, these are all community benefits. (Respondent 2 
2:128) 
 
I do foresee greater pressure from the public in terms of ethical issues 
surrounding GMOs [Genetically Modified Organisms] and that may impact 
our regulatory environment and I do see that outcome having an impact on 
the type of research we do in that particular space.  
I feel there would be more public pressure due to environmental factors. 
So I think that could kick in and could impact on our policy regarding 
biotechnology, especially that particular area of biotech, agro biotech, 
where we are looking at genetically trying to modify crops so it suits our 
environmental conditions in South Africa or the rest of Africa. I am not sure 
where it is going but I do see greater regulatory hurdles moving forward. 
(Respondent 3 3:24) 
 
I think there will be a strong focus on ensuring that that kind of research 
yields some kind of commercial benefit, economic and even social benefit. 
(Respondent 3 3:69) 
 
The social side, our social impact that we have, that is the reason why we 
would prefer to not sell our business and to stay in South Africa. 
(Respondent 11 6:44) 
 
I go a lot to schools, speak to matriculates, I present at universities and I 
try to get the mind-sets of the students as well. (Respondent 11 6:69) 
 
I think the problem in South Africa is that we are dealing with so many 
other issues related to our past, related to our huge burden of disease and 
possibly related to our economy, although our economy, I think, is not the 
problem here. 
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But I think we still carry the burden of apartheid with us. (Respondent 12 
7:44)  
 
Talk about biotech and all of that, it is not going to employ millions of 
people; it is going to employ tens of thousands of people. That is certainly 
an issue. (Respondent 14 9:89)  
 
I just want to do the business and make people happy; you know what I 
mean, and help poverty and diseases and help people get out of their 
misery and make a bit of money on the side. (Respondent 17 12:87) 
 
The bio-economy in South Africa should address the country’s socio- 
economic development goals of poverty reduction and improved quality of 
life, while ensuring continued economic growth. (Documents Case 1 
13:36) 
 
South Africa remains a country of extreme inequality. People living at one 
end of the spectrum enjoy some of the highest living standards in the 
world, while those at the other end lack access to basic amenities, suffer 
from food insecurity and are highly susceptible to major diseases such as 
HIV and tuberculosis. (Documents Case 1 13:55) 
 
The importance of society in the development of biotechnology 
entrepreneurship in South Africa prompted the government to consider a 
quadruple helix model that includes the society in health biotechnology. 
 
South Africa will build its health innovation system using the “quadruple 
helix” model to integrate existing role players – the government, academia, 
industry and civil society – into a unified and coordinated system. 
According to the model, industry operates as the seat of production, 
government provides the framework for secure contractual relationships, 
and universities provide new knowledge, innovation and technology, while 
civil society will provide inputs as users of the innovations, holders of 
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traditional knowledge and co-innovators through consultation. (Documents 
Case 1 13:104) 
 
The summary of the business level influences show that there were challenges 
highlighted by the respondents. The role of the stakeholders - government, venture 
capitalists, research institutions, and large companies - featured in the challenges to 
the development of biotechnology entrepreneurship in South Africa. 
 
5.3 Macro-environment influences  
 
The macro-environment influences experienced by the respondents in South Africa 
include the policy and regulatory environment; the stakeholders involved in 
biotechnology entrepreneurship; and the research and development dynamics in 
South Africa. 
 
Unfavourable policy and regulatory environment 
 
The policy and regulatory environment was one of the areas identified by the 
respondents as important to the development of biotechnology entrepreneurship in 
South Africa, but with gaps in the current environment. 
 
One of the reasons is that we have a very tough regulatory environment, 
extremely tough. It is a fact that the policies around this and all the 
regulations and legislations are just coming out and the world has moved 
so far ahead. (Respondent 4 4:17, 19) 
 
So regulations have been very tricky, bio-prospecting regulations have 
been so very onerous. So there are lots of policy issues that we need to 
sort out. (Respondent 1 1:81 - 82) 
 
We have got to change the policies and regulations to allow bio-
entrepreneurship to develop much more easily. (Respondent 1 1:143) 
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The IPR Act has now put a spanner in the works; although that can be 
negotiated so it is not an absolute thing. (Respondent 12 7:72) 
 
Challenges related to the policy and regulatory environment were highlighted by 
almost all of the respondents interviewed, making it an important aspect of 
biotechnology entrepreneurship in South Africa to be explored further. 
 
Poor implementation of policies and strategies 
 
Another gap identified by the respondents in the environment of biotechnology 
entrepreneurship in South Africa was the implementation gap. Although policies and 
strategies may be at the right level, it was deemed that the challenge was being able 
to implement these in an effective manner. 
 
I think our problem as South Africans have been more about the efficient 
and effective implementation than about developing the right policy or 
strategy, in short. (Respondent 2 2:21) 
 
So this is implementation issues, nothing to do with the concept or 
anything like that. (Respondent 2 2:46) 
 
It is 80% implementation challenge and 20% policy challenge. 
(Respondent 2 2:48-49) 
 
So the policy is one thing, the implementation challenges are much bigger. 
(Respondent 2 2:68) 
 
The rest of the world is going down one route and government is going 
down another route, and what they are doing in practise is not that, they 
are making it more complicated. So again, the implementation challenge is 
significant. (Respondent 2 2:129) 
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These failures in implementation appear to involve significant missed 
opportunities to use research and innovation to support central social and 
economic development objectives of the new government. (Documents 
Case 1 14:75) 
 
The implementation gap is seen by the respondents as a much bigger challenge 
than the policy gap, and this is linked to the lack of skills and capacity at both the 
government and industry levels. 
 
The execution risk is a problem because there are not enough people that 
have got the right skills and experience. So I did see a lot of problems on 
the system, which means you have got serious gaps in capacity at 
government level or whatever, because they just do not know what they 
are looking at. (Respondent 2 2:157-158) 
 
The stakeholders involved in biotechnology entrepreneurship 
 
The key stakeholders in biotechnology entrepreneurship are the government, 
research institutions, venture capitalists, large biotechnology companies, and civil 
society. The government provides an enabling regulatory environment and acts as 
facilitator; the research institutions provide talent and technology transfer 
capabilities; the venture capitalists provide capital; the large companies act as 
cooperation partners, customer and competitor (Ahn and Meeks, 2007); and civil 
society are the users of the biotechnology products. In the case of South Africa, the 
government’s facilitation role includes funding and providing the market for the 
biotechnology products. 
 
Given that the government, and civil society will normally be default stakeholders; 
the venture capitalists, research institutions and the large biotechnology companies 
are the key determinants of whether South Africa has a full complement of the 
stakeholders required for biotechnology entrepreneurship or not. 
Two of these stakeholders, the venture capitalists and the large biotechnology 
companies are not present in South Africa. This may have contributed to the 
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challenges experienced by the respondents in the biotechnology industry in South 
Africa. 
 
We have got non-existent venture capital when it comes to biotechnology. 
(Respondent 16 11:26) 
 
I consider government my number one customer if you like or a 
stakeholder. (Respondent 14 9:21)     
 
The other thing obviously that is not working properly here is the venture 
capital sector. (Respondent 14 9:45)      
 
Our fund and everything we did was private sector driven. 
It was not about building an industry or any other things, or securing 
technology in South Africa. It was about investing and making as much 
return for the investors as possible. (Respondent 13 8:2, 4) 
 
In countries with a smaller and less mature bio-economy, such as South 
Africa, state intervention is imperative to bolster business activities in the 
absence of large private sector players and readily available venture 
capital. To date, the government has played a key role in promoting 
market success in strategic biosectors through its policy instruments and 
by enlisting public research institutions. However, there remains much 
work to be done. (Documents Case 1 13:72) 
 
The absence of these two key players meant that the government tried to close the 
gap by assuming the responsibility for funding and R&D spend. 
 
Low level of research and development spend 
 
R&D is a key step in the discovery of bioentrepreneurial opportunities. This is a 
critical differentiator between biotechnology entrepreneurship and general 
entrepreneurship, and the R&D spend has become one of the key statistics of 
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measuring the commitment of countries to the development of biotechnology 
entrepreneurship. 
 
The new approach is then going to look at the entire value chain and then 
research and development becomes much more important than it was in 
the earlier stage. (Respondent 1 1:53) 
 
The current level of R&D spend in South Africa is below the average for the OECD 
countries. This view is corroborated by the respondents in this research. 
 
So at the moment we are just less than 1% GDP being spent on R&D. 
(Respondent 1 1:35) 
 
We have set a target for 1.4 % of GDP by 2014 which we are now on the 
verge of saying let’s put that back to 2016, and then 2% by...it was going 
to be 2018. (Respondent 1 1:38) 
 
If 2.5 % GDP is the R&D budget, and we are only at 1%, there is a 
significant difference. (Respondent 1 1:105) 
 
Formal R&D is 0.87% of GDP, and the government’s target is to raise this 
to 1% by 2012, quite an ambitious goal, given the industrial structure. 
(Documents Case 1 14:9)  
 
So there is a systemic problem where there is a shortage of R&D funding 
within the system. (Respondent 2 2:40) 
 
We need to look at the level of GDP funding, percentage of GDP.  
I unfortunately do not know a lot about Cuba and Brazil biotechnology, I 
have read about them. But I find similarities because our level of funding is 
very small. (Respondent 5 5:90) 
 
The lack of major R&D taking place here and the lack of capital are the 
two major constraints. (Respondent 16 11:47)  
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The absence of the large, established biotechnology companies in South Africa was 
also highlighted as one of the reasons for the low level of R&D in the biotechnology 
industry in South Africa. 
 
Biotechnology in South Africa is dominated by research projects, science 
councils and small biotechnology firms. There are no large, integrated 
biotechnology firms to speak of that are indigenously South African. 
Multinational corporations have a presence, albeit mostly through their 
distribution and marketing partners. Their research and technology 
development are usually conducted elsewhere. (Documents Case 1 13:59) 
 
In my view what South Africa needs to be doing is encouraging these big 
multinational, big biotech companies to establish a branch in South Africa. 
Not just a distribution branch, but an R&D branch, and hopefully we will be 
pushing that into the strategy, pushing some kind of approach to provide 
incentives to companies to create a branch here, which will then assist in 
our biotech pipeline. (Respondent 1 1:75) 
 
There is a linkage between R&D spend and intensity. These may also be affected by 
the availability of skills, infrastructure and capacity, all of which are deemed to be 
sub-optimal by the respondents. The critical nature of R&D in opportunity discovery 
and/or creation in bioentrepreneurship means that a shortage of funding will 
invariably hamper the development of biotechnology entrepreneurship in South 
Africa. 
 
In concluding this section, it can be said that macro-environmental influences in 
South Africa have unfavourable components according to the respondents in this 
research. The policy and regulatory environment was also deemed unfavourable due 
to difficulties with policy on intellectual property ownership; and policy on technology 
transfer. 
 
Two of the stakeholders required for the efficient development of the biotechnology 
industry in South Africa are not available. Hence, this can be regarded as 
unfavourable component of the macro-environmental influences. Lastly, the R&D 
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dynamics show that, relative to the developing economies, South Africa is doing well 
on both R&D spend and intensity. However, it lags behind the OECD countries in 
terms of both R&D spend and intensity.  
 
5.4 Triple helix of university, industry, and government relationships  
 
Stakeholder collaboration in biotechnology entrepreneurship is a key feature that 
involves the university, industry and government in a triple helix relationship. 
 
The role players within the bio-economy will have to collaborate effectively 
if the bio-economy is to succeed. These role players include industry, 
academia, science councils, non-governmental organisations, community-
based organisations, not-for-profit companies and the government. 
(Documents Case 1 13:45-46) 
 
Biotech stakeholders include government departments, industry and 
academia. (Respondent 1 1:6) 
 
The triple helix relationship in South Africa is controlled by the government, instead 
of the emergence of a knowledge infrastructure generated by overlapping 
institutional spheres. Hence, the government is expected to provide the leadership 
required to develop an environment that enables effective collaboration among the 
key stakeholders in the biotechnology industry in South Africa. 
 
Government really has a role in defining priorities, initiatives, actions and 
stimulating an enabling environment. But also doing much more than that; 
pushing in a particular direction. Without government leadership we are 
not going to be achieving much. (Respondent 1 1:28 - 29) 
 
I am referring to this triple helix approach. It is not that DST is going to 
decide what is going to be done; DST is going to show the leadership 
which is to get the industry and academia input and debate and then 
provide a way forward. But unless somebody is actually doing that driving 
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role, which is government’s role I believe in South Africa, we are not going 
to achieve all that much. (Respondent 1 1:32 - 33) 
 
However, instead of an effective collaboration among the key stakeholders, it does 
appear that there is misalignment of objectives between government and the other 
stakeholders. 
 
I come back to the fact that biotech takes a long time and to some extent 
government wants quicker results. Biotech has got enormous potential and 
I think that is recognised, but what is not appreciated in government 
sufficiently well, is that biotech takes time. (Respondent 1 1:152) 
 
This misalignment is not restricted to external stakeholders in the biotechnology 
industry, but also seems to occur within the government departments tasked with the 
effective implementation of policies and strategies related to biotechnology 
entrepreneurship. 
 
Together with academia, science councils and other institutions, we have 
the collective expertise to drive innovation for South Africa’s benefit.  
However, this expertise is still largely fragmented – conflicted by 
competition and not aligned in a common purpose. (Documents Case 1 
13:5-6) 
 
Secondly you have got DST and you have got DTI, and the bridge 
between the two is very difficult. So you are damned if you do and you are 
damned if you do not. (Respondent 2 2:104-105) 
 
There is a lot of competition among the universities, and as I have said I 
have not explored it but it would be interesting to see in Brazil if there is a 
collaborative type of effort. (Respondent 3 3:55) 
 
Yes, science councils and universities have become competitors rather 
than partners. (Respondent 4 4:23) 
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The experience of the effectiveness of the collaboration among key stakeholders by 
the respondents in this research was not positive. The quotes below are 
representative of the practical experience of the triple helix relations by the 
respondents. 
 
So it is sad that the collaborating is not there and I would like to see a 
change, but at this stage of the game we are not going to have it. 
It is just sad that if I have to become involved in sitting on a committee 
involving government and the industry I would slit my wrist. (Respondent 
16 11:52-55)   
 
I think the fact that government is involved has been a very bad thing for 
us. It is like running the 100m with a ball and chain to your leg, it has not at 
all been a help, and in fact it is fairly detrimental to the business. 
(Respondent 17 12:7) 
 
We are doing it in a sense but I often find that this is certainly an issue 
here; the inability of people here to work together. It is a big problem. It is 
like everybody is doing a bit somewhere and they are not teaming up, they 
are not coming together which is a huge detriment. (Respondent 14 9:74-
75)      
 
So I was interested to commercialise this technology and I had to do it with 
the University of Witwatersrand. It was not well received by the university, 
my attempts, at all. (Respondent 5 5:20-21) 
 
This is a dynamic to be included in your research. This dynamic is called 
the dynamic of strife, the dynamic of war. And this war dynamic I studied 
using the principles of Sun Tzu.  
The art of war, to sharpen both sides of my blades and decapitate the 
large university which birthed me, cut his head off and bleed him to death 
so that my little company can survive. A David and Goliath principle, little 
Altis, a one man show to bring down a large institution to his knees and cut 
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his head off, so that was successfully accomplished. (Respondent 5 5:25-
26) 
 
So in my own experience in human health research I can give you 
examples where the university is interacting with government, or where the 
university is interacting with industry but I cannot think of many situations 
in which the three come together. 
 
Even in these circumstances, it is apparent that there are limited but fairly productive 
levels of collaboration between industry and the university, in particular, with the aim 
of hiring skilled individuals. 
 
The links to academia are very helpful to us to find high quality graduates. 
(Respondent 16 11:28) 
 
I think the universities work pretty well with one another. There was of 
course times that there was some friction between the universities, some 
competitiveness, some jealousy whatever; and I think similarly between 
companies. (Respondent 15 10:39-41)   
 
The dynamics of the triple helix relations in South Africa appear to be at the level of 
triple helix I with the government controlling the relations between the entities. This is 
different from the developed economies, as shown in the literature reviewed for this 
study, which are at the level of triple helix III. 
 
5.5 The key similarities and differences between South Africa and the 
developed economies as experienced by the respondents 
 
This section articulates the key similarities and differences between South Africa and 
the developed economies, which were highlighted by the respondents.  
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Similarities 
 
The key similarities highlighted by the respondents in South Africa were intellectual 
ability and research institutions; implementation challenges; and areas of focus for 
biotechnology entrepreneurship. 
 
Intellectual ability and research institutions 
 
The intellectual ability of the respondents in South Africa was deemed to be similar 
to the bioscientists in the developed economies. 
 
We here have got as much chance of coming up with clever ideas as 
some guy sitting anywhere else. We must never think that we cannot 
compete, we can compete, and that ability to think is a competitive 
advantage that no one can take away from you (Respondent 2 2:159-160) 
 
And I would say the best South African students is competing with the best 
anywhere in the world. (Respondent 15 10:18)          
 
This intellectual ability is not restricted to research and development but extends to 
the quality of publications produced by the bioscientist in South Africa. 
 
I think our innovation, the ability in developing methods and intellectual 
property, that is on par, and that is at university level; our research is top 
class, the University of the Western Cape is one of the best biotechnology 
departments, the publications are world renowned for what they are doing. 
(Respondent 11 6:45) 
 
The academic and research institutions were deemed to be similar to those in 
the developed economies in terms of quality of research and publication. 
 
We have good academic institutions and we definitely have a good 
population with good entrepreneurial drive. (Respondent 16 11:24-25) 
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Another valuable national asset is a too small but good collection of 
established universities and a research institute (science council) system 
with core areas of considerable strength and experience. Centres of 
academic research excellence, mainly located in a nucleus of long-
established universities, achieve high quality in several areas of research, 
as reflected in the presence of South African publications among the top 
1% of internationally cited publications in several fields and in some cases 
in the higher quartiles of that group. (Documents Case 1 14:16) 
 
This similarity meant that the bioscientists and research institutions in South Africa 
compare favourably with their peers in the developed economies. 
 
Implementation challenges 
 
According to the South Africa respondents, the successes associated with the 
developed economies may not be as widespread as previously thought. The 
implementation challenges experienced in South Africa are also deemed to be 
applicable in parts of the developed economies. 
 
Those EU rules are what drive what these agencies do. It is not what 
works, or what the best is, it is what those EU rules allow them to do. They 
also have execution type problems. (Respondent 2 2:164-165) 
 
So it has been a difficult thing not just in developing countries but also if 
you look at Europe, many European companies have not managed to get 
their biotech industries going. Germany was looking good at one point but 
it really has not taken off. Countries like Scotland or areas like Scotland 
within the UK have had a number of success stories but no sustainability. 
You know those companies were sold off or, in the long term, they are 
going nowhere. (Respondent 13 8:17) 
 
Similarity of implementation challenges does not necessarily mean that these 
challenges have the same underlying causes in the developed and developing 
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economies. The context of the implementation challenges in South Africa stemmed 
from the government agencies who have the responsibility for the implementation of 
policies and strategies for biotechnology entrepreneurship in South Africa. 
 
Areas of focus 
 
Some areas of focus for biotechnology entrepreneurship were deemed to be similar 
in South Africa, Brazil, and the developed economies. Environmental biotechnology 
was highlighted as one area that is focused on by South Africa and the developed 
economies.  
 
Similar to the Brazilians looking at environmental biotechnology, so it is the 
same drive in South Africa and the same drive internationally and that is 
where the similarities are. (Respondent 4 4:40) 
 
The focus on environmental biotechnology is primarily driven by the global need for 
environmental sustainability. 
 
In summary, the individual skills of the bioscientists in South Africa are as good as 
any in the developed economies; the universities are as good and the quality of the 
research output of the universities are on par with the developed economies. 
Other areas of similarity highlighted by the respondents are the implementation 
challenges that are not deemed to be unique to South Africa; and the similar focus 
on environmental biotechnology by South Africa and the developed economies. 
 
Differences 
 
The differences highlighted by the respondents are in the areas of the lack of 
aggregate skills and resources; the lack of entrepreneurial skills; the lack of scientific 
literacy; a lack of support mechanisms; implementation challenges; the lack of 
appropriate funding; low levels of commercialisation of research; the small size of the 
biotechnology market in South Africa; the difference in scale; the stigmatisation of 
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failure; the high level of risk; the low level of patency; the lack of effective 
collaboration; and the failure to attract foreign skills. 
 
Lack of aggregate skills and resources 
 
The aggregate skills needed to boost the development and sustainability of the 
biotechnology industry in South Africa is deemed by the respondents to be 
inadequate, and hence different from the developed economies. While the individual 
bioscientists are on par with their peers in the developed economies, the aggregate 
skill is not enough to sustain the industry in the future. 
 
No we will never be competitive, not as it is at the moment because we 
simply do not have critical mass; we do not have the resources; we do not 
have the people and those three things together will not drive us to be a 
force that can ever compete with the likes of Brazil and with China and 
with Europe. I mean it is impossible; it is not going to happen. 
(Respondent 17 12:73-75) 
 
We realise that scientific literacy is very low in South Africa. (Respondent 1 
1:40) 
 
Human resource shortages at all levels in mathematics, science and 
technology. (Documents Case 1 14:15) 
 
The resources needed for the effective development of the biotechnology industry 
were also deemed to be lacking in South Africa as opposed to these resources being 
available in the developed economies. 
 
I think what I would say about the developing world is there are not 
enough resources available, but every country is different. I have not 
picked up the common thread. (Respondent 1 1:130) 
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Generally speaking equipment is 40% more expensive here than what it is 
in Europe and also takes two to three times longer to get here. 
(Respondent 16 11:44) 
 
The challenge with the aggregate skills is a systemic problem in South Africa that is 
driven by the approach to the study of mathematics and sciences at the high school 
and university levels. 
 
Lack of entrepreneurial skills 
 
The entrepreneurial skills in South Africa are deemed to be lower from the developed 
economies. Given the fact that most bioscientists are not necessarily entrepreneurs, 
and that there is a lack of a system of biotechnology entrepreneurship to close the 
gap, it is up to the bioscientists to close this skill gap in their personal capacity. The 
fact that this is highlighted as different from the developed economies means that it 
remains a challenge.  
 
What we have identified as a gap in South Africa is the entrepreneurship 
skills. We are saying we are short of bio-entrepreneurship. (Respondent 1 
1:58-59) 
 
So in South Africa there is a shortage of entrepreneurs. There is a 
shortage of money. There is a lack of ability to structure deals that take 
into account the global competitive nature and the time to market issues. 
(Respondent 2 2:31-33) 
 
Only 1.3% of South Africans own and manage an established business 
that has survived for more than three-and-a-half years, compared to more 
than 10% of adults in Brazil, Thailand, Greece, New Zealand and China. 
South African firms also have a poor success rate in comparison with most 
other developing countries. (Documents Case 1 14:38) 
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Lack of support mechanism 
 
The support mechanisms needed to ensure efficient conduct of biotechnology 
entrepreneurship in South Africa was deemed not to be at an adequate level in 
comparison to the developed economies. 
 
These developed world countries; you notice immediately that the 
opportunities are far greater. If the scientist/entrepreneur wants to 
commercialise, there are support mechanisms. There are funding 
opportunities. There are support opportunities; they can get a leave of 
absence. I think France does two or two-and-a-half years where an 
academic will be guaranteed his position if he wants to come back. There 
are all these kinds of support mechanisms that are much more easily 
available. 
There are charitable foundations, there is philanthropic funding, and there 
are other opportunities. (Respondent 1 1:107-111)   
 
We still have wide and far and we lack interconnectivity between 
institutions. We should list our human capital assets on large databases. 
There is no database in South Africa that lists any doctors or researchers 
that do virus elimination work, it does not exist. (Respondent 5 5:85-87) 
 
And we do not necessarily have very good reward systems to push us to 
excellence much higher; combined with the fact that we are disparate from 
one another, our centres of excellence, the lack of technology parks. 
(Respondent 5 5:94, 96) 
 
The support mechanisms highlighted by the respondents in South Africa which are 
different from the developed economies included different sources of funding 
opportunities; the availability of a leave of absence for bioscientists; interconnectivity 
between institutions; scientific databases; the reward system; and biotechnology 
parks. 
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Implementation challenges 
 
The lack of effective implementation of biotechnology policies was highlighted by the 
respondents as being different from the developed economies, as well as developing 
economies such as Brazil, China and India. These developing economies were 
considered to have better implementation than South Africa. 
 
Whereas in Brazil, and I know a little bit about Brazil but not so much on 
the biotech side, I sort of suspect that they have been a lot more effective 
at actually implementing even on a framework type of thing. (Respondent 
2 2:22) 
 
Brazil has got the rainfall, they make use of their resources and that is 
what they did, apply biotechnology to their resources. South Africa in my 
opinion does not make enough use of it is resources, genetic resources, 
they are not making enough use of these resources. (Respondent 4 4:15-
16) 
 
Other implementation challenges highlighted by the respondents were the 
bureaucratic processes at the government agencies responsible for implementing 
the policies and strategies for biotechnology entrepreneurship and the inability to 
effectively implement the legislated strategy for biotechnology in South Africa. 
 
There is too much red tape and the system is not efficient enough to be 
able to make decisions quicker. DTI are stranding small businesses at the 
moment. (Respondent 11 6:91-92) 
 
We developed a biotechnology strategy before India and China developed 
their biotechnology strategy, South Africa was ahead of all those things. 
Government started putting money in before the Indian government and 
the Chinese government woke up to biotechnology. But now we are way 
behind. (Respondent 13 8:68)  
 
The respondents believed that the biotechnology policies and strategies in South 
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Africa are not flawed, but needed to be implemented effectively in order to realise the 
objectives of the policy and strategies. 
 
Lack of appropriate funding 
 
The lack of appropriate funding was highlighted as one of the key differences 
between South Africa and the developed economies, with specific comparison to the 
developing economy of Brazil. 
 
So in South Africa again, we have to bootstrap ourselves or as any African 
country. (Respondent 2 2:136) 
 
The big difference of course is they have huge amounts of funding for it, 
but not in South Africa. (Respondent 4 4:29) 
 
In Brazil money was put into it. Then I think key drivers were identified and 
funded and they started to work on it and that is why they have been so 
successful. (Respondent 12 7:76)  
 
The funding gap in South Africa was not seen to be only related to government 
funding but also related to the absence of a developed venture capital industry, and 
large established biotechnology companies. 
 
Low levels of commercialisation of research 
 
The ability to commercialise the research from the universities effectively was 
deemed by the respondents to be different among South Africa and the developed 
economies. 
 
The unfortunate part is the value of taking that and making a product out 
of it and industrialising some of the components, that is where the Chinese 
and Europe are above us. (Respondent 11 6:46) 
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I think commercialisation is below the standard. (Respondent 11 6:89) 
 
This difference was thought to be as a result of the lack of entrepreneurial and 
commercialisation skills highlighted by the respondents; as well as the challenges in 
the earlier parts of the value chain of biotechnology entrepreneurship in South Africa. 
 
Small size of the biotechnology market in South Africa 
 
The size of the market for biotechnology products in South Africa was deemed to be 
different from the developed economies, with emphasis on the small and under-
developed nature of the market in South Africa. 
 
Secondly, the market for high tech goods in South Africa is modest, and 
that comes with all its own challenges. (Respondent 2 2:66-67) 
 
The European market is more open, you get your CE mark you get to sell 
it in 27 countries, that is a big plus. (Respondent 15 10:28)  
 
So that is the difference between us and Brazil; it is a huge market so it is 
a disposable income in a way far better than South Africa. When the 
Department of Agriculture tests the product on some cows in Limpopo 
Province they test about 20,000 cows at a time. In Brazil you are talking 
about one or two million at a time. (Respondent 17 12:45-47) 
 
There was also a reference to the openness and efficiency of the European market 
in comparison to the market in South Africa. 
 
The difference in scale 
 
The scale of biotechnology entrepreneurship in South Africa is deemed to be 
different from the developed economies by being relatively smaller in scale. 
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To develop this product we have used only 3.5 million dollars, so the big 
dissimilarity is the quantum of numbers. USA you spend 600 million dollars 
to develop recombinant BMP [Bone Morphology Protein], we spent 3.5; 
the scale is enormously different. (Respondent 5 5:90-91) 
 
She set up a venture capital fund in Brazil to the order of, I think, 150 
million dollars. They have got a development bank over there, with billions 
of dollars as far as I know. I do think that they are on a different scale than 
what we are. (Respondent 14 9:70)     
 
The scale was also deemed to be different between South Africa and the developing 
economy of Brazil, with Brazil seen to operate on a larger scale than South Africa. 
 
The other areas of differences highlighted by a few of the respondents, but which 
was not elaborated on, include the stigmatisation of failure (Respondent 2 2:82); the 
relative low level of risk management skills in South Africa (Respondent 2 2:88-89); 
the low level of patenting (Respondent 3 3:83); the lack of effective collaboration 
among the key stakeholders (Respondent 4 4:31); and the inability to attract foreign 
skills (Respondent 4 4:38 – 39, 61). 
 
The differences highlighted by the respondents are similar to most of the areas of 
challenges highlighted in the “business level influences” and the “macro-
environmental influences” sections. The differences relate to the developed 
economies; with some respondents referring to the developing economies of Brazil, 
India and China. 
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Chapter 6: Case Narrative – Brazil 
 
The narrative summary of the transcripts of the interviews conducted in Brazil is 
provided in this chapter. The interview guide was used to organise the narratives 
according to the categories identified from the literature reviewed, as shown below: 
 
i. Individual level influences  
ii. Business level influences  
iii. Macro-environment influences 
iv. Triple helix relationships 
v. Similarities and differences between Brazil and the developed economies 
 
The case narrative describes the experience of the process of biotechnology 
entrepreneurship by the respondents in Brazil, using the verbatim quotes expressed 
by these respondents during their interviews.  
 
6.1 Individual level influences 
 
The category individual level influences considered the dynamics that exist at an 
individual level across the respondents in Brazil. There is a high level of inter-
connectedness across the university, industry, and government spheres by both the 
bioentrepreneurs and the subject matter experts in this study. Most of the 
respondents have either worked with academia, industry or government; or are 
currently working across these entities. 
 
I started in academia and then we moved to the companies. When we 
created these two companies, I changed my time at the university. I 
continued to work there part-time and part-time in the company. 
(Respondent 8 20:17) 
 
But this was my experience as a scientist and academia and entrepreneur. 
(Respondent 8 20:27) 
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This is basically what I do, I work for EMBRAPA [Brazilian Corporation for 
Farming and Livestock Research], I work very closely with companies, but 
it is different than having your own company, because you have very 
different experiences. By having and running your own company you learn 
a lot on how real life actually works, as far as employing people, dealing 
with clients and so on. (Respondent 6 18:15) 
 
I was able to finance a lot of operations between the academic sector and 
the industry, I had the money, and I had a budget of 90 million dollars a 
year. Then the Catholic University of Brasilia invited me to set up a 
graduate programme. Then with Dario Grattapaglia and one of his friends, 
we set up this programme called Genomics Science and Biotechnology. 
(Respondent 9 21:8, 10) 
 
I used to be in academia but before I came back to Brazil, and since I 
came back I am working in government agencies that finance 
development, research, and technology in general. (Respondent 10 22:1) 
 
The linkages between the respondents in Brazil may have helped in fostering the 
conditions that made it possible to have the successful collaborative projects; 
effective collaboration among the stakeholders; an understanding of the common 
objective of biotechnology entrepreneurship in Brazil; and a consistent 
understanding of the strengths and challenges of the biotechnology industry by all 
the respondents.  
 
These individual influences were also observed during the field work and are 
discussed in the following section. 
 
6.1.1 Observations during fieldwork 
 
Some of the interesting observations noted by the researcher during field work for 
the study that are worthy of inclusion in this report relate to the positive attitude of the 
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respondents in Brazil; the desire to solve the country’s problems; and the uniformity 
of their experience of the biotechnology industry.  
 
The respondents in Brazil are very positive about the biotechnology industry. Even 
when challenges are expressed, there is a recognition of the need to be a part of 
solving these challenges in order to achieve the desired objectives. 
 
But our country is doing well and as I told you, it is not a problem for 
funding, we have a lot of money for basic research at the university, and 
we have money available for venture capital investment. (Respondent 8 
20:72) 
 
The golden thread among the respondents in Brazil is the desire to solve the 
country’s problems and get the country to compete internationally. All the 
respondents see the biotechnology industry as a system to which all the 
stakeholders need to contribute to make it succeed. There was almost no expression 
of individualism, except where it contributed to the common goal. 
 
For example, we have done several tens of thousands of human paternity 
tests, which are not cutting edge technology, it is a very routine type thing, 
but you solve problems. So every time you deliver a report you know you 
are changing the life of some people, so I think that is very motivating for 
me. (Respondent 6 18:19) 
 
My interest is only in the area of trying to help them to build up their 
capacity, hiring people, educating people and things like that. (Respondent 
8 20:50-52) 
 
Yes, but one thing that is important that I always tell my students, is first do 
a good job, do good science and try to link with real problems when you 
are working. Real problems are practical issues that are important for your 
country, help people or help an area that is important for the country, I say 
that all the time. (Respondent 8 20:58) 
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There is a consistent understanding of the industry and the areas designated as 
challenges or strengths among all the respondents. The respondents know almost 
every other stakeholder that is active in the biotechnology industry in person, hence 
pointing to a very high degree of collaboration in the industry in Brazil. 
 
6.2 Business level influences  
 
The business level influences in the environment of biotechnology entrepreneurship 
in Brazil include the economic, social, cultural and political environments. The extent 
to which these environments are conducive to the development of biotechnology 
entrepreneurship determines the success or failure of strategies and initiatives aimed 
at improving the biotechnology industry in Brazil. 
 
The business level influences considered to be favourable to the development of 
biotechnology entrepreneurship in Brazil include: the direction and leadership 
provided by the government; the availability of appropriate funding from different 
sources; the developed market for biotechnology products; and the availability of 
infrastructure.  
 
The other positive business level influences mentioned by one respondent, such as 
a favourable university culture; availability of capacity; and effective international 
collaboration are not be elaborated on as they may not be representative of the 
biotechnology industry in Brazil as a whole.  
 
Government leadership and direction 
 
The government is deemed to have done a good job of providing leadership and 
direction for the development of biotechnology entrepreneurship in Brazil. 
 
The government is very important as a ruler, as giving the institutional and 
regulatory context to this, but I think that is a part of what society is asking 
for the government to do. (Respondent 7 19:56) 
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So they created Biominas foundation, which was a support institution to 
create new companies in Brazil. They decided to create this structure 
because there were huge obstacles to start a business like that in Brazil 
because there was no funding at all, there was no venture capital, nothing, 
nothing, nothing. (Respondent 7 19:4-5) 
 
There is clear evidence of the Brazilian government’s support of biotechnology 
entrepreneurship in Brazil. The government has enacted laws and policies and 
followed through with implementation; provided infrastructure; provided various types 
of funding to address the various needs of the industry; provided an environment that 
attracts foreign skills and large companies; and promoted the collaboration between 
the universities, government agencies and industry. 
 
Because innovation is now on the agenda of all federal government and 
the state government, all the politicians, they are talking innovation all the 
time. This is good because there is a possibility of changing the laws, this 
is the only way of solving this problem, because we have people and 
talent is a question of numbers. If you have a large number of students a 
portion of them will be, like any other areas, so we need to take advantage 
of having this system. (Respondent 8 20:43-44) 
 
Also, in some areas, the government, not all areas, the Minister of Science 
and Technology and the Minister of Education has agents linked to our 
graduate programmes. All those agents are trying to find ways of 
supporting biotechnology in Brazil. (Respondent 9 21:104) 
 
The facilitation role of the government and the multiple aspects of that role, in the 
development of biotechnology entrepreneurship in Brazil, made it imperative that the 
government carried out its function effectively. Any failure by the government 
ultimately impacts on the effectiveness of biotechnology entrepreneurship in Brazil. 
 
Most of the challenges identified by the respondents in Brazil have to do with where 
government has failed in these roles, such as an unfavourable policy and regulatory 
environment; high interest rate; bureaucracy; politics; and corruption. 
122 
 
Availability of appropriate funding from different sources  
 
Appropriate funding was deemed by the respondents to be available in the 
biotechnology industry in Brazil through the government, venture capitalists, and the 
private sector. This is one of the key factors for the effective development of 
biotechnology entrepreneurship and may partly account for the success that Brazil 
has enjoyed in biotechnology entrepreneurship. 
 
Well, it is growing over the last five or six years it is growing, there is more 
and more money available, different organisations that are now putting 
money. 
I think money is not a problem in Brazil, venture capital, it is not a problem 
at all, the problem is how to get as much as possible, young pupils, 
students to get involved in this process, how to handle this problem of 
collaboration with the universities. (Respondent 8 20:61, 64) 
 
Oh, yes, I think the federal government, the state government, all of them. 
I used to go and talk with the people in government institutions and 
everybody knows that we need to invest a lot in innovation in 
biotechnology. I think that it is well supported but laws must change. 
(Respondent 8 20:89-90) 
 
FAPESP [Foundation for Research Support of the State of Sao Paulo] has 
a programme that is called, “Research in Small Innovation Companies”. 
And, in this programme, what we do is we give money, for example, to 
small companies that want to invest in research to do innovation, to 
improve the production of their products. We give money for a PhD 
student who’s just finished his PhD and wants to create a start-up 
company, we give money. We have a whole system for selecting and 
controlling this money, but we do money without asking anything of them. 
(Respondent 8 20:47) 
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The funding for the development of the biotechnology industry in Brazil did not 
emanate from government sources only, but also from large biotechnology 
companies and venture capitalists. 
 
Then Votorantim Group created a branch dedicated to venture capital, and 
they created a company called Votorantim New Business. New business 
means investment in start-up companies involved in biotechnology and 
communication technology or information technology. (Respondent 8 20:8) 
 
The long timeframe of biotechnology entrepreneurship, the high risk and the 
uncertainty of the outcome of R&D means that the traditional form of funding is not 
suitable to biotechnology entrepreneurship. This accounts for why the funding 
mechanism for biotechnology entrepreneurship is specialised, whether through the 
government, private sector, or venture capitalists. 
 
Developed market for biotechnology products  
 
It is the belief of the respondents that the Brazilian market for biotechnology products 
is developed. The emphasis on national priorities and solving the problems of the 
country has meant that the areas of focus, such as agriculture, environment, 
industry, and healthcare, are aligned to the needs of the country. Hence, the local 
demand creates a local market for the biotechnology products. 
 
The positive factor is the Brazilian market, a very good market in terms of 
maturity and size. (Respondent 9 21:101-102) 
 
So, first is the market, and, secondly, a lot of researchers now in the 
biotechnology area. But in molecular biology, biochemistry, biophysics and 
nanotechnology, they are really willing to overcome all the difficulties in 
Brazil to set up their business. We do believe that the biotechnology 
industry is going to make a big change in our industry and it will generate 
more wealth, we do believe this. There is a big desire to move forward in 
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spite all the difficulties, we have a dream, as Martin Luther King said, “We 
have a dream.” (Respondent 9 21:102-103) 
 
Despite having a developed market for biotechnology products, the need to compete 
internationally was expressed by the respondents as one of the factors necessary for 
the development of the industry in Brazil. Hence, the general environment for 
biotechnology entrepreneurship needs to be favourable for the bioentrepreneurs to 
compete favourably; and for Brazil to compete with the developed economies. 
 
Availability of infrastructure 
 
The respondents highlighted the importance of having the necessary infrastructure in 
the value chain of biotechnology entrepreneurship. 
 
And in biotechnology you need to be careful because you need to plan 
very well the activities. It is not the kind of business where you can put 
small amount of money, it is not like that because if you do not have the 
capacity, if you do not have the laboratories and the equipment and the 
entire infrastructure necessary to grow as fast as possible, you do not 
have the result; and if you do not have a result you have nothing. So it is 
the kind of investment that you need to plan very well. (Respondent 8 
20:53) 
 
Most mention of the need for infrastructure pertained to the biotechnology parks, 
which are important to support the system approach to biotechnology 
entrepreneurship. 
 
In 1984, the CNPq [National Council for Scientific and Technological 
Development] launched a programme of support for the creation of 
technology parks in Brazil. The goal had been to foster the creation of 
research spin-offs – an acknowledgement of the role of innovative small 
businesses. (Documents Case 2 33:25) 
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We created a kind of technology park, where you can bring your start-up 
companies, they are private, they can hire students in a way that all the 
inventions that they do in the company belongs to them and not to the 
university. We are not interested in getting money from the innovation that 
is done by this company, we are interested that this company grows, 
develops and makes a lot of money and pays the taxes.  That is a priority 
in the university. This is how we need to do it, it is not simple, but it is the 
way that we are trying to do it. (Respondent 8 20:40-42) 
 
In addition to the biotechnology parks, the government has also introduced support 
services that improve the chances of success for start-up businesses in the 
biotechnology sector in Brazil. 
 
There is one service, they call SEBRAE [Brazilian Service for Small 
Business]. SEBRAE has a service that helps people to structure small 
business, their own business, they give money to support it; is this idea 
commercially viable or not? What would be the pay back if they borrow 
money? They help you to do all this and they finance the incubator at a 
university level to help your professor and your students to put your 
business plan together and that is a big help from the private sector. 
(Respondent 9 21:61) 
 
Furthermore, there is private sector involvement in providing the infrastructure that 
supports the biotechnology industry in Brazil.  
 
The Federal university of Santa Catarina has a big incubator infrastructure. 
That is another process we established in Brazil, financing the incubation 
system. We have an incubator that can incubate a small company. It is 
financing the incubation of a small business, either start up or a spin off. 
This is funded by the private sector in Brazil, the National Industrial 
Confederation of Industry (CNI). (Respondent 9 21:60)  
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These favourable business level influences have been instrumental in the successes 
achieved by Brazil in biotechnology entrepreneurship thus far. 
 
On the other hand, the business level environment of biotechnology 
entrepreneurship in Brazil was also deemed to have a few key challenges among 
which are lack of aggregate skills; a national culture that considers entrepreneurship 
to be impure; high cost of funding; and bureaucratic and inefficient processes by 
government agencies.  
 
The other challenges mentioned by one respondent, such as the negative impact of 
politics and corruption are not elaborated on as they may not be representative of 
Brazil as a whole. 
 
Lack of aggregate skills 
 
The requirement to have individuals with the right psychological, demographic, 
educational and career background for the development of biotechnology 
entrepreneurship in Brazil was corroborated by the respondents and documents 
reviewed for this research. 
 
To be successful in boosting business innovation, these policies will need 
to be complemented by measures aimed at tackling the shortage of skills 
in the labour force; this shortage is among the most important deterrents to 
innovation in Brazil, particularly against the backdrop of a widening gap in 
tertiary educational attainment with respect to the OECD area. 
(Documents Case 2 25:1) 
 
The emphasis on the development of human resources is aimed at developing the 
right bioscientific and entrepreneurial skills needed to sustain the gains made in the 
development of biotechnology entrepreneurship in Brazil. However, the respondents 
deemed the aggregate level of skills required for the effective development of the 
biotechnology industry in Brazil to be inadequate. 
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Ok, I am going to stimulate the bio-industry and then I need technical 
people, and where are they? I am talking about a lack of engineers in 
Brazil; we are importing engineers from abroad, from Europe, where there 
are no jobs, so we are importing engineers from Spain, from Portugal, 
from Italy, from Germany. (Respondent 6 18:123) 
 
The dependency of biotechnology entrepreneurship on skilled individuals makes the 
development of aggregate level of skills important if the successes achieved so far 
are to be sustained and extended. The government of Brazil has several 
programmes of skills development in this respect, which involve both local skills 
development and international exchange programmes.   
 
A national culture that considers entrepreneurship to be impure 
 
The culture of suspicion between business and academics was highlighted by the 
respondents as a challenge to the development of biotechnology entrepreneurship in 
Brazil. A career in academics is seen as pure and mixing this with business is seen 
as being driven by improper motives. 
 
This seems to be an entrenched national culture given that all the respondents 
highlighted it. 
 
All the scientists that were trying to do this were seen under suspicion by 
the university colleagues, they thought they wanted money, that they were 
greedy and things like that, but they were trying to do business as well. 
(Respondent 7 19:19) 
 
Unfortunately it is not very amenable or conducive to business because I 
think we have a very Latin and Catholic inheritance in the way that things 
are done, very different from Anglo-Saxonic, protestant more open and 
with higher value to entrepreneurship and that it is okay to make money. 
For example, the one thing we have suffered in a way is when a scientist 
decides to set up a business in a Latin/Catholic country, a lot of people 
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say, oh he is going to get rich, he will not do research anymore, he is 
selling his soul. 
So there is this very wrong view of entrepreneurship, that setting up a 
company it is not “pure”, you have to stay pure in academia, that sort of 
stuff. So the big challenge for me is to stay as a very productive scientist, 
publishing good stuff, having lots of students, and all at the same time so 
that nobody could say anything, and that is a challenge because as I say 
again, these are long days. (Respondent 6 18:23-27) 
 
This may explain why the bioentrepreneurs in this study were all attached to the 
university at the same time that they were involved in entrepreneurial activities. 
Leaving the academic career entirely to focus on bioentrepreneurial activities would 
have confirmed the views that it was driven by the quest to get rich. 
 
High cost of funding  
 
The high interest rate and taxation are deemed to contribute to the differences in 
cost of doing business between Brazil and the US. This comparison was in the 
context of the fact that the bioentrepreneurs in Brazil consider themselves to be 
competing with the developed economies. 
 
But now the cost, if you buy a reagent in the United States it costs 100 
dollars, if you buy it from a company here, the company has to pay all the 
import tax. So if you are doing sequencing or DNA here it is much more 
expensive than in the United States, despite the fact that the labour is 
cheaper. (Respondent 9 21:99) 
 
The funding initiatives of the government at favourable terms, and sometimes 
designated as “free to operate” (FTO) in which case the recipient is not required to 
repay the grant, alleviate the challenge of the high interest rate experienced by the 
respondents. 
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Bureaucratic and inefficient processes by government agencies 
 
The role of government in promoting and developing biotechnology entrepreneurship 
in Brazil was acknowledged by the respondents. However, there have been 
challenges with the efficiency of government agencies to dispense their duties 
without undue bureaucracy. 
 
For us to operate, we had to buy used equipment, and it took me almost a 
year to do all the bureaucratic paper work to be able to buy used 
equipment. (Respondent 6 18:41) 
 
For example we have the National Sanitary Agency that gives a very hard 
time for doing lots of things. For importing reagents you have to explain 
why you are doing this, what are you going to use it for and it takes 
forever. Then you have an import licence by the revenue service and it 
takes a month for them to allow you to import something. (Respondent 6 
18:110) 
 
We have some universities like Unicamp and companies like Petrobras 
and Embraer, they patent, but the whole process is quite slow. The thing is 
the owner of the patent must pay the fees and maintain the patent and this 
is not something that is made easy here. (Respondent 10 22:55) 
 
These inefficiencies result in the lack of competitiveness of the local 
bioentrepreneurs and have forced some to seek the required services from the 
international market rather than the local. An example was the tendency to register 
patents overseas to avoid the bureaucratic delays experienced at home. 
 
Social linkages 
 
The social linkages to biotechnology entrepreneurship in Brazil were highlighted by 
less than half of the respondents. However, this category is included in the narrative 
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for the business influence of Brazil in order to enrich the understanding of the context 
of biotechnology entrepreneurship in Brazil. 
 
Yes, but one thing that is important that I always tell my students, is first do 
a good job, do good science and try to link with real problems when you 
are working. Real problems are practical issues that are important for your 
country, help people or help an area that is important for the country, I say 
that all the time. (Respondent 8 20:58) 
 
So when I talk about social issues I talk basically education. A serious 
investment in high quality education for the next 50 to 100 years, this is 
what we need. We need solid education for the new generation, so that we 
break this vicious cycle. Because that impacts the family structure, in 
Brazil a quarter of the kids that are born do not have a father on their birth 
certificate, and that is a problem. That means that the family structure 
which is the nucleus of a successful life of a kid, it is still lacking. 
(Respondent 6 18:117-118) 
 
The display of nationalistic tendencies was a common trend among the respondents. 
It is all about the country, all about solving their problems, and all about helping their 
fellow citizens through their research activities. This disposition is complemented by 
the government through policies aimed at solving social problems. 
 
The Brazilian federal policy on biodiesel is aimed at alleviating rural 
poverty (stimulating rural activities to increase employment in rural areas). 
It is an interesting historical note that energy security was the main driver 
at the time of the launch of the PróÁlcool programme. At the time climate 
change had only just started to emerge as a global concern. However, 
GHG emissions savings has become an additional driver for bioethanol 
production in Brazil. (Documents Cross-Case 30:28) 
 
 
In summary of the business level influences show that there were favourable 
influences, as well as challenges highlighted by the respondents. The role of the 
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government featured in both the favourable influences, and the challenges, while the 
role of the other stakeholders such as venture capitalists, large companies and 
research institutions was deemed to impact favourably on the development of 
biotechnology entrepreneurship in Brazil. 
 
6.3 Macro-environment influences  
 
The macro-environment influences experienced by the respondents in Brazil include 
the policy and regulatory environment; the stakeholders involved in biotechnology 
entrepreneurship; and the research and development dynamics in Brazil. 
 
Unfavourable policy and regulatory environment 
 
The policy environment in Brazil is considered unfavourable to the development of 
biotechnology entrepreneurship. Although the national biotechnology development 
policy seemed to be well implemented, the specific policies related to intellectual 
property ownership and technology transfer from the university to the industry were 
deemed unfavourable by the respondents. 
 
There are some legal difficulties for example, a university professor in 
Brazil, a federal university or state university professor. Most of them or I 
would say 95% of them have a contract called, Exclusive Dedication. By 
exclusive dedication it means that you cannot have a business, or maybe 
better said, you can own a business, but you cannot run the business. 
So that also inhibits many scientists to go out and try something because 
they are worried there will be a conflict of interests. (Respondent 6 18:90-
91) 
 
For example, if you are a company investing in research here at the 
university, it is fine but if I discover something interesting or important and I 
want to file a patent on that invention, I cannot license it through the 
company that invested in that research. And this is one of the most 
important problems related to technology transfer and development inside 
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the universities here in Brazil, because all of them are state and public 
universities. And of course if you were a company you will not be 
interested in investing in research and that patent for that invention that 
was discovered during the research because it can go to your competitor. 
(Respondent 8 20:31-33) 
 
We do not have a legal framework well organised, well structured, this is 
inhibiting a lot. (Respondent 9 21:106) 
 
The difficulty of technology transfer from the university to the industry by the 
researchers, owing to legal restrictions, is one of the gaps in commercialising 
research in Brazil. This stemmed from the era when academics were seen as purists 
and kept as far away from business as possible. However, the requirements of 
biotechnology entrepreneurship in Brazil have necessitated university-industry 
technology transfer and the legal environment in Brazil has not kept up with this 
requirement. 
 
The regulatory environment is mostly related to taxation and labour laws, which are 
also considered unfavourable and inhibitory to the development of biotechnology 
entrepreneurship by the respondents in Brazil. 
 
In any case, a company would still have to operate in this very difficult 
business environment. For a number of reasons, interest rates, cost of 
personnel, taxation for import and general tax structure which is a complex 
system of several taxes in cascade. The government knows that, the law 
makers know that, but it is difficult to change things, it takes a while 
because of course the states and federal governments depend on those 
taxes. (Respondent 6 18:51-53) 
 
Then of course you have import taxation on reagents and equipment. 
At the same time a company in Miami, a company in Beijing will buy that 
equipment not for $300 000, not for $650 000, but for $250 000 or even 
lease the machine for $100 000 and pay during the same time I will be 
paying back my investment, and they will compete with me in the 
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globalised service market of DNA genotyping and sequencing, so make 
your calculation. (Respondent 6 18:37-39) 
 
The policy and regulatory environment for biotechnology entrepreneurship in Brazil 
was considered to be unfavourable by all the respondents in Brazil. Given the fact 
that the policy and regulatory environment was seen as an important determinant of 
the success of the biotechnology industry, the challenges identified with intellectual 
property ownership; technology transfer; labour laws; taxation; and high interest 
rates inhibit the ability of Brazil to compete effectively with the developed economies 
in biotechnology entrepreneurship. 
 
The stakeholders involved in biotechnology entrepreneurship 
 
The key stakeholders in biotechnology entrepreneurship are the government, 
research institutions, venture capitalists, large biotechnology companies, and the 
civil society. The government provides an enabling regulatory environment and acts 
as facilitator; the research institutions provide talent and technology transfer 
capabilities; the venture capitalists provide capital; the large companies act as 
cooperation partners, customer and competitor (Ahn and Meeks, 2007); and the civil 
society comprises the users of the biotechnology products. In the case of Brazil, the 
government’s facilitation role includes funding and providing the market for the 
biotechnology products. 
 
Given that the government and the civil society will normally be default stakeholders, 
the venture capitalists, research institutions and the large biotechnology companies 
are the key determinants of whether Brazil has a full complement of the stakeholders 
required for biotechnology entrepreneurship or not. These stakeholders are actively 
involved in biotechnology entrepreneurship in Brazil and contribute to the successes 
attributed to Brazil in the biotechnology industry. 
 
FINEP [Research and Projects Financing] was a government funding 
institution that started a venture capital programme as well, a very huge 
programme.  
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And BNDES, the national bank of social development, that also now has a 
huge fund for biotechnology. (Respondent 7 19:17-18) 
 
The BAT Group, the British American Tobacco Group, has had a lot of 
Agro business in Brazil, in tobacco, and the paper industry. (Respondent 9 
21:2) 
 
Most of the investment was done by Votorantim New Business, but we got 
some investment from the Federal Institution, from the agency called 
FINEP. FINEP provide money for innovation in industry. So we got some 
money from them but most of the money, 90% of it for these two 
companies came from Votorantim New Business. (Respondent 8 20:35-
36) 
 
We have quite a few nice universities, not only here in the state of São 
Paulo, but also in Rio de Janeiro, Minas Gerais, and other states, very, 
very well established universities. (Respondent 8 20:80)  
 
The facilitation role of the government provided the environment necessary to attract 
the large biotechnology companies, most of whom are not native Brazilian 
companies. The venture capitalists for biotechnology are equally attracted to 
environments that are conducive to the development of biotechnology 
entrepreneurship. Furthermore, most of the research in Brazil is conducted through 
the public universities, which is also the responsibility of the government. Hence, the 
government is an important stakeholder in the biotechnology industry in Brazil. 
 
The research and development dynamics in Brazil 
 
Although the R&D spend in Brazil is considered low in comparison to the OECD 
countries, the research activities at public research institutions are believed to be 
higher than in most developing economies.  
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At 1% of GDP, R&D spending (both public and private) is comparatively 
low by OECD standards and is carried out predominantly by the 
government. (Documents Case 2 24:3) 
 
I would say it is general and in a way that is unfortunate because 
innovation type research has not received any preferential treatment, so 
that is also a problem. (Respondent 6 18:35)  
 
The efforts by the government, at national and state levels, to improve the 
environment for research and its funding led to the establishment of various 
successful funding agencies for biotechnology entrepreneurship in Brazil. 
 
In its 41 years of operation, FAPESP has awarded more than 45 thousand 
fellowships and 35 thousand financial awards to research. The balance of 
these years of continuous investment clearly show that the Foundation has 
made a decisive contribution to the expansion and strengthening of 
scientific and technological research in the State of São Paulo, with 
considerable impact on its economic, social and cultural development. 
(Documents Case 2 24:2-6) 
 
These efforts by the government have improved the research intensity in specific 
areas of biotechnology, such as bioenergy and genomics. 
 
We have a lot of research and development being done in this area of 
sugar cane and this will be good for the country because of the investment 
in research. (Respondent 8 20:26) 
 
EMBRAPA has collaborative projects with the pulp and paper business to 
develop methods, genomic based methods of phenotype predictions. So 
basically you use DNA analysis to predict outcomes of phenotypes of 
trees, so you can save time, increase precision and for selecting trees that 
are more drought-tolerant, cold-tolerant, disease-resistant, and more 
productive. (Respondent 6 18:87) 
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The research funding agencies such as FAPESP have a mandate to boost 
innovation in the country and they do have funding arrangements where the recipient 
does not need to pay back the grant. The genome projects in Brazil exemplify 
effective exploitation of opportunities through research, stakeholder collaboration, 
appropriate funding, and commercialisation. 
 
In summary, the macro-environmental influences in Brazil have a mix of favourable 
and unfavourable components according to the respondents in this research. The 
policy and regulatory environment was deemed unfavourable due to difficulties with 
taxation laws, labour laws, policy on intellectual property ownership and policy on 
technology transfer. 
 
The stakeholders required for the efficient development of the biotechnology industry 
in Brazil are all available. Hence, this can be regarded as a favourable component of 
the macro-environmental influences. 
 
Lastly, the R&D dynamics show that relative to the developing economies Brazil is 
doing well on both R&D spend and intensity. However, it lags behind the OECD 
countries in terms of both these factors. There are efforts aimed at improving this 
situation at national and state levels through the funding agencies of government 
and through the private sector. 
 
6.4 Triple helix of university, industry, government relationships  
 
The respondents in Brazil have a practical experience of effective collaboration 
among the university, industry and government. Most of the respondents effectively 
work for all three spheres, which places them in a position where they can 
collaborate to deliver on the common objectives of the government, industry and the 
university. (Respondent 6 18:87) 
 
The epitome of a demonstrable effective triple helix relationship and collaboration in 
the biotechnology industry in Brazil is the genome projects, which involved 
collaboration among hundreds of stakeholders spanning government agencies, 
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universities, research institutions and industry. The results of this collaboration 
elevated Brazil to the status of a global leader in certain areas of biotechnology such 
as genomics and bioenergy. 
 
I had a very interesting and rewarding experience when I set up what we 
called the Genolyptus project, which was a Brazilian network of Eucalyptus 
genome research. I started this project in 2001 and it went on for 7 years 
and it is actually still going on but in a different format. (Respondent 6 
18:59-60) 
 
Some of these collaborations resulted in firm formation and one of the most 
successful biotechnology companies to originate from Brazil was formed as a 
result of the collaboration between university, industry, and government. 
 
Then we created Alellyx, and we put together all the expertise that we 
developed over a long time together with friends from the University of São 
Paulo and the University of the State of São Paulo and the University of 
Campinas and we created a company. (Respondent 8 20:9) 
 
The triple helix relations were supported by the government through initiatives aimed 
at creating a favourable environment for the stakeholders to interact productively. 
The leadership provided by the government and effective implementation of the 
initiatives through its role as facilitator resulted in the successful collaboration that 
currently exists across university, industry, and government.  
 
The measures announced by the federal government include several that 
affect universities and their dealings with industry. Examples include the 
development of targeted research, the promotion of local production and 
innovation systems, support for the introduction of innovative measures in 
small and medium-sized enterprises, and an Innovation Act. The process, 
begun in the 1990s by universities and aimed at speeding up and 
organising interaction with business, has thus reached a new level. 
(Documents Case 2 33:16) 
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The university, industry, and government stakeholders share a common purpose that 
has enabled them to collaborate on projects that have practical significance for the 
imperatives of the country. These projects have often been aligned to the focus 
areas of human health, agricultural biotechnology, industrial biotechnology, and 
environmental biotechnology. 
 
They had to find an alternative to the antibiotics that were used, we have 
to sit together and find one. So then we sat together, they had a problem 
and we had expertise and we then sat together since the beginning, this 
was in 2004 and we have worked together for eight years. We set up our 
research strategy and some of the work is done here and some of the 
work is done in the industry. And now we have several antibiotics that are 
patented worldwide in the industry. (Respondent 9 21:16) 
 
There was no explicit reference to quadruple helix in Brazil, even though the 
references to social linkages imply a consideration for the society and their needs.  
 
It can also be observed that the triple helix dynamics in Brazil constitutes a hybrid of 
Triple Helix I and Triple Helix III in which the government exerts control in an 
environment that enables knowledge infrastructure to flourish. 
 
6.5 The key similarities and differences between Brazil and the 
developed economies as experienced by the respondents 
 
This section discusses the key similarities and differences between Brazil and the 
developed economies, which were highlighted by the respondents.  
 
Similarities 
 
The respondents saw the similarities in biotechnology entrepreneurship between 
Brazil and the developed economies in the areas of support for innovation and 
entrepreneurship; a developed venture capital market; and government leadership. 
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Quality of bioscientists and universities 
 
The individual skills of the bioscientists are deemed to be on par with the 
bioscientists in the developed economies. In addition, the universities and quality of 
research were deemed by the respondents to be of comparable quality to that of the 
developed economies. 
 
I think that we have a very good basic science in this country. Here in 
Brazil we have agricultural companies, like the state company that is 
called EMBRAPA, that is got very well trained people and that is one of the 
good things, but you cannot compare with the US. (Respondent 8 20:70-
71) 
 
We have a very well established training for young students, 
undergraduates and graduates. We have quite a few nice universities, not 
only here in the state of São Paulo, but also in Rio de Janeiro, Minas 
Gerais, and other states, very, very well established universities. So when 
you talk about a country you need to think of big numbers, big numbers 
means that undergraduate and graduate students, we have a reasonable 
number and this is positive. The universities are good and the training is 
good and this is positive. (Respondent 8 20:80)  
 
I think we have good training and I guess the scientific procedure is 
similar. (Respondent 10 22:47) 
 
This similarity has meant that the bioscientists in this research compare favourably 
with their peers in the developed economies and some of them have been 
recognised internationally for the quality of their research. 
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Support for innovation and entrepreneurship 
 
Brazil supports innovation and entrepreneurship through various programmes and 
initiatives aimed at creating a sustained improvement in Brazilian innovation and 
entrepreneurship in the area of biotechnology. 
 
I was in India for a year and Taiwan and the United States. First of all the 
similarities, with the United States, support for small business, both 
countries do have programmes for supporting small business. We have 
money here for supporting start-up companies, incubators within the 
university departments. In the United States they have several 
programmes for supporting small business. (Respondent 9 21:89) 
 
Now, as far as common things, overall I think Brazil is a country where 
people are willing to try. Brazil is a country where people are willing to 
open up businesses and be their own bosses, it is a very clear trend, the 
statistics show this, but not in high-risk type investments like we are talking 
about here. (Respondent 6 18:104-105) 
 
The respondents mostly compared Brazil to the US and commonly benchmarked 
Brazil against the US.  
 
Developed venture capital market 
 
The venture capital market in Brazil was seen as one of the most important factors 
contributing to the development of biotechnology entrepreneurship, similar to the US. 
 
The boom of the biotechnology in the US is mainly driven by the venture 
capital. There is no question about it, if you have a good idea somebody is 
willing to put up the money, is willing to risk the money and make a lot of 
money or not. (Respondent 9 21:90) 
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The ability of the environment of biotechnology entrepreneurship in Brazil to attract 
venture capitalists attests to the environment being deemed favourable by the 
stakeholders in the biotechnology industry. 
 
Government leadership and direction 
 
The important role of government in the development of biotechnology 
entrepreneurship is seen to be the same in Brazil as it is in some of the other 
developing economies, such as India. 
 
And also another similarity between Brazil and India, the government has 
a lot to say about the development of the country. In India you have 
private investors but the government has a big role, as well as in Brazil. 
Brazil’s government also plays a big role in biotech developing in Brazil. 
(Respondent 9 21:93) 
 
This leadership role is aligned to the facilitation role of the government in 
biotechnology entrepreneurship in Brazil, which the government was deemed to 
have performed effectively. 
 
Differences 
 
The differences highlighted by the respondents were in the areas of regulation, 
government inefficiencies, the scale difference between US and Brazil, and the cost 
of doing business. 
 
Regulatory framework 
 
In comparison to the developed economies, the regulatory framework in Brazil is 
seen as lagging behind and inhibitory to the development of biotechnology 
entrepreneurship in Brazil. 
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When you go over there the rules are extremely established, in Brazil the 
rules are still loose. You never know when to put the ends together. At the 
government level you do not have a rational legal framework; Korea has a 
beautiful legal framework. That is the reason why a lot of venture capital 
are moving to Singapore, they have a very good legal framework. 
(Respondent 9 21:92) 
 
The challenges with the regulatory environment were deemed by the respondents to 
be one of the key challenges facing the development and sustainability of 
biotechnology entrepreneurship in Brazil. 
 
Bureaucracy 
 
The level of bureaucracy in Brazil was consistently highlighted as a challenge for the 
development of biotechnology entrepreneurship. This was seen to be worse in Brazil 
than the countries the respondents compared Brazil to, specifically the US. 
 
And also the bureaucratic difficulties between a country like Brazil and a 
country like the US, those I would say are the two main differences that 
inhibit in a way, hinder entrepreneurship in life science. (Respondent 6 
18:103) 
 
The bureaucratic processes and inefficiencies associated with government agencies 
in Brazil negate the efforts of the government to drive the development of the 
biotechnology industry. In specific examples, such as patenting, the respondents 
resorted to filing their patents overseas in order to avoid the inefficiencies and delays 
in Brazil. 
 
Resource availability 
 
The level of resource availability in US was contrasted with the scale in Brazil, and 
lack of resource availability in Brazil was seen as posing a challenge to the 
productivity of the researchers in the biotechnology industry in Brazil. 
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In the United States if we are doing the research here right now and you 
come up with a new idea and you need a new reagent for tomorrow, you 
just go to the internet and the next morning it is delivered, here it takes 
four to six months. (Respondent 9 21:98) 
 
The difference in resource availability was not deemed to be a consequence of the 
distance between Brazil and Europe, but a consequence of the low level of 
production capability of the required resources in Brazil, and the inefficient tax laws 
in Brazil. 
 
Innovation culture  
 
The other difference highlighted between Brazil and the developed economies was 
in the area of innovativeness. Brazilians are deemed to be less innovative than the 
developed economies. 
 
First of all the culture of innovation in a country like the US or Europe, or 
many countries in Europe, not all but several, it is still something that does 
not exist, we are still learning, I think that is a major difference. 
It is a system in place that allows for more innovation to happen, even 
though venture capital sometimes invests in 10 different small start-ups, 
nine fail and one pays for the failure of the other nine, we do not have that 
culture yet. (Respondent 6 18:100-101)  
 
The lack of a culture of innovativeness in Brazil may be linked to the preference for 
an academic career instead of entrepreneurship; and the view of entrepreneurship 
as being impure and the quest for wealth. 
 
Preference for academic career 
 
The respondents in Brazil believe that most bioscientists are more inclined to be in 
academics rather than commercialise research due to society’s perception of 
academics as pure. 
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In Brazil the stimulus is mostly to go towards academia, seen as a pure, 
removed from the real life of business. Although this is changing but it is 
still very strongly felt in academia. (Respondent 6 18:106) 
 
This difference was believed to be changing as Brazil becomes more globalised 
and the researchers are able to link their research to solutions to national 
priorities. 
 
Scale 
 
Another difference highlighted by the respondents was in relation to the difference in 
scale between the biotechnology industry in the US and Brazil. 
 
Yes, completely different, and everything is built to promote and to get 
there as fast as possible and this is something that is very difficult to 
compare. (Respondent 8 20:70-71) 
 
One thing that is very, very, very important and that is we need to focus on 
a small number of projects in areas that are important for the country in 
order to build up the capacity to compete with them. We cannot do it like 
they do, they invest in most things, in all areas, we cannot do this, and we 
need to find a way to focus on a few projects for innovation. Basic science 
is okay, but for innovation we need to focus on a few areas. (Respondent 
8 20:74) 
 
You cannot compare any country with the United States, the amount of 
money they invest in biotechnology is so big and the infrastructure they 
have for research in biotechnology is so big, you cannot compare, not 
even in Europe, or maybe in Japan or in China, it is huge. Not only in 
terms of infrastructure but in terms of the very well-trained people, of 
course we are interested in some areas that the US are interested in. But 
they have all the facilities, but it is not only the facilities, they have 
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companies that produce all the reagents and the equipment and all the 
things that you need to do the research, they have all the companies. 
They work at a velocity that you cannot follow, for example, all the 
reagents and the equipment that you need to do research with, we import 
mostly from the US, and this importation process takes months and in the 
US they can do this in a day, they can ask and have all things in a day, so 
you cannot compare, it is so huge, it is a very different environment. 
(Respondent 8 20:68-69) 
 
 
In concluding this section, the areas of similarities and differences are linked to the 
favourable factors and challenges in the development of biotechnology 
entrepreneurship in Brazil respectively.  
 
This is an important observation that may mean that the process of biotechnology 
entrepreneurship in Brazil is expected by the respondents to be the same as the 
process in the developed economies. Hence, the similarities with the developed 
economies are in the same areas that are considered to be favourable in the 
environment of biotechnology entrepreneurship in Brazil.  
 
On the other hand, the differences with the developed economies are in the same 
areas that are highlighted as challenges in the environment of biotechnology 
entrepreneurship in Brazil. 
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PART III: CASE ANALYSES 
 
Part III consists of chapters 7 and 8. 
 
Chapter 7 presents a detailed analysis of case 1. 
Chapter 8 presents a detailed analysis of case 2. 
 
The case analyses consider how biotechnology entrepreneurship is carried out in 
South Africa and Brazil using the organising framework of the individual-opportunity 
nexus framework of entrepreneurship (Shane, 2003). The nature of the relationship 
across university, industry, and government in both countries is explored using the 
organising framework of the Triple Helix of university, industry, government relations 
(Etzkowitz and Leydesdorff, 1997; Etzkowitz, 1998; Leydesdorff and Etzkowitz, 
1998; Etzkowitz and Leydesdorff, 2000; Etzkowitz, 2001; Leydesdorff and Etzkowitz, 
2001). 
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Chapter 7: Case Analysis – South Africa 
 
The detailed analysis of case 1 integrates the deep interrogation of the current 
empirical and market research studies on biotechnology entrepreneurship in South 
Africa with interview transcripts, the output of Atlas.ti CAQDAS, and documents, to 
get to a consistent and rigorous analytical view (Weitzman, 1999; Rambaree, 2007; 
Hwang, 2008) of the dynamics of biotechnology entrepreneurship in South Africa 
within its original context (Eisenhardt and Graebner, 2007b; Klonoski, 2013). 
 
7.1 Background to biotechnology entrepreneurship in South Africa 
 
Very few empirical studies on the South African biotechnology industry exist (Cloete 
et al., 2006; Gastrow, 2008). To articulate the current state of biotechnology in South 
Africa, the national strategy documents (Department of Science and Technology, 
2001) were used, in addition to industry research conducted by organisations such 
as the OECD (Organisation for Economic Cooperation and Development, 2013d, 
2013b, 2013c, 2013a), and Ernst & Young (Ernst & Young, 2006, 2010a, 2010b). 
 
The national biotechnology strategy was scheduled to be updated in 2008 but was 
not completed until 2013. The updated version of the national biotechnology 
strategy, renamed “the bio-economy strategy” is not publicly available yet and was 
included in the policy documents used in this research.    
 
South Africa has traditionally been strong in first-generation biotechnology, given its 
beer and wine industry (Cloete et al., 2006). However, the third-generation 
biotechnology industry in South Africa is very small relative to this industry in the 
developed economies (see Figure 7.1).  
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Figure 7.1: Revealed technological advantage in biotechnologies, 1999-2001 
and 2009-11 (OECD Patent Database, October 2013) (Organisation for 
Economic Cooperation and Development, 2013d) 
(Note: The bar highlighted in red is the value for South Africa. BRIICS stands for Brazil, Russia, India, Indonesia, China 
and South Africa) 
 
The relative paucity of empirical research on biotechnology entrepreneurship in 
South Africa may have contributed to the low position occupied by South Africa on 
revealed technological advantage in biotechnologies (see Figure 7.1). 
 
7.1.1 National biotechnology strategy 
 
Emphasis on biotechnology in South Africa culminated in the national biotechnology 
strategy of 2001 (Department of Science and Technology, 2001), which aims to 
develop a viable and sustainable biotechnology industry. 
 
The guiding principles for the conception and implementation of the strategy include: 
 
i. The need to meet the national imperatives of job creation, rural development, 
crime prevention, human resource development, the addressing of HIV/AIDS 
and economic growth 
ii. Focus on areas of likely comparative advantage in biotechnology 
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iii. Development of new programmes that harness existing national scientific and 
technological competencies 
iv. Addressing issues of biosafety 
v. Review of the strategy in light of national priorities and international trends in 
biotechnology development 
 
The adoption of this policy framework led to the establishment of four Biotechnology 
Regional Innovation Centres (BRICS), the National Bioinformatics Network (NBN), 
biotechnology incubators and Bioventures (a biotechnology venture capital fund). 
Various government agencies, research institutions and universities were tasked 
with the implementation of the strategy, with the Department of Science and 
Technology having the responsibility of administering the strategy (Cloete et al., 
2006).  
 
7.1.2 Creation of the Technology Innovation Agency 
In 2010, a new public entity was established, which is known as the TIA. The TIA 
replaced the BRICS, the Innovation Fund, Advanced Manufacturing Technology 
Strategy (AMTS) and Tshumisano Trust. The aim of TIA is to stimulate and intensify 
innovation leading to the development of technology based products and services, 
by the public and private sector technology based enterprises, and to create an 
enabling environment in which these could be commercialised (Technology 
Innovation Agency, 2010) 
TIA (2010) provides and mobilises financial and non-financial support across broad 
technology areas in various sectors of the economy through: 
 
i. Appropriately structured financial and non-financial interventions for the 
commercialisation of R&D results 
ii. The development and maintenance of advanced human capacity for 
innovation as opposed to just R&D human capital 
iii. Building a culture of innovation in the South African economy  
iv. Leveraging local and international partnerships in order to facilitate in-bound 
technology transfer, build local technological competencies, and encourage 
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foreign direct investment for the commercialisation of technologies in South 
Africa (Technology Innovation Agency, 2010) 
 
Areas of success are predominantly in agricultural biotechnology and vaccine 
production. However, these successes pale when compared to those of the 
developed economies (see Figure 7.1). The role of TIA as articulated in the section 
above has not been effectively carried out as evidenced by the experience of the 
respondents who participated in this research. 
 
I think the biggest disappointment that many of us in the field have had 
over the last two or three years is that the instrument that TIA was meant 
to represent has not, has not come to the party, has not come to the fore 
and the delays that people are experiencing with TIA at the moment have 
actually meant that in several cases, businesses have had to close down 
and that is an absolute tragedy in a country where there is such a strong 
will to grow biotechnology but there was this major obstacle. (Respondent 
12 7:20)   
 
7.1.3 Constraints  
 
The constraints to the development of biotechnology entrepreneurship in South 
Africa include: 
 
i. Shortage of bioscience skills (Lingelbach et al., 2005; Cloete et al., 2006) 
ii. Shortage of research and publications related to biotechnology (Cloete et al., 
2006; Gastrow, 2008) 
iii. Low levels of patent application (Gastrow, 2008; United States Patent and 
Trademark Office, 2009) 
iv. Low levels of commercialised biotechnology products (Cloete et al., 2006) 
v. Low levels of R&D spend relative to the developed economies (Gastrow, 
2008) 
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vi. Lack of sustained emphasis on biotechnology. The update of the national 
biotechnology strategy scheduled for 2008 was not effected until 2013 
(Department of Science and Technology, 2001) 
vii. Lack of performance on mathematics and science in the national curriculum 
viii. Lack of a developed venture capital industry (Lingelbach et al., 2005; 
Lingelbach et al., 2008; Lingelbach et al., 2013) 
ix. Lack of entrepreneurial culture at universities (Mitchell, 2006; Kabongo and 
Okpara, 2010; Chimucheka, 2014)  
x. Low level of private sector involvement in biotechnology (Cloete et al., 2006) 
 
These constraints impact on the speed and scale of development of biotechnology 
entrepreneurship in South Africa. Literature (Müller et al., 2004; Ahn and Meeks, 
2007) on developed economies shows that the resolution of these constraints is the 
necessary condition for creating an environment that is conducive for the 
development of biotechnology entrepreneurship in South Africa. 
 
7.2 How biotechnology entrepreneurship is carried out in South Africa 
 
The analysis of the process of biotechnology entrepreneurship in South Africa is 
facilitated through the use of the individual-opportunity nexus framework of 
entrepreneurship discussed in Chapter 3, as an organising framework. Hence, the 
components include: 
 
i. Individual attributes 
ii. Environment 
iii. Entrepreneurial opportunities 
iv. Discovery 
v. Entrepreneurial exploitation 
vi. Execution 
 
 
 
152 
 
7.2.1 Individual attributes 
 
There were 12 respondents in South Africa of which seven were designated as 
bioentrepreneurs and five were subject matter experts (SME) across university, 
industry, and government. Among these 12 there were four overlaps, which were 
designated as both bioentrepreneur and subject matter expert. 
 
In choosing the respondents for the research in South Africa, care was taken to 
ensure that the purposive sampling was representative of individuals with a high 
degree of knowledge and competence in the research topic (Romney et al., 1986; 
Guest et al., 2006; Stake, 2006; Bowen, 2008) and hence, with good insights into the 
dynamics of biotechnology entrepreneurship in South Africa.  
 
A summary of the characteristics of the respondents for case 1 is presented in Table 
7.1. 
 
Table 7.1: Summary of characteristics of respondents for South Africa 
Respondent Position Qualification Area of expertise 
1 
Director at a 
government agency 
M.Sc. in 
Environmental 
Biology 
Biotechnology policy development 
and implementation 
2 
Director at the 
university 
B.Engr.; CFA; MBA 
TTO and commercialisation of 
research 
3 
Researcher at a 
government agency 
B.Sc. (Honours); 
MBA; PhD in 
Biochemistry 
Implementation of the biotechnology 
strategy  
4 
Chief scientist at a 
government agency 
B.Sc.; M.Sc.; PhD in 
Chemistry; Associate 
Professor 
Bio-prospecting and the effective use 
of South Africa’s biodiversity 
5 
Founder of a 
biotechnology 
company 
M.Sc. MBA; PhD in 
Biotechnology 
Bioentrepreneur in the area of human 
health specialising in the research 
and development of osteogenic 
biomaterials for use in skeletal 
regeneration therapies in humans 
6 
Founder of a 
biotechnology 
Biotechnologist; 
Management 
Bioentrepreneur in the area of human 
health specialising in the production 
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Respondent Position Qualification Area of expertise 
company advancement 
Programme (MAP) 
of high quality lateral flow rapid 
diagnostic test kits 
7 
Director at the 
university 
Medical doctor; PhD; 
Professor of 
Immunology 
An ex-bioentrepreneur and closely 
involved in academics and 
government initiatives on 
biotechnology 
8 
Ex-director of a 
Venture Capital 
Fund 
MBA; PhD in Cell 
Biology 
Instrumental in setting up and raising 
South Africa’s first venture capital 
fund for biotechnology. 
9 
Managing director 
of a specialist not-
for-profit contract 
research 
organisation 
PhD in Molecular 
Biology 
Combines state-of-the-art information 
rich genomic and proteomic 
technologies with bio-computational 
pipelines to create unique solutions 
for biological problems in the human 
health and the agricultural 
biotechnology sectors 
10 
Founder of a 
biotechnology 
company 
B.Sc. in Applied 
Mathematics and 
Physics; PhD in 
musculoskeletal 
biomechanics; and a 
DSc (Med) in 
biomedical 
engineering 
Medical bioengineering specialising in 
the design and manufacture of 
medical imaging systems for the 
diagnosis of breast cancer 
11 
Co-founder of a 
biotechnology 
company 
Medical doctor; 
Pharmacologist 
Conducts leading-edge biotechnology 
research and related bioservices to 
the biotechnology industry 
12 
Founder of a 
biotechnology 
company 
M.Sc. in Physiology, 
Pathology and 
Related Sciences 
Specialises in the manufacture of 
wide range of both urinalysis and 
lateral flow diagnostics products for 
government, NGO procurement and 
for private use 
 
 
In addition to the psychological attributes, the respondents in South Africa 
possessed the requisite non-psychological factors, such as education and career 
experience (Barro and Lee, 2000), for biotechnology entrepreneurship. The 
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education factor in biotechnology entrepreneurship is a critical requirement 
functioning as a bioentrepreneur.  
 
The bioentrepreneurs interviewed in South Africa either already had successful 
products in the local and international markets or were at an advanced stage of 
product development.  
 
An entrepreneur wants to be independent. 
He wants to start something from scratch and build into something 
substantial, and he likes the insecurity of not having a salary at the end of 
the month because it drives him to try and make some money. 
 It is such a great feeling of accomplishment. (Respondent 5 5:62-65) 
 
We export our malaria kits to countries like Papua New Guinea, Pakistan, 
some African countries via a distributor. And we sell most of our HIV tests, 
pregnancy tests, drug abuse tests in South Africa to pharmaceutical 
wholesalers, Department of Health, Department of Education, some other 
governmental departments and some private companies. (Respondent 11 
6:11-12) 
 
These bioentrepreneurs exhibited individual psychological attributes such as a 
higher level of cognitive functioning, motivation, leadership qualities, propensity to 
take risks, action-oriented, self-efficacy, preference for autonomy, self-direction, and 
differential access to scarce and expensive resources (Shane and Venkataraman, 
2000; Eckhardt and Shane, 2003; Shane, 2003).  
 
And I want to make the first recombinant bone complex in the world, that is 
my next dream. In 2022, I would like to launch the first recombinant 
complex, and I would like to have an interview with you again at that time. 
We meet here in 10 years’ time to see what is happening and how we 
have achieved that. (Respondent 5 5:81-82) 
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I had customers before I produced. And that of course is important in your 
way of thinking as well; profiling, building a company, building a brand, 
building a profile for yourself as an individual. (Respondent 11 6:26-27) 
 
However, these bioentrepreneurs did not believe that their entrepreneurial skills were 
inherited. Most of the respondents designated as bioentrepreneurs believed that they 
were bioscientists who had acquired the business management skills through 
training to qualify as bioentrepreneurs. (Respondent 11 6:7) 
 
Of all respondents designated as bioentrepreneurs in South Africa, only one believed 
that his entrepreneurial qualities were inherited, and, hence, he would have been an 
entrepreneur in any field he chose (Respondent 5 5:55-56). 
 
The respondents in South Africa had the necessary bioscientific educational training 
and were highly qualified academically, as shown in the characteristics listed in 
Table 7.1. They were also inclined to acquire business management skills, which 
enabled them to manage the firms set up to commercialise their biotechnological 
innovations. 
  
Doing my MBA at Wits university was a key step to empower myself with 
sufficient knowledge capital to better understand the business of science. 
How to do financial models, how to calculate net present values, how to 
understand strategies and scenario planning. (Respondent 5 5:12-13) 
 
I also attended a programme hosted by Wits University, called the 
management advancement programme. (Respondent 11 6:7) 
It opened up my eyes to think more like a business person than a scientist. 
Scientists tend to think of the publications we can get, let me do my 
research, I want to publish this paper. (Respondent 11 6:22) 
 
This combination of bioscientific and business management skills predisposed them 
to the “individual” approach to biotechnology entrepreneurship where the scientific 
and entrepreneurial functions reside in one individual; rather than a “system” 
approach where the bioscientist does not necessarily have the responsibility for the 
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entrepreneurial or business management side of the running the firm set up to 
exploit the biotechnological innovation. The system approach is obtainable in 
biotechnology clusters (Ahn and Meeks, 2007) as seen in the developed economies. 
The biotechnology clusters in South Africa are underdeveloped and that may be a 
contributing factor to the tendency for the respondents to adopt the individual 
approach. 
 
Although the lack of entrepreneurial skills is often cited as one of the constraints 
facing biotechnology entrepreneurship in South Africa (Cloete et al., 2006; Gastrow, 
2008; Ernst & Young, 2010b; Organisation for Economic Cooperation and 
Development, 2013a), this is at an aggregate and not at an individual level. The skills 
of the individual bioscientists are deemed to be on par with those elsewhere in the 
world. 
 
Centres of academic research excellence, mainly located in a nucleus of 
long-established universities, achieve high quality in several areas of 
research, as reflected in the presence of South African publications among 
the top 1% of internationally cited publications in several fields and in 
some cases in the higher quartiles of that group. (Documents Case 1 
14:16) 
 
It can be concluded from the analysis above that the psychological and non-
psychological individual attributes for entrepreneurship highlighted in the literature on 
entrepreneurship are possessed by the respondents in South Africa. In addition, they 
display the tendency to obtain business management training to enable them to 
manage their firms effectively as an individual rather than rely on a support system 
that does not exist in South Africa.  
 
In carrying out the entrepreneurial activities required for the management of their 
firms, the respondents mostly believe that their entrepreneurial ability is learned and 
not inherited. 
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7.2.2 Environment 
 
The environment of biotechnology entrepreneurship in South Africa is fraught with 
challenges according to the respondents (see Table 7.2 below). In addition, the 
document analysis highlighted key areas of challenge for biotechnology 
entrepreneurship in South Africa as human capital (skills), knowledge exploitation, 
market development (market size) and governance (government direction). 
 
This strategy is based on the assumption that the issues facing South 
Africa’s bio-economy – including human capital development, knowledge 
exploitation, market development and governance – cannot be addressed 
in isolation, but need to be solved in an integrated, holistic fashion to yield 
coordinated, systemic interventions. (Documents Case 1 13:68) 
 
Table 7.2 shows the areas highlighted by the respondents as affecting the 
environment of biotechnology entrepreneurship in South Africa. Most of these are 
designated as challenges. Of the nineteen (19) areas highlighted only one was 
mostly seen as not a challenge while the remaining eighteen areas were seen as 
challenges by most of the respondents. 
 
The one area that was not seen as a challenge by just over half of the respondents 
was infrastructure. A careful examination of the verbatim comments on this point 
showed that the respondents referred to general infrastructure such as roads and 
electricity; as well as research-oriented infrastructure such as universities and 
research institutions. However, the infrastructure that was mentioned most often was 
the biotechnology park. There was a general acknowledgement of the lack of 
biotechnology parks but about half of the respondents believed that the support 
structures within the park are more important to the development of biotechnology 
entrepreneurship than the bricks and mortar. 
 
Like I said we need, we seriously need a science park in this country 
where we look at the high impacting biotech businesses, and we look at 
their needs. (Respondent 11 6:55) 
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So I have never seen infrastructure as being a problem. We have got 
fantastic roads, we have got great telecommunication. Our basic 
infrastructure is in place. We have got fantastic universities that are very 
well equipped. Again it is not through the creation of a biopark that you are 
going to have a successful biotech industry. (Respondent 12 7:47, 48, 50) 
 
 
Table 7.2: Points highlighted by South African respondents as affecting the 
environment of biotechnology entrepreneurship 
Point mentioned 
This point is mostly 
considered a gap 
 This point is mostly 
not considered a gap 
Policy and regulation √ X 
Funding √ X 
University culture √ X 
Government direction √ X 
Skills √ X 
Market size √ X 
Infrastructure X √ 
Brain drain √ X 
Support √ X 
Capacity √ X 
National culture √ X 
Bureaucracy √ X 
Failure √ X 
Corruption √ X 
Politics √ X 
Implementation √ X 
Large biotechnology 
companies 
√ X 
Stakeholder conflict √ X 
Problematic exit √ X 
 
 
The narrative points were collated by manually going through the narrative summary 
of the verbatim quotes by the respondents in South Africa, and highlighting the areas 
mentioned as impacting on the environment of biotechnology entrepreneurship in 
South Africa. 
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The outcomes of data analysis using Atlas.ti CAQDAS for the codes that have the 
most occurrences, but not necessarily in most of the transcripts (vertical occurrence), 
are shown in Table 7.3. These codes were compared to the narrative points in Table 
7.2;and the codes mentioned by most respondents (horizontal occurrence) (see 
Table 7.4) to establish a pattern. 
 
Table 7.3: The table of codes that were mentioned the most (vertical 
occurrence) 
Number Codes that occur the most (vertical occurrence)  
1 Need for effective collaboration among key stakeholders 
2 Lack of appropriate funding 
3 Lack of developed markets for biotechnology products 
4 Lack of collaboration among key stakeholders 
5 Lack of government direction 
6 Emphasis on country competitiveness 
7 Under-developed venture capital industry 
8 Commercialisation of research 
9 Evidence of collaboration among key stakeholders 
10 Bureaucratic processes 
11 Emphasis on national priorities 
12 Lack of entrepreneurship skills 
13 The academic-bioentrepreneur disconnect 
14 Abundant biodiversity 
15 Lack of commercialisation skills 
16 Obvious socio-economic linkages 
17 Pervasive opportunities 
18 Availability of skills 
19 Lack of conducive environment for biotechnology development 
20 Need for direction or leadership 
21 Non-conducive regulatory environment 
22 University policy on IP ownership 
23 Lack of capacity 
24 University policy on commercialisation 
25 Good support infrastructure 
26 Government is seen as a hindrance by other stakeholders 
27 Lack of critical mass of input 
28 Lack of entrepreneurial culture 
29 Obstacles to commercialisation 
30 Problem opportunity 
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Number Codes that occur the most (vertical occurrence)  
31 Economic value 
32 Need to develop innovation skills 
33 Strategic alliances 
34 University publication-commercialisation disconnect 
 
 
The codes that have the most occurrences in most of the transcripts (horizontal 
occurrence) are in shown in Table 7.4. 
 
Table 7.4: The table of codes that occurred across most of the respondents 
(horizontal occurrence) 
Number Codes that appear in most transcripts (horizontal occurrence) 
1 Evidence of collaboration among key stakeholders 
2 Availability of skills 
3 Lack of appropriate funding 
4 Lack of developed markets for biotechnology products 
5 Under-developed venture capital industry 
6 Abundant biodiversity 
7 Commercialisation of research 
8 Lack of collaboration among key stakeholders 
9 Emphasis on country competitiveness 
10 Lack of government direction 
11 Need for effective collaboration among key stakeholders 
12 Non-conducive regulatory environment 
13 Obstacles to commercialisation 
14 The academic-bioentrepreneur disconnect 
15 Biotechnology timeframe 
16 Bureaucratic processes 
17 Innovation cluster/hub/park 
18 Pervasive opportunities 
19 Problem opportunity 
20 Support for licensing 
21 University publication-commercialisation disconnect 
22 University spin-off/start-ups 
23 Business strategy 
24 Conducive environment for biotechnology development 
25 Failure to commercialise biotehnology projects 
26 Good universities 
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Number Codes that appear in most transcripts (horizontal occurrence) 
27 Government-incentivised entrepreneurial action 
28 Government is seen as a hindrance by other stakeholders 
29 Higher levels of business and market risks 
30 Lack of capacity 
31 Lack of commercialisation skills 
32 Lack of competitiveness 
33 Lack of conducive environment for biotechnology development 
34 Lack of entrepreneurial culture 
 
 
These are outputs of the Atlas.ti CAQDAS that enabled an in-depth analysis of the 
code patterns in different dimensions (Weitzman, 1999; Rambaree, 2007; Hwang, 
2008). 
 
The reason for analysing the codes in different dimensions is because a particular 
point may be mentioned many times in the transcript, but may be the experience of 
one or a few respondents. Hence, it is also important to analyse the codes 
horizontally to determine the occurrence of particular codes across most or all of the 
transcripts.  
The codes that have most mention within (vertical) and across (horizontal) the 
transcripts are deemed to be important in identifying the patterns in the data that 
improve the understanding of the process of biotechnology entrepreneurship in 
South Africa. 
 
The identified patterns in the environment of biotechnology entrepreneurship in 
South Africa are summarised below: 
 
i. Most of the respondents believe that there is a lack of collaboration among 
key stakeholders in biotechnology entrepreneurship in South Africa. Although 
most of the respondents experience evidence of collaboration with key 
stakeholders, they agree that there is a need for effective collaboration among 
key stakeholders 
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ii. Although most of the respondents believe that the scientific and research 
skills needed for biotechnology entrepreneurship are available in South Africa, 
they also deem the entrepreneurial and commercialisation skills to be lacking 
iii. The lack of appropriate funding is consistently deemed to be a constraint by 
most of the respondents 
iv. The lack of developed markets for biotechnology products is consistently 
deemed to be a constraint by most of the respondents 
v. The venture capital industry is consistently deemed to be underdeveloped in 
South Africa 
vi. The lack of direction from the government, through its implementation 
agencies, is consistently deemed to be a constraint by most of the 
respondents and the activities deemed to be hindering the development of the 
biotechnology industry 
vii. The emphasis on country competitiveness is consistently deemed by most of 
the respondents to be an important consideration for biotechnology 
entrepreneurship in South Africa 
viii. The regulatory environment is consistently deemed to be a constraint by most 
of the respondents 
ix. Most of the respondents agree that there is a misalignment between the 
requirements for being an academic and for being an entrepreneur. In 
addition, the university culture is deemed mostly to prioritise publication over 
commercialisation 
x. The abundance of biodiversity is deemed to be a positive factor by most of the 
respondents in the development of biotechnology entrepreneurship in South 
Africa 
xi. The general environment for the development of biotechnology 
entrepreneurship in South Africa is deemed by most of the respondents to be 
unfavourable 
 
The points that were mentioned the most by the respondents as impacting on the 
environment of biotechnology entrepreneurship in South Africa are analysed further 
in the following sections for deeper meaning and explanation (Eisenhardt and 
Graebner, 2007a). These points are: 
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i. Lack of, and the need for, collaboration among the key stakeholders 
ii. Policy and regulation 
iii. Funding 
iv. An inclination to prioritise publication over commercialisation by the 
universities 
v. Government direction 
vi. Skills 
vii. Market size 
 
The lack of collaboration among the key stakeholders 
 
The experience of the collaboration among the key stakeholders in the biotechnology 
industry in South Africa is covered in detail in Section 7.4.  
 
Policy and regulation  
(Represented as “non-conducive regulatory environment” in Tables 7.3 and 7.4) 
 
The policy and regulatory environment of biotechnology entrepreneurship in South 
Africa includes specific policies that impact on biotechnology entrepreneurship such 
as intellectual property policy, policies related to R&D activities, policies that govern 
public universities and research institutions, innovation policies, technology transfer 
policies, policies related to immigration of foreign skills, labour laws, policies related 
to ethics in biotechnology and taxation laws related to research. 
 
The policy and regulatory environment of biotechnology entrepreneurship in South 
Africa appeared as “non-conducive regulatory environment” in the vertical and 
horizontal code occurrences (see Tables 7.3 and 7.4). This policy gap is recognised 
in the new bio-economy strategy to be implemented by the government of South 
Africa (Documents Case 1 14:68). 
 
Although emphasis is being placed on the intellectual property policies, the 
experience of the overall policy and regulatory environment by the respondents in 
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South Africa is unfavourable and supports the assertion that the policy and 
regulatory environment is not enabling. 
 
Well I mean South Africa has a number of problems for entrepreneurship 
that are unique to South Africa like our labour laws, like the difficulty of 
setting up a business, and then more recently the IP legislation if you have 
got any government funding. (Respondent 13 8:18) 
 
A lack of delivery of biotechnology strategy largely hinges, not entirely, but 
largely hinges on the policy environment. They are contradictory and 
unaligned challenging policy regulatory environment. So there are lots of 
things that need to be sorted out, and it's one of the things we hope to 
address through the bio-economy strategy. (Respondent 1 1:77) 
 
And there are a lot of things in our legislation which unfortunately are 
restrictive to biotechnology emerging as a key driver of the economy.  
The first, as I said, is funding, the second is legislation. (Respondent 12 
7:24-25) 
 
In comparison to general entrepreneurship, the policy and regulatory environment 
plays a bigger role in biotechnology entrepreneurship in South Africa due to the 
multifaceted nature of biotechnology (Dibner, 1986; Muller and Fujiwara, 2002; 
Müller et al., 2004; Ahn and Meeks, 2007; Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry Organisation, 2012). Biotechnology impacts on 
critical areas of society such as food security, human health, environmental 
sustainability and energy sufficiency (Dibner, 1986; Muller and Fujiwara, 2002; 
Müller et al., 2004; Ahn and Meeks, 2007; Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry Organisation, 2012). 
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Funding  
(Represented as “lack of appropriate funding” in Tables 7.3 and 7.4) 
 
The funding environment for biotechnology entrepreneurship in South Africa is 
characterised by the code “lack of appropriate funding”, which occurred many times 
within and across the transcripts, as shown in Tables 7.3 and 7.4.  
The availability of capital (Shane, 2003) is an important factor in any entrepreneurial 
activity and biotechnology entrepreneurship is often associated with both 
government and venture capital funding sources (Audretsch et al., 2008).  
The experience of the bioentrepreneurs in South Africa is restricted to the 
government source of funding because of the lack of a developed venture capital 
industry for biotechnology (Audretsch et al., 2008). This situation may be unique to 
the South African biotechnology industry as venture capital funding is a core 
component of biotechnology entrepreneurship in developed economies (Ahn and 
Meeks, 2007; Ahn et al., 2010a). 
 
Funding is very important, an important obstacle and that is at the moment 
mainly provided by government. (Respondent 12 7:17) 
 
And quite frankly you cannot develop anything in the country without 
government funding because it is the only source of funding so you are 
hamstrung from the start. (Respondent 13 8:19) 
 
In addition to having government as the only source of funding for biotechnology 
entrepreneurship in South Africa, there is another challenge that the funding from the 
government is often not appropriate for the nature of the biotechnology industry in 
terms of risk profile and timeframe.  
 
The problem with the government money was that it came with all sorts of 
strings attached which were not necessarily in line with what our mandate 
was which was to make as much money as possible. 
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They put in loans. I mean these were companies that do not make any 
money, how on earth are you supposed to pay a loan back or pay interest. 
(Respondent 13 8:8-9) 
 
An inclination to prioritise publication over commercialisation by the universities 
(Represented as “university publication-commercialisation disconnect” in Tables 7.3 
and 7.4) 
 
The university culture, which was highlighted as a challenge in the environment of 
biotechnology entrepreneurship in South Africa is characterised by the code 
“university publication-commercialisation disconnect” in Tables 7.3 and 7.4. The 
tendency of the universities to prioritise journal publication over the 
commercialisation of intellectual property means that the economic benefits 
associated with the commercialisation of these intellectual properties do not accrue 
to the university or government. 
 
That is definitely an element. Our universities do focus on publication 
rather than on commercialisation. (Respondent 12 7:66) 
 
Okay now think about what you are doing in the context of translating this 
into a useful product. So we are not taught, in the universities to think 
about what we are doing in terms of the market. We just think about it in 
terms of research and in terms of the fact that we need publications in 
order to be able to advance. (Respondent 12 7:68-70) 
 
Researchers are under pressure to publish, but at the same time if they 
publish they lose their intellectual property unless they publish after they 
have registered their IP or their patent, for example. So that is another 
challenge that I think we definitely face. (Respondent 3 3:77) 
 
The rate of scientific publication is often used as a measure for the status of the 
individual scientist within the university as well as the strength of the scientific 
credentials of the university and the country (Organisation for Economic Cooperation 
and Development, 2013e, 2013b, 2013c). Some of the policy actions that the 
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government has taken in South Africa to benefit from both publication and 
commercialisation of intellectual property encourage a cultural change towards 
“commercialise first-publish later” among the universities and research institutions. 
 
We have got still an academic culture and their incentives at this stage are 
to publish and to train students. So we have just introduced our IP Act 
which says before you publish first check to see if you’ve got some IP 
there and if so register this with our national IP management office. 
(Respondent 1 1:138) 
 
Never underestimate the value of good patent; it is possible to be both 
publishing as well as be taking out a patent. The key thing is to make sure 
you register the patent first and then you publish. (Respondent 15 10:22-
23)          
 
Government direction   
(Represented as “lack of government direction” in Tables 7.3 and 7.4) 
 
The agencies of government that are mostly involved with the development of 
biotechnology entrepreneurship in South Africa are the DST and TIA. While the DST 
is responsible for policy and strategy development, TIA is responsible for 
implementing those policies and strategies (Department of Science and Technology, 
2001; Department of Science and Technology and eGoli Bio, 2003; Cloete et al., 
2006; Ernst & Young, 2006; Department of Science and Technology, 2007; Gastrow, 
2008; Technology Innovation Agency, 2010).  
 
The experience of the respondents interviewed for this research highlighted a lack of 
effective leadership and direction from the government, and the activities of these 
government agencies were deemed to be hindering the development of 
biotechnology entrepreneurship rather than promoting it.  
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Government needs to carefully consider the regulations in this area, and 
the policies. They also need to provide a bit more guidance on what the 
needs really are. Where are the priority areas in government? 
 So I think from government’s side they need to provide more guidance in 
these areas. And more emphasis to the scientists, to the researchers 
involved in these areas. We need to move away from bureaucracy. 
(Respondent 4 4:51-55) 
 
TIA is not functioning optimally yet. What TIA should be doing, but it's not 
yet doing properly, is stimulating the bio-economy. It should be creating 
critical mass in certain areas. (Respondent 1 1:118-120) 
 
Yes, but the rest of the world is going down one route and government is 
going down another route, and what they are doing in practice is not that, 
they are making it more complicated. So again, the implementation 
challenge is significant. (Respondent 2 2:129) 
 
Some of the inefficiencies experienced by the respondents with the government 
agencies are attributed to bureaucracy within the agencies.  
 
I think the Technology Innovation Agency [TIA] plays a big role although 
there is red tape. Without TIA being there, there would be nothing. 
(Respondent 11 6:110) 
 
It is bureaucracy in the worst instance and it is so bad that many times we 
decided to pack up and move elsewhere. (Respondent 17 12:17) 
 
In at least two instances, the experience of the bioentrepreneurs with the 
government agencies was very positive and contradicted the general experience of 
most of the respondents. This contradiction points to the possibility that the general 
lack of direction portrayed by most of the respondents in this research may not be 
representative of the reality of government activities in the development of 
biotechnology entrepreneurship in South Africa. 
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I found my experience in South Africa with the government funding 
agencies absolutely fantastic. They understand the dynamic, there is a 
dynamic there of competitiveness. (Respondent 5 5:43-44) 
I have been quietly impressed, particularly with our two departments which 
are involved in this, the Department of Science and Technology and the 
Department and Trade and Industry.  I think they have got a number of 
very good programmes in place of which my company has been a 
beneficiary and so was the University. (Respondent 15 10:35) 
 
Skills  
(Represented as “availability of skills”; “lack of entrepreneurship skills”; and “lack of 
commercialisation skills” in Tables 7.3 and 7.4) 
 
The importance of skills (Department of Science and Technology, 2001; Lingelbach 
et al., 2005; Ahn and Meeks, 2007; Department of Science and Technology, 2007; 
Phan et al., 2008; Ahn et al., 2010a; Ahn et al., 2010b; Battelle/Biotechnology 
Industry Organisation, 2010; Ahn and York, 2011; Ahn et al., 2012; Dunham et al., 
2012; Kelley et al., 2012) to the development of biotechnology entrepreneurship in 
South Africa was highlighted by most of the respondents.  
 
In analysing the experience of the respondents regarding the skills landscape, four 
broad categories of skills were highlighted by the respondents: scientific, research, 
entrepreneurial, and commercialisation skills. While most of the respondents 
believed that there was an availability of scientific and research skills in South Africa, 
the entrepreneurial and commercialisation skills were deemed to be lacking. 
 
So one of the things that we really need to continue and expand is the 
development of bio-entrepreneurship skills. (Respondent 1 1:139) 
 
So universities and science councils do not want to commercialise. 
They would like to commercialise but that is not their passion and they do 
not have the necessary skills and abilities. (Respondent 2 2:35-36) 
170 
 
A part of the problem identified by the respondents to be contributing to the lack of 
entrepreneurial and commercialisation skills is the phenomenon of the brain drain 
where talented individuals are lured away to foreign countries with favourable 
conditions for biotechnology entrepreneurship. 
 
That is very important and it all starts with the scarce skills. Our scarce 
skills are leaving South Africa; they are going overseas because the 
environment is not right here. (Respondent 11 6:72) 
 
The lack of entrepreneurial and commercialisation skills were identified in prior 
studies on biotechnology industry in South Africa in the form of a lack of skills 
(Lingelbach et al., 2005), and low levels of commercialisation of biotechnology 
products (Cloete et al., 2006). This distinction between the types of skills that are 
lacking is important given the general discourse on the low level of mathematics and 
science education in South Africa (Department of Science and Technology, 2001; 
Department of Science and Technology, 2007), which can easily be wrongly 
interpreted to mean a lack of science and research skills for biotechnology 
entrepreneurship in South Africa.  
 
Market size  
(Represented as “lack of developed markets for biotechnology products” in Tables 
7.3 and 7.4) 
 
The lack of developed markets for biotechnology products in South Africa was 
deemed to be a constraint by most of the respondents. The size of the market was 
invariably linked to the size of the industry itself, by most of the respondents. 
 
However the biggest challenge that is faced in South Africa is that the 
South African market itself with its biotechnological innovations are too 
small, the market is too small. (Respondent 4 4:6) 
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The general opinion and the general word when you talk to everyone, is 
that biotechnology industry in South Africa is quite small, that is the 
general opinion of everyone. (Respondent 4 4:13) 
 
There is no market, it does not exist. 
Let us just look from a point of view, our client base is people developing 
drugs, I do not know one single company developing drugs in South 
Africa; none of the pharmaceutical companies, in fact there is no prime 
pharmaceutical development taking place in South Africa. (Respondent 16 
11:7-9)   
 
Amid a consensus about the small size and lack of developed markets for 
biotechnology products among the respondents, there was at least one respondent 
with a contradictory view on the experience of the market in South Africa. 
 
First the market, do we have a direct market for products in South Africa? I 
believe we do. I think we are far along enough to be able to procure 
products for biotechnology companies in South Africa; we have the 
infrastructure to do that. (Respondent 11 6:95-96) 
 
Although the products and solutions developed by these bioentrepreneurs address 
the needs of the government to improve human health; crop yield and food security; 
environmental sustainability; and energy sufficiency; (Biotechnology Industry 
Organisation, 2008; Battelle/Biotechnology Industry Organisation, 2012) they still 
face global competition from other biotechnology and non-biotechnology solutions. 
The need for the government to reach as many recipients of this solution as possible 
often leads to price being the primary consideration for buying either locally or from 
foreign competitors. An example of this scenario is the roll-out of the HIV/AIDS anti-
retroviral treatment in South Africa (Respondent 13 8:27). 
 
The tender process here is totally, totally, totally not in our favour, there is 
a 90-point system in my industry where 60 points they award toward price, 
30 points they award toward local content, BEE and others. 
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We are competing against first world countries like China where they have 
tech parks, science parks where they don’t have to import components. 
So when they come to our country and tender obviously it is cheaper for 
them, so now governments are awarding tenders to the Chinese and to 
other Asian countries based on price. 
They should actually award more points to local content to promote 
companies growing here and government buying from us. (Respondent 11 
6:36-39)  
 
The lack of a developed market for the biotechnology products and solutions results 
in the bioentrepreneurs having to compete in international markets. 
 
We could not survive in South African market because we were not selling 
enough systems. (Respondent 15 10:7)          
 
In concluding this sub-section, there are some differences between the areas 
highlighted as impacting on the environment of biotechnology entrepreneurship in 
prior studies (Cloete et al., 2006; Gastrow, 2008) and the areas identified by the 
respondents. These areas are the policy and regulatory environment; the university 
culture that leads to the low level of commercialisation; the lack of government 
leadership and direction; and the small size of the South African market for 
biotechnology. 
 
The other areas of the environment were mentioned by two or more respondents 
and that are worth emphasising are the lack of support structures; the lack of 
capacity; a national culture that does not support bioentrepreneurship; bureaucracy; 
the stigmatisation of failure; and corruption. These areas were not mentioned by 
most of the respondents. However, those who mentioned these areas saw them as 
challenges to the development of biotechnology entrepreneurship in South Africa. 
 
The overall experience of the environment of biotechnology entrepreneurship in 
South Africa, by the respondents in this research, was unfavourable. However, there 
were areas that were contradicted by some respondents. Hence, while a deeper 
understanding (Eisenhardt and Graebner, 2007b) of the environment of 
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biotechnology entrepreneurship is possible from this analysis; it cannot be taken as a 
conclusive view of the environment of biotechnology entrepreneurship in South 
Africa. 
 
7.2.3 Entrepreneurial opportunities 
 
The entrepreneurial opportunities in biotechnology seem to be different from the 
entrepreneurial opportunities in general entrepreneurship in some key aspects.  
 
While the general entrepreneurial opportunities are not known in advance and 
require enterprising individuals with special psychological attributes (McClelland, 
1961; Kihlstrom and Laffont, 1979; Schere, 1982; Gartner, 1990) to uncover them 
the bioentrepreneurial opportunities are mostly known in advance and require 
bioscientific skills to get to a solution (Müller et al., 2004). 
 
The discovery of general entrepreneurial opportunities requires the individual 
entrepreneur to apply their business management capability towards profit making or 
other forms of positive outcome (Shane, 2003). However, the discovery of 
bioentrepreneurial opportunities involves a process of R&D to get to the desired 
outcome, and is more of a “creation” (Audretsch et al., 2008) than a “discovery” 
(Alvarez and Barney, 2007). 
 
The exploitation of general entrepreneurial opportunities is also mostly dependent on 
the individual entrepreneur and their organising abilities (Shane, 2003). However, the 
exploitation of bioentrepreneurial opportunities mostly requires a strategic alliance 
involving government, large established companies, venture capitalists and research 
institutions (Müller et al., 2004; Rothaermel and Deeds, 2004; Ahn and Meeks, 2007; 
Sytch and Bubenzer, 2008).  
 
Most of the respondents in South Africa see bioentrepreneurial opportunities in the 
areas of biodiversity and problems related to food security and disease control. 
These types of opportunities, linked to problems of diseases, food security, the 
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environment and energy are designated as “problem opportunities” (researcher’s 
synthesis). 
 
The problem opportunities are in the areas of diseases such as HIV, tuberculosis, 
malaria, and typhoid fever; infertility; crime; road accidents due to drunk-driving; 
paternity verification; food shortages; low agricultural yields; unsustainable 
environmental practices; and high energy costs. These problem opportunities are not 
unique to South Africa or to developing economies (Brännback, Carsrud and Renko, 
2007; Battelle/Biotechnology Industry Organisation, 2012) but are predominant in 
these economies in comparison to the developed economies. 
 
We have got huge burden of disease, we have got poverty, and we have 
got unemployment, really important things from a government perspective. 
(Respondent 1 1:86) 
 
My personal view is that because of our rich biodiversity, we as a country 
have a lot to offer in terms of indigenous knowledge and also utilising the 
biodiversity we have in terms of generating biotechnology products. 
(Respondent 3 3:73) 
 
So being situated in South Africa makes sense for us because we are 
diagnostics and your biggest disease and illness and epidemics are in 
Africa. (Respondent 11 6:43) 
 
Health is a big problem, government is spending in excess of R100 million 
every two years for HIV tests alone. (Respondent 11 6:60) 
 
The second form of bioentrepreneurial opportunities identified by the respondents is 
designated as “efficiency opportunities” and is mostly in the areas of bioprocessing 
and biomanufacturing. While the efficiency opportunities may not be as ubiquitous as 
problem opportunities in case 1 because of the low level of industrialisation, the 
realised efficiencies do provide the opportunity to solve some of the problems of food 
security, environmental sustainability, healthier populations and energy sufficiency 
(Biotechnology Industry Organisation, 2008). 
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I think that there is unlimited potential in human health, agricultural 
biotechnology and industrial biotechnology. (Respondent 12 7:31-34)  
 
There are few instances in South Africa where the exploitation of “problem 
opportunities” led to “efficiency and innovation opportunities”. Innovation 
opportunities are those opportunities that lead to the creation of new innovative 
products and services not previously in existence. The innovation opportunities are 
minimal in South Africa and were not mentioned by most of the respondents, as the 
emphasis was on the problem opportunities, followed by the efficiency opportunities. 
 
It came about because De Beers had been suspicious that their workers 
were stealing their diamonds, so they developed a technique for scanning, 
taking a whole body x-ray, to find a diamond. 
I said this technology has got great opportunity for imaging the breast so 
we had another project going on in that direction. 
And we are developing a very innovative product that is taking x-rays and 
ultrasounds into one product; nobody else has done that anywhere else in 
the world. (Respondent 15 10:45-46, 48)  
 
Bioentrepreneurial opportunities in South Africa take the form of “problem 
opportunities” in which problems related to health, food security, the environment 
and energy create bioentrepreneurial opportunities and “efficiency opportunities” in 
which new means of improving existing products and services, such as 
bioprocessing and biomanufacturing, are created. 
 
7.2.4 Discovery 
 
Opportunity discovery in general entrepreneurship is different from opportunity 
discovery in biotechnology entrepreneurship. Opportunity discovery in biotechnology 
entrepreneurship is more of a “creation” (Audretsch et. al., 2008) than a “discovery” 
(Alvarez and Barney, 2007) as the solution to the opportunities is created or 
discovered through R&D. 
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R&D is a key step that differentiates biotechnology entrepreneurship from general 
entrepreneurship. This is also the key step that contributes to the predominance of 
non-psychological factors such as education and career experience (Barro and Lee, 
2000) in biotechnology entrepreneurship. 
 
According to the OECD (2009), the primary requirements for R&D to be effective 
include research universities, other research institutions, a developed scientific 
educational curriculum, a national culture that supports scientific endeavour, a 
favourable regulatory environment and talented individuals.  
 
Some of these conditions were recognised as gaps by the respondents in South 
Africa, and hence they believed that R&D was not well supported in South Africa. 
The R&D spend in South Africa is low in comparison to other developing economies 
such as Brazil; or the developed economies (Organisation for Economic Cooperation 
and Development, 2013b, 2013c).  
 
The new approach is then going to look at the entire value chain and then 
research and development becomes much more important than it was in 
the earlier stage. (Respondent 1 1:53) 
 
If 2.5 % GDP is the R&D budget, and we are only at 1%, there is a 
significant difference. (Respondent 1 1:105) 
 
So there is a systemic problem where there is a shortage of R&D funding 
within the system. (Respondent 2 2:40) 
 
In addition to the expenditures undertaken by the government, large companies in 
biotechnology undertake major research and development as well. However, the 
lack of these large biotechnological companies that undertake major research and 
development projects was highlighted as a gap. 
 
The lack of major R&D taking place here and the lack of capital are the 
two major constraints. (Respondent 16 11:47)  
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The R&D step in biotechnology entrepreneurship is the step that introduces the most 
risk in the process of biotechnology entrepreneurship as the timeframe can be 
indeterminable (Respondent 15 10:9) and there is no guarantee that the R&D will 
result in the expected outcome. 
 
However, the unfortunate part is being a bio-entrepreneur because it is 
high-risk, you need to do research and you are not guaranteed a product 
at the end of the day. (Respondent 11 6:20) 
 
We stimulate publications, high quality work which can then further lead to 
patents and new products and services. 
The cost of research is a huge barrier to bioeconomic development. 
(Respondent 14 9:17-18)    
 
The ability to act on bioentrepreneurial opportunities (Shane, 2003)  is research-
driven. This makes R&D in biotechnology entrepreneurship a critical determinant of 
the output.  
 
The respondents in South Africa believe that the inadequate level of R&D funding 
poses a risk to the development of biotechnology entrepreneurship in South Africa, 
irrespective of the level of other enabling conditions that exist.  
 
If you have R1 then you will have R1 output. Even if you have Albert 
Einstein out there if you give him R1 he cannot build an accelerator, it is 
impossible. At some point the graph will flatten, here is some knowledge 
okay that will bring you somewhere and then it flattens off because he 
cannot do an experiment and that is exactly what is happening here. 
It is in every single aspect of this country and it is very unfortunate 
because there is so much potential but there is no political will. 
(Respondent 17 12:81-83) 
 
In terms of the organising framework of individual-opportunity nexus (Shane, 2003), 
this sub-section highlights a key difference between “opportunity discovery” in 
general entrepreneurship and “research and development” in biotechnology 
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entrepreneurship. Most of the respondents in South Africa deem the funding for 
research and development to be inadequate and see it as a gap in the effort to 
develop the biotechnology industry in South Africa. 
 
7.2.5 Entrepreneurial exploitation 
 
“Entrepreneurial exploitation” (Shane and Venkataraman, 2000; Shane, 2003; 
Murphy et al., 2006) as depicted in the individual-opportunity nexus framework refers 
to the stage of general entrepreneurship in which the discovered opportunity is 
exploited to produce economic value. This exploitation is often an individual 
undertaking in general entrepreneurship in which new markets, new ways of 
organising, new products or new firms can be created by the entrepreneur (Shane 
and Venkataraman, 2000; Shane, 2003). However, the process of exploiting 
bioentrepreneurial opportunities is not an individual undertaking, and involves an 
alliance of stakeholders in the biotechnology industry. The strategic alliance needed 
for effective exploitation of bioentrepreneurial opportunities includes research 
institutions, venture capitalists, large organisations and government (Müller et al., 
2004). 
 
The rationale for these alliances is to fulfil the respective stakeholder roles that 
enable the efficient exploitation of opportunities. The research institutions provide 
talent and technology transfer capabilities; the venture capitalists provide capital; the 
large companies act as cooperation partners, customer and competitor; and the 
government provides an enabling regulatory environment and acts as facilitator (Ahn 
and Meeks, 2007).  
 
The experience of this process in South Africa is deemed to be inadequate due to 
the lack of a developed venture capital industry. The lack of a developed venture 
capital industry in the process of entrepreneurial exploitation was unanimously 
highlighted by the respondents as a key impediment to the development of 
biotechnology entrepreneurship in South Africa. 
 
179 
 
We have got non-existent venture capital when it comes to biotechnology. 
(Respondent 16 11:26) 
 
This situation forces the government into a position of trying to fulfil the funding 
needs of the biotechnology industry in South Africa. This role was highlighted by the 
respondents as a gap in the form of a lack of adequate and appropriate funding by 
the government.  
 
The other roles the government plays in the strategic alliance are the provision of a 
favourable regulatory environment and facilitation (Ahn et al., 2012). In addition, the 
government also acts as a buyer of the biotechnology products and solutions. All of 
these roles were highlighted as gaps in the development of biotechnology 
entrepreneurship in South Africa by most of the respondents.  However, there were 
at least two instances where the government was deemed to have fulfilled these 
roles successfully. 
 
So government supplied the funds, supplied support structures, helped me 
administer the grant money, supplied external experts and reviewers, 
advice, they did a great job. 
The result is we have the first biotechnology product from inception into 
commercialisation. In January this year we received the first revenue from 
sales of this product. (Respondent 5 5:47-49) 
 
I think from a governmental perspective, from a funding perspective, it is 
good enough. (Respondent 11 6:31) 
 
The fact that the government was able to provide appropriate funding on certain 
occasions was explored further to understand the possible factors responsible for 
this contradiction. The data showed that on the two occasions where the 
respondents deemed the government funding to be appropriate, both had spent their 
own money to get their products to the stage of proof of concept; hence, the product 
had reached a late stage, before the government funding was deployed. It can be 
inferred from the data that the government may prefer funding late stage projects 
owing to higher chances of success.   
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I started my own laboratory, private laboratory with private funding, and 
this laboratory is called Altis Biologics. Subsequently, I registered the IP in 
my personal name and gave Bone SA the rights to commercialise the IP in 
the territory of South Africa.  
And once I put my application in a second time to the Innovation Fund 
after 3 years, a number of things had changed. Number 1, there was new 
IP; number 2, it had been filed for PCT giving access to big markets; 
number 3, I had proof of concept in small animals like rats; number 4, I 
had proof of concept in a completed human study in humans, from a tissue 
coming from humans. Therefore I was able to reduce the risk having used 
private money to do it, reduce the risk of sample technology, new 
technology risk. New technology is risky at early stage, you do not know if 
it is going to work, it is just an idea; you need proof of concept, principles. 
(Respondent 5 5:22-24) 
 
I imported some products, so I acquired some market share and 
generated some cash and used that cash to set up my own manufacturing 
facility. (Respondent 11 6:10) 
 
Being a bioentrepreneur you have to spend a lot of money upfront. 
(Respondent 11 6:17) 
 
Another key component of the strategic alliance for the exploitation of 
bioentrepreneurial opportunities is the presence of large biotechnological companies. 
The absence of these large companies was also highlighted as a gap in South 
Africa. 
 
The key thing is that there are these big companies that have deep 
pockets that can buy out ideas; in South Africa we don’t have these big 
companies. (Respondent 1 1:72) 
 
It can be concluded that the process of entrepreneurial exploitation in general 
entrepreneurship is different from bioentrepreneurial exploitation because of the 
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requirement for a strategic alliance between key stakeholders of the latter: venture 
capitalists, large established companies, research institutions and government. 
 
The absence of two key stakeholders in the form of venture capitalists and large 
established companies in the strategic alliances necessary for bioentrepreneurial 
exploitation represents a gap which the government has been trying to close. While 
most respondents saw the government efforts as inadequate, there was at least one 
example of where the government had successfully fulfilled these roles. 
 
7.2.6 Execution 
 
The end point of the individual-opportunity nexus framework for entrepreneurship is 
execution, in which value is created for the entrepreneur and the economy (Shane, 
2003). The predominant way of doing this in general entrepreneurship is through the 
creation of a new firm as a vehicle to introduce new goods and services, ways of 
organising, markets, processes, and raw materials through organising efforts that 
previously had not existed (Shane, 2003:4).  
 
However, in biotechnology entrepreneurship, the execution can be effected through 
a new firm formation or through licensing the biotechnological innovation to another 
entity (Audretsch and Stephan, 1998; Mowery and Shane, 2002; Shane, 2004a; 
Audretsch and Lehmann, 2005a; Audretsch et al., 2008). The process of execution 
in biotechnology entrepreneurship is often referred to as “commercialisation of 
research”, or as “commercialisation of intellectual property” (Müller et al., 2004). 
 
Commercialisation of research is at the end of the value chain of biotechnology 
entrepreneurship (Gittelman, 1999; Feldman and Ronzio, 2001; Kettler and Casper, 
2001). The effective strategic alliance required for the exploitation of 
bioentrepreneurial opportunities ultimately results in the effective commercialisation 
of research (Ahn et al., 2010a; Ahn et al., 2010b; Ahn and York, 2011; Ahn et al., 
2012; Dunham et al., 2012). 
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The bioentrepreneurs in South Africa practise the process of execution through both 
firm formation and licensing.  
 
You had a lot of companies emanating from research. With research 
coming out of the universities people were able to start up various biotech 
businesses. (Respondent 3 3:6) 
 
I think we have to become much better at licensing especially at 
universities. It is not that a university should not create spinouts or things 
like that. Should be able to license and do lots of licensing. (Respondent 2 
2:73-75) 
 
Develop the IP and then try license it out because we don’t have a local 
presence and a big firm or a big biotech. (Respondent 1 1:73) 
 
Although this process does take place in South Africa, challenges were identified by 
the respondents in the areas of commercialisation skills and funding for 
commercialisation. 
 
I think personally in South Africa, the universities lack certain things in 
terms of commercialisation. They do the research and they do the training 
of the students but to complete that innovation chasm, they do not do that. 
No, they do not have the skills and the capacity to do that, they are not 
setup to do that. (Respondent 4 4:21-22) 
 
The other reason is lack of funding for commercialisation. You can fund 20 
R&D projects and probably three serious commercialisation attempts. 
Secondly, to commercialise globally is a big challenge, both in terms of 
people, partners and money. (Respondent 2 2:28-30) 
 
In addition, the challenges with the environment of biotechnology entrepreneurship, 
the inadequate funding of R&D, and the inadequate exploitation of bioentrepreneurial 
opportunities in the earlier part of the value chain negatively impact on 
commercialisation of research in South Africa.  
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Another challenge highlighted by the respondents in relation to the 
commercialisation of research is the culture in the universities that make the 
researchers more inclined to publish instead of commercialise. 
 
Yes, we lack in commercialisation, we are doing brilliant research, we are 
publishing the research and I promise you the Chinese and the European, 
they are probably downloading our own papers here and making a product 
out of it, where we lack. (Respondent 11 6:47) 
 
All these challenges experienced by the respondents at the stage of 
commercialisation, and at the earlier stages of the value chain, contributed to the 
limited success with commercialisation of research in South Africa (Cloete et al., 
2006) whether through firm formation or licensing.  
 
7.3 Similarities and differences between the process of biotechnology 
entrepreneurship in South Africa and the developed economies 
 
In order to understand how the process of biotechnology entrepreneurship in South 
Africa compares to the developed economies, the practical experiences articulated in 
Section 7.3 using the organising framework of the individual-opportunity nexus is 
compared to the literature on the process of biotechnology entrepreneurship in the 
developed economies. 
 
Table 7.5 summarises the key similarities and differences between the process of 
biotechnology entrepreneurship in South Africa and the developed economies as 
exemplified by the individual-opportunity nexus framework (Shane, 2003). 
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Table 7.5: Summary of key similarities and differences between the process of biotechnology entrepreneurship in South 
Africa and the developed economies 
Measure Literature on developed economies 
Insights from this research on 
South Africa 
Some supporting data from 
respondents 
Individual attributes 
 
 
Higher levels of non-psychological 
attributes measured by research output 
and patent applications in addition to 
psychological attributes. 
The bioscientists are supported by a 
system of other capabilities required for 
effective business management and 
commercialisation of research, which is 
often available within biotechnology and 
innovation parks 
  
(Ahn and Meeks, 2007; Ahn et al., 2010a; Ahn 
et al., 2010b; Battelle/Biotechnology Industry 
Organisation, 2010; Ahn and York, 2011; Ahn 
et al., 2012; Dunham et al., 2012) 
Non-psychological and psychological and 
attributes are thought to be on par with 
the developed economies at individual 
bioscientist level.  
 
However, the aggregate level of skills lags 
that of the developed economies hence 
the lower levels of research output and 
patent applications. 
 
The bioscientists in South Africa do not 
have the support system that provides 
other capabilities needed for effective 
business management and 
commercialisation of research. This forces 
the bioscientists to try to acquire these 
skills and in the process their approach to 
biotechnology entrepreneurship is 
“individual” as opposed to “system”. 
 
“Centres of academic research excellence, 
mainly located in a nucleus of long-established 
universities, achieve high quality in several areas 
of research, as reflected in the presence of 
South African publications among the top 1% of 
internationally cited publications in several fields 
and in some cases in the higher quartiles of that 
group.” (Documents Case 1 14:16) 
 
 
 
“Doing my MBA at Wits university was a key 
step to empower myself with sufficient 
knowledge capital to better understand the 
business of science. 
How to do financial models, how to calculate 
net present values, how to understand 
strategies and scenario planning.” (Respondent 
5 5:12-13) 
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Measure Literature on developed economies 
Insights from this research on 
South Africa 
Some supporting data from 
respondents 
Environment 
 
Favourable economic, political and 
cultural factors.  
In addition the support structure, 
infrastructure, and critical mass of input 
are all available in the environment of 
biotechnology entrepreneurship in the 
developed economies 
 
(Lingelbach et al., 2005; Kelley et al., 2012; 
Urban, 2013) 
The environment of biotechnology 
entrepreneurship in South Africa has 
many challenges among which are 
unfavourable policy and regulatory 
environment; lack of appropriate funding; 
lack of government direction; an 
unfavourable university culture; lack of 
aggregate skills and capacity; and a lack 
of developed market for biotechnology 
products. 
 
Other necessary support structure and 
infrastructure, such as biotechnology 
parks, are also lacking in South Africa 
“Well I mean South Africa has a number of 
problems for entrepreneurship that are unique to 
South Africa like our labour laws, like the 
difficulty of setting up a business, and then more 
recently the IP legislation if you have got any 
government funding.” (Respondent 13 8:18) 
 
“This strategy is based on the assumption that 
the issues facing South Africa’s bio-economy – 
including human capital development, 
knowledge exploitation, market development 
and governance – cannot be addressed in 
isolation, but need to be solved in an integrated, 
holistic fashion to yield coordinated, systemic 
interventions.” (Documents Case 1 13:68) 
 
Entrepreneurial 
opportunities 
 
Prevalence of efficiency and innovation 
opportunities aimed at improving existing 
industrial processes or bringing new 
innovative products and solutions to the 
market especially in the areas of 
pharmaceuticals, personalised medicine, 
cure for rare and lifestyle diseases, and 
industrial biotechnology  
 
Prevalence of problem opportunities 
aimed at addressing diseases such as 
malaria, HIV/AIDS, tuberculosis, and 
other human health conditions; food 
security; and improvement in agricultural 
yield.   
 
There were opportunities for efficiency 
and innovation identified but these were 
“We have got huge burden of disease, we have 
got poverty, and we have got unemployment, 
really important things from a government 
perspective.” (Respondent 1 1:86) 
 
“My personal view is that because of our rich 
biodiversity, we as a country have a lot to offer 
in terms of indigenous knowledge and also 
utilising the biodiversity we have in terms of 
generating biotechnology products.” 
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Measure Literature on developed economies 
Insights from this research on 
South Africa 
Some supporting data from 
respondents 
(Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry 
Organisation, 2010) 
small in comparison to the problem 
opportunities. 
 
Biodiversity was deemed to be another 
key bioentrepreneurial opportunity in 
South Africa 
(Respondent 3 3:73) 
 
“Being situated in South Africa makes sense for 
us because we are diagnostics and your 
biggest disease and illness and epidemics are 
in Africa. (Respondent 11 6:43) 
Health is a big problem, government is 
spending in excess of R100 million every two 
years for HIV tests alone.” (Respondent 11 
6:60) 
 
Opportunity 
discovery 
 
Intense R&D with a high level of R&D 
spend as a percentage of the GDP on the 
part of the government; and the presence 
of large companies that undertake major 
R&D activities 
 
(Gastrow, 2008; Organisation for 
Economic Cooperation and Development, 
2009, 2013b, 2013c) 
The R&D spend and intensity are below 
the average for the developed economies 
and hence constitute a gap. This is both 
as a percentage of GDP and also due to 
the absence of large companies that 
undertake major R&D activities 
 
“If 2.5 % GDP is the R&D budget, and we are 
only at 1%, there is a significant difference.” 
(Respondent 1 1:105) 
 
“So there is a systemic problem where there is a 
shortage of R&D funding within the system.” 
(Respondent 2 2:40) 
 
“The lack of major R&D taking place here and 
the lack of capital are the two major constraints.” 
(Respondent 16 11:47) 
 
Opportunity 
exploitation 
The necessary conditions required for 
effective exploitation of bioentrepreneurial 
Constrained by the lack of all necessary 
conditions for effective exploitation of 
“We have got non-existent venture capital when 
it comes to biotechnology.” (Respondent 16 
11:26) 
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Measure Literature on developed economies 
Insights from this research on 
South Africa 
Some supporting data from 
respondents 
 opportunities are in place. These include 
enabling regulatory environment, a 
developed venture capital industry, large 
established companies, research 
institutions, government support and 
economies of scale 
 
(Lingelbach et al., 2005; Phan et al., 
2008) 
bioentrepreneurial opportunities. These 
include an unfavourable regulatory 
environment, under-developed markets, 
lack of a venture capital industry, lack of 
commercialisation and entrepreneurial 
skills, and low levels of aggregate skills 
and capacity. 
 
The lack of a venture capital industry in 
South Africa forces the government to 
fulfil the role that would have been 
undertaken by venture capitalists; in 
addition to its primary role as a funder and 
facilitator 
 
 
“So government supplied the funds, supplied 
support structures, helped me administer the 
grant money, supplied external experts and 
reviewers, advice, they did a great job. 
The result is we have the first biotechnology 
product from inception into commercialisation. In 
January this year we received the first revenue 
from sales of this product.” (Respondent 5 5:47-
49) 
 
Execution Efficient because of the necessary 
technology transfer infrastructure being in 
place. In addition, the conditions for the 
earlier stages of the value chain such as 
environment, R&D and opportunity 
exploitation are favourable 
 
(Lingelbach et al., 2005; Phan et al., 
Inefficient because of the lack of 
necessary technology transfer 
infrastructure being in place. In addition, 
there were challenges identified with the 
earlier stages of the value chain such as 
unfavourable environment; low levels of 
R&D spend; and intensity; and lack of 
some of the necessary stakeholders 
“I think personally in South Africa, the 
universities lack certain things in terms of 
commercialisation. They do the research and 
they do the training of the students but to 
complete that innovation chasm, they do not do 
that. 
No, they do not have the skills and the capacity 
to do that, they are not setup to do that.” 
(Respondent 4 4:21-22) 
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Measure Literature on developed economies 
Insights from this research on 
South Africa 
Some supporting data from 
respondents 
2008; Nilsson, Rickne and Bengtsson, 
2010a) 
required for effective exploitation of 
bioentrepreneurial opportunities, such as 
venture capitalists and large companies 
 
Other factors highlighted as contributing 
to the inefficient commercialisation of 
research in developing economies are the 
lack of commercialisation and 
entrepreneurial skills and the university 
culture of prioritising publication over 
commercialisation 
 
“The other reason is lack of funding for 
commercialisation. You can fund 20 R&D 
projects and probably three serious 
commercialisation attempts. 
Secondly, to commercialise globally is a big 
challenge, both in terms of people, partners and 
money.” (Respondent 2 2:28-30) 
 
“Yes, we lack in commercialisation, we are doing 
brilliant research, we are publishing the research 
and I promise you the Chinese and the 
European, they are probably downloading our 
own papers here and making a product out of it, 
where we lack.” (Respondent 11 6:47) 
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From the comparisons in Table 7.5, it can be concluded that: 
 
i. The psychological and non-psychological attributes of the bioentrepreneurs in 
South Africa are similar to those of the bioentrepreneurs in the developed 
economies. The differences in skills and capacity are at an aggregate level 
rather than an individual level 
ii. There are marked differences in the environment of biotechnology 
entrepreneurship between South Africa and the developed economies. While 
the environment in the developed economies can be summed up as 
favourable across many dimensions the environment in South Africa can be 
summed up as unfavourable across many dimensions 
iii. The bioentrepreneurial opportunities in South Africa are mostly different from 
those of the developed economies, with a small overlap in the area of 
innovation opportunities. The bioentrepreneurial opportunities are designated 
as mostly problem opportunities, followed by efficiency opportunities and a 
very small component of innovation opportunities. The developed economies 
exhibit the reverse of this order, leading with innovation opportunities, 
efficiency opportunities, and problem opportunities related to human health. 
South Africa also has opportunities associated with biodiversity which is not 
present in the developed economies 
iv. The process of opportunity discovery in biotechnology is through R&D. This 
process in South Africa is different from the developed economies in terms of 
R&D spend, and the intensity of R&D 
v. Opportunity exploitation in South Africa is inefficient due to the lack of the key 
stakeholders required at this stage of the biotechnology value chain, such as 
venture capitalists and large biotechnology companies. This process in the 
developed economies has all the necessary conditions and hence is effective 
vi. Execution or commercialisation of research goes through the same process of 
firm formation or licensing in South Africa as it does in the developed 
economies. However, the lack of entrepreneurial and commercialisation skills, 
coupled with inefficiencies in the earlier parts of the biotechnology value chain 
makes this process less efficient in South Africa than in the developed 
economies 
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The result of the efficiencies in the developed economies is that the output of 
biotechnology entrepreneurship is much more rapid, visible and on a much higher 
scale than in South Africa (Biotechnology Industry Organisation, 2008; Gastrow, 
2008; Organisation for Economic Cooperation and Development, 2009; 
Battelle/Biotechnology Industry Organisation, 2010; Organisation for Economic 
Cooperation and Development, 2013b, 2013c). 
 
7.4 The nature of the relationship across the university, industry, and 
government 
 
The relevance of the interactions across the university, industry and government, in 
transferring academic research into societal and economic capital, is evidently 
demonstrated in the field of biotechnology (Liebeskind et al., 1996; Agrawal, 2001; 
Müller et al., 2004; Rothaermel and Deeds, 2004; Powell et al., 2005; Ahn and 
Meeks, 2007; Sytch and Bubenzer, 2008). The collaboration among these three 
stakeholders (Etzkowitz and Leydesdorff, 1997; Leydesdorff and Etzkowitz, 1998, 
2001) has recently been considered to involve a fourth stakeholder (Afonso, 
Monteiro and Thompson, 2010; Marcovich and Shinn, 2011; Afonso, Monteiro and 
Thompson, 2012; Leydesdorff, 2012). The fourth stakeholder in the quadruple helix 
is context-specific and in the case of South Africa this has been designated as 
society.  
 
South Africa will build its health innovation system using the “quadruple 
helix” model to integrate existing role players – the government, academia, 
industry and civil society – into a unified and coordinated system.  
(Documents Case 1 13:104) 
 
Most of the respondents in South Africa believe that the relations across university, 
industry and government in the biotechnology industry in are ineffective, and 
negatively impact on the development of biotechnology entrepreneurship in South 
Africa. 
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So in my own experience in human health research I can give you 
examples where the University is interacting with government, or where 
the University is interacting with industry but I cannot think of many 
situations in which the 3 come together. (Respondent 12 7:74) 
 
We are doing it in a sense but I often find that this is certainly an issue 
here; the inability of people here to work together. 
It is a big problem. It is like everybody is doing a bit somewhere and they 
are not teaming up, they are not coming together which is a huge 
detriment. (Respondent 14 9:74-75)      
 
Although the relationship among the university, industry, and government is deemed 
to be inefficient at an overall level, there are instances where the respondents 
believe that there is a very productive and efficient relationship among the 
stakeholders.  
 
The links to academia are very helpful to us to find high quality graduates. 
(Respondent 16 11:28) 
 
So I think that is also a real plus and I think you just need more companies 
like mine who have had a positive experience both with government and 
with the university to say yes this really is working and can continue to 
work and expand. (Respondent 15 10:37)  
 
Although there are few collaborative projects in biotechnology that have been 
successfully concluded in South Africa (Cloete et. al., 2006), the mixed experiences 
of the respondents in South Africa have meant that although most believe that the 
relationship within the triple helix is inefficient there are pockets of success that point 
to the possibility of making the relationship more efficient in future. 
 
Given that the “need for collaboration among key stakeholders” is among the codes 
that has the most mentioned by the respondents, it is acknowledged that without 
effective implementation the bio-economy of South Africa stands very little chance of 
success. 
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The role players within the bio-economy will have to collaborate effectively 
if the bio-economy is to succeed. These role players include industry, 
academia, science councils, non-governmental organisations, community-
based organisations, not-for-profit companies and the government. 
(Documents Case 1 13:45-46) 
 
In addition to the lack of collaboration across the three stakeholders of the triple 
helix, there is also a lack of collaboration within some of the stakeholder groups. 
Hence, the government agencies do not have effective collaboration; likewise the 
universities and industry. 
 
I know from speaking to the DST these guys hardly ever talk to the DTI, 
and that is certainly an issue. (Respondent 14 9:92)       
 
There is a lot of competition amongst the universities, and as I have said I 
have not explored it but it would be interesting to see in Brazil if there is a 
collaborative type of effort. (Respondent 3 3:55) 
 
Yes, science councils and universities have become competitors rather 
than partners (Respondent 4 4:23) 
 
The government controls the relationship with the university and the industry, from a 
policy, regulation and funding point of view. It is very apparent that the triple helix 
relationship in South Africa is at what is described by Etzkowitz and Leydesdorff 
(2000) as triple helix I, which represents a configuration in which the government 
encompasses both industry and university and directs the interaction and relations 
between them. 
 
The literature suggests that as countries progress towards a knowledge economy 
there is a transition from triple helix I, to triple helix II, and then to triple helix III in 
which the government influence is sequentially diminished and overlapping 
institutional spheres generate a knowledge infrastructure, with overlapping roles and 
hybrid organisations emerging at the interfaces (Etzkowitz and Leydesdorff, 2000).  
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However, with South Africa being at the triple helix I stage, with government 
influence unlikely to diminish, a high level of socio-economic linkages, and the 
government considering implementing a Quadruple Helix approach, the path of the 
triple helix in South Africa is expected to bypass the sequential progression to triple 
helix II and III and go to what can be termed the “Quadruple Helix of government-
controlled university, industry, society relations”.  
 
In concluding this sub-section, effective collaboration across the university, industry, 
and government (Etzkowitz and Leydesdorff, 2000) is acknowledged to be important 
to the development of the biotechnology industry in South Africa. The current 
experience of the respondents is such that most deem the relationship to be 
inefficient. There are instances of competition within the stakeholder groups, instead 
of the expected collaboration within and between the stakeholders. 
 
The model of Triple Helix experience in South Africa is Triple Helix I (Etzkowitz and 
Leydesdorff, 2000) and there is an indication from this research that South Africa will 
not go through a sequential progression to triple helix II and III but may progress to a 
form of a Quadruple Helix that includes the society as a fourth stakeholder (Afonso 
et al., 2010; Marcovich and Shinn, 2011; Afonso et al., 2012; Leydesdorff, 2012).  
 
7.5 Summary of within-case analysis of South Africa  
 
The process of biotechnology entrepreneurship in South Africa starts with 
bioscientists who have the necessary research and scientific skills to carry out 
biotechnological R&D. Owing to the lack of an adequate support system for providing 
the entrepreneurial and commercialisation skills needed to commercialise their 
research, these bioscientists are often forced to acquire entrepreneurial and 
commercialisation skills to commercialise their research effectively. Consequently, 
their practice of biotechnology entrepreneurship is as individuals rather than as a 
part of a system. 
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The environment under which biotechnology entrepreneurship is practised in South 
Africa has many challenges across the economic, political and cultural environments 
(Shane, 2003) key among which are unfavourable policy and regulatory 
environment; lack of appropriate funding; lack of government direction; an 
unfavourable university culture; lack of aggregate skills and capacity; and a lack of a 
developed market for biotechnology products. 
 
The bioentrepreneurial opportunities were identified predominantly in the area of 
problem opportunities, followed by efficiency opportunities and a small instance of 
innovation opportunities. In addition, abundant biodiversity is seen as a competitive 
source of bioentrepreneurial opportunities in South Africa. 
 
The discovery of these bioentrepreneurial opportunities requires research and 
development. The intensity and the R&D spend in South Africa is deemed to be 
below the levels of the developed economies, thereby negatively impacting on the 
effectiveness of the development of the biotechnology industry. 
 
The exploitation of these bioentrepreneurial opportunities requires a strategic 
alliance of research institutions, venture capitalists, large established biotechnology 
companies and government. However, this process in South Africa lacks the key 
stakeholders of venture capitalists and large established biotechnology companies. 
This forces the government into other roles, which are usually performed by these 
absent stakeholders in the developed economies. 
 
The execution step of the process of biotechnology entrepreneurship involves the 
commercialisation of research. The commercialisation of research in South Africa 
utilises both firm formation and licensing and is deemed to be inefficient due to a lack 
of entrepreneurial and commercialisation skills. In addition, the challenges with the 
environment and inefficiencies in the stages of R&D and opportunity exploitation 
impact on the effectiveness of commercialisation of research. 
 
The diagrammatic representation of the process of biotechnology entrepreneurship, 
as experienced by the respondents in this research, is shown in Figure 7.2. 
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Figure 7.2: A graphical depiction of the process of biotechnology 
entrepreneurship in South Africa 
 
The direction of the arrows in Figure 7.2 shows that the individual attributes, the 
bioentrepreneurial opportunities and the environment are deemed to affect all the 
stages of biotechnology entrepreneurship from R&D to entrepreneurial exploitation 
and commercialisation of research. While this does not prove causality, the 
importance of the individual attributes, entrepreneurial opportunities and the 
environment to entrepreneurship is supported by previous studies (Liebeskind et al., 
1996; Audretsch and Stephan, 1998; Agrawal, 2001; Shane, 2003; Müller et al., 
2004; Rothaermel and Deeds, 2004; Powell et al., 2005; Ahn and Meeks, 2007; 
Sytch and Bubenzer, 2008). 
 
This research extends this knowledge by clearly identifying the type of 
bioentrepreneurial opportunities that are predominant in the biotechnology industry 
of South Africa; the environmental conditions in which the process of exploiting these 
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opportunities takes place; and the individual attributes that are used in carrying out 
this process in South Africa. 
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Chapter 8: Case Analysis – Brazil 
 
The detailed analysis of case 2 integrates the deep interrogation of the current 
empirical and market research studies on biotechnology entrepreneurship in Brazil 
with interview transcripts, the output of Atlas.ti CAQDAS, and documents, to get to a 
consistent and rigorous analytical view (Weitzman, 1999; Rambaree, 2007; Hwang, 
2008) of the dynamics of biotechnology entrepreneurship in Brazil within its original 
context (Eisenhardt and Graebner, 2007b; Klonoski, 2013). 
 
8.1 Background to biotechnology entrepreneurship in Brazil 
 
Brazil is currently among the developing economies that are recognised as making 
significant progress in biotechnology. Some of the notable successes include a 
pioneer status in biofuels, leadership in agricultural biotechnology, being the world’s 
second-largest user of genetically modified (GM) crops, and the formation of 
innovation-focused biotechnology companies (Ernst & Young, 2010b). The unveiling 
of the world’s first commercially produced aircraft to operate solely on biofuel in 
2005, by Empresa Brasileira de Aeronáutica (EMBRAER), marked the recognition of 
Brazil as a leader in biofuel technology (Bound, 2008). This achievement was 
acknowledged by Scientific American as one of the most important of the year, and 
Brazil accounts for about 43% of the global supply of ethanol (Bound, 2008). 
 
The classification of Brazil as an efficiency-driven economy (Herrington et al., 2008; 
Bosma and Levie, 2010; Herrington et al., 2010) may seem at odds with the 
requirements to be an effective player in bioentrepreneurship, which is innovation 
driven (Bosma and Levie, 2010). However, given the pervasiveness of 
biotechnology, Brazil has already achieved a leadership position in biofuels (Ernst & 
Young, 2010b). In addition, the benefits of biotechnology entrepreneurship align to 
the development imperatives of Brazil.  
 
The biotechnology industry in Brazil is estimated to be worth $2.6 billion in annual 
turnover in 2012; it employs 28,000 people and has great potential for growth 
(Zylberberg, Zylberberg and Oner, 2012). Brazil is among the top countries in 
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revealed technological advantage in biotechnologies in the OECD studies that 
comprise both developed and developing economies (Organisation for Economic 
Cooperation and Development, 2013c) (see Figure 8.1). 
 
 
Figure 8.1: Revealed technological advantage in biotechnologies, 1999-2001 
and 2009-11 (OECD Patent Database, October 2013) (Organisation for 
Economic Cooperation and Development, 2013d) 
(Note: The bar highlighted in red is the value for Brazil. BRIICS stands for Brazil, Russia, India, Indonesia, China and 
South Africa) 
 
Other achievements that have set Brazil apart in technology entrepreneurship are: 
 
i. About a ten-fold increase in the number of postgraduates enrolled in 
universities in the decades from 1985 to 2005 
ii. 12% annual growth in the number of science PhDs from 1995 to 2009 (see 
Figure 8.2)  
iii. One of the fastest growing countries in the world in terms of scientific 
publications in the 21st century 
iv. One of the most productive agricultural nations in the world, and the 
enactment of the Biosafety law in 2005  
v. R&D spend of 1% of GDP in 2005 and projected to increase to 1.5% of GDP 
in 2010 
0.0
0.5
1.0
1.5
2.0
2.5
D
e
n
m
a
rk
S
in
g
a
p
o
re
B
e
lg
iu
m
S
p
a
in
N
e
w
 Z
e
a
la
n
d
A
u
s
tr
a
lia
U
n
it
e
d
 S
ta
te
s
C
a
n
a
d
a
Is
ra
e
l
C
h
in
e
s
e
 T
a
ip
e
i
Ir
e
la
n
d
B
ra
z
il
N
e
th
e
rl
a
n
d
s
F
ra
n
c
e
S
w
it
z
e
rl
a
n
d
U
n
it
e
d
 K
in
g
d
o
m
In
d
ia
O
E
C
D
A
u
s
tr
ia
M
e
x
ic
o
P
o
la
n
d
E
U
2
8
R
u
s
s
ia
n
 F
e
d
e
ra
ti
o
n
N
o
rw
a
y
K
o
re
a
H
u
n
g
a
ry
It
a
ly
S
w
e
d
e
n
S
o
u
th
 A
fr
ic
a
G
e
rm
a
n
y
B
R
II
C
S
F
in
la
n
d
J
a
p
a
n
C
h
in
a
T
u
rk
e
y
Index 2009-11 1999-2001
199 
 
vi. Abundance of natural resources, endowments and assets that has earned it 
the term “natural knowledge economy”. An example of Brazil’s natural 
resources is the Amazon rainforest, which holds a third of all plant species (da 
Silveira and de Carvalho Borges, 2005; Marques and Gonçalves Neto, 2007; 
Bound, 2008; Zylberberg et al., 2012) 
 
Of particular interest is Brazil’s emphasis on the development of the higher level 
skills required for the development of the biotechnology industry, as shown in 
Figures 8.2 and 8.3.  
 
 
Figure 8.2: Masters and doctoral degrees granted annually in Brazil 
(Zylberberg et al., 2012) 
 
 
The growth in the number of postgraduates translates into skills employed in the 
biotechnology industry, as shown in Figure 8.3 (BRBIOTEC Brasil and CEBRAP, 
2011). The presence of employees with postgraduate qualifications is evident in 
small and medium enterprises, as well as large businesses with more than 100 
employees (BRBIOTEC Brasil and CEBRAP, 2011). 
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Figure 8.3: Percentage of MScs and PhDs in companies of different sizes. 
 
 
8.1.1 The national biotechnology development policy 
 
The national biotechnology policy of Brazil was developed in February 2007 as the 
official legislated policy for the development of biotechnology entrepreneurship in 
Brazil. The purpose of the national biotechnology development policy, as articulated 
in the policy document, is given below:  
 
The overall objective of the Biotechnology Development Policy is to 
promote and perform actions with a view to establishing appropriate 
environment for the development of innovative biotechnological products 
and processes, encourage increased efficiency of the national productive 
structure, the innovative capacity of Brazilian companies, absorption 
technologies, business generation and export expansion.  
 
The focus areas of biotechnology development in the policy are human health, 
agricultural biotechnology, industrial biotechnology, and environmental 
biotechnology. These are outlined below. 
 
201 
 
Human Health 
 
The emphasis on this area of biotechnology is aimed at domestic production of 
strategic products for human health through biotechnological means, and within the 
bounds of the national health policy. It also focuses on the competitive positioning of 
the Brazilian biotechnology industry in the area of biomanufacturing, with the 
potential to generate new business, expand its exports, integrate up the value chain 
and stimulate new demand for innovative products and processes. 
 
Agricultural biotechnology  
 
The emphasis on agricultural biotechnology is aimed at stimulating the generation of 
strategic agricultural products to boost Brazilian global competitiveness, and achieve 
food security locally through biotechnology-driven product differentiation.  
 
Industrial biotechnology 
The emphasis on industrial biotechnology is aimed at stimulating domestic 
production of strategic industrial products for biomanufacturing with the potential to 
expand Brazilian exports, achieve global competitiveness and stimulate demand for 
new products and processes.  
 
Environmental biotechnology 
The emphasis on environmental biotechnology is aimed at stimulating the generation 
of strategic products in environmental management in order to achieve new levels of 
environmental quality and competitiveness; conservation and sustainable use of 
biodiversity; social inclusion; and development of clean technologies.  
 
The government body set up to implement the national biotechnology development 
policy is the National Biotechnology Committee, with responsibilities for the following: 
i. Coordinate the implementation of the biotechnology development policy, 
promoting the necessary improvements to its full implementation 
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ii. Conduct its activities in a coordinated and integrated manner to define and 
implement actions and programmes related to the implementation of the 
biotechnology development policy  
iii. Set up working groups on specific topics that require technical expertise to 
support the activities of the Committee  
iv. Harmonize the biotechnology development policy with the other existing 
related policies  
v. Invite professionals and renowned experts in the field or from other agencies 
or entities and society to advise on their activities  
vi. Propose to update the policy development of biotechnology  
 
Evidently the implementation of the national biotechnology policy of Brazil has been 
relatively successful given the successes achieved so far and the positioning of 
Brazil in the global biotechnology industry. Some of the government initiatives that 
were instrumental to the achievement of these successes, and the collaborative 
projects are articulated in the sections below. 
 
8.1.2 Government initiatives 
 
Government initiatives in support of biotechnology include the biotechnology 
development policy and a 10-year US$4.0 billion biotechnology development 
programme (Ernst & Young, 2010b). In addition, the Ministry of Science and 
Technology (MCT) coordinates the national science and technology policy, which 
brings together key players in the biotechnology sector such as the National Council 
for Scientific and Technological Development (CNPq), Research and Projects 
Financing (FINEP) and Brazilian Corporation for Farming and Livestock Research 
(EMBRAPA); policies and regulations such as Innovation Law of 2004, which was 
designed to strengthen the university-industry research relationship; Good Law of 
2005, which was meant to encourage private R&D investment and employment of 
post graduates in the sector; Programme of Accelerated Growth in Science, 
Technology and Innovation of 2007, which was meant to raise the level of R&D 
expenditure as a percentage of GDP from 1% to 1.5%; and Productive Development 
Policy of 2007, which provides spending targets and tax breaks for key sectors like 
203 
 
biotechnology with the aim of increasing high technology exports (da Silveira and de 
Carvalho Borges, 2005; Marques and Gonçalves Neto, 2007; Bound, 2008). 
 
Figure 8.4 shows the result of the sustained increase in R&D spend in Brazil, which 
supports the increased relevance of Brazil in the 21st century knowledge economy. 
Although Brazil still lags behind the developed economies in R&D spend, like other 
developing economies, it is among the top countries in Latin America. 
 
 
Figure 8.4: R&D intensity, Brazil and selected OECD and Latin American 
comparison countries, 2005 (Bound, 2008) 
Note: R&D Expenditure as % of GDP, 2005 unless otherwise stated 
 
8.1.3 Collaborative projects 
 
One of the key strengths of Brazil in the area of genome sequencing is the formation 
of collaborative networks (Camargo and Simpson, 2003; Júdice and Vedovello, 
2007; BRBIOTEC Brasil and CEBRAP, 2011). This is one of the examples of 
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effective collaboration among key stakeholders in the Brazil biotechnology industry 
as shown in Figures 8.5 and 8.6. 
 
 
 
 
 
 
 
 
 
Some of the notable genome sequencing collaborative projects include: 
 
i. The Eucalyptus genome project, in which four paper companies collaborated 
with research institutions (Camargo and Simpson, 2003; Júdice and 
Vedovello, 2007) 
ii. The coffee genome project with a collaboration of 700 researchers and 40 
institutions (Camargo and Simpson, 2003; Júdice and Vedovello, 2007) 
iii. The xylella fastidiosa project in which 65 laboratories, 75 research groups and 
450 researches collaborated. This included international institutions (Camargo 
and Simpson, 2003; Júdice and Vedovello, 2007) 
iv. The sugar cane genome project (Camargo and Simpson, 2003; Júdice and 
Vedovello, 2007) 
v. The chromobacterium violaceum project (Camargo and Simpson, 2003; 
Júdice and Vedovello, 2007) 
 
In addition to collaboration among researches and institutions, there is also a close 
collaboration among key government institutions such as the MCT, the Ministry of 
Development, Industry and Foreign Trade (MDIC), Ministry of Agriculture, 
Figure 8.5: Does the company have a 
relationship with universities or 
research institutes? (BRBIOTEC Brasil 
and CEBRAP, 2011) 
 
Figure 8.6: What is the aim of this partnership? (BRBIOTEC 
Brasil and CEBRAP, 2011) 
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Stockbreeding and Supply (MAPA) and the Ministry of Education (MEC) among 
other institutions (Zylberberg et al., 2012). 
 
8.1.4 Constraints 
 
Some of the constraints of biotechnology entrepreneurship in Brazil relate to 
infrastructure, capital, regulatory challenges, competition, inequality and 
environmental sustainability (Zylberberg et al., 2012). 
 
8.2 How biotechnology entrepreneurship is carried out in Brazil 
 
The analysis of the process of biotechnology entrepreneurship in Brazil is facilitated 
through the use of the individual-opportunity nexus framework of entrepreneurship 
discussed in Chapter 3, as an organising framework. Hence, the components 
include: 
 
i. Individual attributes 
ii. Environment 
iii. Entrepreneurial opportunities 
iv. Discovery 
v. Entrepreneurial exploitation 
vi. Execution 
 
8.2.1 Individual attributes 
 
There were five respondents in Brazil, of which two were designated as 
bioentrepreneurs and three were SMEs across university, industry, and government 
for the purposes of this research. Among these five there were two overlaps, where 
respondents were designated as both bioentrepreneur and SME. 
 
In choosing the respondents for the research in Brazil, care was taken to ensure that 
the purposive sampling was representative of individuals with a high degree of 
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knowledge and competence in the research topic (Romney et al., 1986; Guest et al., 
2006; Stake, 2006; Bowen, 2008); and hence with good insights into the dynamics of 
biotechnology entrepreneurship in Brazil.  
 
A summary of the characteristics of the respondents for Brazil is provided in Table 
8.1. 
 
Table 8.1: Summary of characteristics of respondents for Brazil 
Respondent Position Qualification Area of expertise 
1 
Co-founder of a 
biotechnology 
company; lecturer; 
research scientist 
Forest Engineer; 
PhD in Genetics; 
Professor 
Bioentrepreneur in Bioservices; 
Research scientist at a government 
institution; Lecturer in Biotechnology 
and Genomic Sciences 
2 
Lecturer, 
researcher and 
advisor for 
graduate 
programme in 
Biotechnology 
PhD in Science and 
Technology Policy 
Studies; Adjunct 
Professor 
Specialises in science and technology 
policy research 
3 
Founder of a 
biotechnology 
company; lecturer; 
head of Centre for 
Molecular Biology 
and Genetic 
Engineering 
PhD in Molecular 
Biology; Professor 
Specialises in molecular biology, 
genetics, gene cloning, sequencing 
and genomics 
4 
Director of graduate 
programme in 
Genomic Science 
and Biotechnology; 
former director of 
the National 
Research Council 
Agronomic Engineer; 
Masters in Mineral 
Nutrition of Plants; 
PhD in Plant 
Biochemistry and 
Tissue Culture; 
Professor 
Lecturing and research in 
biochemistry, with emphasis on 
enzymology and cellular metabolism; 
policy formulation and implementing 
strategic programmes aimed at 
university-industry collaboration in 
biotechnology 
5 
Area director for a 
government 
research funding 
agency; licensed 
researcher  
PhD in Policy 
Studies in Science 
and Technology 
Specialises in the economics of 
production engineering with emphasis 
on technological innovation 
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In addition to the psychological attributes, the respondents in Brazil possessed the 
requisite non-psychological factors, such as education and career experience (Barro 
and Lee, 2000), for biotechnology entrepreneurship. All the respondents had a 
minimum qualification of a PhD in biosciences and related fields; and were all 
professors in their fields, with the exception of one respondent. The education factor 
in biotechnology entrepreneurship is a critical requirement for functioning as a 
bioentrepreneur.  
 
The respondents were highly qualified, experienced and experts in the field of 
biotechnology entrepreneurship. Some had won national and international awards in 
their personal capacity for their contribution to the development of biotechnology 
entrepreneurship in Brazil. 
 
The bioentrepreneurs in Brazil operated within the “system” of biotechnology 
entrepreneurship and were involved in shaping the policies related to the efficient 
development of the biotechnology industry in Brazil. The “system” model of 
biotechnology entrepreneurship in Brazil is driven by the integration between the 
biotechnology parks and the universities. 
 
A majority of Brazil’s incubators and technology parks are affiliated with 
institutions of higher education. In 2003, there were 207 incubators and 10 
technology parks operating in Brazil. Of the 207 incubators, 107 were 
technology-based, and of those 80% had formal ties with universities. All 
ten of the technology parks had formal and informal ties with universities. 
(Documents Case 2 33:27) 
  
The emphasis is on being able to contribute to solving the problems of the country 
rather than being seen as an excellent entrepreneur. On one instance, the 
bioentrepreneur returned to a full professorship at the university after managing one 
of the most celebrated biotechnology entrepreneurship successes in Brazil. 
 
Yes, I used to be a bioentrepreneur. I am a professor at the University of 
Campinas since 1975, which is a long time. And I have been working in 
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plant molecular biology for a while. I did my PhD here at university of 
Campinas, and then I work at post doctorate in England. 
Then I returned to Brazil and I started this centre for Molecular Biology. 
 
In another instance, the bioentrepreneur was driven by the need to solve the national 
problems; and although he owned his own biotechnology company, he also worked 
for the government’s agricultural agency as well as being a professor and researcher 
at one of the universities tasked with developing young skills for the biotechnology 
industry.  
 
But there are some people like myself that enjoy more seeing science 
being applied towards solving a problem, so I think that is the basic thing, 
internal motivation. (Respondent 6 18:13) 
 
I was working for the government as a research scientist. 
In ’96, myself and a colleague of mine, we decided to set up a DNA 
analysis laboratory to use the technologies that we commonly used in our 
everyday research. It is a private company, called Hereditas DNA 
Technologies, it was founded in June 1996 and since then, so it is 16 
years now, we have been working with DNA genotyping of humans and 
plants. (Respondent 6 18:2-3) 
 
None of the two bioentrepreneurs considered themselves to be born with 
entrepreneurial skills or have familial inclination to one. Their training and experience 
obtained from practical application of research to real-life problems qualified them as 
bioentrepreneurs and all their activities were geared towards developing the system 
of bioentrepreneurship in Brazil, rather than developing individual bioentrepreneurs. 
 
No, I do not have any history of entrepreneurship in my family, as far as I 
know. (Respondent 8 20:57) 
 
In this company I was responsible for the science programme and also for 
intellectual property. It was very interesting and a very, very nice 
experience for me because we did not have any experience in intellectual 
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property in academia because we do not play well with intellectual 
property in academia here in Brazil because it is a little difficult for people 
to clearly understand how to manage intellectual property. 
But working in the company it was very interesting because I learnt a lot 
from other people and other companies and this was very interesting. 
(Respondent 8 20:28-29) 
 
First I think was my early experience out of undergraduate, working at a 
private company, and I think I enjoyed it very much, I learned a lot. I was a 
good student and everybody wanted me to go and get a Masters right 
away and I said no. So they offered me this job and I went to work and it 
was a five-year learning experience on how to actually put in practice what 
you do in the laboratory. And I think that always motivated me a lot, so to 
try and see some problem being solved. (Respondent 6 18:11) 
 
In conclusion, the analysis on the individual attributes of the respondents in Brazil 
shows that they had the necessary psychological and non-psychological attributes to 
function effectively as bioentrepreneurs.  
 
Their business management skills were learned from practical experience rather 
than formal training in business management and there was reliance on the “system” 
of biotechnology entrepreneurship (Ahn and Meeks, 2007) in Brazil rather than on 
the “individual”. Hence, the respondents commit time and effort in developing this 
“system” for the effective development of the biotechnology industry in Brazil, by 
being involved with government, industry, and the university irrespective of their 
primary areas of responsibility. 
 
8.2.2 Environment 
 
The environment of biotechnology entrepreneurship in Brazil, as experienced by the 
respondents, is mixed with an equal occurrence of key challenges and areas 
considered not to represent gaps in the development of biotechnology 
entrepreneurship in Brazil.  
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The challenges include the regulatory environment, especially related to taxation; 
shortage of aggregate skills; national culture of seeing entrepreneurship as impure; 
high interest rate, which results in a high cost of funds; bureaucracy; corruption and 
politics. 
 
Then you have the general business environment of a country, and for 
Brazil it is not well ranked, and we know that. (Respondent 6 18:28) 
 
In any case, a company would still have to operate in this very difficult 
business environment. For a number of reasons, interest rates, cost of 
personnel, taxation for import and general tax structure which is a complex 
system of several taxes in cascade. (Respondent 6 18:51-52) 
 
Because innovation is now on the agenda of all federal government and 
the state government, all the politicians, they are talking innovation all the 
time. This is good because there is a possibility of changing the laws, this 
is the only way of solving this problem, because we have people and 
talent is a question of numbers. If you have a large number of students a 
portion of them will be, like any other areas, so we need to take advantage 
of having this system. (Respondent 8 20:43-44) 
 
On the other hand, the areas considered not to represent challenges are the 
provision of direction and leadership by the government; availability of appropriate 
funding; the size of the market for biotechnology products in Brazil; availability of 
relevant infrastructure; a university culture that is conducive to the development of 
biotechnology entrepreneurship; availability of adequate capacity for biotechnology 
entrepreneurship; and good scope for international collaboration. 
 
Moreover, the success that the country has achieved with the results of 
their research in biotechnology has greatly influenced the demand for 
cooperation bilateral and/or multilateral agreements with other countries in 
biotechnology, which can boost its international relations, attracting 
international capital flows and interest in pursuing new business 
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arrangements that enhance the competitiveness of domestic industries. 
(Documents Case 2 34:33) 
 
Table 8.2 shows the areas highlighted by the respondents that affect the 
environment of biotechnology entrepreneurship in Brazil. There is an equal split 
between the factors designated as favourable and those seen as challenges. Of the 
14 areas highlighted seven were highlighted as gaps, and seven, not as gaps. 
 
Table 8.2: Points highlighted by Brazilian respondents as affecting the 
environment of biotechnology entrepreneurship 
Point mentioned 
This point is mostly 
considered a gap 
 This point is mostly 
not considered a gap 
Policy and regulation √   
Government direction   √ 
Funding   √ 
Skills √ 
 
National culture √   
High interest rate √   
Bureaucracy √   
Market size 
 
√ 
Infrastructure   √ 
University culture   √ 
Capacity   √ 
International collaboration   √ 
Corruption √   
Politics √   
 
 
The narrative points were collated by manually going through the narrative summary 
of the verbatim quotes by the respondents in Brazil, and highlighting the areas 
mentioned as impacting on the environment of biotechnology entrepreneurship in 
Brazil. 
 
The outcomes of data analysis using Atlas.ti CAQDAS for the codes that have the 
most occurrences, but do not necessarily occur in most of the transcripts (vertical 
occurrence), are shown in Table 8.3. These codes were compared to the narrative 
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points listed in Table 8.2; and the codes mentioned by most respondents (horizontal 
occurrence) (see Table 8.4) to establish a pattern. 
 
Table 8.3: The table of codes that were mentioned the most (vertical 
occurrence) 
Number  Codes that occur the most (vertical occurrence) 
1 Government-incentivised entrepreneurial action 
2 Evidence of collaboration among key stakeholders 
3 Non-conducive regulatory environment 
4 Need for effective collaboration among key stakeholders 
5 The need to compete globally 
6 Need to increase the capacity for innovation 
7 Conducive environment for biotechnology development 
8 High cost of funding 
9 Availability of appropriate funding 
10 Government inefficiencies 
11 Obvious socio-economic linkages 
12 Developed venture capital industry 
13 Emphasis on country competitiveness 
14 Emphasis on national priorities 
15 Abundant biodiversity 
16 Emphasis on solving problems 
17 Bureaucratic processes 
18 Positive future outlook 
19 Emphasis on skills development 
20 Availability of local market for biotechnology products 
21 Good support infrastructure 
22 Evidence of social and cultural challenges 
23 Improved agricultural output 
24 Personal motivation 
25 Political-industry disconnect 
26 Availability of skills 
27 
Eagerness to contribute to the development of the biotechnology 
industry 
28 High inflation 
29 Need for favourable tax laws 
30 Need to increase research and development spend 
31 New markets 
32 Skills development through collaboration 
33 Ability to attract foreign skills and expertise 
34 Good universities 
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The codes that have the most occurrences in most of the transcripts (horizontal 
occurrence) are as shown in Table 8.4. 
 
Table 8.4: The table of codes that occurred across most of the respondents 
(horizontal occurrence) 
Number Codes that appear in most transcripts (horizontal occurrence) 
1 Abundant biodiversity 
2 Evidence of collaboration among key stakeholders 
3 Good universities 
4 Government-incentivised entrepreneurial action 
5 Need for effective collaboration among key stakeholders 
6 Non-conducive regulatory environment 
7 Political-industry disconnect 
8 Availability of appropriate funding 
9 Availability of local market for biotechnology products 
10 Availability of skills 
11 Career 
12 Conducive environment for biotechnology development 
13 Emphasis on country competitiveness 
14 Emphasis on national priorities 
15 Emphasis on solving problems 
16 Evidence of social and cultural challenges 
17 Good research facilities 
18 Good support infrastructure 
19 Government inefficiencies 
20 Government policy on innovation 
21 High inflation 
22 Higher levels of business and market risks 
23 Negative view of entrepreneurship 
24 Support for patenting 
25 The need to compete globally 
26 Academic background 
27 Agricultural biotechnology 
28 Availability of good quality bioscientists 
29 Biofuels 
30 Bureaucratic processes 
31 Developed venture capital industry 
32 
Eagerness to contribute to the development of the biotechnology 
industry 
33 Emphasis on skills development 
34 High cost of funding 
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These are outputs of the Atlas.ti CAQDAS that enabled an in-depth analysis of the 
code patterns in different dimensions (Weitzman, 1999; Rambaree, 2007; Hwang, 
2008). 
 
The reason for analysing the codes in different dimensions is that a particular point 
may be mentioned many times in the transcript, but may be the experience of one or 
a few respondents. Hence, it is important also also analyse the codes horizontally to 
determine the occurrence of particular codes across most or all of the transcripts.  
The codes that have most mention within (vertical) and across (horizontal) the 
transcripts are deemed to be important in identifying the patterns in the data that 
improve the understanding of the process of biotechnology entrepreneurship in 
Brazil. 
 
The identified patterns in the environment of biotechnology entrepreneurship in 
Brazil are summarised below: 
 
i. There is collaboration among the key stakeholders and this collaboration is 
acknowledged to be important to the effective development of biotechnology 
entrepreneurship in Brazil 
ii. The government plays an important role in incentivising bioentrepreneurial 
activities in Brazil 
iii. The regulatory environment for biotechnology entrepreneurship in Brazil is 
deemed to be unfavourable 
iv. Appropriate funding is available for the development of biotechnology 
entrepreneurship in Brazil 
v. The high cost of funding in Brazil constrains the development of the 
biotechnology industry 
vi. The abundant biodiversity constitutes a source of competitive advantage for 
the development of the biotechnology industry in Brazil 
vii. The universities in Brazil are good at conducting the research required for the 
development of biotechnology entrepreneurship in Brazil 
viii. The politicians do not have a full understanding of the requirements of the 
biotechnology industry 
ix. The local market for biotechnology products is considered developed 
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x. The research and scientific skills necessary for the development of 
biotechnology entrepreneurship are available. The entrepreneurial and 
commercialisation skills are available through the system of biotechnology 
entrepreneurship in Brazil 
xi. Global competitiveness is a key factor in the approach to biotechnology 
entrepreneurship in Brazil 
xii. The aggregate capacity for innovation needs to be improved 
xiii. The inefficiencies of the government and its agencies affect the effectiveness 
of the development of biotechnology entrepreneurship in Brazil 
xiv. There is an overall enabling environment for the development of 
biotechnology entrepreneurship in Brazil 
 
The areas that were mentioned the most by the respondents in the narrative 
analysis; and the areas that were mentioned the most within (vertical) and across 
(horizontal) the transcripts are explored further in the following sections. 
 
The top seven areas highlighted in the environment of biotechnology 
entrepreneurship in Brazil are: 
 
i. The importance of collaboration among the key stakeholders 
ii. Policy and regulation  
iii. Government direction  
iv. Funding 
v. Skills 
vi. High interest rate 
vii. Bureaucracy  
 
The importance of collaboration among the key stakeholders 
 
The experience of the collaboration among the key stakeholders in the biotechnology 
industry in Brazil is covered in details in Section 8.4.  
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Policy and regulation  
(Represented as “non-conducive regulatory environment” in Tables 8.3 and 8.4) 
 
The experience of challenges with the policy and regulatory environment for 
biotechnology entrepreneurship in Brazil was unanimous across all the respondents. 
The specific areas that were highlighted as challenges were policies related to 
intellectual property ownership; policies related to technology transfer from the 
university to the industry; taxation laws; and labour laws. 
 
They have to charge more and more taxes to be able to operate. So you 
have a very complex system of taxation with state taxes, federal taxes and 
all kinds of different constantly changing taxation systems. So that also 
scares a lot of people, you hear a lot of difficult stories of people that set 
up business and just went down because they just could not deal with all 
the complex taxation systems. (Respondent 6 18:33) 
 
Yes, policies and because of the law. Most of the research universities in 
Brazil that do almost 100% or 95% of their research in this country are 
public universities. Public universities mean that they are regulated by law, 
the state laws because it is very difficult for intellectual property and 
technology transfer. It still exists, and this is a major problem, we need to 
change this. This is one of the most important points for technology 
transfer in this country. (Respondent 8 20:30, 34) 
 
There are several legal obstacles that prevent public universities in Brazil 
from negotiating with enterprises in a flexible and “fluid” manner, and the 
foundations were designed to help universities overcome these obstacles. 
(Documents Case 2 33:20) 
 
There are some legal difficulties, for example, a university professor in 
Brazil, a federal university or state university professor. Most of them or I 
would say 95% of them have a contract called, Exclusive Dedication. By 
exclusive dedication it means that you cannot have a business, or maybe 
better said, you can own a business, but you cannot run the business. 
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So that also inhibits many scientists to go out and try something because 
they are worried there will be a conflict of interests. (Respondent 6 18:90-
91) 
 
I say that the biotechnology in Brazil is not developed a lot, there are 
several variables, but the biggest variable is that we do not have legal 
safety. The rules are not well established, when the rules are not well 
established, they are not well carried out. (Respondent 9 21:79) 
 
And government is investing a lot but their restrictions are very tough. 
Yes, do not forget that Brazil is a country where everybody is guilty until 
proven innocent. Then they put money in all of them, lots of money, but 
the law is not good enough. (Respondent 10 22:11-13) 
 
On the other hand, the patent law was deemed to be well established but plagued by 
implementation challenges due to bureaucracy. 
 
The patent laws in Brazil are fairly well established from my point of view 
because I make a lot of patents and I have applied in Brazil and outside 
the country. The problem is, the structure for approving patents takes 
three or four years to get your patent registered, and when you apply for it 
you are protected. (Respondent 9 21:80) 
 
The challenges in the policy and regulatory environment highlighted by the 
respondents discourage an individual approach to biotechnology entrepreneurship 
and further entrench the system approach to biotechnology entrepreneurship in 
Brazil.  
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Government direction  
(Represented as “government-incentivised entrepreneurial action” in Tables 8.3 and 
8.4) 
 
The experience of the respondents in Brazil in relation to the leadership and setting 
of direction from the government was positive. The respondents acknowledged the 
role of the government in establishing the policy framework for the development of 
the biotechnology industry; the infrastructure and support structures; the funding 
agencies at national and state levels; the platforms for collaborative projects; and the 
involvement of stakeholders such as industry and academia in decision making. 
 
Then the government in all levels are implementing several kinds of 
programmes to stimulate innovation and entrepreneurship, but the results 
are very small. (Respondent 10 22:14) 
 
But innovation became an obsession in Brazil. (Respondent 10 22:45) 
 
Government was mainly the driving force, because a lot of us that 
somehow had the experience outside of academia went to the 
government, to be in the government. We knew that we had to change the 
way we are working in science and technology in Brazil. We had to 
support the industrial sector but the government has been the big driving 
force I would say. And now the market is where it is internationally 
competitive. (Respondent 9 21:57) 
 
The government is very important as a ruler, as giving the institutional and 
regulatory context to this, but I think that is a part of what society is asking 
for the government to do. (Respondent 7 19:56) 
 
If you look at bioentrepreneurship around the world, the government has 
always had and still has an important role. (Respondent 6 18:121) 
 
The national funding agency, FINEP and the state funding agencies such as 
FAPESP play a very important role in funding research and development in Brazil. 
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In its 41 years of operation, FAPESP has awarded more than 45 thousand 
fellowships and 35 thousand financial awards to research. The balance of 
these years of continuous investment clearly show that the Foundation has 
made a decisive contribution to the expansion and strengthening of 
scientific and technological research in the State of São Paulo, with 
considerable impact on its economic, social and cultural development. 
(Documents Case 2 24:2-6) 
 
FINEP is an organisation of the Brazilian federal government under the MCT, which 
is devoted to funding of science and technology in the country. FAPESP is a public 
foundation with the aim of providing grants, funds and programmes to support 
research, education and innovation of private and public institutions and companies 
in the state of São Paulo. 
 
Funding  
(Represented as “availability of appropriate funding” in Tables 8.3 and 8.4) 
The availability of capital (Shane, 2003) is an important factor in any entrepreneurial 
activity and biotechnology entrepreneurship is often associated with both 
government and venture capital funding sources (Audretsch et al., 2008).  
The respondents to this research were of the opinion that appropriate funding is 
available for the biotechnology industry in Brazil. The sources of this funding are 
primarily the government through its national and state funding agencies; the private 
sector; and venture capitalists (Audretsch et al., 2008). The availability of appropriate 
funding in Brazil through these sources is similar to the process of biotechnology 
entrepreneurship in developed economies (Ahn and Meeks, 2007; Ahn et al., 
2010a). 
 
I think we have 100 funds active in Brazil. It can be seed money, 
mezzanine money or equity in this 100. The Brazilian government puts a 
lot of money in biotechnology; it is called a special programme, a strategic 
programme. So I believe it is the government, but I am not sure of the 
numbers. (Respondent 7 19:47-48)  
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There is a lot of interest not only from capitalists in Brazil, but outside 
Brazil that are interested in investing in the country. This has been done in 
the last five or six years in the area of bioenergy for example. People 
investing, big multinational companies, merging with Brazilian companies 
and setting up big sugar cane deals and this is important and this is 
positive and there is a lot of money available. (Respondent 8 20:83) 
 
FAPESP also has specific programmes to support small businesses. 
(Respondent 10 22:20) 
 
Basically this programme gives you money for you to go from your 
research findings to your product. They give you money for researchers, 
for the goods you need for getting your process moving on. (Respondent 9 
21:48) 
 
A key component of the funding adequacy in Brazil is the role played by the venture 
capitalists in the strategic alliance required to exploit bioentrepreneurial opportunities 
(Ahn and Meeks, 2007). 
 
Skills  
(Represented as “availability of skills” in Tables 8.3 and 8.4) 
 
The respondents in Brazil believed that the research and scientific skills are available 
at individual levels for the development of biotechnology entrepreneurship in the 
country. However, the aggregate skills were deemed to be inadequate and as having 
a negative impact on the speed and scale of the development of the industry. 
 
In the state of São Paulo we have three big universities, Unicamp, the 
University of São Paulo and the University of the State of São Paulo. All 
together graduate and undergraduate students, we used to have 
something like 300,000 students and of course a portion of these students 
are very talented people. There are people with entrepreneurship skills 
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and talented people who could be used in the innovation system. 
(Respondent 8 20:38) 
 
Now it is amazing, when I arrived here in the 90s, I do not think there were 
many, there were just a few. There are lots of people that are coming from 
PhDs; there is a huge programme of doctor formation in Brazil, which is 
mostly funded by the government. (Respondent 7 19:31-32) 
 
Do we have manpower for this industry? Do we have qualified people? 
Well, not really and why? (Respondent 6 18:126) 
 
Human resources are a key challenge. Currently there are only 1.48 
researchers per 1000 total employment (2006) and only 10.7% of all 
university graduates have degrees in science and engineering. 
(Documents Case 2 32:3) 
 
The basic difference I guess is education; they are very good in 
mathematics. We do not have very good talent for exact sciences. 
(Respondent 10 22:51-52) 
 
We have lots of jobs for qualified people and at the same time we have 
unemployment, which means we have a lot of people that did not have the 
opportunity to actually go to a decent school, could not learn anything. 
They are barely literate I would say and are looking for jobs, and the jobs 
that are out there in bioentrepreneurship, the jobs that we would be 
creating are qualified jobs. I am not talking about PhD, I am talking about 
just good high school graduates, good technical, we lack those people but 
at the same time we have unemployment. (Respondent 6 18:116) 
 
When the skills gap did appear, international collaboration and the attraction of 
foreign skills were used to fill the gaps. That this went on smoothly points to the fact 
that Brazil has an environment that is conducive for biotechnology entrepreneurship 
development that attracts foreign skills. 
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We hired people with PhD here in Brazil or in other countries, mostly the 
United States. We invested in post doctorates with experience abroad. But 
we train people also, we used to train people, to send people for training 
and we did that for intellectual property, we sent people for training in the 
United States. One important thing is we maintained this since the 
beginning, very close collaboration with scientists in the US and Europe. 
We used to have a kind of scientific counselling with very important 
scientists from Europe and from the US, and this was very important. 
(Respondent 8 20:21) 
 
And to do this you need the expertise and sometimes we have the 
expertise here in Brazil, but sometimes we do not have the expertise. So 
we used to bring people with the strongest experience in biotechnology in 
the industry in creating our start-up companies and this was very useful for 
us to do that. (Respondent 8 20:22) 
 
The entrepreneurial and commercialisation skills were not identified as challenges by 
the respondents in Brazil, which supports the view that the process of biotechnology 
entrepreneurship in Brazil utilises the “system” approach rather than the “individual” 
approach. The system provides the commercialisation and entrepreneurial 
capabilities necessary for the successful exploitation of bioentrepreneurial 
opportunities. 
 
High interest rate  
(Represented as “high cost of funding” in Tables 8.3 and 8.4) 
 
The recent past of very high inflation in Brazil may be over, but the respondents 
deem the interest rate on funding to be high, in this way contributing to an 
environment with a high cost of doing business. 
 
In the past, if you borrow money from the bank, it is suicide. 
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Then the industrial sector of Brazil, because of the high inflation rate, they 
are not willing to invest in any R&D effort that has high risk. They prefer to 
buy technology outside of Brazil. (Respondent 9 21:43-45) 
Although we do not have high inflation like we had the previous time, but it 
still costs a lot of money if you borrow money. (Respondent 9 21:107)  
 
Before that we had inflation until 1994, between 1980 and 1994 there was 
almost 15 years of very high inflation, where it was difficult to think of 
investing because it was hard to plan anything. (Respondent 6 18:31) 
 
The challenge provided by the high interest rate is alleviated by the funding initiatives 
of the government at favourable terms and sometimes designated as “free to 
operate” (FTO), in which case the recipient is not required to repay the grant. 
 
So the money is free, it is FTO, so they have all the freedom to operate.  
I think this is a very nice programme, we invested last year about 50 
million dollars in different projects. I think this is one of the most important 
programmes in Brazil, trying to stimulate the creation of start-up 
companies in all areas. (Respondent 8 20:47) 
 
Other factors that address the high interest rate challenge are the fact that most 
research in Brazil is conducted through the public universities, which means that the 
funding for the research is from the government and not the individuals and most 
bioentrepreneurial activities involve large established companies.  
 
Bureaucracy  
(Represented as “bureaucratic processes”; and “government inefficiencies” in Tables 
8.3 and 8.4) 
 
The bureaucracy and inefficiencies experienced in government processes were 
highlighted as challenges to the development of biotechnology entrepreneurship in 
Brazil. 
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But if you see how the agencies work, you see a high level of bureaucracy. 
(Respondent 10 22:8) 
 
In Brazil, the system that controls the private investment is so bureaucratic 
they do not want to see the results; they want to see the process. If all the 
people are put in the right order, fine, but it does not matter if you make 
good use of the money or not, if you got a good result. (Respondent 9 
21:94) 
 
For us to operate, we had to buy used equipment, and it took me almost a 
year to do all the bureaucratic paper work to be able to buy used 
equipment. (Respondent 6 18:41) 
 
Talking about patents, the national institute of intellectual property in 
Brazil, for us to register the brand of our company, it took 10 years, a 
name, a brand, 10 years. (Respondent 6 18:99) 
 
In concluding the section on the environment of biotechnology entrepreneurship in 
Brazil, it is worth noting that the constraints in the development of the biotechnology 
industry in Brazil identified by Zylberberg et al. (2012) include infrastructure, capital, 
regulatory challenges, competition, inequality and environmental sustainability. 
However, only one of these constraints, regulatory challenges, was highlighted by 
the respondents in this research as a challenge. The infrastructure and support 
structures were deemed to be available and adequate; the capital was deemed to be 
appropriate and sufficient; competition was seen as a positive motive for the 
development of the biotechnology industry, and not a constraint; inequality was 
highlighted as a social linkage and not directly a constraint of biotechnology 
entrepreneurship; and environmental sustainability was seen as one of the areas of 
emphasis and not as a constraint. 
 
One other area of the environment, which was mentioned by two or more 
respondents, that is worth emphasising is the national culture of seeing 
entrepreneurship as “impure” in comparison to academics.  
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8.2.3 Entrepreneurial opportunities 
 
The bioentrepreneurial opportunities are mostly aligned to the Brazilian biodiversity; 
efficiency and innovation opportunities; and a component of problem opportunities. 
 
I would say that the opportunities in life science are very wide, many 
areas. Brazil is a big agricultural country, certainly a power house in that 
area. Then there is an area of service in biotechnology that is difficult 
because again the competition with the cost structure of a company 
abroad. It is difficult for us because our cost structure is complex. 
Then you have an area of generating products, bioproducts. You develop 
or you discover a molecule in some biodiversity source. I think that is an 
area where Brazil has the best opportunity to evolve. (Respondent 6 
18:74-79) 
 
The problem opportunities are in the areas of diseases such as lifestyle diseases; 
infertility; paternity verification; and food shortages. These problem opportunities are 
not unique to Brazil or to developing economies in general (Brännback et al., 2007; 
Battelle/Biotechnology Industry Organisation, 2012) but are predominant in 
comparison to the developed economies. 
 
For example, we have done several tens of thousands of human paternity 
tests, which are not cutting edge technology, it is a very routine type thing, 
but you solve problems. So every time you deliver a report you know you 
are changing the life of some people, so I think that is very motivating for 
me. (Respondent 6 18:19) 
 
We need to improve yield, we need to fight against the diseases and 
biotechnology can help a lot to do this and this is why I believe that the 
world, and not only the countries, all the world needs to invest heavily in 
biotechnology. (Respondent 8 20:54) 
 
The efficiency opportunities are mostly in the areas of bioenergy; genomics; 
pharmaceuticals; bioprocessing and biomanufacturing. The realised efficiencies 
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provide the opportunity to solve some of the problems of food security, and 
environmental sustainability, promote healthier populations and contribute to energy 
conservation. 
 
As Brazil is very rich in natural resources the agenda has always been 
connected with the exploration of these resources. (Respondent 10 22:2) 
 
Another competitive advantage of Brazil for the development of 
biotechnology is its remarkable biodiversity. There are about 200,000 
species of plants, animals and microorganisms that have already been 
registered and it is estimated that this number could reach one million 
eight hundred thousand species. It is almost a fifth of all global biodiversity 
distributed in six biomes (Amazon, Cerrado, Caatinga, Atlantic Forest, 
Pantanal and Pampa), plus the coastal and marine zone. (Documents 
Case 2 34:36) 
 
All the biotechnology companies today, they have two words, food and 
fuel, because plants can supply both, fuel and food. When we are talking 
about fuel, sugar cane is a premium crop to produce bioenergy, and all of 
those companies elected sugar cane as a big bioenergy crop to invest in. 
(Respondent 8 20:24) 
 
We are a tropical country with a lot of sun and water and a lot of land 
available and a good temperature. So we need to invest in Agro industry. 
We need to invest in agriculture to improve our crop yield and we need to 
invest in for example, bioenergy and to try and develop all the needs from 
bioenergy crops and develop industries around this area. I think this is 
something we can do here, we have a competitive advantage. 
(Respondent 8 20:75) 
 
I think Brazilian is more focussed on natural resources, biodiversity and 
biofuels. Also if you see the agricultural side it is also based on the most 
important Brazilian products, there are more products and they do 
research on them because we are the biggest producer of oranges in the 
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world. The first genome programme was in oranges. (Respondent 7 19:49-
51) 
 
The innovation opportunities are in the areas of bioenergy; genomics; vaccines; 
antibiotics; and the use of indigenous knowledge and biodiversity. 
 
The government is trying to propose to the university, to researchers to 
work and try to solve the problems we have in Brazil. Because of the high 
cost in Brazil, the Federal government, several decades ago, set up the 
foundation for developing a vaccine in biopharmaceutical that they use on 
a large scale in Brazil. The big pharmaceutical companies, they are not 
going to produce for example products for controlling childhood disease, 
childhood disease is only for Africa and Latin America. 
Another big force is the potential of biodiversity; we have been exploring 
the potential biodiversity in Brazil. Personally we do have a lot of potential 
exploring biodiversity in Brazil, every time somebody uses a plant for 
curing a tumour and you go deeply, you find chemical principles involved 
in controlling tumours. One of the plants in Brazil now, there is already a 
product going to market for curing cancer, from one of the plants in Brazil. 
(Respondent 9 21:105) 
 
Develop and promote the sustainable use of Brazilian biodiversity with a 
view to economic and social development of the country, particularly for 
the competitiveness of Brazilian biomanufacturing, respecting the rights 
and obligations arising from activities access to genetic resources and 
associated traditional knowledge. (Documents Case 2 34:12) 
 
This characteristic of the bioentrepreneurial opportunities in Brazil means that it 
straddles the opportunity continuum between the developing and developed 
economies, with problem and efficiency opportunities aligning it to the characteristics 
of developing economies and innovation opportunities aligning it to the 
characteristics of developed economies. 
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8.2.4 Discovery 
 
According to the OECD (2009), the primary requirements for R&D to be effective 
include research universities, other research institutions, a developed scientific 
educational curriculum, a national culture that supports scientific endeavour, a 
favourable regulatory environment and talented individuals.  
 
So it is an easy equation, you know there is a certain demand and it is just 
a matter of doing it right, which is not necessarily easy. Especially with 
recombinant DNA molecules, doing it in the laboratory is one thing, 
expressing it into small scale; another thing is producing a product that will 
pass through all the clinical trials. (Respondent 6 18:85) 
 
R&D in Brazil is well supported and funded through the national and state 
government agencies; private sector initiatives; international collaboration; and large 
biotechnological companies. In spite of this, the R&D spend still falls below the 
OECD average and the respondents believed that more needs to be done to sustain 
the level of research intensity in the industry. However, there are initiatives by the 
government to increase the R&D spend (Bound, 2008). 
 
At 1% of GDP, R&D spending (both public and private) is comparatively 
low by OECD standards and is carried out predominantly by the 
government. (Documents Case 2 24:3) 
 
So unless there is like a full tax exemption for R&D in life science for 20 
years in Brazil, there is no way we can really build strong biotech/life 
science innovation industry, there is no way. (Respondent 6 18:44) 
 
The discovery of, or ability to act on (Shane, 2003), bioentrepreneurial opportunities 
is research-driven. This makes R&D in biotechnology entrepreneurship important. 
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8.2.5 Entrepreneurial exploitation 
 
The strategic alliance needed for effective exploitation of bioentrepreneurial 
opportunities includes the research institutions, venture capitalists, large 
organisations and government (Müller et al., 2004). 
 
So it is an alliance between my employer which is EMBRAPA and the 
companies. The companies will not do it themselves; they will count on the 
support of the governmental research agency. (Respondent 6 18:88) 
 
All these stakeholders are present in the biotechnology sector in Brazil and this has 
resulted in the successful exploitation of opportunities. 
 
He got support from the government national agency called FINEP that 
finances industrial development. Then he got money for doing the R&D 
work from FINEP. He got from our developing bank; he got financing to 
build an industrial park. He also got money from our National Research 
Council for doing the R&D work. (Respondent 9 21:31) 
 
Well, it is growing over the last five or six years it is growing, there is more 
and more money available, different organisations that are now putting 
money. 
I think money is not a problem in Brazil, venture capital, it is not a problem 
at all, the problem is how to get as much as possible, young pupils, 
students to get involved in this process, how to handle this problem of 
collaboration with the universities. (Respondent 8 20:61, 64) 
Then Votorantim Group created a branch dedicated to venture capital, and 
they created a company called Votorantim New Business. New business 
means investment in start-up companies involved in biotechnology and 
communication technology or information technology. (Respondent 8 20:8) 
 
The other roles the government plays in the strategic alliance are the provision of a 
favourable regulatory environment and facilitation (Ahn et al., 2012). In the case of 
Brazil, the government also acts as a buyer of the biotechnology products and 
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solutions. Among these government roles, the regulatory environment and 
bureaucratic processes were highlighted as gaps in the development of 
biotechnology entrepreneurship in Brazil.  
 
8.2.6 Execution 
 
Commercialisation of research is at the end of the value chain of biotechnology 
entrepreneurship (Gittelman, 1999; Feldman and Ronzio, 2001; Kettler and Casper, 
2001). The effective strategic alliance required for the exploitation of 
bioentrepreneurial opportunities ultimately results in the effective commercialisation 
of research (Ahn et al., 2010a; Ahn et al., 2010b; Ahn and York, 2011; Ahn et al., 
2012; Dunham et al., 2012). 
 
Then the company became important, not only nationally but 
internationally, and then we started receiving contracts with the big players 
in the agricultural biotechnology market. Then, in December 2008, our 
companies were bought by Monsanto. Monsanto is one of the largest 
agricultural biotechnology companies in the world. (Respondent 8 20:13-
15) 
 
All the research from industry came here to the laboratory at the University 
of Brasilia and it was good research and then they made it the first insulin 
produced worldwide. They produced the first commercially viable insulin in 
‘84 or ’85. (Respondent 9 21:25) 
 
The low number of challenges in the individual context, the environment of 
biotechnology entrepreneurship, research and development, and the exploitation of 
bioentrepreneurial opportunities in the earlier part of the value chain positively 
impacts on commercialisation of research in Brazil. However, the level of 
commercialisation of research in Brazil is still deemed to be below the level for the 
developed economies. 
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I think we still miss this scaling up of knowledge, we still miss that. 
(Respondent 6 18:86) 
 
Despite academic excellence in many niche areas, including photonics, 
materials science, biotechnology and tropical agriculture, other indicators 
point to the need for improvement, particularly in terms of converting 
knowledge into productivity gains in the business sector. (Documents 
Case 2 24:7) 
 
8.3 Similarities and differences between the process of biotechnology 
entrepreneurship in Brazil and the developed economies 
 
In order to understand how the process of biotechnology entrepreneurship in Brazil 
compares to the developed economies, the practical experiences reported in Section 
8.2 using the organising framework of the individual-opportunity nexus are compared 
to the literature on the process of biotechnology entrepreneurship in the developed 
economies. 
 
Table 8.5 summarises the key similarities and differences between the process of 
biotechnology entrepreneurship in Brazil and the developed economies as 
exemplified by the individual-opportunity nexus framework (Shane, 2003). 
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Table 8.5: Summary of key similarities and differences between the process of biotechnology entrepreneurship in Brazil 
and the developed economies 
Measure Literature on developed economies 
Insights from this research on 
Brazil 
Some supporting data from 
respondents 
Individual attributes 
 
 
Higher levels of non-psychological 
attributes measured by research output 
and patent applications in addition to 
psychological attributes. 
The bioscientists are supported by a 
system of other capabilities required for 
effective business management and 
commercialisation of research, which is 
often available within biotechnology and 
innovation parks. 
  
(Ahn and Meeks, 2007; Ahn et al., 2010a; Ahn 
et al., 2010b; Battelle/Biotechnology Industry 
Organisation, 2010; Ahn and York, 2011; Ahn 
et al., 2012; Dunham et al., 2012) 
Non-psychological and psychological 
attributes are thought to be on par with 
the developed economies at individual 
bioscientist level.  
 
However, the aggregate level of skills lags 
that of the developed economies hence 
the lower levels of research output and 
patent applications. 
 
The bioscientists in Brazil have the 
support system that provides other 
capabilities needed for effective business 
management and commercialisation of 
research. This makes them inclined to the 
“system” approach to biotechnology 
entrepreneurship.  
“We ran these companies for six-and-a-half 
years and we developed a lot of technologies. 
You know that biotechnology is heavily 
dependent on intellectual property. And this is 
the most important part of biotechnology 
because it takes a long time to have a product 
so you need to start at the beginning, having 
intellectual property and you create intellectual 
property, patent families in order to protect the 
technology that you are investing in.” 
(Respondent 8 20:11) 
 
“So I am a forest engineer by training in 
undergraduate and then I did my PHD in 
Genetics.” (Respondent 6 18:1) 
 
“My background is in Agronomic engineering, I 
am an Agronomist. Then I moved to the 
University of São Paulo where I did work with 
biochemists of a plant virus. Later I went to Ohio 
State in Columbus to get my PhD in 
enzymology, to work with enzymes 
I work mainly from fungus enzymes from the 
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Measure Literature on developed economies 
Insights from this research on 
Brazil 
Some supporting data from 
respondents 
Amazon basin, from hot spots in Brazil.” 
(Respondent 9 21:1) 
Environment 
 
Favourable economic, political and 
cultural factors.  
In addition the support structure, 
infrastructure and critical mass of input 
are all available in the environment of 
biotechnology entrepreneurship in the 
developed economies. 
 
(Lingelbach et al., 2005; Kelley et al., 2012; 
Urban, 2013) 
The environment of biotechnology 
entrepreneurship in Brazil has some 
challenges among which are unfavourable 
policy and regulatory environment; lack of 
aggregate skills and capacity; high cost of 
doing business; and bureaucracy. 
 
The funding for research is adequate and 
the government provides effective 
direction and leadership. 
“In my research laboratory in EMBRAPA, I buy 
equipment and reagents with tax exemptions 
because it is government, although it is not 
totally exempt, I still pay about 15% on top of the 
FOB cost of the equipment. If I am in a 
company, my tax cost on top of the FOB is about 
110%.” (Respondent 6 18:37) 
 
“And this is one of the most important problems 
related to technology transfer and development 
inside the universities here in Brazil, because all 
of them are state and public universities.” 
(Respondent 8 20:33) 
 
“But unfortunately I can say that there is this 
sense that academia is far removed from 
society, it is an elitist view of the universe, and 
this is very damaging I would say to the 
possibility of entrepreneurship.” (Respondent 6 
18:27) 
 
“For a patent to be analysed in Brazil, what I 
know from colleagues of mine that have 
submitted patents, it takes at least five to seven 
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Measure Literature on developed economies 
Insights from this research on 
Brazil 
Some supporting data from 
respondents 
years to get a patent analysed, not approved.” 
(Respondent 6 18:99) 
Entrepreneurial 
opportunities 
 
Prevalence of efficiency and innovation 
opportunities aimed at improving existing 
industrial processes or bringing new 
innovative products and solutions to the 
market; especially in the areas of 
pharmaceuticals, personalised medicine, 
cures for rare and lifestyle diseases, and 
industrial biotechnology.  
 
(Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry 
Organisation, 2010) 
Prevalence of efficiency and innovation 
opportunities aimed at improvement in 
agricultural yield; efficiencies in 
biomanufacturing; and innovation in 
bioenergy.   
 
There were problems identified but these 
were small in comparison to the efficiency 
and innovation opportunities. 
 
Biodiversity was deemed to be another 
key bioentrepreneurial opportunity in 
Brazil 
“Another competitive advantage of Brazil for the 
development of biotechnology is its remarkable 
biodiversity. There are about 200,000 species of 
plants, animals and microorganisms that have 
already been registered and it is estimated that 
this number could reach 1,800,000 species. It is 
almost a fifth of all global biodiversity distributed 
in six biomes (Amazon, Cerrado, Caatinga, 
Atlantic Forest, Pantanal and Pampa), plus the 
coastal and marine zone.” (Documents Case 2 
34:36) 
 
“We have areas where we are leading, this 
business of bioenergy.” (Respondent 8 20:80-
82) 
 
“Then they set up one of the first biotechnology 
centres in Brazil for bioplant and I was the R&D 
director in this bioplant and therefore I worked 
with a private business for several years trying to 
develop biotechnology applied to plant systems 
and we worked in different lines at that time.” 
(Respondent 9 21:3) 
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Measure Literature on developed economies 
Insights from this research on 
Brazil 
Some supporting data from 
respondents 
Opportunity 
discovery 
 
Intense R&D with a high level of R&D 
spend as a percentage of the GDP on the 
part of the government; and the presence 
of large companies that undertake major 
R&D activities. 
 
(Gastrow, 2008; Organisation for 
Economic Cooperation and Development, 
2009, 2013b, 2013c) 
The R&D spend and intensity are below 
the average for the developed economies 
and hence constitutes a gap. However, 
they are improving and there are large 
companies that undertake major R&D 
activities. 
 
“We have to have an incentive, like 
entrepreneurship is an area that is much 
incentivised in Brazil. We have an institution that 
is working exclusively on this in Brazil; it is called 
SEBRAE (Brazilian Service for Small Business).” 
(Respondent 7 19:55) 
 
“In 1998 we started a very big project on 
genomics and this project was financed by 
FAPESP, which is the research funding agency 
of the state of São Paulo.” (Respondent 8 20:4) 
Opportunity 
exploitation 
 
The necessary conditions required for 
effective exploitation of bioentrepreneurial 
opportunities are in place. These include 
an enabling regulatory environment, 
developed venture capital industry, large 
established companies, research 
institutions, government support and 
economies of scale. 
 
(Lingelbach et al., 2005; Phan et al., 
2008) 
 
Most of the necessary conditions required 
for effective exploitation of 
bioentrepreneurial opportunities are in 
place. These include developed a venture 
capital industry, large established 
companies, research institutions, and 
government support. 
 
 
“Then in 2002, we created a start-up company 
called Alellyx Applied Genomics, and we created 
this company with investment from the 
Votorantim Group, Votorantim is one of the large 
industrial corporations in Brazil.” (Respondent 8 
20:7) 
 
“In the last five years we have had a relatively 
large contract with the Brazilian government, so 
we are the reference laboratory for doing all the 
fingerprinting for all protected varieties of crop 
plants in Brazil.” (Respondent 6 18:9) 
 
“FINEP was a government funding institution 
that started a venture capital programme as well, 
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Measure Literature on developed economies 
Insights from this research on 
Brazil 
Some supporting data from 
respondents 
a very huge programme.  
And BNDES, the national bank of social 
development, that also now has a huge fund for 
biotechnology.” (Respondent 7 19:17-18) 
Execution Efficient because of the necessary 
technology transfer infrastructure being in 
place. In addition, the conditions for the 
earlier stages of the value chain such as 
environment, R&D and opportunity 
exploitation are favourable. 
 
(Lingelbach et al., 2005; Phan et al., 
2008; Nilsson et al., 2010a) 
Mostly efficient because of the necessary 
technology transfer infrastructure being in 
place. In addition, the conditions for the 
earlier stages of the value chain such as 
environment, R&D and opportunity 
exploitation are mostly favourable. 
 
“At the same time, the second company 
CanaVialis developed a huge sugar cane 
germoplast bank, and then started to make 
contracts with a sugar cane mill. In 2008, we had 
about 25% of the market contracted with our 
companies.” (Respondent 8 20:13) 
 
“They had to go through all the process of 
authorisation, doing all the red tape and then 10 
years later it was being marketed in Brazil. 
Producing 80% of the national needs for insulin 
and exporting the crystals to Europe and 
Russia.” (Respondent 9 21:28) 
 
“So either you sell the company to a bigger 
stakeholder or you license it, which is right, there 
is nothing wrong.” (Respondent 9 21:70) 
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From the comparisons in Table 8.5, it can be concluded that: 
 
i. The psychological and non-psychological attributes of the bioentrepreneurs in 
Brazil are similar to those of the bioentrepreneurs in the developed 
economies. The differences in skills and capacity are at an aggregate level 
rather than an individual level 
ii. There are similarities and differences in the environment of biotechnology 
entrepreneurship between Brazil and the developed economies. While the 
environment in the developed economies can be summed up as favourable 
across many dimensions the environment in Brazil can be summed up as 
mostly favourable, and unfavourable across few dimensions 
iii. The bioentrepreneurial opportunities in Brazil are similar to those of the 
developed economies, being predominantly efficiency and innovation 
opportunities. The bioentrepreneurial opportunities are designated as mostly 
efficiency opportunities, followed by innovation opportunities and a very small 
component of problem opportunities. The developed economies exhibit a 
slightly different trend, leading with innovation opportunities, efficiency 
opportunities, and problem opportunities related to human health. Brazil also 
has opportunities associated with biodiversity, which category is not present in 
the developed economies 
iv. The process of opportunity discovery in biotechnology is through R&D. This 
process in Brazil is different from the developed economies in terms of R&D 
spend, and the intensity of R&D but better than most developing economies 
v. Opportunity exploitation in Brazil is mostly efficient due to the availability of 
key stakeholders required at this stage of the biotechnology value chain, such 
as venture capitalists and large biotechnology companies. This process in the 
developed economies has all the necessary conditions and hence is effective 
vi. Execution or commercialisation of research goes through the same process of 
firm formation or licensing in Brazil as it does in the developed economies. In 
addition, the “system” approach to biotechnology entrepreneurship is similar 
to the approach as adopted in the developed economies. 
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Although Brazil has been recognised for its leadership position in some areas of 
biotechnology, the result of the efficiencies in the developed economies is that the 
output of biotechnology entrepreneurship is much more rapid, visible and at a much 
higher scale in these economies than it is in Brazil (Biotechnology Industry 
Organisation, 2008; Gastrow, 2008; Organisation for Economic Cooperation and 
Development, 2009; Battelle/Biotechnology Industry Organisation, 2012; 
Organisation for Economic Cooperation and Development, 2013b, 2013c). 
 
8.4 The nature of the relationship across the university, industry, and 
government 
 
The relevance of the interactions among the university, industry and government, in 
transforming academic research into societal and economic capital, is evidently 
demonstrated in the field of biotechnology (Liebeskind et al., 1996; Agrawal, 2001; 
Müller et al., 2004; Rothaermel and Deeds, 2004; Powell et al., 2005; Ahn and 
Meeks, 2007; Sytch and Bubenzer, 2008). The collaboration among these three 
stakeholders (Etzkowitz and Leydesdorff, 1997; Leydesdorff and Etzkowitz, 1998, 
2001) has recently been considered to involve a fourth stakeholder (Afonso et al., 
2010; Marcovich and Shinn, 2011; Afonso et al., 2012; Leydesdorff, 2012). The 
quadruple helix is context-specific and in the case of Brazil the socio-economic 
linkages may point to the possibility of the fourth stakeholder being the society.  
 
Article 2 shall put in place the process of communication and participation 
for the Brazilian society.  
Article 3 should ensure that biotechnology and economic and 
technological cooperation are accessible to the whole society, to ensure 
added value to products and promote social inclusion and quality of life 
throughout the production process. (Documents Case 2 34:14-15) 
 
The triple helix relationship across the university, industry and government in Brazil 
functions effectively. Although the respondents believe that there is room for 
improvement, there have been collaborative projects in Brazil that are internationally 
acclaimed, such as the genome projects. 
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A growing scientific community has allowed for the development of 
collaborative research programmes that require a large number of 
researchers. Recent experience in this area is promising and has the 
potential for engaging the business sector in commercially-oriented 
research. For example, the Genome Project, set up in São Paulo in 
partnership with the Citrus Producers Association (Fundecitrus), resulted 
in the DNA sequencing of a phyto-pathogenic bacterium, the Xylella 
Fastidiosa, which allowed Fundecitrus researchers to devise ways to 
protect orange trees from a disease (citrus variegated chlorosis, CVC) that 
had been associated with considerable economic loss in the past. The 
joint venture also generated at least two spin-off companies in the field of 
genomics and bioinformatics. Another example is the Biota Research 
Programme, a conservation and sustainable development-oriented 
biodiversity research effort to study and map biodiversity in the state of 
São Paulo. (Documents Case 2 25:24) 
 
Government leadership has also prioritised the collaboration between the 
stakeholders to the extent that this has been fairly institutionalised in the industry and 
has become the way of doing business. The effectiveness of this collaboration in 
Brazil has helped the country become a leader in bioenergy. 
 
Since the beginning we said we have to establish a relationship with 
industry, otherwise we are doing biotechnology fiction. I went to the 
minister of Science and Technology and almost forced them to invest in 
this agreement between industry, academia and government.  
(Respondent 9 21:11-12) 
 
Also I think other important landmarks are the genomics in Brazil, you 
know this story as well. This is São Paulo’s part because São Paulo was 
the leader in this process, all the genomic research was done by networks 
in Brazil and this trained a lot of scientists in doing this because you 
cannot do this in small laboratories, you have to do it in huge laboratories, 
so it was a process of learning. (Respondent 7 19:29) 
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The respondents in Brazil have a very positive view of the collaboration among the 
university, industry and government. This collaboration has resulted in some major 
collaborative projects and outcomes that exploit the efficiency and innovation 
opportunities. 
 
I had a very interesting and rewarding experience when I set up what we 
called the Genolyptus project, which was a Brazilian network of Eucalyptus 
genome research. I started this project in 2001 and it went on for seven 
years and it is actually still going on but in a different format. We got 
matching funds from industry, from a pool of industries, pulp and paper 
and energy industry that plant forests. The government put some money 
and we developed a long and complex project to develop some genomic 
resources, some experimental resources, some field experiments and also 
to enhance the understanding of this interaction of genomics into plant 
breeding for trees. (Respondent 6 18:59) 
 
Government controls the relationship with the university and the industry, from a 
policy, regulation, and funding point of view. It is very apparent that the triple helix 
relation in Brazil is a hybrid of what is described by Etzkowitz and Leydesdorff (2000) 
as triple helix I, which represents a configuration in which the government 
encompasses both industry and university and directs the interaction and relations 
between them and triple helix III, in which overlapping institutional spheres generate 
a knowledge infrastructure, with overlapping roles and hybrid organisations emerging 
at the interfaces. This configuration aims to create an innovation environment that 
supports knowledge-based economic development in which collaborations and 
alliances are aimed at creating, reinforcing and sustaining the knowledge 
infrastructure (Etzkowitz and Leydesdorff, 2000) without direct control by any of the 
institutions.  
 
The unique dynamic in Brazil is that triple helix III characteristics are exhibited but 
with a direct control from the government, which is a characteristic of triple helix I. 
With every indication of a continued government control, improvement of the 
environment in which triple helix III flourishes, and strong social linkages, it is 
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possible that the evolution of the triple helix in Brazil will go the route of a “Quadruple 
Helix of government-controlled university, industry, society relations”.  
 
8.5 Summary of within-case analysis of Brazil 
 
Biotechnology entrepreneurship in Brazil is conducted by bioscientists who have the 
necessary research and scientific skills to carry out biotechnological R&D. The 
availability of infrastructure and support structures, which provides the 
entrepreneurial and commercialisation skills, enables the bioscientists to employ the 
system approach to biotechnology entrepreneurship.  
 
Biotechnology entrepreneurship in Brazil faces certain challenges across the 
economic, political and cultural environments in which it operates (Shane, 2003). 
Key among these are unfavourable policy and regulatory environment; lack of 
aggregate skills and capacity; and bureaucratic and inefficient government 
processes. 
 
On the other hand, there were noted positives in the environment of biotechnology 
entrepreneurship in Brazil, such as the availability of appropriate funding, 
government-incentivised entrepreneurial activities, availability of large established 
biotechnology companies, availability of venture capital companies and effective 
collaboration among the key stakeholders. 
 
The bioentrepreneurial opportunities were identified predominantly in the area of 
efficiency opportunities, followed by innovation opportunities and a small instance of 
problem opportunities. In addition, abundant biodiversity is seen as a competitive 
source of bioentrepreneurial opportunities in Brazil. 
 
The discovery of these bioentrepreneurial opportunities requires R&D. The R&D 
intensity and spend in Brazil are deemed to be adequate and are being improved by 
the government and the private sector. However, they are below the levels of the 
developed economies. 
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The exploitation of these bioentrepreneurial opportunities requires a strategic 
alliance of research institutions, venture capitalists, large established biotechnology 
companies and government. This process in Brazil employs all the key stakeholders: 
venture capitalists, research institutions, government and large established 
biotechnology companies. This is similar to the process of exploiting 
bioentrepreneurial opportunities in the developed economies. 
 
The execution step of the process of biotechnology entrepreneurship involves the 
commercialisation of research. The commercialisation of research in Brazil utilises 
both firm formation and licensing and is deemed to be efficient due to the efficiencies 
in the earlier parts of the biotechnology value chain and the availability of the system 
to enable the commercialisation of research. A diagrammatic representation of the 
process of biotechnology entrepreneurship, as experienced by the respondents in 
Brazil, is shown in Figure 8.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7: A graphical depiction of the process of biotechnology 
entrepreneurship in Brazil 
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The direction of the arrows in Figure 8.7 shows that the individual attributes, the 
bioentrepreneurial opportunities and the environment are deemed to affect all the 
stages of biotechnology entrepreneurship, from R&D, to entrepreneurial exploitation 
and commercialisation of research. While this does not prove causality, the 
importance of the individual attributes, entrepreneurial opportunities and the 
environment to entrepreneurship is supported by previous studies (Liebeskind et al., 
1996; Audretsch and Stephan, 1998; Agrawal, 2001; Shane, 2003; Müller et al., 
2004; Rothaermel and Deeds, 2004; Powell et al., 2005; Ahn and Meeks, 2007; 
Sytch and Bubenzer, 2008).  
 
This research extends this knowledge by clearly identifying the type of 
bioentrepreneurial opportunities that are predominant in the biotechnology industry 
of Brazil the environmental conditions under which the process of exploiting these 
opportunities takes place and the individual attributes that are used in carrying out 
this process in Brazil. 
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PART IV: CROSS-CASE ANALYSIS, DISCUSSION AND THEORY 
DEVELOPMENT 
 
Part IV consists of Chapter 9. 
 
Chapter 9 presents a cross-case analysis of South Africa and Brazil, a discussion of 
the results of the analysis, and theory development. 
 
The sub-sections include: 
 
i. Patterns identified from within-case analysis of South Africa and Brazil 
ii. Themes identified from the patterns 
iii. The proposed theoretical framework of biotechnology entrepreneurship 
iv. Summary of the cross-case analysis of South Africa and Brazil  
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Chapter 9: Cross-Case Analysis  
 
The cross-case analysis is an aggregate view (Stake, 2006) of the research on the 
dynamics of biotechnology entrepreneurship in South Africa and Brazil. The patterns 
that emerged from the peculiarities of the individual case studies are aggregated to 
themes and contrasted with the literature on biotechnology entrepreneurship to 
enable an accurate interpretation towards developing theory.  
 
 
9.1 Patterns identified from within-case analyses of South Africa and 
Brazil 
 
The patterns identified from the within-case analyses of South Africa and Brazil are 
presented in Table 9.1 below. 
 
Table 9.1: Patterns from within-case analyses of South Africa and Brazil 
Emerging 
themes 
Patterns in South Africa Patterns in Brazil 
Individual versus 
system approach 
Owing to lack of adequate 
support system to provide the 
entrepreneurial and 
commercialisation skills 
needed to commercialise their 
research, these bioscientists 
are often forced to acquire 
entrepreneurial and 
commercialisation skills to 
commercialise their research 
effectively. Consequently, their 
practice of biotechnology 
entrepreneurship is as 
individuals 
The availability of infrastructure 
and support structures, which 
provides the entrepreneurial 
and commercialisation skills, 
enables the bioscientists to 
employ the system approach 
to biotechnology 
entrepreneurship 
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Emerging 
themes 
Patterns in South Africa Patterns in Brazil 
Collaboration 
Most of the respondents 
believe that there is a lack of 
collaboration among key 
stakeholders in biotechnology 
entrepreneurship in South 
Africa. Although most of the 
respondents experience 
evidence of collaboration with 
key stakeholders, they agree 
that a need exists for effective 
collaboration among key 
stakeholders 
There is collaboration among 
the key stakeholders and this 
collaboration is acknowledged 
to be important to the effective 
development of biotechnology 
entrepreneurship in Brazil 
The role of 
government  
The lack of direction from the 
government, through its 
implementation agencies, is 
consistently deemed to be a 
constraint by most of the 
respondents and the activities 
deemed to be hindering the 
development of the 
biotechnology industry 
The government plays an 
important role in incentivising 
bioentrepreneurial activities in 
Brazil 
Regulation  
The regulatory environment is 
consistently deemed to be a 
constraint by most of the 
respondents 
The regulatory environment for 
biotechnology 
entrepreneurship in Brazil is 
deemed to be unfavourable 
Funding 
The lack of appropriate 
funding is consistently deemed 
to be a constraint by most of 
the respondents 
There is availability of 
appropriate funding for the 
development of biotechnology 
entrepreneurship in Brazil 
Markets for 
biotechnology 
The lack of developed markets 
for biotechnology products is 
The local market for 
biotechnology products is 
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Emerging 
themes 
Patterns in South Africa Patterns in Brazil 
products consistently deemed to be a 
constraint by most of the 
respondents 
considered developed 
The skills required 
for biotechnology 
entrepreneurship  
Although most of the 
respondents believe that the 
scientific and research skills 
needed for biotechnology 
entrepreneurship are available 
in South Africa, they also 
deem the entrepreneurial and 
commercialisation skills to be 
lacking 
 
There is an availability of the 
research and scientific skills 
necessary for the development 
of biotechnology 
entrepreneurship. The 
entrepreneurial and 
commercialisation skills are 
available through the system of 
biotechnology 
entrepreneurship in Brazil 
Nature of 
bioentrepreneurial 
opportunities 
The bioentrepreneurial 
opportunities were identified 
predominantly in the area of 
problem opportunities, 
followed by efficiency 
opportunities and a small 
instance of innovation 
opportunities 
The bioentrepreneurial 
opportunities were identified 
predominantly in the area of 
efficiency opportunities, 
followed by innovation 
opportunities and a small 
instance of problem 
opportunities 
Biodiversity 
The abundance of biodiversity 
is deemed to be a positive 
factor by most of the 
respondents in the 
development of biotechnology 
entrepreneurship in South 
Africa 
The abundant biodiversity 
constitutes a source of 
competitive advantage for the 
development of the 
biotechnology industry in Brazil 
R&D is the 
defining step in 
biotechnology 
The discovery of these 
bioentrepreneurial 
opportunities requires R&D. 
The intensity and the R&D 
spend in Brazil are deemed to 
be adequate and are being 
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Emerging 
themes 
Patterns in South Africa Patterns in Brazil 
entrepreneurship 
in South Africa 
and Brazil 
 
The intensity and the R&D 
spend in South Africa are 
deemed to be below the levels 
of the developed economies 
improved by the government 
and the private sector. 
However, they are below the 
levels of the developed 
economies 
Exploitation of 
bioentrepreneurial 
opportunities 
effected through 
collaboration 
The exploitation of these 
bioentrepreneurial 
opportunities requires a 
strategic alliance of research 
institutions, venture capitalists, 
large established 
biotechnology companies, and 
government. This process in 
South Africa lacks the key 
stakeholders: venture 
capitalists and large 
established biotechnology 
companies 
This process in Brazil has all 
the key stakeholders: venture 
capitalists, research 
institutions, government and 
large established 
biotechnology companies 
Commercialisation 
of research is 
determined by the 
dynamics of the 
earlier steps in the 
process of 
biotechnology 
entrepreneurship 
The commercialisation of 
research in South Africa 
utilises both firm formation and 
licensing and is deemed to be 
inefficient due to a lack of 
entrepreneurial and 
commercialisation skills 
The commercialisation of 
research in Brazil utilises both 
firm formation and licensing 
and is deemed to be efficient 
due to the efficiencies in the 
earlier parts of the 
biotechnology value chain, and 
the availability of the system to 
enable the commercialisation 
of research 
Country 
competitiveness 
The emphasis on country 
competitiveness is consistently 
deemed by most of the 
Global competitiveness is a 
key factor in the approach to 
biotechnology 
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Emerging 
themes 
Patterns in South Africa Patterns in Brazil 
respondents to be an 
important consideration for 
biotechnology 
entrepreneurship in South 
Africa 
entrepreneurship in Brazil 
Environment of 
biotechnology 
entrepreneurship 
The general environment for 
the development of 
biotechnology 
entrepreneurship in South 
Africa is deemed by most of 
the respondents to be 
unfavourable 
There is an overall conducive 
environment for the 
development of biotechnology 
entrepreneurship in Brazil 
 
Most of the respondents agree 
that there is a misalignment 
between the requirements for 
being an academic and being 
an entrepreneur. In addition, 
the university culture is 
deemed to be mostly prioritise 
publication over 
commercialisation 
 
 
 
The venture capital industry is 
consistently deemed to be 
underdeveloped in South 
Africa 
 
 
 The high cost of funding in 
Brazil constrains the 
development of the 
biotechnology industry 
  The universities in Brazil are 
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Emerging 
themes 
Patterns in South Africa Patterns in Brazil 
good at conducting the 
necessary research required 
for the development of 
biotechnology 
entrepreneurship in Brazil 
 
 The politicians do not have a 
full understanding of the 
requirements of the 
biotechnology industry 
 
 The aggregate capacity for 
innovation needs to be 
improved 
 
 The inefficiencies of the 
government and its agencies 
affect the effectiveness of the 
development of biotechnology 
entrepreneurship in Brazil 
 
 
The patterns that emerged from the within case analyses of South Africa and Brazil 
(see Table 9.1) resulted in 14 areas of alignment between South Africa and Brazil, 
from which the emerging themes were derived. The patterns referred to the same 
concept but not necessarily with the same experience or outcome. Hence, there 
were instances of positive versus negative experiences across the patterns.  
 
The patterns that were a function of the other patterns; and the patterns that 
appeared in only one of the cases were not considered for inclusion as themes.  
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9.2 Themes identified from the patterns 
 
Based on the patterns identified from the within-case analyses of South Africa and 
Brazil the following themes were derived. 
 
1. There is a dual approach to the practice of biotechnology entrepreneurship, 
which can be seen as a “system” or as an “individual” 
2. Biotechnology opportunities occur in the form of problem, efficiency, and 
innovation opportunities 
3. Regulation is a critical factor in biotechnology entrepreneurship in South 
Africa and Brazil 
4. An overall conducive environment is necessary for the effective development 
of biotechnology entrepreneurship in South Africa and Brazil 
5. R&D is the defining step in biotechnology entrepreneurship in South Africa 
and Brazil 
6. There are four types of skills required in biotechnology entrepreneurship in 
South Africa and Brazil: research, scientific, entrepreneurial and 
commercialisation skills 
7. Effective collaboration among key stakeholders is important to the 
development of biotechnology entrepreneurship in South Africa and Brazil 
8. The government plays an important role in biotechnology entrepreneurship in 
South Africa and Brazil 
9. Funding is a critical factor in biotechnology entrepreneurship in South Africa 
and Brazil 
10. The local market for biotechnology products is a critical factor in 
biotechnology entrepreneurship in South Africa and Brazil 
 
The details of these cross-case themes are discussed in the following sub-sections. 
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9.2.1 Theme 1  
 
“There is a dual approach to the practice of biotechnology entrepreneurship, which 
can be seen as a ‘system’ or as an ‘individual’” 
 
 
Meaning of theme 1 in the context of this research 
 
The system approach to biotechnology entrepreneurship is applicable when the skills 
and capabilities required for effective commercialisation of research do not rest in a 
single individual. The individual bioscientist brings to the process the scientific and 
research skills; and the other stakeholders bring entrepreneurial and 
commercialisation capabilities, and other support structures. The effective 
collaboration between the bioscientist and the other stakeholders results in a system 
of biotechnology entrepreneurship that has all the necessary requirements for the 
effective commercialisation of research. 
 
The individual approach to biotechnology entrepreneurship is applicable when the 
skills and capabilities required for effective commercialisation of research rest in a 
single individual. In addition to having the scientific and research skills, the individual 
is required to have the necessary entrepreneurial and commercialisation capabilities. 
In this approach the other support structures may or may not be available in which 
case it may be the responsibility of the individual to provide the support structures. 
This approach leaves little room for collaboration, encourages competition, and is 
similar to the role of the individual entrepreneur in general entrepreneurship.  
 
Biotechnology as an industrial activity is still very highly research-
dependent. Often the organisation that generates an idea does not have 
all the skills necessary to take that idea to eventual product roll-out. This is 
one reason why clustering became an important feature of the 
development of biotechnology. (Documents Cross-Case 30:35) 
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Manifestation of theme 1 in South Africa and Brazil 
 
The manifestation of theme 1 resulted in dual approaches to the process of 
biotechnology entrepreneurship in South Africa and Brazil. With the availability of 
infrastructure and support structures, as experienced by the respondents in Brazil, 
the “system” approach to biotechnology entrepreneurship was adopted. On the other 
hand, the lack of infrastructure and support structures, as experienced by the 
respondents in South Africa, manifested in the adoption of the “individual” approach 
to biotechnology entrepreneurship.  
 
In the “system” approach to biotechnology entrepreneurship, a bioscientist may not 
necessarily need to acquire the entrepreneurial and business management skills 
necessary to manage the commercialisation of research successfully. The “system” 
delivers the entrepreneurial and commercialisation resources required for effectively 
carrying out biotechnology entrepreneurship, through the government, venture 
capitalists, large biotechnology companies, or a combination of these.  
 
This form of biotechnology entrepreneurship is manifested in Brazil through the 
commercialisation of research that involved the provision of the entrepreneurial and 
commercialisation resources by large biotechnology companies and government.  
 
Then in 2002, we created a start-up company called Alellyx Applied 
Genomics, and we created this company with investment from the 
Votorantim Group, Votorantim is one of the large industrial corporations in 
Brazil. (Respondent 8 20:7) 
 
This is further manifested in the availability of incubators and technology parks 
and the effective collaboration that provides the other support structures needed 
for the effective commercialisation of research. 
 
A majority of Brazil’s incubators and technology parks are affiliated with 
institutions of higher education. In 2003, there were 207 incubators and 10 
technology parks operating in Brazil. Of the 207 incubators, 107 were 
technology-based, and of those 80% had formal ties with universities. All 
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ten of the technology parks had formal and informal ties with universities. 
(Documents Case 2 33:27) 
 
The bioscientists who participated in this research in Brazil did not need to go 
through formal training to acquire the entrepreneurial and commercialisation skills 
necessary for the commercialisation of their research. The system delivered this 
capability and they were up-skilled in commercialisation through practical experience 
(Respondent 6 18:11; Respondent 8 20:28-29). 
 
 
The “individual” approach entails bioscientists acquiring the entrepreneurial and 
commercialisation skills that enable them to manage the commercialisation of 
research successfully (Respondent 5 5:12-13; Respondent 11 6:7; Respondent 11 
6:22). This form of biotechnology entrepreneurship develops as a result of the lack of 
the support structures and infrastructure to provide the entrepreneurial and 
commercialising resources.   
 
This form of biotechnology entrepreneurship is manifested in South Africa due to the 
lack of a developed venture capital industry, the large established biotechnology 
companies and other critical infrastructure and support structures. The bioscientists 
acquire the necessary entrepreneurial and commercialisation skills through formal 
training and approach the process in their individual capacity as is often the case in 
general entrepreneurship. 
 
I imported some products, so I acquired some market share and 
generated some cash and used that cash to set up my own manufacturing 
facility. (Respondent 11 6:10) 
 
The bioscientists who participated in this research in South Africa needed formal 
training in business management to acquire the entrepreneurial and 
commercialisation skills needed for effective commercialisation of their research. 
This training took the form of a Master of Business Administration (MBA) 
(Respondent 5 5:12-13); Management Advancement Programme (MAP) 
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(Respondent 11 6:7); and entrepreneurial skills development programme run by 
some of the stakeholders and sponsored by the government (Respondent 12 7:7-9). 
 
Comparison with the literature 
 
The literature on general entrepreneurship recognises the role of the individual in the 
process of entrepreneurship in developed and developing economies. The 
psychological attributes necessary for the individual to function effectively as an 
entrepreneur include higher levels of cognitive functioning, motivation, leadership 
qualities, propensity to take risk, action-orientation, self-efficacy, preference for 
autonomy, self-direction, and differential access to scarce and expensive resources 
(Shane and Venkataraman, 2000; Eckhardt and Shane, 2003; Shane, 2003). 
 
In addition to the psychological attributes, the requisite non-psychological factors 
such as education and career experience (Barro and Lee, 2000) are necessary for 
biotechnology entrepreneurship.  
 
Studies also recognise the role of the environment or “external forces” (Tushman 
and Anderson, 1986; Hannan and Freeman, 1987; Ács and Audretsch, 2003) in the 
process of entrepreneurship in developed and developing economies. In addition, 
the process of biotechnology entrepreneurship in the developed economies has ben 
een to be driven primarily through collaboration of stakeholders (Müller et al., 2004;), 
which is similar to having a system of biotechnology entrepreneurship.  
 
The literature on the determinants for researchers’ choice to engage in 
commercialisation (Nilsson et al., 2010a) highlights four factors: the perceived role of 
the university, supportive infrastructure, industrial actor set-up, and networks. The 
details of these factors include the university culture, university infrastructure such as 
the TTO, national infrastructure for commercialisation of research, large companies 
that have receiver capabilities, and collaboration among key stakeholders. 
 
A third component of the literature is the addition of the role of entrepreneurial 
opportunities (Shane and Venkataraman, 2000). The integration of the individual, 
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environmental and entrepreneurial opportunities (Cunningham and Lischeron, 1991; 
Shane and Venkataraman, 2000) in exploring the dynamics of biotechnology 
entrepreneurship has the prospect of providing an in-depth understanding of the key 
aspects of biotechnology entrepreneurship in South Africa and Brazil. This informed 
the decision to use the individual-opportunity nexus framework of entrepreneurship 
(Shane, 2003) as an organising framework for this research. 
 
This research confirms and extends the existing literature in a number of ways. 
There was a confirmation of the importance of the roles played by the individual and 
the environment. The psychological and non-psychological individual attributes are 
critical to the success of biotechnology entrepreneurship in South Africa and Brazil. 
Similarly, the environment in which biotechnology entrepreneurship is conducted 
constitutes the biggest difference between the developing and developed 
economies; and within the cases in this study the environment of biotechnology 
entrepreneurship constitutes the biggest difference between South Africa and Brazil. 
 
The existing literature was extended by articulating the impact of the environment on 
the approach to biotechnology entrepreneurship in South Africa and Brazil. The 
individual and system approaches, applicable to South Africa and Brazil respectively, 
showed that different approaches are employed in different contexts based on the 
environmental dynamics of each context.  
 
9.2.2 Theme 2  
 
“Biotechnology opportunities occur in the form of problem, efficiency, and innovation 
opportunities” 
 
Meaning of theme 2 in the context of this research 
 
Bioentrepreneurial opportunities pre-exist and do not require the special 
psychological attributes possessed by a few individuals to be discovered. However, 
these opportunities require R&D to be exploited.  
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For all of these examples, the problems that need to be solved are known 
in advance. These include the problem diseases, the types of crop traits 
that would improve agricultural output, and the types of industrial products 
that can be replaced with biomass. In addition, the size of the potential 
market for products such as biofuels or anti-cancer drugs can be 
estimated with a reasonable degree of accuracy. (Documents Cross-Case 
31:25) 
 
Bioentrepreneurial opportunities take the form of “problem opportunities”, in which 
problems related to diseases, human health, food security, the environment and 
energy create bioentrepreneurial opportunities; “efficiency opportunities”, in which 
new means of improving existing products and services, such as bioprocessing and 
biomanufacturing, are created; and “innovation opportunities”, in which new 
innovative products and services, not previously in existence, are created. 
 
 
Manifestation of theme 2 in South Africa and Brazil 
 
Most of the respondents in South Africa see bioentrepreneurial opportunities in the 
areas of biodiversity and problems related to diseases and food security. These 
types of opportunities, linked to problems of diseases, food security, the environment 
and energy are designated as “problem opportunities” (researcher’s synthesis). 
 
The biodiversity highlighted by the respondents falls within the second category of 
opportunities. The second form of bioentrepreneurial opportunities identified by the 
respondents is designated as “efficiency opportunities”, which mostly occur in the 
areas of bioprocessing and biomanufacturing. While the efficiency opportunities may 
not be as ubiquitous as problem opportunities in case 1 due to the low level of 
industrialisation, the realised efficiencies do provide the opportunity to solve some of 
the problems of food security and environmental sustainability, and create healthier 
populations and energy sufficiency (Biotechnology Industry Organisation, 2008). 
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There are few instances in South Africa where the exploitation of the “problem 
opportunities” has led to “efficiency and innovation opportunities”. The innovation 
opportunities are minimal in South Africa and were not mentioned by most of the 
respondents, as the emphasis was on the problem opportunities, followed by the 
efficiency opportunities (Respondent 15 10:45-46, 48). The manifestation of problem 
and efficiency opportunities was highlighted by the respondents in South Africa 
(Respondent 1 1:86; Respondent 3 3:73; Respondent 12 7:31-34). Hence, 
bioentrepreneurial opportunities in South Africa take the form of “problem 
opportunities” and “efficiency opportunities”. 
 
In Brazil, the bioentrepreneurial opportunities are mostly aligned to efficiency and 
innovation opportunities and a component of problem opportunities (Respondent 6 
18:74-79). 
 
The efficiency opportunities are manifested mostly in the areas of biodiversity; 
bioenergy; genomics; pharmaceuticals; bioprocessing and biomanufacturing. The 
realised efficiencies do provide the opportunity to solve some of the problems of food 
security and environmental sustainability, and achieve healthier populations and 
energy conservation (Respondent 10 22:2; Documents Case 2 34:36; Respondent 8 
20:24; Respondent 8 20:75; Respondent 7 19:49-51). 
 
Another competitive advantage of Brazil for the development of 
biotechnology is its remarkable biodiversity. There are about 200,000 
species of plants, animals and microorganisms that have already been 
registered and it is estimated that this number could reach 1,800,000 
species. It is almost a fifth of all global biodiversity distributed in six biomes 
(Amazon, Cerrado, Caatinga, Atlantic Forest, Pantanal and Pampa), plus 
the coastal and marine zone. (Documents Case 2 34:36) 
 
The innovation opportunities are manifested in the areas of bioenergy; genomics; 
vaccines; antibiotics; and the use of indigenous knowledge and biodiversity 
(Respondent 9 21:105; Documents Case 2 34:12). 
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The nature of the bioentrepreneurial opportunities in Brazil means that it straddles 
the opportunity continuum between the developing and developed economies, with 
problem and efficiency opportunities aligning it to the characteristics of developing 
economies; and innovation opportunities aligning it to the characteristics of 
developed economies. Hence, the different types of bioentrepreneurial opportunities 
are designated as problem, efficiency, and innovation opportunities (researcher’s 
synthesis). 
 
Comparison with the literature 
 
The entrepreneurial opportunities in biotechnology seem to be different from the 
entrepreneurial opportunities in general entrepreneurship in some key aspects. 
While general entrepreneurial opportunities are not known in advance and require 
enterprising individuals with special psychological attributes (McClelland, 1961; 
Kihlstrom and Laffont, 1979; Schere, 1982; Gartner, 1990) to uncover them 
bioentrepreneurial opportunities are mostly known in advance and require 
bioscientific skills to obtain a solution (Müller et al., 2004). 
 
The discovery of general entrepreneurial opportunities requires the individual 
entrepreneur to apply their business management capability towards profit making or 
other forms of positive outcome (Shane, 2003). However, the discovery of 
bioentrepreneurial opportunities involves a process of R&D to get to the desired 
outcome, and is more of a “creation” (Audretsch et. al, 2008) than a “discovery” 
(Alvarez and Barney, 2007). 
 
The exploitation of general entrepreneurial opportunities is also mostly dependent on 
the individual entrepreneurs and their organising abilities (Shane, 2003). However, 
the exploitation of bioentrepreneurial opportunities mostly requires a strategic 
alliance involving government, large established companies, venture capitalists, and 
research institutions (Liebeskind et al., 1996; Audretsch and Stephan, 1998; 
Agrawal, 2001; Shane, 2003; Müller et al., 2004; Rothaermel and Deeds, 2004; 
Powell et al., 2005; Ahn and Meeks, 2007; Sytch and Bubenzer, 2008).  
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This research extends the existing literature by providing a differentiation of the types 
of bioentrepreneurial opportunities that exist in South Africa and Brazil. By 
comparison to existing literature, the three types of bioentrepreneurial opportunities 
that form a continuum of opportunities in the developed and developing economies 
are problem, efficiency, and innovation opportunities. These types of opportunities 
are linked to the needs and priorities of the different contexts.  
 
9.2.3 Theme 3 
 
"Regulation is a critical factor in biotechnology entrepreneurship in South Africa and 
Brazil” 
 
Meaning of theme 3 in the context of this research 
 
The regulatory environment of biotechnology entrepreneurship in South Africa and 
Brazil includes specific policies that impact on biotechnology entrepreneurship such 
as the national bio-economy strategy of South Africa; the national biotechnology 
development policy of Brazil; the intellectual property policy; policies related to R&D 
activities; policies that govern public universities and research institutions; innovation 
policies; technology transfer policies; policies related to immigration of foreign skills; 
labour laws; policies related to ethics in biotechnology; and taxation laws related to 
research. 
 
The regulatory environment affects innovation in many ways. It influences 
the size and behaviour of firms, as well as input and output markets. The 
government plays an important role in setting standards and decreasing 
administrative burden. Regulations aim to respond to market failures and 
improve welfare. Regulations are inherently linked to reducing risks for 
economic agents and the environment, while innovation is about taking 
risks. To balance risk and innovation, governments should promote 
innovation through market incentives and goal-based approaches when 
developing good regulation. (Documents Cross-Case 29:29) 
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The development and implementation of these policies and regulations by the 
government impact on the degree of effectiveness of biotechnology entrepreneurship 
in South Africa and Brazil. 
 
Manifestation of theme 3 in South Africa and Brazil 
 
The regulatory environment of biotechnology entrepreneurship in South Africa was 
deemed to be non-conducive for biotechnology entrepreneurship by the respondents 
(Respondent 13 8:18; Respondent 12 7:24-25). This regulatory challenge was also 
recognised in the new bio-economy strategy to be implemented by the government 
of South Africa (Documents Case 1 14:68). 
 
A lack of delivery of biotechnology strategy largely hinges, not entirely, but 
largely hinges on the policy environment. They are contradictory and 
unaligned challenging policy regulatory environment. So there are lots of 
things that need to be sorted out, and it's one of the things we hope to 
address through the bio-economy strategy. (Respondent 1 1:77) 
 
Similarly, the experience of challenges with the regulatory environment for 
biotechnology entrepreneurship in Brazil was unanimous across all the transcripts. 
The specific areas that were highlighted as challenges are policies related to 
intellectual property ownership; policies related to technology transfer from the 
university to the industry; taxation laws; and labour laws (Respondent 8 20:30,34; 
Documents Case 2 33:20; Respondent 6 18:90-91; Respondent 9 21:79; 
Respondent 10 22:11-13) 
 
They have to charge more and more taxes to be able to operate. So you 
have a very complex system of taxation with state taxes, federal taxes and 
all kinds of different constantly changing taxation systems. So that also 
scares a lot of people, you hear a lot of difficult stories of people that set 
up business and just went down because they just could not deal with all 
the complex taxation systems. (Respondent 6 18:33) 
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The regulatory environment of biotechnology entrepreneurship in South Africa and 
Brazil defines the existence of the industry, the rules of engagement among the 
stakeholders and the general environment in which the industry operates.  
 
Comparison with the literature 
 
The regulatory environment is important for general entrepreneurship (Shane and 
Venkataraman, 2000; Eckhardt and Shane, 2003; Shane, 2003; Lingelbach et al., 
2005; Phan et al., 2008) and determines the effectiveness of the process of 
entrepreneurship to some extent. 
 
The regulatory environment is also considered to be one of the primary requirements 
for effective R&D, in addition to research universities, other research institutions, a 
developed scientific educational curriculum, a national culture that supports scientific 
endeavour, and talented individuals (Organisation for Economic Cooperation and 
Development, 2009). The GEM also highlights the regulatory environment as one of 
the differentiators of the efficiency-driven and innovation-driven countries (Kelley et 
al., 2012) in relation to the effectiveness of the process of entrepreneurship. 
 
Specifically in biotechnology entrepreneurship, the role of the government includes 
the provision of a favourable regulatory environment (Müller et al., 2004; Nilsson et 
al., 2010). 
 
In comparison to general entrepreneurship, the policy and regulatory environment 
plays a bigger role in biotechnology entrepreneurship in South Africa and Brazil due 
to the multifaceted nature of biotechnology (Dibner, 1986; Muller and Fujiwara, 2002; 
Müller et al., 2004; Ahn and Meeks, 2007; Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry Organisation, 2012). Biotechnology impacts on 
critical areas of the society such as food security, human health, environmental 
sustainability and energy sufficiency (Dibner, 1986; Muller and Fujiwara, 2002; 
Müller et al., 2004; Ahn and Meeks, 2007; Biotechnology Industry Organisation, 
2008; Battelle/Biotechnology Industry Organisation, 2012). 
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This research confirms the views of existing literature on the critical importance of a 
favourable regulatory environment to the process of biotechnology entrepreneurship. 
 
9.2.4 Theme 4 
 
“An overall conducive environment is necessary for the effective development of 
biotechnology entrepreneurship in South Africa and Brazil” 
 
Meaning of theme 4 in the context of this research 
 
The overall environment of biotechnology entrepreneurship in South Africa and 
Brazil includes the regulatory environment; political environment; economic 
environment; cultural environment; social environment; innovation and 
entrepreneurial environment; available pool of skills; governance (government 
leadership); funding; infrastructure; and the size of the market for biotechnology 
products.  
 
The experience of the respondents in South Africa and Brazil was set within the 
context of these environments, with the regulatory environment being the dominant 
environment. 
 
Manifestation of theme 4 in South Africa and Brazil 
 
The overall environment of biotechnology entrepreneurship in South Africa presents 
many challenges according to the respondents (see Table 7.2 on page 158). The 
challenges highlighted by most of the respondents include a policy and regulatory 
environment that is not conducive to entrepreneurship; lack of appropriate funding; 
an inclination by the universities to prioritise publication over commercialisation of 
research; lack of government leadership and direction; lack of aggregate skills, as 
well as entrepreneurial and commercialisation skills; and lack of a developed market 
for biotechnology products. These challenges were corroborated by the document 
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analysis, which highlighted areas of challenge such as human capital, knowledge 
exploitation, market development and governance (Documents Case 1 13:68). 
 
But I think one of the biggest caveats is that that environment, that 
nurturing environment is not there, either virtually or physically. 
(Respondent 14 9:65)   
 
Of the 19 areas highlighted only one was mostly seen as not a challenge while the 
remaining 18 areas were seen as challenges by most of the respondents (see Table 
7.2 on page 158). 
 
In relation to Brazil, the environment of biotechnology entrepreneurship, as 
experienced by the respondents, is mixed with an equal occurrence of key 
challenges and areas considered not to represent gaps in the development of 
biotechnology entrepreneurship in Brazil. Table 8.2 (see Table 8.2 on page 211) 
shows the areas highlighted by the respondents as affecting the environment of 
biotechnology entrepreneurship in Brazil. There is an equal split between the factors 
designated as favourable and those seen as challenges. Of the 14 areas highlighted 
seven, were highlighted as gaps, and seven, not as gaps. 
 
The challenges include the regulatory environment, especially related to taxation; 
shortage of aggregate skills; national culture of seeing entrepreneurship as impure; 
high interest rate, which results in high cost of funds; bureaucracy; corruption and 
politics (Respondent 6 18:51-52; Respondent 8 20:43-44). 
 
On the other hand, the areas considered not to represent challenges are the 
provision of direction and leadership by the government; availability of appropriate 
funding; the size of the market for biotechnology products in Brazil; availability of 
relevant infrastructure; a university culture that is conducive to the development of 
biotechnology entrepreneurship; availability of adequate capacity for biotechnology 
entrepreneurship; and good scope for international collaboration (Documents Case 2 
34:33). 
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The overall environment was deemed unconducive for the development of 
biotechnology entrepreneurship in South Africa by the respondents. In contrast, the 
respondents in Brazil believed that the overall environment in Brazil was conducive 
for the development of biotechnology entrepreneurship. 
 
Comparison with the literature 
 
The institutional environment needed for supporting the development of 
entrepreneurship in general (Kelley et al., 2012; Urban, 2013) is also applicable to 
biotechnology entrepreneurship. The three categories of factors believed to influence 
productive entrepreneurial activity are the economic, political and cultural 
environments (Shane, 2003). 
 
However, the overall environment for the development of biotechnology 
entrepreneurship in South Africa and Brazil includes regulatory and social 
environments. The regulatory environment is particularly important in the 
environment of biotechnology entrepreneurship (Müller et al., 2004; Ahn and Meeks, 
2007). Also the innovation and entrepreneurial environment proposed by Kelley, 
Singer and Herrington (2012) contains key elements that are important to the 
development of biotechnology entrepreneurship, such as entrepreneurial finance, 
government policies, government entrepreneurship programmes, entrepreneurship 
education, R&D transfer, commercial and legal infrastructure for entrepreneurship, 
internal market openness, physical infrastructure for entrepreneurship, and cultural 
and social norms. 
 
There are marked differences between the developed and developing countries in all 
three categories of environmental factors (Shane, 2003). While the four aspects of 
the economic environment: wealth, economic stability, capital availability and 
taxation, are all at advanced levels and favourable for productive entrepreneurship in 
the developed economies, the developing economies face issues of poverty, 
economic instability, lack of capital and restrictive tax laws (Herrington et al., 2008; 
Bosma and Levie, 2010). Similarly, political instability in developing economies and 
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low levels of a national culture of innovation and entrepreneurship hamper 
productive entrepreneurial activity (Herrington et al., 2010).   
 
This research confirms the existing literature on the importance of an overall 
environment that is conducive to the development of biotechnology entrepreneurship 
in South Africa and Brazil. While the literature reviewed was on general 
entrepreneurship or bioentrepreneurship in the developed economies, its 
applicability to biotechnology entrepreneurship in South Africa and Brazil was 
confirmed in this research. 
 
9.2.5 Theme 5 
 
“Research and development is the defining step in biotechnology entrepreneurship in 
South Africa and Brazil” 
 
Meaning of theme 5 in the context of this research 
 
The ability to act on bioentrepreneurial opportunities is research-driven. This makes 
R&D in biotechnology entrepreneurship a critical determinant of the output.  
 
To exploit the opportunities in biotechnology, individuals with the research and 
scientific skills have to go through a process of R&D. These opportunities are known 
in advance and fall within the categories of problem, efficiency and innovation 
opportunities. An example of a problem opportunity in South Africa is a cure for 
HIV/AIDS. The opportunity for a cure for HIV/AIDS can only be attained through 
R&D, and subsequently using the entrepreneurial and commercialisation capabilities 
to commercialise the research.  
 
The R&D step in biotechnology entrepreneurship is the step that introduces the most 
risk in the process of biotechnology entrepreneurship, as the timeframe and cost can 
be indeterminable and there is no guarantee that the R&D will result in the expected 
outcome. 
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R&D in the context of this research refers to all R&D activities that the bioscientists 
undertake in order to get to a desired solution or product that addresses a problem, 
improves existing processes, or introduces new innovative products and solutions. It 
also includes the environment of R&D in South Africa and Brazil in terms of R&D 
spend and intensity.  
 
Manifestation of theme 5 in South Africa and Brazil 
 
According to the OECD (2009), the primary requirements for R&D to be effective 
include research universities, other research institutions, a developed scientific 
educational curriculum, a national culture that supports scientific endeavour, a 
favourable regulatory environment and talented individuals.  
 
Most of the respondents in South Africa deem the funding for R&D to be inadequate 
and see it as a gap in the effort to develop the biotechnology industry in South Africa. 
The R&D spend in South Africa is low in comparison to other developing economies 
such as Brazil or the developed economies (Respondent 1 1:105; Respondent 2 
2:40).  
 
In addition to the expenditures undertaken by the government, large companies in 
biotechnology undertake major R&D. The lack of these large biotechnological 
companies that undertake major R&D projects was highlighted as a gap by the 
respondents in South Africa (Respondent 16 11:47). 
 
So there is a systemic problem where there is a shortage of R&D funding 
within the system. (Respondent 2 2:40) 
 
The lack of major R&D taking place here and the lack of capital are the 
two major constraints. (Respondent 16 11:47)  
 
By contrast, R&D in Brazil is well supported and funded through the national and 
state government agencies; private sector initiatives; international collaboration; and 
large biotechnological companies. In spite of this, the R&D spend still falls below the 
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OECD average and the respondents believed that more needed to be done to 
sustain the level of research intensity in the industry (Documents Case 2 24:3; 
Respondent 6 18:44).  
 
At 1% of GDP, R&D spending (both public and private) is comparatively 
low by OECD standards and is carried out predominantly by the 
government. (Documents Case 2 24:3) 
 
The experience of the respondents in South Africa and Brazil was that the level of 
R&D spend lags behind the developed economies. Although the respondents in 
Brazil highlighted the availability of different sources of funding for research, they 
believed that more needed to be done for them to compete with the developed 
economies. The level of R&D spend, as a percentage of GDP, is still not on par with 
that obtainable in most of the developed economies, and the OECD countries 
(Organisation for Economic Cooperation and Development, 2013b). 
 
Comparison with the literature 
 
Opportunity discovery in general entrepreneurship is different from opportunity 
discovery in biotechnology entrepreneurship. Opportunity discovery in biotechnology 
entrepreneurship is more of a “creation” (Audretsch et. al., 2008) than a “discovery” 
(Alvarez and Barney, 2007) as the solution to exploit the opportunities is created or 
discovered through R&D. 
 
R&D is a key step that differentiates biotechnology entrepreneurship from general 
entrepreneurship. This is also the key step that contributes to the predominance of 
non-psychological factors such as education and career experience (Barro and Lee, 
2000) in biotechnology entrepreneurship. 
 
Historically, developed economies are more R&D intensive than developing 
economies are. Consequently, R&D-driven technologies and industries, such as 
biotechnology, are more prevalent in the developed than the developing economies. 
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The US leads the R&D expenditure chart (Organisation for Economic Cooperation 
and Development, 2013b), followed by the rest of the developed countries. South 
Africa’s R&D expenditure is assumed to depict the level of R&D expenditure by 
developing economies, given the fact that South Africa is ranked among the 
efficiency-driven economies in the GEM research (Herrington et al., 2008; Bosma 
and Levie, 2010; Herrington et al., 2010). Although Brazil is not included in the 
OECD biotechnology statistics, the level of total R&D expenditure in Brazil is among 
the highest in Latin America as shown in Figure 8.4 on page 203. 
 
The intensity of biotechnology R&D as a percentage of industry value added is also 
highest in the US, with South Africa coming in ahead of Russian Federation in last 
position among all the countries included in the survey (Organisation for Economic 
Cooperation and Development, 2009).   
 
Given that the discovery of biotechnological opportunities requires R&D, it simply 
follows that the direct consequence of low R&D spend and activities in developing 
economies is low levels of biotechnological activities. This research therefore 
supports the existing literature regarding the importance of R&D to the development 
of biotechnology entrepreneurship in the developed economies and finds it to be 
equally applicable to South Africa and Brazil. 
 
9.2.6 Theme 6  
 
“There are four types of skills required in biotechnology entrepreneurship in South 
Africa and Brazil, namely: research, scientific, entrepreneurial, and 
commercialisation skills” 
 
Meaning of theme 6 in the context of this research 
 
In the context of this research “skills” refers to all the identified skills necessary for 
the effective commercialisation of research in South Africa and Brazil. These skills 
are research, scientific, entrepreneurial, and commercialisation skills. 
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The “research skill” refers to the ability of a bioscientist to conduct scientific research 
with the rigour and thoroughness that leads to a desirable outcome.  The “scientific 
skill” refers to the ability of the bioscientist to understand and apply accepted 
scientific methods and standards towards scientific activities like research, 
publication, and dissemination of knowledge.  The “entrepreneurial skill” refers to the 
business management acumen necessary to manage a firm effectively to achieve 
the desired socio-economic and financial performance.  The “commercialisation skill” 
refers to the capabilities needed to convert laboratory research successfully into 
economic and social value. 
 
Manifestation of theme 6 in South Africa and Brazil 
 
The importance of skills to the development of biotechnology entrepreneurship in 
South Africa was highlighted by most of the respondents. In analysing the 
experience of the respondents regarding the skills landscape, the four broad 
categories of skills highlighted by the respondents were scientific, research, 
entrepreneurial, and commercialisation skills. 
 
While most of the respondents believed that scientific and research skills are 
available in South Africa, the entrepreneurial and commercialisation skills were 
deemed to be lacking (Respondent 2 2:35-36). 
 
So one of the things that we really need to continue and expand is the 
development of bio-entrepreneurship skills. (Respondent 1 1:139) 
 
The respondents in Brazil believed that the research and scientific skills are available 
at individual levels for the development of biotechnology entrepreneurship in the 
country. However, the aggregate skills were deemed to be inadequate and as 
negatively impacting on the speed and scale of the development of the industry 
(Respondent 8 20:38; Respondent 6 18:126; Respondent 6 18:116). 
 
Human resources are a key challenge. Currently there are only 1.48 
researchers per 1000 total employment (2006) and only 10.7% of all 
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university graduates have degrees in science and engineering. 
(Documents Case 2 32:3) 
 
The entrepreneurial and commercialisation skills were not identified as challenges by 
the respondents in Brazil, which supports the view that the process of biotechnology 
entrepreneurship in Brazil utilises the “system” approach rather than the “individual” 
approach. The system provides the commercialisation and entrepreneurial 
capabilities necessary for the successful exploitation of bioentrepreneurial 
opportunities. 
 
The different levels of availability of all the identified skills in South Africa and Brazil 
may contribute to the differences in success of commercialisation of research in the 
two countries. While Brazil has all the identified capabilities within the system of 
biotechnology entrepreneurship; South Africa tries to get all the necessary skills 
within the individuals; and the scale of successes has been in favour of Brazil. 
  
Comparison with the literature 
 
The lack of entrepreneurial and commercialisation skills was identified in prior 
studies on the biotechnology industry in South Africa in the form of a lack of skills 
(Lingelbach et al., 2005), and low levels of commercialisation of biotechnology 
products (Cloete et al., 2006). This distinction between the types of skills that are 
lacking is important given the general discourse on the low level of mathematics and 
science education in South Africa (Department of Science and Technology, 2001; 
Department of Science and Technology, 2007), which can easily be wrongly 
interpreted to mean a lack of science and research skills for biotechnology 
entrepreneurship in South Africa.  
 
There has also been much emphasis on the importance of skills in biotechnology 
entrepreneurship across industry research; empirical research on developed 
economies; and empirical research on developing economies. (Department of 
Science and Technology, 2001; Lingelbach et al., 2005; Ahn and Meeks, 2007; 
Department of Science and Technology, 2007; Phan et al., 2008; Ahn et al., 2010a; 
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Ahn et al., 2010b; Battelle/Biotechnology Industry Organisation, 2010; Ahn and York, 
2011; Ahn et al., 2012; Dunham et al., 2012; Kelley et al., 2012). 
 
In contrast to general entrepreneurship, the research and scientific skills are must-
haves for participation in biotechnology entrepreneurship, as R&D is used to 
discover or create opportunities in biotechnology entrepreneurship (Ahn and Meeks, 
2007; Phan et al., 2008; Ahn et al., 2010a; Ahn et al., 2010b; Battelle/Biotechnology 
Industry Organisation, 2010; Ahn and York, 2011; Ahn et al., 2012; Dunham et al., 
2012).  
 
This research confirms the critical importance of skills in biotechnology 
entrepreneurship in South Africa and Brazil. It also extends the existing literature in 
understanding the different skills required for biotechnology entrepreneurship in 
South Africa and Brazil; and how the availability of these four skills in South Africa 
and Brazil influences the model of biotechnology entrepreneurship practised in South 
Africa and Brazil. 
 
9.2.7 Theme 7 
 
“Effective collaboration among key stakeholders is important to the development of 
biotechnology entrepreneurship in South Africa and Brazil” 
 
Meaning of theme 7 in the context of this research 
 
The stakeholders in biotechnology entrepreneurship in South Africa and Brazil are 
the government, research institutions, venture capitalists, large biotechnology 
companies, and society (Documents Cross-Case 30:36).  
 
These stakeholders are aligned to the triple helix of university, industry, government 
relations model. In this model, the government represents the government sphere of 
the model; the research institutions represent the university sphere; and the venture 
capitalists and large biotechnology companies represent the industry sphere. The 
society stakeholder is a fairly recent addition to the academic discourse on the triple 
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helix model, which has led to proposals for a quadruple helix with society as the 
fourth sphere. 
 
The determination of these stakeholders was informed by the literature on 
biotechnology and entrepreneurship; the analysis of the transcripts of the interviews; 
and the organising framework of the triple helix of university, industry, government 
relations model. 
 
The role players within the bio-economy will have to collaborate effectively 
if the bio-economy is to succeed. These role players include industry, 
academia, science councils, non-governmental organisations, community-
based organisations, not-for-profit companies and the government. 
(Documents Case 1 13:45-46) 
 
The stakeholders contribute different requirements to the process of biotechnology 
entrepreneurship in South Africa and Brazil. In addition, they have different needs.  
 
The research institutions provide talent and technology transfer capabilities; the 
venture capitalists provide capital; the large companies act as cooperation partners, 
customer and competitor; and the government provides an enabling regulatory 
environment and acts as facilitator. The needs of the stakeholders vary between 
economic development, financial return and commercialisation of research.  
 
This rise of convergence, in turn, reinforces the importance of strategic 
collaborations. With convergence, there is a strong need for a “bigger 
bench” of scientists - both within academia and industry - undertaking 
discovery and development. Convergence will require capabilities not 
typically possessed in a single organization and so lead to more 
collaboration and strategic partnering. (Documents Cross-Case 27:21) 
 
Given the different roles and needs of the stakeholders, it is important that the 
collaboration among the stakeholders is effective for achieving the goal of the 
development of biotechnology entrepreneurship in South Africa and Brazil. 
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Manifestation of theme 7 in South Africa and Brazil 
 
The key manifestation of the importance of effective collaboration among the 
stakeholders in biotechnology entrepreneurship in South Africa and Brazil relates to 
collaborative projects, which resulted in positive outcomes in Brazil, where the 
collaboration among the stakeholders was deemed to be effective. In South Africa, 
where the collaboration among the stakeholders was deemed to be ineffective, few 
successful collaborative projects were achieved. 
 
The genome projects defined the success of effective collaboration among key 
stakeholders in Brazil, and resulted in international recognition for the biotechnology 
industry in Brazil. Some of the notable genome sequencing collaborative projects in 
Brazil include: the Eucalyptus genome project, in which four paper companies 
collaborated with research institutions; the coffee genome project with a 
collaboration of 700 researchers and 40 institutions; and the xylella fastidiosa project 
in which 65 laboratories, 75 research groups and 450 researches collaborated. This 
included international institutions; the sugar cane genome project; and the 
chromobacterium violaceum project.  
 
A growing scientific community has allowed for the development of 
collaborative research programmes that require a large number of 
researchers. Recent experience in this area is promising and has the 
potential for engaging the business sector in commercially-oriented 
research. For example, the Genome Project, set up in São Paulo in 
partnership with the Citrus Producers Association (Fundecitrus), resulted 
in the DNA sequencing of a phyto-pathogenic bacterium, the Xylella 
Fastidiosa, which allowed Fundecitrus researchers to devise ways to 
protect orange trees from a disease (citrus variegated chlorosis, CVC) that 
had been associated with considerable economic loss in the past. The 
joint venture also generated at least two spin-off companies in the field of 
genomics and bioinformatics. Another example is the Biota Research 
Programme, a conservation and sustainable development-oriented 
biodiversity research effort to study and map biodiversity in the state of 
São Paulo. (Documents Case 2 25:24) 
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The personal experience of one of the pioneers of the collaborative genome projects 
in Brazil was described as rewarding (Respondent 6 18:59). 
 
There was no successful collaborative research project in South Africa highlighted by 
the South African respondents; and a few successful collaborative research projects 
in South Africa were highlighted in the literature on South Africa (Cloete et al., 2006). 
This may be as a result of the ineffective collaboration among the key stakeholders. 
 
We are doing it in a sense but I often find that this is certainly an issue 
here; the inability of people here to work together. It is a big problem. It is 
like everybody is doing a bit somewhere and they are not teaming up, they 
are not coming together which is a huge detriment. (Respondent 14 9:74-
75)      
 
However, there was an acknowledgement of the importance of effective 
collaboration among the stakeholders in biotechnology entrepreneurship by 
some of the respondents in South Africa; despite the fact that there were no 
successful collaborative projects similar to those in Brazil (Respondent 15 
10:37). 
 
Further indication of the importance of effective collaboration among the key 
stakeholders in the biotechnology industry was the emphasis which the respondents 
placed on it in this research.  Effective collaboration was highlighted as one of the 
top codes, in terms of frequency of occurrence within and across the transcripts, in 
both South Africa and Brazil.  
 
The importance of effective collaboration among the key stakeholders in the 
biotechnology industry was also demonstrated by the governments’ prioritising of the 
collaboration between the stakeholders as a necessary condition to the development 
of biotechnology entrepreneurship in South Africa and Brazil. This collaboration, 
which is often takes the form of a triple helix of university, industry, government 
relations, is legislated in the national biotechnology policy documents for both South 
Africa and Brazil. 
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Comparison with the literature 
 
The relevance of the interactions among the university, industry and government, in 
transforming academic research into societal and economic capital, is demonstrated 
in the field of biotechnology (Liebeskind et al., 1996; Agrawal, 2001; Müller et al., 
2004; Rothaermel and Deeds, 2004; Powell et al., 2005; Ahn and Meeks, 2007; 
Sytch and Bubenzer, 2008).  
 
The collaboration among these three stakeholders (Etzkowitz and Leydesdorff, 1997; 
Leydesdorff and Etzkowitz, 1998, 2001) has recently been considered to involve a 
fourth stakeholder (Afonso et al., 2010; Marcovich and Shinn, 2011; Afonso et al., 
2012; Leydesdorff, 2012) leading to a quadruple helix. The quadruple helix is 
context-specific and in the case of the developing economies the socio-economic 
linkages may point to the possibility of the fourth stakeholder being the society.  
 
The triple helix relations in South Africa and Brazil, based on the experience of the 
respondents in this research, do not follow a sequence of triple helix I, II and III as 
postulated by Etzkowitz and Leydesdorff (2000). In the model, in the progression 
from triple helix I to III the influence and control of the government is diminished. 
However, it is envisaged that the influence and control of the government will not 
diminish in the biotechnology industry in South Africa and Brazil. 
 
This leads to a scenario where there is a possibility of a hybrid model of Triple Helix 
I, which represents a configuration in which the government encompasses both 
industry and university and directs the interaction and relations between them; and 
Triple Helix III, in which overlapping institutional spheres generate a knowledge 
infrastructure, with overlapping roles and hybrid organisations emerging at the 
interfaces (Etzkowitz and Leydesdorff, 2000) without direct control by any of the 
institutions.  
 
The uniqueness of this hybrid model is that the gains of Triple Helix III will be 
appropriated in an environment where the government maintains the influence and 
control over the interactions of the stakeholders. It is also noteworthy that this 
bypasses the Triple Helix II, in which the three institutional spheres are separate with 
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strong borders dividing them and restricted relations (Etzkowitz and Leydesdorff, 
2000). In support of this assertion is that there is little chance of separation from the 
government, given its importance and the needs of the industry. 
 
This research confirms and extends the existing literature in a number of ways. The 
stakeholders of biotechnology entrepreneurship are confirmed as being the 
government, research institutions, venture capitalists, large biotechnology 
companies, and society.  In addition, effective collaboration among the stakeholders 
is confirmed as being important for biotechnology entrepreneurship. 
 
The existing literature is extended by highlighting the role played by stakeholder 
collaboration in the dual approach to biotechnology entrepreneurship. The “system” 
approach is predominant in an environment of effective collaboration among the key 
stakeholders while the “individual” approach is predominant in an environment of 
ineffective collaboration among the key stakeholders.  
 
Another extension to existing literature is the articulation of the nature of triple helix 
relations that are practised in the biotechnology industry of South Africa and Brazil, 
based on the experience of the respondents to this research. The hybrid model is a 
combination of triple helix I and III; bypasses triple helix II; and maintains 
government control. 
 
9.2.8 Theme 8  
 
"The government plays an important role in biotechnology entrepreneurship in South 
Africa and Brazil” 
 
Meaning of theme 8 in the context of this research 
 
The roles of the government in biotechnology entrepreneurship in South Africa and 
Brazil include provider of a favourable regulatory environment, facilitator, and funder 
of R&D, buyer of biotechnology products, and establisher and maintainer of public 
research institutions. 
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Of the five roles highlighted above, the roles of providing a favourable regulatory 
environment and facilitation were highlighted in existing literature. In addition, the 
role of the establishment and maintenance of public research institutions is a known 
responsibility of government. 
 
However, the roles of government as funder of R&D and buyer of biotechnology 
products, as experienced by the respondents in South Africa and Brazil, extend the 
responsibility of the government and hence its importance in the development of 
biotechnology entrepreneurship in South Africa and Brazil. 
 
Manifestation of theme 8 in South Africa and Brazil 
 
The terms of reference for engaging in biotechnology entrepreneurship in South 
Africa and Brazil are legislated by the governments in the national policies related to 
the biotechnology strategy of both countries. The national bio-economy strategy of 
South Africa and the national biotechnology development policy of Brazil are the 
policy bases for the practice of biotechnology entrepreneurship in South Africa and 
Brazil respectively.  
 
In Brazil, where government leadership and direction were deemed to be effective 
there have been notable successes in biotechnology entrepreneurship. 
 
Government was mainly the driving force, because a lot of us that 
somehow had the experience outside of academia went to the 
government, to be in the government. We knew that we had to change the 
way we are working in science and technology in Brazil. We had to 
support the industrial sector but the government has been the big driving 
force I would say. And now the market is where it is internationally 
competitive. (Respondent 9 21:57) 
 
Moreover, the success that the country has achieved with the results of 
their research in biotechnology has greatly influenced the demand for 
cooperation bilateral and/or multilateral agreements with other countries in 
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biotechnology, which can boost its international relations, attracting 
international capital flows and interest in pursuing new business 
arrangements that enhance the competitiveness of domestic industries. 
(Documents Case 2 34:33) 
 
The challenges to biotechnology entrepreneurship in Brazil identified by most of the 
respondents were also mostly in areas of government responsibility such as the 
policy and regulatory environment; bureaucracy and inefficiencies of the government 
agencies; high cost of funding; lack of aggregate skills; politics; and corruption. 
 
By contrast, the respondents in South Africa highlighted the lack of government 
leadership and direction as one of the challenges in the environment of 
biotechnology entrepreneurship. The government agencies tasked with the 
implementation of the policies and strategies for biotechnology entrepreneurship 
were deemed to be ineffective by most of the respondents. Hence, all but one of the 
19 areas highlighted by the respondents as impacting on the environment of 
biotechnology entrepreneurship in South Africa were designated as challenges. 
 
Yes, but the rest of the world is going down one route and government is 
going down another route, and what they are doing in practice is not that, 
they are making it more complicated. So again, the implementation 
challenge is significant. (Respondent 2 2:129) 
 
Theme 8 is further revealed in the codes, with most occurrences within and across 
the transcripts in South Africa and Brazil. These include policy and regulation; 
government-incentivised entrepreneurial action; government direction and 
leadership; bureaucratic processes associated with the government agencies; 
government inefficiencies; funding; and skills development.  
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Comparison with the literature 
 
The role of the government in biotechnology entrepreneurship is to provide an 
enabling regulatory environment and act as a facilitator (Müller et al., 2004; Ahn and 
Meeks, 2007; Nilsson et al., 2010).  
 
The regulatory environment includes the policies and laws that impact on 
biotechnology entrepreneurship in South Africa and Brazil, such as the national bio-
economy strategy of South Africa; the national biotechnology development policy of 
Brazil; the intellectual property policy; the technology transfer policy; the taxation 
laws; and labour laws. The role of the government as a facilitator includes creating a 
favourable environment for biotechnology entrepreneurship and providing grants and 
incentives (Müller et al., 2004). 
 
These roles as articulated in the literature relate to the developed economies, and 
specifically to Germany and Japan (Müller et al., 2004). This is corroborated by the 
role of the government in the biotechnology industry of the US (Ahn and Meeks, 
2007) and the rest of the developed economies.  
 
Few studies on the role of the government in biotechnology entrepreneurship are 
specific to the developing economies. However, from a general entrepreneurship 
point of view, the nature of entrepreneurial action in the developing economies is 
non-accidental and purposefully orchestrated by government, providing resource 
endowments, institutions and markets. Government provides both macro- and 
microeconomic factors aimed at providing incentives for entrepreneurial action (Phan 
et al., 2008) (see Table 2.3). 
 
This research extends the existing literature on the role of government in 
biotechnology entrepreneurship in a number of ways. The respondents in South 
Africa and Brazil highlighted the role of the government in funding research and 
development through dedicated funding agencies. This extends the earlier role of 
facilitator, which includes grants and incentives (Müller et al., 2004), to the role of the 
government as a funder of R&D in the biotechnology industry of South Africa and 
Brazil. 
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This research highlights an additional role of the government as a buyer of 
biotechnology products. The prevalence of problem opportunities in South Africa, 
driven by diseases such as HIV/AIDS and tuberculosis, makes the government the 
biggest buyer of biotechnology solutions to these diseases for its citizens. Similarly, 
the prevalence of efficiency opportunities in Brazil, driven by the need to improve 
agricultural crop yields and biomanufacturing, makes the government the facilitator 
and buyer of the products to meet the needs of its citizens.  
 
The role of the government as a buyer of biotechnology products influences the size 
of the market for biotechnology products in South Africa and Brazil.   
 
9.2.9 Theme 9 
 
“Funding is a critical factor in biotechnology entrepreneurship in South Africa and 
Brazil” 
Meaning of theme 9 in the context of this research 
 
“Funding” in the context of this research refers to the funding of R&D; the funding for 
infrastructure development; the funding of capacity-building activities; the funding of 
support structures and activities; the funding of opportunity exploitation activities; and 
the funding of commercialisation of research. 
 
These different types of funding are provided by different sources such as the 
government, venture capitalists, large organisations and other private sector entities. 
Where these sources exist and the funding is adequate and appropriate, the funding 
environment was deemed to be favourable. On the other hand, where these sources 
of funding do not exist or funding is inadequate or inappropriate for the needs of 
biotechnology entrepreneurship, the funding environment was deemed to be 
unfavourable. 
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Manifestation of theme 9 in South Africa and Brazil 
 
The funding environment for biotechnology entrepreneurship in South Africa was 
deemed unfavourable by the respondents (Respondent 12 7:17; Respondent 13 
8:19). The lack of a developed venture capital industry and large biotechnology 
companies meant that the government was deemed to be the only source of funding 
for biotechnology entrepreneurship in South Africa. This presented another 
challenge in that the funding from the government is often not appropriate for the 
nature of the biotechnology industry in terms of risk profile and timeframe 
(Respondent 13 8:8-9). 
 
By contrast, the respondents in Brazil were of the opinion that appropriate funding 
was available in the biotechnology industry in Brazil. The sources of this funding are 
primarily the government through its national and state funding agencies; the private 
sector; and venture capitalists (Respondent 7 19:47-48; Respondent 10 22:20; 
Respondent 9 21:48). 
 
There is a lot of interest not only from capitalists in Brazil, but outside 
Brazil, that are interested in investing in the country. This has been done in 
the last five or six years in the area of bioenergy, for example. People 
investing, big multinational companies, merging with Brazilian companies 
and setting up big sugar cane deals and this is important and this is 
positive and there is a lot of money available. (Respondent 8 20:83) 
 
The contrasting scenarios in South Africa and Brazil in terms of the availability of 
appropriate funding may play a key role in the performance of the biotechnology 
industry in both countries. Given the research-intensive nature of discovering or 
creating biotechnology opportunities, the high risk associated with the industry, and 
the timeframe from research to commercialisation, the emphasis of the respondents 
on funding as either a challenge or an enabler points to the importance of funding in 
the process of biotechnology entrepreneurship.   
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In the experiences of the respondents in South Africa, those who had appropriate 
funding from the government were not as critical of the funder role of government in 
biotechnology entrepreneurship. On the contrary, those who had not received 
appropriate funding from the government were very critical of government’s funder 
role. In other instances, the lack of appropriate funding was held responsible for the 
collapse of biotechnology companies in South Africa (Respondent 13 8:30-32). 
 
Comparison with the literature 
 
The availability of capital (Shane, 2003) is an important factor in any entrepreneurial 
activity and biotechnology entrepreneurship is often associated with both 
government and venture capital funding sources (Audretsch, Taylor Aldridge and 
Perry, 2008).  
 
Financing mechanisms are increasingly used to focus research on 
priorities. A challenge for governments is to find a balance between funds 
for basic research and funds for output-driven research, and between 
stable, institutional funding and project or programme-based funding tied 
to specific objectives and missions. 
Institutional funding, including for infrastructure, is critical for long-term 
research capacity while project-based funding is used to promote 
competition within the research system. (Documents Cross-Case 29:46) 
 
The experience of the bioentrepreneurs in South Africa was mostly restricted to the 
government source of funding, owing to the lack of a developed venture capital 
industry for biotechnology (Audretsch et al., 2008). This situation may be unique to 
the South African biotechnology industry, as venture capital funding is a core 
component of biotechnology entrepreneurship in developed economies (Ahn and 
Meeks, 2007; Ahn et al., 2010a). The availability of appropriate funding in Brazil 
through these sources is similar to the process of biotechnology entrepreneurship in 
developed economies (Ahn and Meeks, 2007; Ahn et al., 2010a), where the 
government plays a big role despite the availability of other sources of funding. 
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The US industrial biotechnology drive has been led centrally, initiated by 
government and/or the administration, with massive public research 
funding. (Documents Cross-Case 30:18) 
 
This research confirms the existing literature on the critical importance of funding to 
the process of biotechnology entrepreneurship. 
 
9.2.10 Theme 10  
 
“The local market for biotechnology products is a critical factor in biotechnology 
entrepreneurship in South Africa and Brazil” 
 
Meaning of theme 10 in the context of this research 
 
The areas of emphasis for the bioentrepreneurs in South Africa and Brazil are 
primarily driven by the needs of the local market. While in South Africa the 
predominance of problem opportunities influences emphasis on diseases, in Brazil 
the predominance of efficiency opportunities influences emphasis on improvements 
to agriculture, healthcare, the environment, and industrial processes. Hence, the 
local market is a critical factor in biotechnology entrepreneurship in South Africa and 
Brazil. 
 
Of the bioentrepreneurs who participated in this research, all had access to other 
markets besides their home markets, for their biotechnology products and services. 
For those that predominantly exploited problem opportunities, their accessible 
markets were predominantly in the developing economies. Conversely, for those 
who rendered bioservices and exploited efficiency and innovation opportunities, their 
markets were predominantly in the developed economies. The same is applicable to 
biotechnology companies outside of South Africa and Brazil, which have access to 
the South African and Brazilian markets, depending on their area of focus and the 
nature of the bioentrepreneurial opportunity being exploited. Hence, the size of the 
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local market is an important factor in the dynamics of biotechnology 
entrepreneurship.  
 
Manifestation of theme 10 in South Africa and Brazil 
 
The size of the market for biotechnology products in South Africa and Brazil was 
seen as a critical factor in biotechnology entrepreneurship. In South Africa, the size 
of the market was deemed small and underdeveloped by most of the respondents 
(Respondent 1 1:27; Respondent 12 7:30; Respondent 13 8:10; Respondent 15 
10:7). 
 
However the biggest challenge that is faced in South Africa is that the 
South African market itself with its biotechnological innovations are too 
small, the market is too small. (Respondent 4 4:6) 
 
From a medical diagnostics point of view, there seems to be an adequate market in 
South Africa. This may be due to the nature of the products and the target market 
(Respondent 11 6:95-96). 
 
The government was seen as the biggest buyer of biotechnology products in South 
Africa and, hence, influences the size of the market. The ability of the local 
companies to sell to the government determines their success in the local market. If 
the local biotechnology companies cannot win the competition in their local market, 
the odds are heavily against them making inroads in the international market with 
competitors with a far better operational environment than in South Africa 
(Respondent 13 8:61-63). 
 
By contrast, the respondents believe that the Brazilian market for biotechnology 
products is developed (Respondent 9 21:102-103). The emphasis on national 
priorities and solving the problems of the country means that the areas of focus, 
such as agriculture, environment, industry and healthcare, are aligned to the needs 
of the country. Hence, the local demand creates a local market for the biotechnology 
products.  
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The positive factor is the Brazilian market, a very good market in terms of 
maturity and size. (Respondent 9 21:101-102) 
 
Despite having a developed market for biotechnology products, the need to compete 
internationally was expressed by the respondents as one of the factors necessary for 
the development of the industry in Brazil. The competitive pressure highlighted by 
the respondents in their local market was from biotechnology companies outside the 
borders of their local market, in both developing and developed economies. Hence, 
biotechnology entrepreneurship is global; the choice of market is mostly determined 
by the type of bioentrepreneurial opportunity that is being exploited by the 
bioentrepreneur; and a developed local market may be a factor in favourably 
positioning the bioentrepreneur to compete globally.  
 
Comparison with the literature 
 
The empirical research on biotechnology in South Africa (Gastrow, 2008) did not 
address the relevance of the local market for biotechnology products. The 
importance of the local market in Brazil was alluded to in the study carried out by 
Zylberberg, Zylberberg and Oner (2012). There may have been more empirical 
research to this effect in Brazil, but these studies would most likely have been written 
in Portuguese. This limitation has been accounted for in the section on the limitations 
of this study.  
 
According to industry research, biotechnology has assumed global importance in the 
areas of healthcare, environmental protection, agriculture, chemistry and material 
science (Biotechnology Industry Organisation, 2008; Battelle/Biotechnology Industry 
Organisation, 2012) in the 21st century. This is in response to the large-scale global 
issues such as human health, food security, renewable resources and environmental 
sustainability. 
 
The areas highlighted as the focus areas by the respondents, such as human health, 
agriculture, industrial biotechnology and environmental biotechnology in the local 
market are aligned to the areas of global emphasis in the literature. This research 
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extends the existing literature on the critical importance of the local market for 
biotechnology products in South Africa and Brazil. 
 
9.3 The proposed theoretical framework of biotechnology 
entrepreneurship in South Africa and Brazil 
 
The organising frameworks that guided this research, the individual-opportunity 
nexus framework of entrepreneurship (Shane, 2003) and the triple helix of university, 
industry, government relations (Etzkowitz and Leydesdorff, 2000), are frameworks 
for general entrepreneurship and are not specific to biotechnology entrepreneurship.  
 
The existing literature on biotechnology entrepreneurship that has a framework 
related to the process of biotechnology entrepreneurship is that of Müller, Fujiwara 
and Herstatt (2004), on the study of sources of bioentrepreneurship in Germany and 
Japan. However, the model by Müller et al. (2004) is restricted to the stakeholders 
needed for the exploitation of bioentrepreneurship opportunities.  
 
Two previous empirical studies on biotechnology in South Africa (Gastrow, 2008) 
addressed the quantitative profile of biotechnology research and development in 
South Africa and the state of biotechnology in South Africa, with emphasis on the 
national biotechnology strategy and its implementation respectively. Other industry 
studies on the biotechnology industry in South Africa have concentrated on the key 
initiatives driven by the government and the performance of the industry (Ernst & 
Young, 2006; Organisation for Economic Cooperation and Development, 2009; Ernst 
& Young, 2010a, 2010b; Organisation for Economic Cooperation and Development, 
2013b, 2013a). 
 
No current empirical or industry study has addressed the process of biotechnology 
entrepreneurship in South Africa by the bioentrepreneurs and stakeholders engaged 
in the process. 
 
Previous studies on biotechnology entrepreneurship in Brazil have been more 
extensive in addressing the biotechnology industry holistically (Zylberberg et al., 
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2012). However, a language limitation prevented the researcher from being able to 
review studies in Brazil that were published in Portuguese. 
 
There is no existing theoretical framework of biotechnology entrepreneurship that 
enables the study and understanding of the process of biotechnology 
entrepreneurship in different contexts, whether in the developed or developing 
economies.  
 
The themes identified in the cross-case analysis of South Africa and Brazil have 
characteristics that differentiate the process of biotechnology entrepreneurship from 
the process articulated in the organising framework of the individual-opportunity 
nexus of entrepreneurship. 
 
At the level of individual attributes, the process of biotechnology entrepreneurship 
utilises two models, the individual model and the systemic model. The individual 
model is based on the psychological and non-psychological attributes of the 
individual and the acquisition of entrepreneurial and commercialisation skills. The 
systemic model is based on the psychological and non-psychological attributes of 
the individual, in addition to a system of biotechnology entrepreneurship that 
provides entrepreneurial capabilities, commercialisation capabilities and support 
structures. Both models are driven by the environmental conditions that exist in the 
context of the study. Hence, while the individual model is practised in South Africa, 
the systemic model is practised in Brazil and the developed economies. 
 
The individual attributes for general entrepreneurship, based on the organising 
framework of the individual-opportunity nexus of entrepreneurship, are concerned 
with the individual only. 
 
At the level of entrepreneurial opportunities, the bioentrepreneurial opportunities are 
known in advance and differ in different contexts. Hence, while problem opportunities 
predominate in South Africa, efficiency opportunities predominate in Brazil. The 
entrepreneurial opportunities in the organising framework are not specific to the 
context and their discovery is dependent on the enterprising individual. 
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At the level of environment for entrepreneurship, the themes related to the overall 
environment for biotechnology entrepreneurship, regulatory environment, funding, 
skills, and size of local market show that there are differences in the environment of 
entrepreneurship in the organising framework and the experience of the respondents 
in this research.  
 
While the environment in the organising framework includes industry and the macro-
environment, the environment for biotechnology entrepreneurship is broader and 
includes innovation and entrepreneurial conditions, in addition to industry and the 
macro-environment. 
 
At the level of discovery, opportunity discovery in general entrepreneurship is 
dependent on the enterprising individual. However, this process in biotechnology 
entrepreneurship is dependent on R&D. R&D, in turn, is dependent on skills, 
infrastructure and funding, all of which are part of the innovation and entrepreneurial 
conditions. 
 
At the level of opportunity exploitation, this stage in general entrepreneurship is 
dependent on the individual entrepreneur. In contrast, the theme from this research 
shows that this stage in biotechnology entrepreneurship in South Africa and Brazil is 
dependent on effective collaboration among the key stakeholders. The existing 
literature (Müller et al., 2004) on the exploitation of bioentrepreneurial opportunties 
shows that this requires a strategic alliance of government, research institutions, 
venture capitalists and large biotechnology companies. 
 
At the level of execution, the individual entrepreneur engages in resource assembly, 
organisational design and strategy (Shane, 2003) to create commercial value. In the 
process for biotechnology entrepreneurship, the collaboration among key 
stakeholders enables the efficient commercialisation of research through firm 
formation or licensing.  
 
Furthermore, while the outcome of execution in general entrepreneurship satisifies 
the value creation need of the individual entrepreneur, the outcome of 
commercialisation of research in biotechnology entrepreneurship satisfies the need 
290 
 
of multiple stakeholders in the form of economic development, financial return, and 
commercialisation (Ahn and Meeks, 2007), as well as social benefit. 
 
Gaps exist in current empirical literature and industry research related to the process 
of biotechnology entrepreneurship in South Africa and Brazil. In addition, there are 
differences between the process of general entrepreneurship, based on the 
organising framework of individual-opportunity nexus, and the process of 
biotechnology entrepreneurship in South Africa, based on the cross-case themes for 
this research. 
 
To address these gaps and differences, a theoretical framework of biotechnology 
entrepreneurship in South Africa and Brazil is proposed as shown in Figure 9.1. 
 
291 
 
 
 
Figure 9.1: A proposed theoretical framework of biotechnology entrepreneurship in South Africa and Brazil (adapted from 
Shane, 2003:11) 
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The proposed theoretical framework of biotechnology entrepreneurship in South 
Africa and Brazil (see Figure 9.1) captures the process of biotechnology 
entrepreneurship in the developing economies of South Africa and Brazil. 
 
The individual and systemic models of biotechnology entrepreneurship are driven by 
environmental conditions. Given that the systemic model is operational in developed 
economies, it may mean that favourable environmental conditions support the 
emergence of the systemic model, while unfavourable environmental conditions 
support the emergence of the individual model. 
 
Emphasis at this stage should be on providing the capabilities and support structures 
for developing a system rather than training individuals to operate in the individual 
model. 
 
The bioentrepreneurial opportunities are known in advance and are often informed 
by the needs and priorities of the country, which are both social and economic. The 
approach in choosing which bioentrepreneurial opportunities to focus on should be 
informed by the areas that would make the biggest impact on solving the problems of 
the country. Another consideration would be areas of competitive advantage such as 
biodiversity in South Africa and Brazil. 
 
The environment is where most of the differences occur between different contexts. 
This is because most of the factors are environmental factors and the extent to which 
the environment is conducive to bioentrepreneurial development determines to a 
large extent the ability to attract foreign skills, other sources of funding and large 
biotechnological companies and the ability to develop entrepreneurial and 
commercialisation capabilities within the system, and ultimately the success of 
biotechnology entrepreneurship. The government often plays a big role in 
determining the effectiveness of the environmental factors. 
 
The individual attributes and the environment determine the effectiveness of R&D in 
the next step. 
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R&D is dependent on skills, infrastructure and funding. This is the defining point of 
biotechnology entrepreneurship, as the timeframe, outcome and cost can all be 
indeterminate, with no guaranteed outcome. Most of the costs incurred in 
biotechnology entrepreneurship occur at this stage; hence, multiple funding sources 
are often required to drive R&D. R&D spend and intensity are often used as 
measures to determine how committed countries are to research-intensive industries 
such as biotechnology, and often determine the output. 
 
In South Africa and Brazil, the abundance of genetic materials as raw materials for 
R&D, through the biodiversity, is considered a competitive advantage. Only 
successful outcomes at the R&D stage lead to the exploitation of bioentrepreneurial 
opportunities. Although the strategic alliances needed to exploit the 
bioentrepreneurial opportunities is the next step, the R&D step often requires funding 
from multiple stakeholders who will eventually participate in the exploitation of the 
successful output of the R&D. 
 
The exploitation of bioentrepreneurial opportunities requires effective collaboration 
among the key stakeholders, specifically a strategic alliance of government, research 
institutions, venture capitalists and large companies. At this stage considerable 
resources are needed to go from the laboratory to the market and this works better in 
a systemic model than in an individual model, as the capabilities required are often 
beyond an individual. The availability of all these stakeholders defines the process of 
biotechnology entrepreneurship in the developed economies. In this study, Brazil has 
an availability of stakeholders while South Africa does not. That may explain the 
different approaches in these two developing economies in terms of adopting the 
individual or systemic approach. The stage of bioentrepreneurial exploitation leads to 
commercialisation of research, which is the final stage in the model. 
 
The success of the stage of commercialisation of research is dependent on the 
success of the preceding stages in the framework. This is achieved either through 
firm formation or licensing. The different stakeholders have different needs, which 
are realised through successful commercialisation of the research. 
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The government is involved in most of the stages of the framework in South Africa 
and Brazil, through multiple roles such as facilitator, funder and buyer of 
biotechnology products. The extent of government involvement is determined by the 
specific context of each country.  
 
The triple helix of university, industry, government relations plays a key part in 
biotechnology entrepreneurship because of the high level of collaboration required. 
In this study, the triple helix of university, industry, government relations is controlled 
by the government, which creates a hybrid of triple helix I and III in Brazil while South 
Africa implements a triple helix I model. 
 
The direction of the arrows in Figure 9.1 shows that the individual attributes, the 
bioentrepreneurial opportunities and the environment are deemed to affect all the 
stages of biotechnology entrepreneurship from R&D to entrepreneurial exploitation 
and commercialisation of research. While this does not prove causality, the 
importance of the individual attributes, entrepreneurial opportunities and the 
environment to entrepreneurship is supported by previous studies (Liebeskind et al., 
1996; Audretsch and Stephan, 1998; Agrawal, 2001; Shane, 2003; Müller et al., 
2004; Rothaermel and Deeds, 2004; Powell et al., 2005; Ahn and Meeks, 2007; 
Sytch and Bubenzer, 2008). 
 
9.4 Summary of Chapter 9 
 
The cross-case analysis of South Africa and Brazil aims to aggregate the data for the 
individual cases into a higher level abstract that aids generalisation from data to 
theoretical proposition (Eisenhardt, 1989, 1991; Yin, 2009). 
 
The cross-case analysis resulted in ten themes derived from the patterns identified in 
the within-case analyses of South Africa and Brazil.  
 
The comparison of the themes to existing literature shows that there were instances 
of confirmation of the existing literature and instances of extension of the literature. 
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The confirmation of existing literature lends credence to the use of organising 
frameworks of general entrepreneurship to study biotechnology entrepreneurship. 
 
The extension of existing literature represents an addition to the body of knowledge 
on biotechnology entrepreneurship in South Africa and Brazil. Furthermore, this 
provides an understanding of the process of biotechnology entrepreneurship in 
South Africa and Brazil, which is neither extrapolated from the developed economies 
nor inferred from general entrepreneurship. 
 
The exploratory nature of this research because of a paucity of empirical research on 
biotechnology entrepreneurship in South Africa and Brazil meant that existing 
literature was not contradicted. Instead, insights that were different from the existing 
literature on general entrepreneurship were designated as extension rather than 
contradiction since they could not be directly compared. 
 
These themes form the basis of understanding the dynamics of biotechnology 
entrepreneurship in South Africa and Brazil and the development of the proposed 
theoretical framework of biotechnology entrepreneurship in South Africa and Brazil. 
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PART V: CONCLUSIONS AND IMPLICATIONS 
 
Part V consists of Chapter 10. 
 
Chapter 10 contains the conclusions relative to the research questions, contributions 
made by this research, implications for stakeholders and recommendations for future 
research. 
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Chapter 10: Conclusions and implications 
 
This chapter concludes the thesis entitled “Dynamics of biotechnology 
entrepreneurship in South Africa and Brazil”. 
 
The sub-sections of this chapter present conclusions relative to research questions; 
the empirical contribution of this study to the literature; its methodological 
contribution to the literature; and theoretical contribution to the literature; policy and 
other implications for the government; implications for the other stakeholders; and 
recommendations for future research. 
 
10.1 Conclusions relative to research questions 
 
This section articulates how the research questions for this study were addressed by 
the outcome of the research. 
 
The methodological approach for this research was designed to achieve an in-depth 
understanding of the process of biotechnology entrepreneurship in South Africa and 
Brazil in their original contexts. The within-case analysis of each individual case, and 
the cross-case analysis of South Africa and Brazil; provide the themes that address 
the research questions. 
 
Research Question 1 
 
How do bioscientists carry out biotechnology entrepreneurship in the 
developing economies of South Africa and Brazil? 
 
The process of biotechnology entrepreneurship in South Africa and Brazil starts with 
bioscientists who have the necessary research and scientific skills to carry out 
bioscientific research. Given that the bioentrepreneurial opportunities are known in 
advance to be predominantly in the categories of problem and efficiency 
opportunities, the environment in which the process of biotechnology 
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entrepreneurship takes place plays a key role in determining the approach to the 
process. 
 
Where a system provides the support structures and entrepreneurial and 
commercialisation capabilities needed to commercialise research, the bioscientists 
adopt the systemic approach to the process of biotechnology entrepreneurship. The 
systemic approach is the approach that is practised in Brazil.  
 
On the other hand, where a system that provides the support structures and 
entrepreneurial and commercialisation capabilities needed to commercialise 
research is lacking, the bioscientists are forced to acquire entrepreneurial and 
commercialisation skills to commercialise their research effectively. Consequently, 
their practice of biotechnology entrepreneurship follows the individual approach. The 
individual approach is the approach that is practised in South Africa. 
 
The environment in which biotechnology entrepreneurship is practised in South 
Africa presents many challenges across the economic, political and cultural 
environments (Shane, 2003). Key among these challenges are an unfavourable 
policy and regulatory environment; lack of appropriate funding; lack of government 
direction; an unfavourable university culture; lack of aggregate skills and capacity; 
and a lack of a developed market for biotechnology products. 
 
By contrast, the environment in which biotechnology entrepreneurship is practised in 
Brazil presents challenges and positives. The challenges are across the economic, 
political and cultural environments (Shane, 2003). Key among them are an 
unfavourable policy and regulatory environment; lack of aggregate skills and 
capacity; and bureaucratic and inefficient government processes. 
 
On the other hand, the positives include the availability of appropriate funding, 
government-incentivised entrepreneurial activities, availability of large established 
biotechnology companies, availability of venture capital companies, and effective 
collaboration among the key stakeholders. 
The bioscientists in South Africa and Brazil operate in these environments to exploit 
bioentrepreneurial opportunities identified predominantly in the area of problem and 
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efficiency opportunities and occasionally innovation opportunities. In addition, 
abundant biodiversity is seen as a competitive source of bioentrepreneurial 
opportunities in South Africa and Brazil. 
 
The discovery of these bioentrepreneurial opportunities requires R&D. The intensity 
and the R&D spend in South Africa and Brazil are deemed to be below the levels of 
the developed economies, in this way negatively impacting on the effectiveness of 
the development of the biotechnology industry. 
 
The exploitation of these bioentrepreneurial opportunities requires effective 
collaboration of the stakeholders, specifically a strategic alliance of research 
institutions, venture capitalists, large established biotechnology companies and 
government. However, South Africa lacks the key stakeholders of venture capitalists 
and large established biotechnology companies. This forces the government into 
roles that are performed by these absent stakeholders in the developed economies. 
In Brazil all the key stakeholders are available, which makes the process of 
exploiting bioentrepreneurial opportunities similar to the process followed in the 
developed economies. 
 
The execution step of the process of biotechnology entrepreneurship involves the 
commercialisation of research. The commercialisation of research in South Africa 
and Brazil utilises both firm formation and licensing. In South Africa the process is 
deemed to be inefficient because of a lack of entrepreneurial and commercialisation 
skills. In addition, the challenges presented by the environment and inefficiencies in 
the stages of R&D and opportunity exploitation impact the effectiveness of the 
commercialisation of research. The commercialisation of research in Brazil is 
deemed to be efficient because of the efficiencies in the earlier parts of the 
biotechnology value chain and the availability of the system to enable the 
commercialisation of research. 
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Research Question 2 
 
How is biotechnology entrepreneurship conducted by bioscientists in 
developing economies similar to the process defined in the literature for 
developed economies? 
 
The similarities between the processes of biotechnology entrepreneurship in the 
developing economies and the process defined in the literature for developed 
economies are defined at two levels: the theoretical and the thematic levels. 
 
At a theoretical level, using the proposed theoretical framework for biotechnology 
entrepreneurship, the process of biotechnology entrepreneurship in South Africa and 
Brazil is similar to the process defined in the literature for developed economies. 
Hence, the process incorporates individual attributes, either as an individual model 
or systemic model; utilises bioentrepreneurial opportunities; engages in R&D; 
operates within an environment of industry, macroeconomic, and innovation and 
entrepreneurial conditions; exploits bioentrepreneurial opportunities through a 
strategic alliance of the biotechnology stakeholders; and commercialises research 
through firm formation or licensing. 
 
However, at the thematic level the similarities are restricted to certain components of 
the process. There are no thematic similarities between South Africa and the 
developed economies in the process of biotechnology entrepreneurship. In Brazil, 
these similarities include predominance of the systemic model to biotechnology 
entrepreneurship; a favourable overall environment for the development of 
biotechnology entrepreneurship; availability of entrepreneurial and commercialisation 
capabilities; effective collaboration among the stakeholders; effective government 
leadership and direction; availability of appropriate funding; and a developed market 
for biotechnology products. 
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Research Question 3 
 
How is biotechnology entrepreneurship conducted by bioscientists in 
developing economies different from the process defined in the literature for 
developed economies? 
 
The differences in the process of biotechnology entrepreneurship between the 
developing and developed economies are more defined at the thematic level. 
 
The thematic differences in the process of biotechnology entrepreneurship between 
South Africa and the developed economies include the predominance of the 
individual model to biotechnology entrepreneurship; the predominance of problem 
opportunities; the non-conducive regulatory environment; unfavourable overall 
environment for the development of biotechnology entrepreneurship; the low level of 
R&D spend; lack of an aggregate level of skills; lack of entrepreneurial and 
commercialisation skills; lack of effective collaboration among the stakeholders; lack 
of government leadership and direction; lack of appropriate funding; and an 
underdeveloped market for biotechnology products in South Africa.  
 
The thematic differences in the process of biotechnology entrepreneurship between 
Brazil and the developed economies include the predominance of efficiency 
opportunities; the non-conducive regulatory environment; the low level of R&D 
spend; and lack of an aggregate level of skills in Brazil. 
 
Research Question 4 
 
What are the factors that influence biotechnology entrepreneurship in 
developing economies, and how do they exert their influence? 
 
The factors that influence biotechnology entrepreneurship in South Africa and Brazil 
are determined as the means through which the stakeholders influence the 
theoretical framework of biotechnology entrepreneurship towards an outcome. 
Hence, the stakeholders control the factors, which in turn influence the theoretical 
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framework, which results in an outcome. The diagrammatical representation of this 
relationship is shown in Figure 10.1.  
 
 
Figure 10.1: Factors that influence the process of biotechnology 
entrepreneurship in South Africa and Brazil 
 
 
As shown in Figure 10.1, the government controls the factors of regulation, funding, 
infrastructure and market for biotechnology products; the research institutions control 
the factor of skills; the large biotechnology companies control the factors of funding, 
entrepreneurial and commercialisation capabilities, and market for biotechnology 
products; the venture capitalists control the factors of funding, and entrepreneurial 
and commercialisation capabilities; and the society controls the factor of social 
development. 
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The factors that influence the process of biotechnology entrepreneurship in South 
Africa and Brazil are regulation; funding; infrastructure; skills; entrepreneurial and 
commercialisation capabilities; market for biotechnology products; and social 
development. 
 
Regulation has the highest influence on the theoretical framework because it 
influences all the stages of the theoretical framework.  
 
In the experience of the respondents in South Africa and Brazil, the unconducive 
regulatory environment for biotechnology entrepreneurship impacted on intellectual 
property ownership (opportunity exploitation); technology transfer from the university 
to the industry (commercialisation of research); cost of doing business through 
taxation (environment); and availability of skills through labour laws (individual 
attributes and R&D). 
 
Funding, infrastructure and skills primarily influence R&D as well as opportunity 
exploitation, commercialisation of research, and the environment for the 
development of biotechnology entrepreneurship in South Africa and Brazil.  
 
In the experience of the respondents in South Africa and Brazil, the lack of these 
factors in South Africa influenced the framework items negatively and this was 
highlighted as a challenge. The reverse was true in Brazil, where these factors were 
available and were not highlighted as challenges. In both South Africa and Brazil, 
skills at individual level were deemed available, but the aggregate skills were 
deemed lacking. 
 
Entrepreneurial and commercialisation capabilities influence the exploitation of 
bioentrepreneurial opportunities and the commercialisation of research. 
 
In the experience of the respondents, these capabilities were lacking in South Africa 
and hence the exploitation of bioentrepreneurial opportunities and commercialisation 
of research were deemed ineffective. The lack of these capabilities may stem from 
the lack of the stakeholders that control these capabilities, namely large 
biotechnology companies and venture capitalists, in South Africa. These capabilities 
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were present in Brazil and hence the experience of the respondents regarding 
opportunity exploitation and commercialisation of research was positive. 
 
Markets for biotechnology products influence R&D; opportunity exploitation; and the 
commercialisation of research. 
 
In the experience of the respondents in South Africa and Brazil, the market for 
biotechnology products was deemed underdeveloped in South Africa and developed 
in Brazil. Consequently, the impacted framework items were deemed challenges in 
South Africa but not challenges in Brazil. 
 
Social development influences the environment for biotechnology development in 
South Africa and Brazil.  
 
In the experience of the respondents in South Africa and Brazil, the social linkages to 
biotechnology entrepreneurship were highlighted. However, social development was 
expressed as a need rather than a factor and hence there was not sufficient data in 
this research to designate social development as a challenge or not a challenge.   
 
Research Question 5 
 
What triple helix of university, industry, government relations are experienced 
by the stakeholders in the biotechnology industry of South Africa and Brazil? 
 
In the experience of the respondents in South Africa and Brazil, the government 
controls the relationship with the university and the industry, through the factors of 
regulation, funding, infrastructure and market for biotechnology products. 
 
The factors within government’s control allow it to influence the overall environment 
of biotechnology entrepreneurship in South Africa and Brazil, in which the university 
and industry participate as stakeholders. 
 
In the South African biotechnology industry, the government has a near monopoly of 
the factors. For this reason the triple helix relation in South Africa is at what is 
305 
 
described by Etzkowitz and Leydesdorff (2000) as Triple Helix I, which represents a 
configuration in which the government encompasses both industry and university 
and directs the interaction and relations between them. 
 
The experience of the triple helix relations by the respondents in South Africa was 
deemed inefficient and instances of competition within the stakeholder groups were 
mentioned, instead of the expected collaboration within and among the stakeholders. 
 
There is an indication from this research that South Africa will not go through a 
sequential progression to Triple Helix II and III, but may progress to a form of a 
Quadruple Helix that includes the society as a fourth stakeholder (Afonso et al., 
2010; Marcovich and Shinn, 2011; Afonso et al., 2012; Leydesdorff, 2012).  
 
In the Brazilian biotechnology industry, the government does not have a monopoly of 
the factors; hence, the triple helix relation in Brazil is a hybrid of what is described by 
Etzkowitz and Leydesdorff (2000) as Triple Helix I, which represents a configuration 
in which the government encompasses both industry and university and directs the 
interaction and relations between them, and Triple Helix III, in which overlapping 
institutional spheres generate a knowledge infrastructure, with overlapping roles and 
hybrid organisations emerging at the interfaces.  
 
The unique dynamic in Brazil is that Triple Helix III characteristics are exhibited but 
with a direct control from the government, which is a characteristic of Triple Helix I. 
With every indication of a continued government control, improvement of the 
environment for Triple Helix III to flourish and strong social linkages, there may be a 
possibility that the evolution of the Triple Helix in Brazil will go the route of the 
“Quadruple Helix of government-controlled university, industry, society relations”. 
 
In light of the above, it can be concluded that the triple helix of university, industry, 
government relations experienced by the stakeholders in the biotechnology industry 
of South Africa and Brazil is a hybrid of the existing triple helix models, with a strong 
possibility of progressing to a quadruple helix that includes the society as a fourth 
stakeholder. 
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10.2 Empirical contributions to the literature 
 
The main empirical contribution of this research to the literature is the contribution to 
the body of knowledge, which addresses the gap created by the paucity of empirical 
research on biotechnology entrepreneurship in the context of developing economies. 
Most of the current empirical research is carried out in developed economies, as 
single case studies using a nomothetic philosophical approach (Guba and Lincoln, 
1994; Chandler and Lyon, 2001), and cannot be directly extrapolated to developing 
economies because of differences at individual, institutional and environmental 
levels between the developed and developing economies (Lingelbach et al., 2005). 
 
Most research related to biotechnology entrepreneurship is conducted as either 
empirical general entrepreneurship research (Baumol, 1993; Ács and Audretsch, 
2003; Shane, 2003; Lingelbach et al., 2005; Audretsch and Lehmann, 2005a; 
Alvarez and Barney, 2007; Lingelbach et al., 2008; Acs, 2010; Lingelbach et al., 
2013) or biotechnology industry research (Cloete et al., 2006; Gastrow, 2008; 
Natesh and Bhan, 2009; Ernst & Young, 2010b; Ahn and York, 2011; Meyers and 
Pruthi, 2011; Ahn et al., 2012; Battelle/Biotechnology Industry Organisation, 2012; 
Organisation for Economic Cooperation and Development, 2013a), as the field of 
biotechnology entrepreneurship is relatively new (Meyers, 2012). 
 
Few empirical research studies are specific to biotechnology entrepreneurship 
(Schoemaker and Schoemaker, 1998; Müller et al., 2004; Audretsch et al., 2008; 
Carsrud, Brännback and Renko, 2008; Oliver, 2008; Gunn, Dever, Tzagarakis-
Foster, Lorton Jr, Kane and Masterson, 2013).  
 
Furthermore, of the empirical research that is specific to biotechnology 
entrepreneurship, most studies are specific to the developed economies and few are 
specific to the developing economies (Onyeka, 2011). The paucity of empirical 
research on biotechnology entrepreneurship in the developing economies’ context 
creates a gap that this research seeks to address.  
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In the words of Audretsch et al. (2008): 
 
The exact role of entrepreneurship in industries such as biotechnology has 
generally eluded the analytical lens of scholars. (Audretsch et al., 2008)  
 
The late twentieth century has witnessed a scientific gold rush of 
astonishing proportions: the headlong and furious haste to commercialise 
genetic engineering. This enterprise has proceeded so rapidly – with so 
little outside commentary – that its dimensions and implications are hardly 
understood at all. (Audretsch et al., 2008:179) 
 
In contributing to addressing the gap created by the paucity of literature on 
biotechnology entrepreneurship in South Africa and Brazil, an in-depth 
understanding of the process of biotechnology entrepreneurship in these two 
countries was achieved.  
 
The process of biotechnology entrepreneurship in South Africa utilises the individual 
model of biotechnology entrepreneurship due to the challenges presented by the 
environment. While the process of biotechnology entrepreneurship in South Africa is 
theoretically similar to the developed economies, it is thematically different to the 
developed economies and this contributed to the observed differences between the 
output of biotechnology entrepreneurship in South Africa and the developed 
economies. 
 
The process of biotechnology entrepreneurship in Brazil utilises the systemic model 
of biotechnology entrepreneurship due to the overall conducive environment for 
biotechnology entrepreneurship. The process of biotechnology entrepreneurship in 
Brazil is theoretically similar to the developed economies and also thematically 
similar to the developed economies in certain areas. This may have contributed to 
the observed successes of biotechnology entrepreneurship in Brazil. 
 
Another empirical contribution of this research is the identification of the thematic 
similarities and differences between South Africa and Brazil and the developed 
economies, based on the experience of the respondents for this research.  
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The thematic differences of the process of biotechnology entrepreneurship between 
South Africa and the developed economies provide a deeper understanding of the 
observed differences between the biotechnology industry in South Africa and the 
developed economies.  
 
On the other hand, the thematic similarities of the process of biotechnology 
entrepreneurship between Brazil and the developed economies provide a deeper 
understanding of the observed similarities between the biotechnology industry in 
Brazil and the developed economies. 
 
Another empirical contribution of this research is the identification of the factors that 
influence biotechnology entrepreneurship in South Africa and Brazil, and how these 
factors exert their influence. A framework (see Figure 10.1) for the relationship 
across stakeholders, the factors, the proposed theoretical framework, and the 
outcome of biotechnology entrepreneurship guided the identification of the factors.  
 
These seven factors: regulation, funding, infrastructure, skills, entrepreneurial and 
commercialisation capabilities, market for biotechnology products, and social 
development, exert their respective influences on different components of the 
theoretical framework and are controlled by the stakeholders, who are: government, 
research institutions, large biotechnology companies, venture capitalists and society.        
 
A further empirical contribution of this study is the articulation of the nature of the 
triple helix relations experienced by the respondents in South Africa and Brazil. The 
respondents in South Africa experienced a lack of effective collaboration among the 
key stakeholders in biotechnology entrepreneurship. Consequently, a triple helix I 
model is practised in South Africa, in which the government controls the relationship 
between the university and industry. However, the inclusion of the society in a 
quadruple helix will see South Africa go from triple helix 1 to a quadruple helix 
without going sequentially through triple helix II and III as advocated in the literature 
(Etzkowitz and Leydesdorff, 2000). 
 
The respondents in Brazil experienced effective collaboration among the key 
stakeholders in biotechnology entrepreneurship. A hybrid model of triple helix I and 
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III is practised in Brazil, in which government control, characteristic of triple helix I, is 
combined with the generation of knowledge infrastructure, characteristic of triple 
helix III. Similarly, triple helix II is bypassed and a possibility exists of implementing a 
quadruple helix that includes the society due to the strong social linkages. 
 
10.3 Methodological contributions to the literature 
 
The few studies on biotechnology entrepreneurship, in developing economies, 
employ mostly survey methodology and single case studies within one developing 
economy. The use of qualitative multiple case studies, in the idiographic 
philosophical tradition, in two developing economies, is deemed to enrich the 
discourse in biotechnology entrepreneurship and hence make a contribution to the 
knowledge of biotechnology entrepreneurship in developing economies. 
 
A qualitative multiple case study method was used for this study, at a country level of 
analysis. The use of a holistic multiple case study approach provided the opportunity 
for literal and theoretical replication (Yin, 2009). The case selection was purposefully 
aimed at good candidates for biotechnology entrepreneurship in the developing 
economies with sufficient similarity, and variability, to provide a suitable context for 
this research (Yin, 2009).  
 
Within the cases, the selection of the respondents was based on individuals with a 
high degree of knowledge on and competence in the research topic (Romney et al., 
1986; Bowen, 2008) and who have either commercialised a biotechnological 
innovation through firm formation or licensing or are SMEs in the area of 
biotechnology entrepreneurship affiliated to the university, industry or government. In 
addition, industry policy and research documents from credible organisations such 
as the OECD, Ernst & Young, BIO, and Battelle were reviewed and coded for this 
research to augment the in-depth interviews in providing a complete and triangulated 
view of the dynamics of biotechnology entrepreneurship in South Africa and Brazil 
from multiple sources.  
 
310 
 
Semi-structured in-depth interviews were conducted with the bioscientists and SMEs 
using the earlier developed interview guide (see Appendices E and F) and the case 
study protocol (see Appendix D). The development of the interview guide was guided 
by the literature review, the research questions and the organising frameworks for 
this research. 
 
A CAQDAS called Atlas.ti version 7.1.6 was used for the data analysis. The use of 
Atlas.ti aided rapid, consistent and rigorous qualitative data analysis (Weitzman, 
1999; Rambaree, 2007; Hwang, 2008), and extended the researcher’s ability to 
organise, remember and be systematic (Zdenek, 2008).  
 
Another methodological contribution of this research was the use of Atlas.ti CAQDAS 
to demonstrate data saturation for both cases (see Figures 4.6 and 4.7 respectively). 
The definition of saturation in this context is the point where few or no new codes 
(insights) are generated from additional respondents or documents (Morse et al., 
2002; Guest et al., 2006). The literature on how to demonstrate saturation is sparse, 
even though it is considered to be a desirable feature of good qualitative research 
(Guest et al., 2006). 
 
The case narratives provided a rich, “thick” description of the experiences of the 
respondents within a real-life context (Eisenhardt and Graebner, 2007b; Yin, 2009) 
of biotechnology entrepreneurship, which guided the identification of patterns and 
themes towards theory development (Carroll and Swatman, 2000; Eisenhardt and 
Graebner, 2007b; Welch et al., 2011; Klonoski, 2013). 
 
The framework for presenting the case narratives and analyses was derived from 
literature and guided by the interview guide and case study protocol, as well as the 
organising frameworks of the individual-opportunity nexus framework of 
entrepreneurship and the triple helix of university, industry, government relations. 
The within-case analysis was conducted for each of the two cases to identify the 
emerging patterns. This represented a further aggregation of data to a higher level of 
abstraction towards theory building (Lillis, 1999; Miles and Huberman, 1999; 
Eisenhardt and Graebner, 2007b; Klonoski, 2013).  
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The cross-case analysis of the combined cases yielded themes that were compared 
to the literature to deepen interpretation and understanding, as well as enhance 
generalisability (Eisenhardt and Graebner, 2007b; Welch et al., 2011; Klonoski, 
2013). The themes formed the basis of the proposed theoretical framework of 
biotechnology entrepreneurship in South Africa and Brazil. 
 
10.4 Theoretical contributions to the literature 
 
The main theoretical contribution of this research is the development of a theoretical 
framework of biotechnology entrepreneurship, which defines the dynamics of 
biotechnology entrepreneurship in South Africa and Brazil.  
 
The research followed the idiographic tradition, defining themes that are tested 
against literature. The proposed theoretical framework of biotechnology 
entrepreneurship is based on the themes that emerged from the cross-case analysis 
of the process of biotechnology entrepreneurship in South Africa and Brazil. The 
within-case analysis of each case incorporated the lived experiences of the 
bioscientists, bioentrepreneurs, and SMEs in biotechnology entrepreneurship in 
South Africa and Brazil. 
 
At the time of this research, there is no known theoretical framework of 
biotechnology entrepreneurship, especially from a developing economies’ context. 
 
The theoretical framework incorporates the individual attributes that define the 
psychological and non-psychological orientations of the bioscientists involved in 
biotechnology entrepreneurship. In addition to cognition and motivation, education 
and experience in the field of bioscience are necessary individual attributes. The 
process of biotechnology entrepreneurship in South Africa and Brazil was shown to 
work according to an individual model and systemic model respectively.  
 
The theoretical framework also defines the bioentrepreneurial opportunities as pre-
existing in one of the three areas of problem, efficiency or innovation opportunities, 
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with problem and efficiency opportunities predominating in South Africa and Brazil 
respectively. 
 
The environmental context of the theoretical framework consists of industry and the 
macroeconomic environment, as well as innovation and entrepreneurial conditions. 
Regulation, funding, infrastructure, skills, entrepreneurial and commercialisation 
capabilities, market for biotechnology products, and social development are the key 
factors that impact on the environmental context of biotechnology entrepreneurship 
in South Africa and Brazil. 
 
R&D is defined in the theoretical framework as a unique form of opportunity 
discovery or creation in biotechnology entrepreneurship. In South Africa and Brazil, 
the abundance of genetic materials as raw materials for R&D, through the 
biodiversity, is considered a competitive advantage. 
 
The exploitation of bioentrepreneurial opportunities, in the theoretical framework, 
requires effective collaboration among the key stakeholders, consisting of 
government, research institutions, venture capitalists and large companies. 
According to the respondents for this study, all the stakeholders are present in Brazil, 
while South Africa lacks the venture capitalists and large biotechnology companies. 
 
The theoretical framework defines the commercialisation of research as the 
culmination of the process of biotechnology entrepreneurship. This is achieved either 
through firm formation or licensing. The effective collaboration required throughout 
the framework also plays a part in effective commercialisation of research. 
 
Although this theoretical framework cannot be generalised to all developing 
economies, it provides the means to study the process of biotechnology 
entrepreneurship in other developing and developed economies. The in-depth 
understanding of the process of biotechnology entrepreneurship in South Africa and 
Brazil informs policy recommendation for the government and recommendations for 
other industry stakeholders. 
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10.5 Policy and other implications for the government 
 
The theoretical contribution of this research has policy implications for the 
government as a policymaker and government agencies responsible for formulating 
and implementing policies related to biotechnology entrepreneurship. 
 
One of the themes identified through the cross-case analysis is “the government 
plays an important role in biotechnology entrepreneurship in South Africa and Brazil”. 
In addition, the policy and regulatory environment was among the top challenges 
identified for the development of biotechnology entrepreneurship in the developing 
economies that provided the focus of this research. 
 
The role of government in providing a favourable environment for the development of 
biotechnology entrepreneurship includes legislation on the national biotechnology 
strategy, policies on public research institutions, policies related to research funding, 
intellectual property policies, regulations on university-industry technology transfer, 
regulations on taxation, labour laws, policies on the acquisition of scarce skills, 
policies on science and mathematics in the education curriculum, and policies 
related to regional and international collaboration on biotechnology entrepreneurship. 
 
The government also controls most of the factors that influence the process of 
biotechnology entrepreneurship in South Africa and Brazil, and hence should utilise 
this leverage to foster an environment that is conducive for the development of 
biotechnology entrepreneurship. 
 
The availability of the relevant policies and regulations; the effectiveness of 
implementing these policies by the government agencies; and the leadership and 
direction provided by government were highlighted as some of the differences 
between the developed and developing economies.  
 
The governments of South Africa and Brazil should endeavour to review the policies 
and regulations related to biotechnology entrepreneurship regularly to ensure that 
they are aligned to the needs of the industry. They should ensure the effective 
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implementation of such policies and regulations through appropriate resourcing and 
mandates and continuously monitor the experience of the stakeholders in the 
industry to assess the relevance of the policies and regulations. 
 
The empirical contributions of this research have other implications for the 
government. The government plays the roles of facilitator, buyer of biotechnology 
products and solutions, and funder, in addition to the role of providing a favourable 
policy and regulatory environment. This makes it an important component of the 
value chain. 
 
The facilitation role of the government includes the provision of leadership, 
infrastructure, capacity, research institutions and platforms for local and international 
collaborations among key stakeholders. The role of government as a buyer is 
necessitated by the social obligation of government to provide improved healthcare, 
food security, energy sufficiency and sustainable environmental practices. The role 
of the government as a funder includes the funding of R&D, infrastructure funding 
and project funding. 
 
It is recommended that the government of South Africa, in particular, find effective 
ways of delivering on these roles to create a conducive environment for the 
development of biotechnology entrepreneurship.  
 
The empirical and theoretical contributions of this research are expected to inform 
government policy formulation and implementation related to the development of 
biotechnology entrepreneurship in South Africa and Brazil. 
 
10.6 Implications for the other stakeholders 
 
The empirical contribution of this research has implications for the other stakeholders 
involved in the biotechnology industry, such as the research institutions, venture 
capitalists, large biotechnology companies and bioentrepreneurs. 
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A clearer understanding of the dynamics of biotechnology entrepreneurship in 
developing economies is expected to aid decision making related to the 
biotechnology entrepreneurship by these stakeholders. There are multiple points of 
stakeholder collaboration and strategic alliances in the proposed theoretical 
framework for biotechnology entrepreneurship. These are in the environment for 
biotechnology entrepreneurship; R&D; opportunity exploitation; and 
commercialisation of research. 
 
The research institutions need to review their policies on intellectual property and the 
transfer of technology from the university to the industry, in alignment with similar 
policies by the government. This was highlighted as one of the gaps in the 
development of biotechnology entrepreneurship in these developing economies. 
Furthermore, the culture of the universities and research institutions needs to be 
changed from prioritising publication to being focused on commercialisation of 
research to realise economic and social value.  
 
The understanding of the dynamics of biotechnology entrepreneurship in these 
developing economies, especially in South Africa where there is a lack of a 
developed venture capital industry, will aid the venture capitalists in understanding 
the peculiarities of the environment, the challenges and gaps, the role of the 
government and the opportunities that can be exploited. Importantly, the lessons 
from the success of the venture capital market in Brazil can be implemented in South 
Africa, given an enabling regulatory environment. 
 
The absence of large biotechnology companies was highlighted as one of the gaps 
in South Africa. Given the involvement of the large biotechnology companies in 
major R&D; their role as cooperation partners, customer and competitor; and the 
availability of good research universities and skilled researchers in South Africa, 
there is an opportunity for the large biotechnology companies to seek out 
collaboration opportunities in South Africa, provided the enabling environment 
expected to be provided by the government is in place. Similarly, they can use their 
expertise in Brazil to enter the South African biotechnology industry. 
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The seven factors that influence the process of biotechnology entrepreneurship in 
South Africa and Brazil, identified in this research, are controlled by the stakeholders 
in various degrees. This provides clarity on the scope of control and influence 
available to each stakeholder in the biotechnology industry. 
 
10.7 Recommendations for future research 
 
The proposed theoretical framework of biotechnology entrepreneurship should be 
empirically tested for its applicability to the context of other developing economies 
apart from those used for this research. 
 
In addition, the proposed theoretical framework of biotechnology entrepreneurship 
should be empirically tested for its applicability to the context of developed 
economies, given the global nature of biotechnology entrepreneurship. 
 
Another area of possible future research related to the proposed theoretical 
framework of biotechnology entrepreneurship is in the evaluation of the relative 
contribution of the components of the framework to the success of biotechnology 
entrepreneurship in a particular context. 
 
It is recommended that the factors that influence the process of biotechnology 
entrepreneurship be tested in different contexts. In addition, further study of the 
influence of the social development factor is recommended to understand how this 
influence is exerted. 
 
This research also uncovers possible deviations from the triple helix of university, 
industry, government relations model (Etzkowitz and Leydesdorff, 2000), which 
involves a hybrid model that retains government control and influence, while seeking 
to create a knowledge economy. Another area of possible future research is to study 
how the triple helix model is applicable to the developing economies. 
 
In addition, the social linkages and the intentions of implementing a quadruple helix 
of university, industry, government, society relations (Afonso et al., 2010; Marcovich 
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and Shinn, 2011; Afonso et al., 2012; Leydesdorff, 2012) in a developing economy 
context are recommended for further research. 
 
It is recommended that future research in the field of biotechnology entrepreneurship 
utilise a qualitative multiple case study approach in order to understand the “how” 
and “why” of the phenomenon of biotechnology entrepreneurship in its original 
context (Creswell, 2009; Yin, 2009). 
 
Finally, given the limitations of this study in terms of purposive sampling and the 
language barrier, it is recommended that future research use a different sampling 
methodology and conduct the research in the native language of the context in 
question. 
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Appendix A: Participation information sheet 
 
Dear Respondent, 
I am a doctoral student at WITS business school, University of Witwatersrand, 
Johannesburg, South Africa. I am working on a doctoral study titled: “Dynamics of 
biotechnology entrepreneurship in South Africa and Brazil”. The research proposal 
for this study was approved by the university panel on the 29th of September 2011, 
and all academic and ethics requirements needed for the research to proceed have 
been met.  
This exploratory study is expected to lead to a practical understanding of the process 
of biotechnology entrepreneurship in these two developing economies, which is 
expected to guide government policy-making and stakeholders involved in 
biotechnology entrepreneurship towards optimising the potentials of biotechnology in 
the twenty first century. 
Case study method will be used and this requires in-depth interviews of respondents. 
I have identified you as an ideal candidate for this study and will appreciate it if you 
accept the invitation to participate in this study. Each interview will last about two 
hours and will be tape-recorded to ensure accuracy of information when transcribed. 
There may be more than one interview session, or a need for a follow up. I will also 
request to have access to recent and archived documents relevant to the study.  
Anonymity is guaranteed through coding of interview transcripts and information from 
other sources. The researcher will also sign a confidentiality and non-disclosure 
agreement provided by you. In addition, draft write-up of all information and 
conversation will be verified with you for accuracy before the final version is 
produced. 
Should you require further clarification of any aspect of this study, my contact details 
are: Cell phone: 072 922 0206; Office: 011 631 2957; Office email: 
Manessah.Alagbaoso@standardbank.co.za; Home email: manessah@iburst.co.za 
My supervisors’ contact details are: Prof. Terri Carmichael – 
Terri.Carmichael@wits.ac.za and Dr Kerrin Myres – resonate@icon.co.za 
I look forward to your participation in this study and do thank you in anticipation. 
Yours sincerely, 
Alagbaoso Manessah 
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Appendix B: Letter of acceptance to participate in the study 
 
I ………………………………………………… do accept to participate in the doctoral 
research titled: “Dynamics of biotechnology entrepreneurship in South Africa and 
Brazil”, which is being carried out by Manessah Alagbaoso of the Wits Business 
School, University of Witwatersrand, Johannesburg, South Africa.   
I confirm that my participation is voluntary and I will provide information that upholds 
the integrity and quality of the research outcome. 
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Appendix C: Letter of consent for interview to be tape-recorded 
 
I ………………………………………………… do consent to the tape-recording of the 
interview of which I am an interviewee. I understand that the purpose of tape-
recording the interview is to ensure an accurate representation of the interview 
discussion.  
 
In addition, I understand that this interview is necessary for the doctoral research 
titled: “Dynamics of biotechnology entrepreneurship in South Africa and Brazil”, 
which is being carried out by Manessah Alagbaoso of the Wits Business School, 
University of Witwatersrand, Johannesburg, South Africa.   
 
I confirm that my participation and my consent for the interview to be tape-recorded 
are voluntary and I will provide information that upholds the integrity and quality of 
the research outcome. 
 
 
 
 
Signed: ………………………………                 Date: …………………………………… 
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Appendix D: Case Study Protocol 
 
1. Introduction to the Case study and purpose of the protocol 
This case study aims to explore the dynamics of biotechnology entrepreneurship, in 
its real-life context, in South Africa and Brazil. The in-depth understanding of the 
process of biotechnology entrepreneurship in these two developing economies will 
provide a basis for policy and decision-making related to biotechnology 
entrepreneurship that is specific to the contexts of these developing economies. 
The purpose of the protocol is to guide the operational conduct of the data collection 
procedure by the investigator in a single case, which forms part of the multiple 
cases. 
 
1.1 Case study questions 
Question 1 - relates to the dynamics of biotechnology entrepreneurship in South 
Africa (if the case in question is in South Africa); and the dynamics of biotechnology 
entrepreneurship in Brazil (if the case in question is in Brazil) 
Question 2 - relates to the similarities between the process of biotechnology 
entrepreneurship in the developed and developing economies 
Question 3 – relates to the differences between the process of biotechnology 
entrepreneurship in the developed and developing economies 
Question 4 - relates to the factors that influence the process of biotechnology 
entrepreneurship developing economies 
Question 5 – relates to the Triple Helix of University, Industry and Government 
 
Note: These questions are aligned to the theoretical framework and propositions; 
and will be posed at the individual level of analysis. 
 
 
1.2 Theoretical framework and propositions 
The organising frameworks for this case study are the individual-opportunity nexus 
framework of entrepreneurship; and the triple helix of university, industry, 
government relations.  
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The components of the individual-opportunity nexus framework of entrepreneurship 
are:  
i. Individual attributes of the bioscientist 
ii. Environment 
iii. Entrepreneurial opportunities 
iv. Discovery  
v. Entrepreneurial exploitation  
vi. Execution 
 
The components of the triple helix of university, industry, government relations are:  
i. Triple Helix I 
ii. Triple Helix II 
iii. Triple Helix III 
 
The theoretical propositions based on the literature and organising frameworks are: 
Proposition 1 – the case study will show how biotechnology entrepreneurship in 
developing economies is carried out by the bioscientists 
Proposition 2 – the case study will show similarities in the process of biotechnology 
entrepreneurship between the developed and developing economies 
Proposition 3 – the case study will show differences in the process of biotechnology 
entrepreneurship between the developed and developing economies 
Proposition 4 - the case study will show the factors that influence the process of 
biotechnology entrepreneurship in developing economies 
Proposition 5 – the case studies will show the applicable Triple Helix of University, 
Industry, Government relations that is practiced in South Africa and Brazil as it 
relates to biotechnology entrepreneurship 
Note: that the five case study questions are aligned to these five propositions 
respectively. 
1.3 Role of protocol in guiding the case study investigator 
The protocol is a standardised agenda for the investigator’s line of inquiry.  The 
effective use of the protocol for each case in the multiple case study guarantees 
uniformity of data collection aligned to the research questions, theoretical framework 
and propositions. This is expected to enhance the reliability of the research. 
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2. Data collection procedures 
The details of the data collection procedure are populated in the table below. 
 
2.1 Details of cases to be visited 
Country 
Interviews  
Documents 
Designation Date 
South Africa 
 5 – Nicholas Duneas 
 11 – Ashley Uys 
 12 – Michael Pepper 
 14 - Reinhard Hiller 
 15 – Kit Vaughan 
 16 – Justine Devine 
 17 - Louis Roux 
 
Bioentrepreneur 2012/2013 
 2 – Duncan 
Raftesath 
Subject Matter Expert - 
University 
2012 
 13 – Heather 
Sherwin 
 
Subject Matter Expert - 
Industry 
 
 1 – Ben Durham 
 3 – Mohammed 
Sayed 
 4 – Vinesh Maharaj 
 
Subject Matter Expert - 
Government 
2011/2012 
 12 – Michael Pepper 
 15 – Kit Vaughan 
 16 – Justine Devine 
 17 - Louis Roux 
Both bioentrepreneur and 
SME 
 2013 
 National bio-
economy strategy 
 Technology 
Innovation Agency 
Documents  
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Country 
Interviews  
Documents 
Designation Date 
(TIA) Act  
 WITS University 
Intellectual Property 
Policy  
 
Brazil 
 6 – Dario 
Grattapaglia 
 8 - Paulo Arruda 
Bioentrepreneur 
 
2012 
 6 – Dario 
Grattapaglia 
 7 – Valeria Judice 
 8 - Paulo Arruda 
 9 – Ruy Caldas 
 
Subject Matter Expert - 
University 
2012 
 7 – Valeria Judice 
 9 – Ruy Caldas 
Subject Matter Expert - 
Industry 
2012 
 6 – Dario 
Grattapaglia  
 8 - Paulo Arruda 
 9 – Ruy Caldas 
 10 - Conceicao 
Vedovello 
Subject Matter Expert - 
Government 
2012 
 6 – Dario 
Grattapaglia 
 8 - Paulo Arruda 
Both bioentrepreneur and 
SME 
2012 
 National 
biotechnology 
development policy 
 FAPESP creation, 
structural and co-
Documents  
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Country 
Interviews  
Documents 
Designation Date 
ordination  
 OECD Biotechnology 
Industry documents 
 
 
2.2 Data collection plan 
The data collection plan includes multiple sources of evidence as listed: 
i. Interviews with the bioscientists and subject matter experts 
ii. Documents - formal prior studies of the same case, administrative documents, 
company reports, and media reports pertaining to the bioscientists 
iii. Archival records - records pertaining to the bioscientists 
iv. Direct observation - researcher to be present in the real-life environment of 
the cases where applicable 
 
 
2.3 Expected preparation prior to site visits 
Prior to site visits, the investigator is expected to: 
i. Have background knowledge of the bioscientist or subject matter expert, if 
possible, from electronic sources, published works, previous case studies and 
information available in the media  
ii. Review the case study protocol 
iii. Re-confirm the appointment 
iv. Ensure that all equipments (laptop, tape recorder) and materials (writing 
materials) are ready and in good working order 
 
 3. Outline of case study report 
The outline of the case study report is expected to be as shown below, but the 
researcher will maintain enough flexibility to review the outline as the case study 
develops. 
i. The dynamics of biotechnology entrepreneurship in developing economies 
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ii. The similarities between biotechnology entrepreneurship in developed and 
developing economies 
iii. The differences between biotechnology entrepreneurship in developed and 
developing economies 
iv. The factors that influence biotechnology entrepreneurship in developing 
economies 
v. The dynamics of the Triple Helix of University-Industry-Government relations 
in South Africa and Brazil 
vi. Empirical, theoretical and methodological contributions of the study 
vii. Policy implications for the government 
viii. Decision-making implications for other biotechnology stakeholders 
ix. Recommended areas of further research 
 
 
 
4. Case study questions 
1. The dynamics of biotechnology entrepreneurship in developing economies 
i. Describe how the commercialisation of your intellectual property came into 
being in detail. (For an SME this question is adapted to: What is you’re his 
role in the biotechnology industry in South Africa or Brazil?) 
ii. What are your views on the dynamics of biotechnology entrepreneurship in 
South Africa? 
i.  
ii. Describe your operations in details. This need to cover the following areas: 
a. Your individual role, at psychological and non-psychological levels 
b. The effect of environmental factors, emphasising the economic, 
political and cultural environments 
c. The details of bioentrepreneurial opportunities; how they are 
discovered and why particular opportunities are pursued 
d. The process of research and development 
e. The process of entering into strategic alliances 
f. The process of commercialisation of intellectual property 
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2. The similarities between the process of biotechnology entrepreneurship in the 
developed and developing economies. 
i. In what ways is biotechnology entrepreneurship in developing economies 
similar to the developed economies? 
 
3. The differences between the process of biotechnology entrepreneurship in the 
developed and developing economies. 
i. In what ways is biotechnology entrepreneurship in developing economies 
different from the developed economies? 
 
4. The factors that influence biotechnology entrepreneurship in developing 
economies. 
i. What are the factors that influence biotechnology entrepreneurship in 
developing economies? 
 
5. The dynamics of the Triple Helix of University-Industry-Government relations 
in a developing economy context. 
i. From which of the three perspectives, University, Industry, Government, do 
you operate? 
ii. Do you perceive your role to be fully contained within one perspective or 
cutting across the different perspectives? If yes, which ones? 
iii. What are the dynamics at play with the relations between these three 
perspectives? 
iv. What are the sub-dynamics at play within your own perspective and across 
these three perspectives? 
v. How would you access the efficacy of the current relations between the 
University, Industry and Government? 
vi. What are the positives of the current relations between the three 
perspectives? 
vii. What are the constraints of the current relations between the three 
perspectives? 
viii. What would be ideal relations between the University, Industry and 
Government, for biotechnology entrepreneurship in a developing economy 
like South Africa and Brazil? 
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Appendix E: Interview guide - Bioentrepreneur 
 
The interview guide gives a general outline of the type of interview questions needed 
to cover all the relevant aspects of the study. Given that this will be semi-structured 
interview, the exact questions posed during the interview may differ slightly but will 
convey the same meaning and understanding. 
 
Preliminaries 
i. Formal introduction and thank the interviewee for his/her participation 
ii. Clarification of the purpose of the interview and the study, and confirmation of 
the duration of the interview 
iii. Indicate that the interview will be tape-recorded and get interviewee consent 
for that 
iv. Give the interviewee opportunity to ask questions before the interview 
commences 
 
Likely interview questions 
1. The dynamics of biotechnology entrepreneurship in developing economies 
iii. How did your career as a bioscientist get started?  
iv. What skills are required at individual level in order to engage in biotechnology 
entrepreneurship?  
v. Why are these skills important for biotechnology entrepreneurship? 
vi. How does the economic environment affect your operations? 
vii. How does the political environment affect your operations? 
viii. How does the cultural environment affect your operations? 
ix. What are the bioentrepreneurial opportunities that you see that exist in this 
economy? 
a. How are these opportunities discovered? 
x. How do you carry out research and development? 
xi. How do you engage in strategic alliances? 
xii. Why do you engage in strategic alliances? 
xiii. What strategy do you employ to commercialise your intellectual property? 
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xiv. Why do you employ this particular strategy to commercialise your intellectual 
property? 
 
2. The similarities between the process of biotechnology entrepreneurship in the 
developed and developing economies. 
i. How is your process of biotechnology entrepreneurship similar to 
bioentrepreneurship in developed economies? 
 
3. The differences between the process of biotechnology entrepreneurship in the 
developed and developing economies. 
i. How is your process of biotechnology entrepreneurship different from 
bioentrepreneurship in developed economies? 
 
 
4. Factors that influence biotechnology entrepreneurship in developing 
economies. 
i. What are the factors that influence your process of biotechnology 
entrepreneurship? 
 
5. The dynamics of the Triple Helix of University-Industry-Government relations 
in a developing economy context. 
ix. From which of the three perspectives, University, Industry, Government, do 
you operate? 
x. Do you perceive your role to be fully contained within one perspective or 
cutting across the different perspectives? If yes, which ones? 
xi. What are the dynamics at play with the relations between these three 
perspectives? 
xii. What are the sub-dynamics at play within your own perspective and across 
these three perspectives? 
xiii. How would you access the efficacy of the current relations between the 
University, Industry and Government? 
xiv. What are the positives of the current relations between the three 
perspectives? 
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xv. What are the constraints of the current relations between the three 
perspectives? 
xvi. What would be ideal relations between the University, Industry and 
Government, for biotechnology entrepreneurship in a developing economy 
like South Africa and Brazil? 
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Appendix F: Interview guide – Subject Matter Expert 
 
The interview guide gives a general outline of the type of interview questions needed 
to cover all the relevant aspects of the study. Given that this will be semi-structured 
interview, the exact questions posed during the interview may differ slightly but will 
convey the same meaning and understanding. 
 
Preliminaries 
v. Formal introduction and thank the interviewee for his/her participation 
vi. Clarification of the purpose of the interview and the study, and confirmation of 
the duration of the interview 
vii. Indicate that the interview will be tape-recorded and get interviewee consent 
for that 
viii. Give the interviewee opportunity to ask questions before the interview 
commences 
 
Likely interview questions 
1. The dynamics of biotechnology entrepreneurship in developing economies 
xv. What is your role in the biotechnology industry in South Africa? 
xvi. What are your views on the dynamics of biotechnology entrepreneurship in 
South Africa? 
xvii. How does the economic environment affect biotechnology entrepreneurship in 
South Africa? 
xviii. How does the political environment affect biotechnology entrepreneurship in 
South Africa? 
xix. How does the cultural environment affect biotechnology entrepreneurship in 
South Africa? 
xx. What are the bioentrepreneurial opportunities that you see that exist in this 
economy? 
a. How are these opportunities discovered? 
 
2. The similarities between the process of biotechnology entrepreneurship in the 
developed and developing economies. 
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ii. How is your process of biotechnology entrepreneurship similar to 
bioentrepreneurship in developed economies? 
 
3. The differences between the process of biotechnology entrepreneurship in the 
developed and developing economies. 
ii. How is your process of biotechnology entrepreneurship different from 
bioentrepreneurship in developed economies? 
 
4. Factors that influence biotechnology entrepreneurship in developing 
economies. 
ii. What are the factors that influence your process of biotechnology 
entrepreneurship? 
 
5. The dynamics of the Triple Helix of University-Industry-Government relations 
in a developing economy context. 
xvii. From which of the three perspectives, University, Industry, Government, do 
you operate? 
xviii. Do you perceive your role to be fully contained within one perspective or 
cutting across the different perspectives? If yes, which ones? 
xix. What are the dynamics at play with the relations between these three 
perspectives? 
xx. What are the sub-dynamics at play within your own perspective and across 
these three perspectives? 
xxi. How would you access the efficacy of the current relations between the 
University, Industry and Government? 
xxii. What are the positives of the current relations between the three 
perspectives? 
xxiii. What are the constraints of the current relations between the three 
perspectives? 
xxiv. What would be ideal relations between the University, Industry and 
Government, for biotechnology entrepreneurship in a developing economy 
like South Africa and Brazil? 
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Appendix G: Observational form 
 
The attached table shell will be used to record direct observations. The attributes are 
not exhaustive and will be updated as the research progresses. 
  
Observed attribute Comments 
Physical location of the bioscientist e.g. in an industrial complex, 
biotechnology park, office blocks etc 
Scientific laboratory  e.g. co-located at the company’s offices, 
not co-located at the company’s offices 
Appearance of scientific laboratory e.g. spotlessly clean, untidy, unhealthy 
etc 
Access restrictions to scientific laboratory e.g. staff only access, limited access to 
non-staff, public access allowed etc 
Manufacturing facility e.g. present or not present 
Scale of manufacturing facility e.g. extensive, small 
Attitude of bioscientist e.g. professional, friendly, hostile 
Document management e.g. fully electronic, combination of 
electronic and manual, fully manual 
Evidence of innovation e.g. awards, recognition of achievements 
 
 
 
 
 
 
 
 
 
 
 
 
 
